%PDF-1.6%âãÏÓ
1 0 obj<</Lang(en-US)/Metadata 2 0 R/Pages 3 0 R/Type/Catalog/ViewerPreferences<</Direction/L2R>>>>endobj2 0 obj<</Length 8390/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="ï»¿" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c002 79.dba3da3, 2023/12/13-05:06:49        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:ExtensisFontSense="http://www.extensis.com/meta/FontSense/">
         <xmp:CreateDate>2024-03-04T14:48:29-05:00</xmp:CreateDate>
         <xmp:MetadataDate>2024-03-04T14:48:30-05:00</xmp:MetadataDate>
         <xmp:ModifyDate>2024-03-04T14:48:30-05:00</xmp:ModifyDate>
         <xmp:CreatorTool>Adobe InDesign 19.2 (Macintosh)</xmp:CreatorTool>
         <xmpMM:InstanceID>uuid:c6b7f89c-5cfa-294f-b44b-5984e58337dc</xmpMM:InstanceID>
         <xmpMM:OriginalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.id:d26d4221-1e82-4d9d-8fbe-c3e9fc8b34a8</xmpMM:DocumentID>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>xmp.iid:1002752c-92f7-43cb-95e0-6dee3e9d6f86</stRef:instanceID>
            <stRef:documentID>xmp.did:f8bd02c7-78aa-471e-ba45-4e74ffb9c164</stRef:documentID>
            <stRef:originalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</stRef:originalDocumentID>
            <stRef:renditionClass>default</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>converted</stEvt:action>
                  <stEvt:parameters>from application/x-indesign to application/pdf</stEvt:parameters>
                  <stEvt:softwareAgent>Adobe InDesign 19.2 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
                  <stEvt:when>2024-03-04T14:48:29-05:00</stEvt:when>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <dc:format>application/pdf</dc:format>
         <pdf:Producer>Adobe PDF Library 17.0</pdf:Producer>
         <pdf:Trapped>False</pdf:Trapped>
         <ExtensisFontSense:slug>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2061318306</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2061318306</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Cn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1252007918</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1252007918</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>ArialMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3939600684</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3939600684</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Arial-BoldMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3357634683</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3357634683</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>4073973744</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>4073973744</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3030352917</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3030352917</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-CnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3691150952</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3691150952</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Bd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
            </rdf:Bag>
         </ExtensisFontSense:slug>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj3 0 obj<</Count 10/Kids[5 0 R 6 0 R 7 0 R 8 0 R 9 0 R 10 0 R 11 0 R 12 0 R 13 0 R 14 0 R]/Type/Pages>>endobj5 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 15 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 3 0 R/Resources<</ExtGState<</GS0 16 0 R>>/Font<</C2_0 17 0 R/T1_0 18 0 R/T1_1 19 0 R>>/ProcSet[/PDF/Text]>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00660038006200640030003200630037002D0037003800610061002D0034003700310065002D0062006100340035002D003400650037003400660066006200390063003100360034>/LastModified<FEFF0044003A00320030003200340030003300300034003100390034003800320039005A>/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 474>>/PageWidthList<</0 612.0>>>>>>>>endobj6 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 20 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 3 0 R/Resources<</ExtGState<</GS0 21 0 R/GS1 16 0 R/GS2 22 0 R/GS3 23 0 R>>/Font<</T1_0 18 0 R/T1_1 19 0 R/T1_2 24 0 R/T1_3 25 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 26 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00660038006200640030003200630037002D0037003800610061002D0034003700310065002D0062006100340035002D003400650037003400660066006200390063003100360034>/LastModified<FEFF0044003A00320030003200340030003300300034003100390034003800320039005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[377.0 0.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 626>>/PageWidthList<</0 612.0>>>>>>>>endobj7 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 27 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 3 0 R/Resources<</ExtGState<</GS0 21 0 R/GS1 16 0 R>>/Font<</T1_0 19 0 R/T1_1 24 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 28 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00660038006200640030003200630037002D0037003800610061002D0034003700310065002D0062006100340035002D003400650037003400660066006200390063003100360034>/LastModified<FEFF0044003A00320030003200340030003300300034003100390034003800320039005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 678>>/PageWidthList<</0 612.0>>>>>>>>endobj8 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 29 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 3 0 R/Resources<</ExtGState<</GS0 21 0 R/GS1 16 0 R>>/Font<</T1_0 19 0 R/T1_1 24 0 R/T1_2 18 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 28 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00660038006200640030003200630037002D0037003800610061002D0034003700310065002D0062006100340035002D003400650037003400660066006200390063003100360034>/LastModified<FEFF0044003A00320030003200340030003300300034003100390034003800320039005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 730>>/PageWidthList<</0 612.0>>>>>>>>endobj9 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 30 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 3 0 R/Resources<</ExtGState<</GS0 21 0 R/GS1 16 0 R/GS2 22 0 R>>/Font<</T1_0 18 0 R/T1_1 19 0 R/T1_2 24 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 28 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00660038006200640030003200630037002D0037003800610061002D0034003700310065002D0062006100340035002D003400650037003400660066006200390063003100360034>/LastModified<FEFF0044003A00320030003200340030003300300034003100390034003800320039005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 784>>/PageWidthList<</0 612.0>>>>>>>>endobj10 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 31 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 3 0 R/Resources<</ExtGState<</GS0 21 0 R/GS1 16 0 R>>/Font<</T1_0 19 0 R/T1_1 18 0 R/T1_2 24 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 28 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00660038006200640030003200630037002D0037003800610061002D0034003700310065002D0062006100340035002D003400650037003400660066006200390063003100360034>/LastModified<FEFF0044003A00320030003200340030003300300034003100390034003800320039005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 837>>/PageWidthList<</0 612.0>>>>>>>>endobj11 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 32 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 3 0 R/Resources<</ExtGState<</GS0 21 0 R/GS1 22 0 R/GS2 16 0 R>>/Font<</T1_0 18 0 R/T1_1 19 0 R/T1_2 33 0 R/T1_3 24 0 R>>/ProcSet[/PDF/Text]/Properties<</MC0 34 0 R>>/XObject<</Fm0 28 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00660038006200640030003200630037002D0037003800610061002D0034003700310065002D0062006100340035002D003400650037003400660066006200390063003100360034>/LastModified<FEFF0044003A00320030003200340030003300300034003100390034003800320039005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -360.0 270.0 -346.846 1.0 0.0 0.0 1.0 288.0 0.0]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 889>>/PageWidthList<</0 612.0>>>>>>>>endobj12 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 35 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 3 0 R/Resources<</ExtGState<</GS0 21 0 R/GS1 16 0 R>>/Font<</C2_0 17 0 R/TT0 36 0 R/TT1 37 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 38 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00660038006200640030003200630037002D0037003800610061002D0034003700310065002D0062006100340035002D003400650037003400660066006200390063003100360034>/LastModified<FEFF0044003A00320030003200340030003300300034003100390034003800330030005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[463.0 0.0 3.0 -270.0 -360.046 270.0 -349.446 1.0 0.0 0.0 1.0 -195.0 -285.046]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 1533>>/PageWidthList<</0 612.0>>>>>>>>endobj13 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 39 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 3 0 R/Resources<</ExtGState<</GS0 21 0 R/GS1 16 0 R>>/Font<</C2_0 17 0 R/TT0 36 0 R/TT1 37 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 38 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00660038006200640030003200630037002D0037003800610061002D0034003700310065002D0062006100340035002D003400650037003400660066006200390063003100360034>/LastModified<FEFF0044003A00320030003200340030003300300034003100390034003800330030005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[463.0 0.0 3.0 -270.0 -360.046 270.0 -349.446 1.0 0.0 0.0 1.0 -195.0 -285.046]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 31950>>/PageWidthList<</0 612.0>>>>>>>>endobj14 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 40 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 3 0 R/Resources<</ExtGState<</GS0 21 0 R/GS1 16 0 R>>/Font<</C2_0 17 0 R/TT0 36 0 R/TT1 37 0 R>>/ProcSet[/PDF/Text]/Properties<</MC0 41 0 R>>/XObject<</Fm0 38 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00660038006200640030003200630037002D0037003800610061002D0034003700310065002D0062006100340035002D003400650037003400660066006200390063003100360034>/LastModified<FEFF0044003A00320030003200340030003300300034003100390034003800330030005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[463.0 0.0 3.0 -270.0 -360.046 270.0 -349.446 1.0 0.0 0.0 1.0 -195.0 -285.046]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 26807>>/PageWidthList<</0 612.0>>>>>>>>endobj40 0 obj<</Length 14331>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 36.5 623.8066 cm
0 0 m
539 0 l
S
Q
q 1 0 0 1 36.5 574.4266 cm
0 0 m
539 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
-0.023 Tc 0.139 Tw 10 0 0 10 45.5 715.0277 Tm
[(T)0.5 (h)0.5 (e )0.6 (mo)0.5 (st )0.6 (co)0.5 (mmo)0.5 (n)0.5 ( )0.6 (si)0.5 (d)0.5 (e )0.6 (effects )0.6 (o)0.5 (f )0.6 (O)0.5 (PDUAL)0.5 (AG)0.6 ( )0.5 (i)0.6 (n)0.5 (cl)0.5 (u)0.6 (d)0.5 (e:)]TJ
ET
0 0 0 0 k
/GS0 gs
45.5 710.348 260.5 -13.04 re
306 710.348 260.5 -13.04 re
45.5 697.307 260.5 -13.04 re
306 697.307 260.5 -13.04 re
45.5 684.267 260.5 -13.04 re
306 684.267 260.5 -13.04 re
45.5 671.227 260.5 -13.04 re
306 671.227 260.5 -13.04 re
f
BT
0 0 0 1 k
/GS1 gs
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
10 0 0 10 51.3067 700.1874 Tm
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(muscle )0.6 (and )0.6 (bone )0.6 (pain)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
(rash)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.069 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
[(t)0.5 (iredness)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
[(it)0.5 (ching)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.069 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(decreased )0.6 (red )0.7 (blood )0.6 (cell )0.6 (and )0.6 (whit)0.5 (e )0.6 (blood )0.6 (cell )0.6 (count)0.5 (s)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
(diarrhea)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.069 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(increased )0.6 (liver )0.6 (f)0.5 (unct)0.5 (ion )0.6 (t)0.5 (est)0.6 ( )0.5 (result)0.5 (s)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(decreased )0.6 (salt)0.5 ( )0.6 (\(sodium\) )0.6 (in )0.6 (your )0.6 (blood)]TJ
-29.65 -1.388 Td
[(T)0.5 (hese )0.6 (are )0.6 (not)0.5 ( )0.6 (all )0.6 (t)0.5 (he )0.6 (possible )0.6 (side )0.6 (ef)18.5 (f)0.5 (ect)0.5 (s )0.6 (of)0.5 ( )0.6 (O)0.5 (PDUALAG)0.5 (.)]TJ
0 Tw 0 -1.388 Td
[(Call )0.5 (your )0.5 (doct)0.5 (or )0.5 (f)0.5 (or )0.6 (medical )0.5 (advice )0.5 (about)0.5 ( )0.5 (side )0.5 (ef)18.6 (f)0.5 (ect)0.5 (s.)0.5 ( )18.6 (Y)92.1 (ou )0.5 (may )0.6 (report)0.5 ( )0.5 (side )0.5 (ef)18.5 (f)0.6 (ect)0.5 (s )0.5 (t)0.5 (o )0.5 (F)0.5 (DA)55.5 ( )0.5 (at)0.5 ( )0.6 (1-800-F)0.5 (DA-1088.)]TJ
/TT0 1 Tf
0.139 Tw 0 -2.45 Td
[(G)0.5 (en)0.5 (eral)0.5 ( )0.6 (i)0.5 (n)0.5 (fo)0.5 (rmati)0.5 (o)0.5 (n)0.5 ( )0.6 (ab)0.5 (o)0.5 (u)0.5 (t )0.6 (th)0.5 (e )0.6 (safe )0.6 (an)0.5 (d)0.5 ( )0.6 (effecti)0.5 (ve )0.6 (use )0.6 (o)0.5 (f )0.6 (O)0.5 (PDUAL)0.5 (AG)0.5 (.)]TJ
/TT1 1 Tf
-0.026 Tc -0.014 Tw 0 -1.388 Td
[(Medicines are sometimes prescribed for purposes ot)0.5 (her t)0.5 (han t)0.5 (hose list)0.5 (ed in a Medicat)0.5 (ion Guide. )18.4 (Y)92.1 (ou can ask your pharmacist)-25.9 ( )]TJ
-0.023 Tc 0 Tw 0 -1.1 Td
[(or )0.5 (healt)0.5 (hcare )0.5 (provider )0.6 (f)0.5 (or )0.5 (inf)0.6 (ormat)0.5 (ion )0.6 (about)0.5 ( )0.5 (O)0.5 (PDUALAG)0.5 ( )0.5 (t)0.5 (hat)0.5 ( )0.5 (is )0.5 (writ)0.5 (t)0.5 (en )0.5 (f)0.5 (or )0.6 (healt)0.5 (h )0.5 (prof)0.5 (essionals.)]TJ
/TT0 1 Tf
0.139 Tw 0 -2.45 Td
[(W)0.5 (h)0.5 (at )0.6 (are )0.6 (th)0.5 (e )0.6 (i)0.5 (n)0.5 (g)0.5 (red)0.5 (i)0.5 (en)0.5 (ts )0.6 (i)0.5 (n)0.5 ( )0.6 (O)0.5 (PDUAL)0.5 (AG)0.5 (?)]TJ
0 -1.568 Td
[(Acti)0.5 (ve )0.6 (i)0.5 (n)0.5 (g)0.5 (red)0.6 (i)0.5 (en)0.5 (ts:)]TJ
/TT1 1 Tf
/Span<</ActualText<FEFF00A0>>> BDC 
( )Tj
EMC 
9.091 0 Td
[(nivolumab )0.6 (and )0.6 (relat)0.5 (limab)]TJ
/TT0 1 Tf
0.103 Tw -9.091 -1.568 Td
[(I)0.5 (n)0.5 (acti)0.5 (ve i)0.5 (n)0.6 (g)0.5 (red)0.5 (i)0.5 (en)0.5 (ts:)]TJ
/TT1 1 Tf
/Span<</ActualText<FEFF00A0>>> BDC 
( )Tj
EMC 
[(hist)0.5 (idine,)0.5 ( L-hist)0.5 (idine hydrochloride monohydrat)0.5 (e,)0.5 ( pent)0.5 (et)0.5 (ic acid,)0.5 ( polysorbat)0.5 (e 80,)0.5 ( sucrose,)0.5 ( and W)37.6 (at)0.5 (er)-23 ( )]TJ
0.139 Tw 0 -1.1 Td
[(f)0.5 (or )0.6 (I)0.5 (nject)0.5 (ion.)]TJ
-0.018 Tc 0.018 Tw 9 0 0 9 45.5 498.0666 Tm
[(O)0.5 (PDUALAG)]TJ
0 Tc 0 Tw 5.04 0 0 5.04 93.834 501.2142 Tm
(\231)Tj
-0.018 Tc 9 0 0 9 98.7816 498.0666 Tm
[( )0.5 (is )0.5 (t)0.5 (rademark )0.5 (of)0.5 ( )0.5 (Brist)0.5 (ol-Myers Squibb )0.6 (Company)74.6 (.)0.5 ( )0.5 (O)0.5 (t)0.5 (her )0.5 (brands )0.5 (list)0.5 (ed )0.5 (are )0.5 (t)0.5 (he )0.5 (t)0.5 (rademarks )0.5 (of)0.6 ( t)0.5 (heir )0.5 (respect)0.5 (ive owners.)]TJ
-5.92 -1.371 Td
[(Manuf)0.5 (act)0.5 (ured )0.5 (by:)0.5 ( )0.5 (Brist)0.5 (ol-Myers )0.5 (Squibb )0.5 (Company )0.5 (Princet)0.5 (on,)0.5 ( )0.5 (NJ )0.5 (08543 )0.6 (USA)55.6 ( )0.5 ( )0.5 (U.)0.5 (S.)0.6 ( License )0.5 (No.)0.5 ( )0.5 (1713)]TJ
0 -1.371 Td
[(F)0.5 (or )0.5 (more )0.5 (inf)0.5 (ormat)0.5 (ion,)0.5 ( )0.5 (call )0.5 (1-855-673-4861 )0.5 (or )0.5 (go )0.5 (t)0.5 (o )0.5 (www)55.4 (.O)0.5 (PDUALAG)0.5 (.)0.5 (com.)]TJ
ET
4 M 
36 463.887 540 267.921 re
S
q 1 0 0 1 36 424.7335 cm
0 0 m
540 0 l
S
Q
BT
-0.023 Tc 0.139 Tw 9 0 0 9 36 447.8335 Tm
[(T)0.5 (his )0.6 (Medicat)0.5 (ion )0.6 (G)0.5 (uide )0.6 (has )0.6 (been )0.6 (approved )0.6 (by )0.6 (t)0.5 (he )0.6 (U.)0.5 (S.)0.5 ( )0.6 (F)0.5 (ood )0.6 (and )0.6 (Drug )55.8 (Administ)0.5 (rat)0.5 (ion.)]TJ
-0.018 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -2.111 Td
( )Tj
EMC 
50.981 0 Td
[(Revised:)0.5 ( )0.5 (March )0.5 (20)60.2 (2)40.2 (2)]TJ
ET
q
0 0 612 792 re
W n
BT
0 Tc 48.617 Tw /Span<</ActualText<FEFF0009>>> BDC 
9 0 0 9 36 413.7935 Tm
( )Tj
EMC 
( )Tj
ET
Q
BT
9 0 0 9 478.3867 413.7935 Tm
[(1425-US-2400035 )0.5 ( )0.5 (03/)0.5 (24)]TJ
ET
/PlacedPDF /MC0 BDC 
q
236.563 391.92 138.874 19.12 re
W n
/GS0 gs
q 1 0 0 1 241.8615 392.4074 cm
0 0 m
-0.143 -0.296 -0.449 -0.487 -0.778 -0.487 c
-0.909 -0.487 -1.036 -0.458 -1.155 -0.401 c
-3.866 0.914 -5.299 3.23 -5.299 6.299 c
-5.299 9.764 l
-5.299 10.241 -4.911 10.628 -4.434 10.628 c
-3.958 10.628 -3.57 10.241 -3.57 9.764 c
-3.57 6.299 l
-3.57 3.905 -2.503 2.175 -0.4 1.155 c
0.028 0.947 0.208 0.429 0 0 c
-2.556 8.032 m
-2.556 7.542 -2.16 7.145 -1.67 7.145 c
-1.18 7.145 -0.783 7.542 -0.783 8.032 c
-0.783 15.104 l
-0.783 15.594 -1.18 15.991 -1.67 15.991 c
-2.16 15.991 -2.556 15.594 -2.556 15.104 c
h
0.187 8.237 m
0.187 7.748 0.584 7.351 1.074 7.351 c
1.564 7.351 1.961 7.748 1.961 8.237 c
1.961 17.746 l
1.961 18.236 1.564 18.632 1.074 18.632 c
0.584 18.632 0.187 18.236 0.187 17.746 c
h
2.93 7.583 m
2.93 7.094 3.327 6.697 3.817 6.697 c
4.307 6.697 4.704 7.094 4.704 7.583 c
4.704 16.119 l
4.704 16.609 4.307 17.006 3.817 17.006 c
3.327 17.006 2.93 16.609 2.93 16.119 c
h
5.674 6.454 m
5.674 5.979 6.059 5.594 6.534 5.594 c
7.009 5.594 7.394 5.979 7.394 6.454 c
7.394 12.222 l
7.394 12.697 7.009 13.082 6.534 13.082 c
6.059 13.082 5.674 12.697 5.674 12.222 c
h
f
Q
q 1 0 0 1 258.4387 400.4902 cm
0 0 m
0.002 0.053 l
1.118 0.437 1.809 1.108 1.809 2.307 c
1.809 2.49 l
1.809 3.866 0.691 4.998 -1.59 4.998 c
-4.746 4.998 l
-4.746 -5.739 l
-1.361 -5.739 l
0.856 -5.739 2.378 -4.625 2.378 -2.841 c
2.378 -2.733 l
2.378 -1.341 1.558 -0.322 0 0 c
-3.365 3.786 m
-1.787 3.786 l
-0.283 3.786 0.484 3.216 0.484 2.197 c
0.484 2.089 l
0.484 0.858 -0.581 0.463 -1.979 0.463 c
-3.365 0.463 l
h
0.964 -2.717 m
0.964 -4.046 -0.083 -4.543 -1.61 -4.543 c
-3.365 -4.543 l
-3.365 -0.672 l
-1.586 -0.672 l
-0.082 -0.672 0.964 -1.172 0.964 -2.548 c
h
6.89 2.39 m
7.288 2.39 l
7.288 1.132 l
6.966 1.132 l
5.678 1.132 4.834 0.488 4.834 -1.215 c
4.834 -5.739 l
3.546 -5.739 l
3.546 2.39 l
4.834 2.39 l
4.834 0.933 l
4.896 0.933 l
5.126 1.669 5.724 2.39 6.89 2.39 c
8.435 2.39 1.289 -8.129 re
9.865 4.214 m
9.865 3.586 9.579 3.292 9.079 3.292 c
8.578 3.292 8.293 3.586 8.293 4.214 c
8.293 4.842 8.578 5.154 9.079 5.154 c
9.579 5.154 9.865 4.842 9.865 4.214 c
16.87 -3.5 m
16.87 -5.065 15.705 -5.892 14.002 -5.892 c
12.284 -5.892 11.149 -5.156 11.057 -3.5 c
12.345 -3.5 l
12.391 -4.497 13.128 -4.819 14.002 -4.819 c
14.876 -4.819 15.582 -4.436 15.582 -3.592 c
15.582 -1.613 11.149 -2.978 11.149 0.227 c
11.149 1.562 12.13 2.543 13.925 2.543 c
15.567 2.543 16.656 1.731 16.778 0.151 c
15.49 0.151 l
15.413 1.102 14.754 1.47 13.925 1.47 c
12.99 1.47 12.407 1.04 12.407 0.227 c
12.407 -1.69 16.87 -0.509 16.87 -3.5 c
19.843 2.39 m
21.592 2.39 l
21.592 1.255 l
19.843 1.255 l
19.843 -3.239 l
19.843 -4.42 20.15 -4.665 20.932 -4.665 c
21.147 -4.665 21.392 -4.635 21.592 -4.619 c
21.592 -5.724 l
21.346 -5.77 21.024 -5.801 20.794 -5.801 c
19.199 -5.801 18.555 -5.172 18.555 -3.438 c
18.555 1.255 l
17.189 1.255 l
17.189 2.39 l
18.555 2.39 l
18.555 4.998 l
19.843 4.998 l
h
25.398 2.543 m
23.388 2.543 22.315 1.163 22.315 -1.076 c
22.315 -2.273 l
22.315 -4.512 23.388 -5.892 25.398 -5.892 c
27.407 -5.892 28.481 -4.512 28.481 -2.273 c
28.481 -1.076 l
28.481 1.163 27.407 2.543 25.398 2.543 c
27.177 -2.197 m
27.177 -4.129 26.502 -4.758 25.398 -4.758 c
24.293 -4.758 23.619 -4.129 23.619 -2.197 c
23.619 -1.153 l
23.619 0.78 24.293 1.409 25.398 1.409 c
26.502 1.409 27.177 0.78 27.177 -1.153 c
h
29.843 4.998 1.289 -10.737 re
43.559 4.998 m
45.746 4.998 l
45.746 -5.739 l
44.381 -5.739 l
44.381 3.51 l
44.304 3.51 l
41.558 -3.962 l
39.886 -3.962 l
37.172 3.51 l
37.095 3.51 l
37.095 -5.739 l
35.745 -5.739 l
35.745 4.998 l
38.039 4.998 l
40.745 -2.46 l
40.822 -2.46 l
h
52.011 2.39 m
53.315 2.39 l
49.711 -8.347 l
48.377 -8.347 l
49.282 -5.801 l
46.643 2.39 l
48.008 2.39 l
49.956 -3.945 l
50.018 -3.945 l
h
56.777 2.543 m
54.768 2.543 53.694 1.102 53.694 -1.076 c
53.694 -2.273 l
53.694 -4.512 54.768 -5.892 56.777 -5.892 c
58.388 -5.892 59.339 -5.003 59.661 -3.484 c
58.342 -3.484 l
58.111 -4.42 57.59 -4.758 56.777 -4.758 c
55.673 -4.758 54.997 -4.129 54.997 -2.197 c
54.997 -2.089 l
59.706 -2.089 l
59.706 -1.076 l
59.706 1.102 58.787 2.543 56.777 2.543 c
56.777 1.409 m
57.82 1.409 58.386 0.794 58.401 -1.076 c
54.999 -1.076 l
55.017 0.794 55.688 1.409 56.777 1.409 c
64.483 2.39 m
64.882 2.39 l
64.882 1.132 l
64.56 1.132 l
63.272 1.132 62.428 0.488 62.428 -1.215 c
62.428 -5.739 l
61.14 -5.739 l
61.14 2.39 l
62.428 2.39 l
62.428 0.933 l
62.49 0.933 l
62.719 1.669 63.318 2.39 64.483 2.39 c
71.385 -3.5 m
71.385 -5.065 70.22 -5.892 68.517 -5.892 c
66.799 -5.892 65.664 -5.156 65.572 -3.5 c
66.861 -3.5 l
66.907 -4.497 67.643 -4.819 68.517 -4.819 c
69.391 -4.819 70.097 -4.436 70.097 -3.592 c
70.097 -1.613 65.664 -2.978 65.664 0.227 c
65.664 1.562 66.646 2.543 68.441 2.543 c
70.081 2.543 71.171 1.731 71.294 0.151 c
70.005 0.151 l
69.928 1.102 69.269 1.47 68.441 1.47 c
67.505 1.47 66.922 1.04 66.922 0.227 c
66.922 -1.69 71.385 -0.509 71.385 -3.5 c
81.626 -2.901 m
81.626 -4.819 80.307 -5.892 78.282 -5.892 c
76.38 -5.892 74.815 -4.972 74.616 -2.917 c
76.042 -2.917 l
76.211 -4.129 77.07 -4.696 78.267 -4.696 c
79.632 -4.696 80.245 -3.883 80.245 -2.978 c
80.245 0.074 74.785 -1.69 74.785 2.314 c
74.785 4.031 76.15 5.151 78.052 5.151 c
79.892 5.151 81.426 4.246 81.518 2.13 c
80.092 2.13 l
79.969 3.433 79.141 3.955 78.037 3.955 c
76.732 3.955 76.165 3.187 76.165 2.375 c
76.165 -0.325 81.626 1.27 81.626 -2.901 c
87.447 1.409 m
87.384 1.409 l
87.036 2.126 86.375 2.543 85.53 2.543 c
83.52 2.543 82.6 1.163 82.6 -1.076 c
82.6 -2.273 l
82.6 -4.512 83.52 -5.892 85.53 -5.892 c
86.375 -5.892 87.036 -5.475 87.384 -4.758 c
87.447 -4.758 l
87.447 -5.739 l
87.447 -8.347 l
88.736 -8.347 l
88.736 2.39 l
87.447 2.39 l
h
85.683 -4.758 m
84.579 -4.758 83.904 -4.129 83.904 -2.197 c
83.904 -1.153 l
83.904 0.78 84.579 1.409 85.683 1.409 c
86.788 1.409 87.463 0.78 87.463 -1.153 c
87.463 -2.197 l
87.463 -4.129 86.788 -4.758 85.683 -4.758 c
94.653 2.39 m
95.942 2.39 l
95.942 -5.739 l
94.653 -5.739 l
94.653 -4.696 l
94.592 -4.696 l
94.285 -5.355 93.626 -5.892 92.598 -5.892 c
91.08 -5.892 90.144 -5.033 90.144 -3.116 c
90.144 2.39 l
91.448 2.39 l
91.448 -2.932 l
91.448 -4.236 91.985 -4.804 92.951 -4.804 c
93.887 -4.804 94.653 -4.175 94.653 -2.595 c
h
97.596 2.39 1.288 -8.129 re
103.818 2.543 m
102.961 2.543 102.308 2.126 101.963 1.409 c
101.901 1.409 l
101.901 2.39 l
101.901 4.998 l
100.613 4.998 l
100.613 -5.739 l
101.901 -5.739 l
101.901 -4.758 l
101.963 -4.758 l
102.308 -5.475 102.961 -5.892 103.818 -5.892 c
105.828 -5.892 106.748 -4.512 106.748 -2.273 c
106.748 -1.076 l
106.748 1.163 105.828 2.543 103.818 2.543 c
105.444 -2.197 m
105.444 -4.129 104.769 -4.758 103.665 -4.758 c
102.561 -4.758 101.886 -4.129 101.886 -2.197 c
101.886 -1.153 l
101.886 0.78 102.561 1.409 103.665 1.409 c
104.769 1.409 105.444 0.78 105.444 -1.153 c
h
111.218 2.543 m
110.36 2.543 109.707 2.126 109.362 1.409 c
109.3 1.409 l
109.3 2.39 l
109.3 4.998 l
108.012 4.998 l
108.012 -5.739 l
109.3 -5.739 l
109.3 -4.758 l
109.362 -4.758 l
109.707 -5.475 110.36 -5.892 111.218 -5.892 c
113.227 -5.892 114.147 -4.512 114.147 -2.273 c
114.147 -1.076 l
114.147 1.163 113.227 2.543 111.218 2.543 c
112.844 -2.197 m
112.844 -4.129 112.169 -4.758 111.064 -4.758 c
109.96 -4.758 109.285 -4.129 109.285 -2.197 c
109.285 -1.153 l
109.285 0.78 109.96 1.409 111.064 1.409 c
112.169 1.409 112.844 0.78 112.844 -1.153 c
h
99.027 4.214 m
99.027 3.586 98.741 3.292 98.241 3.292 c
97.74 3.292 97.455 3.586 97.455 4.214 c
97.455 4.842 97.74 5.154 98.241 5.154 c
98.741 5.154 99.027 4.842 99.027 4.214 c
f
Q
q 1 0 0 1 373.928 405.5204 cm
0 0 m
-0.73 0 -1.323 -0.594 -1.323 -1.323 c
-1.323 -2.053 -0.73 -2.646 0 -2.646 c
0.73 -2.646 1.323 -2.053 1.323 -1.323 c
1.323 -0.594 0.73 0 0 0 c
0 -2.832 m
-0.832 -2.832 -1.509 -2.155 -1.509 -1.323 c
-1.509 -0.491 -0.832 0.186 0 0.186 c
0.832 0.186 1.509 -0.491 1.509 -1.323 c
1.509 -2.155 0.832 -2.832 0 -2.832 c
f
Q
q 1 0 0 1 373.6636 404.2366 cm
0 0 m
0.284 0 l
0.377 0 0.45 0.024 0.502 0.07 c
0.554 0.118 0.581 0.182 0.581 0.263 c
0.581 0.348 0.557 0.414 0.508 0.461 c
0.46 0.507 0.387 0.531 0.292 0.533 c
0 0.533 l
h
0.308 -0.223 m
0 -0.223 l
0 -0.834 l
-0.276 -0.834 l
-0.276 0.755 l
0.283 0.755 l
0.466 0.755 0.608 0.714 0.708 0.632 c
0.807 0.55 0.857 0.431 0.857 0.275 c
0.857 0.168 0.831 0.079 0.78 0.008 c
0.729 -0.064 0.657 -0.119 0.566 -0.158 c
0.923 -0.82 l
0.923 -0.834 l
0.627 -0.834 l
h
f
Q
EMC 
Q
endstreamendobj38 0 obj<</BBox[0.0 792.0 612.0 0.0]/Length 407/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/Resources<</ExtGState<</GS0 16 0 R>>/Font<</TT0 42 0 R>>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 36 743.6949 cm
0 0 m
540 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
-0.018 Tc 0.018 Tw 0 Ts 100 Tz 0 Tr 12 0 0 12 36 747.3099 Tm
[(O)0.5 (PDUAL)0.5 (AG)]TJ
0 Tc 0 Tw 6.72 0 0 6.72 102.1859 751.2567 Tm
(\231)Tj
-0.018 Tc -0.014 Tw 12 0 0 12 108.7826 747.3099 Tm
[( \(n)0.5 (i)0.5 (vo)0.5 (l)0.5 (umab)0.5 ( an)0.5 (d)0.5 ( rel)0.6 (atl)0.5 (i)0.5 (mab)0.5 (-rmb)0.5 (w)0.5 (\))]TJ
ET
endstreamendobj42 0 obj<</BaseFont/HZWTVT+Arial-BoldMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 43 0 R/LastChar 153/Subtype/TrueType/ToUnicode 44 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 0 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 0 722 0 0 778 0 0 0 0 611 0 0 778 667 0 0 0 0 722 0 0 0 0 0 0 0 0 0 0 0 556 611 0 611 556 0 0 0 278 0 0 278 889 611 611 0 0 389 0 333 611 556 778 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1000]>>endobj43 0 obj<</Ascent 1010/CapHeight 716/Descent -376/Flags 32/FontBBox[-628 -376 2000 1010]/FontFamily(Arial)/FontFile2 45 0 R/FontName/HZWTVT+Arial-BoldMT/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 136/Type/FontDescriptor/XHeight 519>>endobj44 0 obj<</Filter/FlateDecode/Length 360>>stream
H‰\’ÏŠƒ0Æï>EÛCQCMZa±-xØ?¬»`“±+¬1D{ğíw&Sº°Í/dæ›/™¤uslÜ°ˆô=L¦…Eôƒ³æéˆ\—äRØÁ,÷Uü›±óIŠÉí:/06®Ÿ’²énÎKXÅÓ³.°IÒ·`!î*¾êv#ÒöæıŒà‘‰ªzzéük7‚HcÚ¶±¸?,ësş">WBÆuÎfÌdaöĞ¹+$e†£åG•€³ÿö¥â´Ko¾»”’‚³'ä=óøÀ| >2‘wydœwÌ;bÍ¬‰kæšøÌŒfÊ‚kT«(˜dÅšŠ4•d–Ä¬¯H_q¼ŠñìM‘7ÅµÕRìS‘Oub>³E4ëkÒ×¬¯I_³¾&}­˜1ŸKÓ¹TWæRÆ‹½ß ]1¾ñèŸ¹…€­‹Ï%öŒº58x¼(?yYô%¿   ÿÿ   ÿÿ pÍªDendstreamendobj45 0 obj<</Filter/FlateDecode/Length 20572/Length1 47814>>stream
H‰Œ•	XW€«¦»«¹EÁ™îè1Ö¸Ê²‘%Ï¸‡‘Dw ˆ r*‰J6èPƒŞ
x€÷-ŠŠ<¸<gğŒ:.&®ŸYw€Ù7ÀÇf¿ıòeß|U]õ^Õ÷æııª:}ÚŒ8pà rÄÈwúBû01‰M‰IËáËš 0ÀıÓØ™érû²ÇJ qL|Ú¤”v¿;‹’&%Ï‰/-™Ş@àÛ”3ñ–Ç› ¡° 6Ñ:©€„”ôÙ~@p}rjlKuHÁü[)1³ÓÚ×·gJ“÷°ªG=óÙ¾ü¤´Ôéé¶@¸	P\o_O›×_üŠıßZà¸zÕIÀAX'ôc§ğkr5¯òpTj‘WÙß¶30{Ku´ç>Hö³5u­a?1F Úl6¶¯A(µï<Ó*À¶½?f¡/‚IöT©ì1ÿ=Ø"Ç$:8:©]º¸º¹{xzywõéÖİ×¯‡F+É:½€bèùV¯À·ƒ~Õû>¿îÛ/ø7!¿}·èïÂŞ?bÀÀAƒ‡ı`ØïÿğÇ?ÿpDäGõç¿|òéè1cÇ}5>:&ÄNŒ‹Ÿ”091)9eJjÚÔiÓÓgÌœ5{ÎÜÏ¿˜7AÆ—ı*sá¢¿e}³xÉÒor—-_±rUŞê5k×Á†›6çnÙºm{Qñ»¸İ{öîÛàà¡ÃG–;^zâä©²ÓgÎÂ¹òó.^ª¬º|åêµj¨©­«¿~ã&Ü¾c4İ57 ïÎÌ*B0ÌG›JVVíáü¹\*7ƒ›Ïes‹¹î*÷šwáGğ‹Oá‚ğLxEy“IJQdS4‰š$Í9M¥Æ¦] ]¯ıAûFò–4Òi¸ô‰4Z+}&Í“KåRd”^H¯¤VÙUÖË¹·ÜG–Cå09\,GÉ©òy¥|D'è<u>:½Î ë­ûP7J¥ËÔ­ÒëUzÒ»ê=ôŞz_½¤ï¥[?L£óWù»ùëPTŠ³â¦x)İ”J€¤+aJ²’¡d*YÊbe…R ìV*¥ÊI¥\¹¬\Sn+a†Ã@C´!ÖoH2¤%ÍêíSä[¤³ª¬!Ö0k¸u€u°õ€õ©ÕÖ<¡åı–—-Í­ş­Í¶fû=c7,_*jŒj/ÀEréÜ\.“Q[Êmáª¹ù.|$Ÿ%,ª…ï	HÍ¨iIG-Fj€QKÖ”kZµ ÍĞæk_J u“di˜ÙAm¼”!•*¤Ò]é¥ôš]vF-Që+÷ï¤–È¨åÊùmÔºvP®©Ë¨åvRsgÔºëµÔ¢õÛ¨É?C-²“Z®’¯ìì¤VÉ¨İbÔB;©Åµè tFÍ§H¶¢Uc}—Q‹°²µÖY››£ZÂÛ¨É­vj¶¬>_0©eıè=&½ì×:Ù®ùjf¶—`sus•ÀzNsíÊ²)àÿ‚uË€Ç¬º-ŞO‹»ÅÕâbq¶¨-NG‹h!‹`á,*<³¿#h\Èd“ÌÆ7÷Šg=OdvÉóşLg7².×Ø0§±ÔråAPãRËš†â†<s¹Ğœ`ŞnÏoğ1O5g^s„¹Ÿ9À4Ô4Äfêo
1õ3õ1õ2éM~&/›Œãã#ã}{–±ÂxÚXf,aÖyã6ã>ãã@ã c€QoÔµ×6j<j>ïï!”±Ü ®×‰kÛÏIO)ÜåKó3¸Ø¶®Åº>Ç:8?Ì$CÈbz¹pŒE³nL!T(kÏvĞ2éãĞ×a¢C¾£À©«}ÖÉ£C†Â/§`§™f}ÚiæOfÛúvûŒÓ†ŸÍ]d§¬/ó—öúIæ8§¨N{ÌÿÖiÅ«ÃÔ	ÿÀÁÈ„…\äÁcXK!6ÂØ
nÍ~+à{ø–ÀjÈBdßÓ°	vÂ?à%¼‚BØ¡öÀˆ…\˜•à\…*¸Wà;ˆ‡¸Õ°&A,ƒz¨…:H€§`¯!&C¤@2L|H…©Ó`:Ì€t˜	³à	Ì†¹0>‡yğ”@,€ùì+ÿ%<ƒçpóp5ªC°B3®Áµ¸×C´"¡ˆ`Ã¸7áfÌÇtD'T£3âx?âVÜ†Û±‹qîÄ]¸÷à^Ü‡ûñ ÄCğO¸Ù˜ƒ‡ñÅ<†.Øc)º¢º£4Â=ôD/<'Ñ»âb<…exÏàYü}°ìƒıØ}ñ–£ö@jñ<VÀøÜ‡(¡Œ:Ôã¼ˆ—°«ğ2^Á«è¨ ¯a5Ö`-Öa=”bO|{a <„Gx²)‡ÓZJßP.-£å´‚VÒ*Ê£Õ´F µ´¶ÓzÚ@im¦|* BÚB[im§">‘O¢bÚA;ií¦=´—öÑ~:@éæ“ù:BG©„Ñq*¥t’NQ¦3t–¾¥sTNç©‚.ĞEºD•TE—é
]¥kTÍ7ó-|+o@@A%p/	¢à 8
N‚šj¨–êè:İ ›t‹nÓ2’‰î’™¨‘îÑ}z@é=¦ïè	«õgd¡çôwjÂxoám¼ƒFµ‡è&º‹¢§è%z‹]E±›Ø]ô{ˆQ+J¢,êD½ÚSí¥öV»ªÔÿ¦¹¾ƒ»,Ò8€¿ûìïÙ}÷Ù$€@ ¤ÒPTPAz/¡¨è)rVĞÅB‘&5¡ŠíîÄ®ˆˆs¶SN)‘Ş;BB ¹õnîıkgggùÌî÷+‡ä°‘£rLË	9éÊ]…«tW\•»êªİ5wİÕ¸ÚhUQ°­lk›d“mŠMµi6İf`’4”FöE;ÙN±Sí4û’ngØ™v–m_¶sì\;ÏÎ·ìB[d‹í"»8Ø°K‚ßíR»Ì.÷¯×
ÿŠ½f_·oØ7íßìßí?ì[Áîà`O°ß'À}v¥}Û¾cßµïÙ÷íöCû‘ıØ®²ŸØÕöS»Æ~f×Jc‰“&ÒTâ¥™$Hsi!-%QZIkI’dI‘ÔHQ¤˜:E¡;©3u¡®Ô-2ºSêI½¨7õ¡¾ÔúÓ Hƒ¨ÓJÃè.N#h$İM£h4‰,–4I—É”,É–6’#§ä´œ‘³rNr%Oòi.Í£ù´€RÓ"ZLKh)-£åô
­ Wé¨F¢$¨RuA]T{Õ%U¦.«
U©®¨*uUe¨juM]W5*Óg« |Ğ@0`€!TY à 
u .Ä@,ÔƒúĞ@eÃĞPµQ9ĞC4¦Í šûŒ6ÇçD•«ò •Ê‡ÖÉ©é!ÒVöÈ^Ù'ç¥T.ÈEÚ™ÙĞr ò 
 -Ü7Ñ´	ga<ÏÃğ"L†)0¦ÁKôL‡´™~¦-´•¶Ñv*¡_hıJ¿ÑNÚE¿ÓnúƒöĞ^ÚGûé ¤Ct˜ĞQ:FÇé¤Ót†ÎÒ9:O¥t.Ò%*£ËTNTIW¨Š®ÂL˜…1KÕtëa}ºN5Ø oÀ†Øˆj9`Å€15GÙ°ebæ…6Á¦Í0›s”ëp]ÁØ±Çr=®ÏønÈ¸1ÇqnÊñÜŒ¸9·à–œÈ­¢†“8™S8•Ó838[cgq6·áÎå<ÎçnË7òMÜoæ[0SøVnÏø6¾ïàÜ‰ïäÎÜ…»Ê%)ãnÜ=j£åh•¨ãÜ“{qoîÃ}¹÷ç<q!æ!<”‡E£Ñ:ÑºÑ¾‹‡óÉwó(Ícø¾—ïã±|??Àáù!¹ÌãøaÏåGøQ~Œç'øIÀù)˜ó`>,€…PÅ°Ã)‡¥°–Ã+°^…×àuxƒŸ–
©”+RgåmY)ïÈ»ò¼/È‡˜/Wá<”êÉzª~IÏĞ³ô\=_ëÅz¹~Íw€•ú=ışH¯Ò«õZı…şF¯Óëõ&½.èı›Ş­÷éCú˜>¥ÏéR}.Â%(ƒËPP	W°ŞŒ·ÈGò±¬’j¹&×¥Fj] Upªá\‡¨ÕV´Ö8«S1oÅöxŞáOwÂÎØ»cOì‹q×ÍqŞ‹à8|ŸÀ§t
>ƒÏû\4§átœ‰³qÎÃ>#-Â%¸Ì÷ÊWu¾oâ[ø.~ˆŸàgø9~‰_á·ø½o6›q–è,Ü»pÀ#:Oà,Å2¬Äj¬õ½Çú_×Äšú¦‘>câL3ß‚ZøDŸhZ›d“jÒM¦É69º­É3¦oH·ù´ßÉtÖdº˜®¦›énz˜¦—émú˜¾¦Ÿéo˜f)4ƒÍ3Ô3w™á~g„¬–5ÿŸµh÷¿ù˜‘fŒk4ÉZÎ¸ĞÕqõ\C×Ä%¸D—ìR]ºËt9®Àµsíİ®³ëîz»ş®Ğs#İ7Ö=èÆ¹ñ²?Ú8§ö©ıê€:¨©Ã\¡
!Ôa$ÄĞ„6¤Ã0”Ğ…Ñ°NX7Œ	cÃzaı°:¢F*"•‘+‘ªÈÕHµl•m²]JäÙ!¿Êo²SvÉï²NÂ)8gd}°:øf›õª X||¯k‚Ï‚dC0%XÌĞ}}ïè;Ô 5WÍ“z°¢‡êaz.kÂZ	‚ruB”€ºI´Dà»ÈóÁ×â¿[±#±n«Ûæ¶»xYş–ç‚+ƒ"u{0_uTO©…ªH«§ƒªIÂf‚™h†ò…|)_É×òüK¾•ïdl„aü›ágØ[al‡øvÀ~8 á†#pÁq8áuvğa!ÖÍuİR'z“÷áX¼ß;í‡ıq€W:Çà=^n/ì}¼µp=nğŞ~Æ-¸ÕÛ}'àD¯øQ|×):U§ét¯ùYœ„ÏyÉ³¼çŞóËŞ÷:CgzÕu–ÎÖmtÎÕy:_x¥—±+¼Ø³xÏ{§1^j½?ïôNÌ8oõa3^ŸÑ§ı:ë]vô2ïôÒâ!<ìõ¦yÃ)Şpv59&×›Nò³¼â[M{ÓÓ0M·Õ7ê2}¿âÿ»Ş	â#ÉA|ÔıßUUu…Ï¹ïî&„@–¿„$@ßæ‘H³	!À’ìh
¸Àîæ§“ •XUÂï„y¤-H--òçÏP	 ìĞqJ)H‘¢2("HfR)…"ìë÷6!’ÎÈ{ûsî=÷Şóî9÷¾‘jëgÿ‹«è]ú¶~Ûİ¨¬ÿJO§=|›’è*ÈÁ4$İDÍşêÛ©'M£¨@ûS"M§	¨“ÙCõ¼ÑZh]¡Qô<m±öñrk'ğÏ¡J¿>•LÃiÖOG¥~E»DAë·KuÔ™FÒTN¤0*–3t<¼@ëé0?cİÕğ¿ç)ÆÒXëˆu‡2©^®uœíô'TôÙi•[ÕÔÒÈëŒõePÅëàÉÃMr<¹Qå¯¢—8Yû Ñ_D8^ÌÖ
ï‚Òšúÿi2ÑY|Àİ¹ØqÖÑbıÊºLNêAÀS5]á¡<Ql•ñÖhëÍ¤ıô>äµß&9SnsÌŒŒ±^±Ş£^´5ş;|Ä1Äñ›»Ë¬ß[oR<øL2ô4GĞ¡ü‹¾µV-§P>Šª\G­=€Ï –X"–h§h ¤nŸ¢ß‘‚EĞA:İü5ÿ%Tü©üc.CÌ|ƒê¤BœĞ6j{µÓ’åèÛ tèh¢ëíht‚8ÿa.æ9<=Ë+|A(qMÜ”±r…üVŞudD.D¾µ&Y7¨7¥ĞOĞõÔB·ˆÆÿ_é#ô[×é?è9r¸
}ŒB6º†ê(ML5bƒØ*Ş@nX§‘Ce¾|\—çkbÂ1‘;¯E^ˆ¼9ií³NÂwºâü*„F—Á+¶Ò»èÆ>Bú	]´ıçäR~Tæój^~è(º«’¢oš)| :OüzZ½M·"Ø9àœøD|-nh-ğ$îD¥5jÓ¾”.™!ÊÁr²,EO0ï8d„í]÷-ˆ›
gó+ÔÔ+cİÍ¼ûi„"UÙß…'-†&6£Û|º8ˆó4ò1¬ğoX!½ÓCà{rOäGyWòr®C.{‰7¢Ó{@Ô“iÂ#ÆŠ•¨ßêPìÅ{ ¹ìŒ8+šÁy’f wÖ&h¥ÚLí	È°@[¢­„f×i;µÚ)í²ö•Ö«%É~ò)¹X¾,·É½ò$2ÈÏñnÁ=Ùä8é¸ã¸ãÎgç ä”íÎ‹1Î˜a1ÅèNÇ\­A˜	ÎuºïÉˆÁ~b§è)k¹}YR$÷À%ˆŠë4F‹À.]m<xë%’e{§Ó+ö/àƒ4”R­ShL$/Ğn>/.È?‹QèbCœ,·iO8>nÚ…l´V¼#r>íyb†Ø¤_âít	şşKZÏó|ÚÅÍœËÏòp®¥Ó"Q+á•”gm’;ñn!p@Ëd=F|x§+‘Í²‹|ù©‘6À¢¯Óg¼ƒn³Ãº†ì¦!…‘eêáï«ÈÎz³gµˆÇdd¹Î´—D1Ã£åbj¡ÿÒÇxT>2éåHµÜ,?·†[Ùˆ0DmGÜUÑ8DÌ%xÉ!ŒíÑ,DzrÉDu1•R=‹¬·ÎRÖ&k…µÈšGbïmô!·ùUDD#väÑûxŸ£yâpÜƒåü¾'RAMt•{s:A<4;âfÚ‰ºê°ã¸s0´½’6Â£/Â›ã A9¤«t“ca›dÊ¢GÀoxĞ\ÔQ§Pbv òx~›$óqÊrhoâùb£yb¦³,8	•ƒ~,Î)‚ŠÕ¯Á‚+xf*µ3ékÈİ•sÄĞóâ¤ÈZMàé<}	m[Q¾²|<gİ¤G©†Q17ÀoÓdVŸvúîÏ.Êç4ş#ö…¡]©/p|Î‚²"“¬Q­ÂcaşUÜ^©4ŠŸ	ã.õâÉ442<œbM*ş{”‹—E¥U§=™KÒØÄ+Æø¼c§yÇŒ•72wDÎğ¡ühÈà‡ÌÎòdşpÀCéı4·şƒ~}û¤¦$÷NJìÕ³G÷n®„®]â;ÇuŠq:¤&˜²üFaHW!%3Œñã³í±ÆDø¾‰Ò1UØqÒCÑezÇ•^¬üÙÿ­ô¶®ô¶¯d—GyÙYºßĞÕqŸ¡7ré” à_ûŒ ®š£ğÄ(¼6
wìvcƒîï]åÓ‡t¿*\XeúC>×Ğ9®À(¨ŒËÎ¢†¸Î ;RIFM'æ( ’ü¹‚b»€)•bøü*ÙğÙ(-İ®PÅS~_ªÛÌÎR\Pn”)2òU‚'º„
¢d”³@ÅDÉèÕ¶4´FoÈj2ë]TòÄWáY¥…ƒ6nĞõ©¤Å_ôşnˆÃ»êîÇ¦j¦¿wµnM³NWMS÷cİöo0ˆ3°W¤†ÌB®‡‹JtP«‚Å«@R·%±¥j•¯ÒğÛ3¡9ºêdäUæœL“b*šºÈ½;%Å»ßº@)~İœ0ÜjLªûú4ô$sê¢=É^=¹#&;«ÁÕ­U±]Ú€ø.÷•í¸(]nCESÛ5Ë6GÆ8„ÒËup0 SıS™Cfy–á	2v©
X¤Zu*™®\{ŞŞ¯é.C7o<Àh¾Öq&Ü6ãLwİ ´ı¤İÕ€¿+GefÚ.S ›‚ÇÑÑñĞì¬…b˜QãÒñõQ1tæ‚úİnÛÀk½T†Z:%Ğ:Ö©,u7yy‚J„lLÓ=L¯é6fé=LûöOŞK¸œ¨—ŠÍhÿ$¸{ø«r'> ]ÙŠ/*1Š¦”t¿jÓmÑ´£V|N;®R=
ZªhƒDªÅÂ)gµ/¶x%ÓñqFºBipÊèë…ÊßúŒs»¿wOcLì}›­{Wôï»mm\ª\OÇñÈãÜÅ›ø•¢hZ©iÆuÀ"™f¡¡š!3Üh--3t—aîÛÄ6³ÆºgĞFëÀšTUX„Uœg”ß`ğê)^^]RØïúÙÕÛÔuÆÏ9÷í8Îõû•_'mbNì$¤sÉ…P `¼j¦[”$P6pÕB·µYª!İ£Ò „!¢ª”u¼Â#É ÆèÖ?6µLƒ¶B ûÃİÔF)Uâ›}Çéº¡ùZçúŞsåû}¿Ç÷ƒºgÅS§	&móÓéJD(Ğ¦4ÿÁ/’Í8Ö`I`Œ¼"Ï„¹€ÃH‚Õ©ybòx*—j•ÇR-¹j€ßò$Uñ 5h-‡CÇŸT™‘ICHeG`­€5–‘Nî:’ÑBÍ-:ÊQÂH’‘M¼ˆK‘„0ŒˆìÓLÒ—æƒ*g	;HöX<Kß¨gscY9‹ä”ïÂ:.“Ù^[— Äé°¹]dãå7û7¬Ú9ÒÛñxM™±lñXC’;ŒÕŸ¿m¼{°FÒ‘hùHš4O„DL¤ÃÔˆ¾k$QFğµÉ4&çc:#~É4Óhl›i4ÙÜİGƒ±Ïej’„I¸lN‡@˜'–/x¬¸½÷RßÑùÍïËN¿ÿğöŸã_ãÙ7Œ’‡ıÓ3&h$ópÙDúÿj-Çtõ:`CfTØÙ²ÌNF*ŠÃ´—=²Åk•ïê-ò}ÍÎêUq; =Da=ì5F!Jº$Eê0piÂó†0uS“êê“|apjD“¢5I^ƒ®njKƒ˜ƒaª`+¸¨i¶yªãÌ›Ñf²‘iç:ÅÓ¦èISª“$±‚„a-%8`ÉÆK,«r¼ƒãxÑ¤ù”¹&úŠŸ’4•†áYi_Ğ,¼@8ö¦¢Ùíö¡A²N+àü©3x„4) á¸Ô-i˜„OH*‡9oÁÓhÊczKÎ;®gÆôŒ'×úÄÆ÷Ar€zCª%kµÕÏNåb±T7+ÖóòÕYzäTªçêÕS<i\ñÔ))&Q,45Ÿ,XŞ|²ü8„˜)ã´Èš†§@jòÏÎ¡Ÿ4Îè±ü'dàÀA;Ãp—Œ÷»sç~h\#ßÁõ^Ã-Æ 7<ùQsw(òû ùu€¼Œè'Z"
`.rod7š¹
w½{±+íêtqõîZÿMn°–cDì¶ò"YôFN˜Ò3  1ägš½;ˆÕ`<H‚V›ŠT9.yüt@­Z>õ]‹¬gÆc™–lŞ€yÿ!=JV»]yòô(bk¢ºn.©I†Ã‘pÙ>¢œo{e°­²®½åÕõoç®ãè­—ê¯M¥¶,Ÿ{–._1Fÿ|öÕşÍöÊdÅ¶êÇk·Y¨b×OrÁ;*º©-œSÒ\²JØ.n7ïwšw¹wú%ŞÍûmn›?jz¢¾h‰¸¸à{ì
iMÁföÇì<ÏûÎYÎÉ^“oÈ£²…)æUDeğÕàßË	Æ®âJ^²i[ÒÖ¼ÄíšÓ“´â¨Váª,‚ÍV½kávÄ¶ŠT•!>µ4^JJ½‘~.2Lqc‚]‡§ÑŒZe}œ‚&e3yÍ †ÜXL¿kÈZ©‚2±Ü¦ b]Ç5A+Ï–•† 2[]mBeİ\8\VÊ;e[¢º¶®†i ]ºqøì}ãØ{#C?ÿ[qb¦ñià7İWî=¸ ÿ®‘ø¿Ê®é½Œ;®ßÃÏ¬mº÷aİ–—Ç¿0&Œ‰¦ä0äy6qG¸ãPz×|K°=a™r‰,çƒê¡bêz‚(é|ÕĞIo•Zp[(á´ê$ ‡p”ÜáO4}Eµ˜†F¡"X„¿¥­ìãúÄæVÄ‚E,<Ï‹Ò›°Ãú¢s7Û+öšw[vÙz{œ{Ü{<»}fÁ&:ŸÓæsø<NŸ`¯,”¼•ãŠœ0ad’Mê4¾šW4¥MÙ¦t+ı
¯*ÿRˆ"Gú.ĞšEI(îúı·$ä«ç›mÈÒğõÒíÉºÚZŠ2²Ê(¨"ì  ƒXğtcõo;z`w²Ëè2.CF®ºêÔßo?‡üõÎm§c?0~e2¶â×qç×ÆÔÔÔäÃ	ŠÃ€ñCğ$Åa‡VÎsC!³ˆÃÜß8b³–Z,È/ƒäH]ÿçBW@‰“§ÈEÿËIñ£FüÖ‡Ô…ùŠô/?*˜Ñéà©Ë¼R£¹ßÀŸaËw»­ïkİü§ËoØŞøôâš~nØ¼u¢gp“Õ™»Á^1Úf­Ÿ·´³ĞšÙ¼† /zM›#ˆ‚$ÈnÑ%-IÂji•¼_î³pt•Ï»n8ïñã|A¡ÙeF(·Kæµğ/lèµRÍ¿Ôßæg¶ù»ıDõÇıış?ëÇj7îñ2^š¤¯ê…G«ÍsãútÃÏæë/%0cZ`>-Ğ¢l!e¥´ÌÔìÅÑûë/uuûp4şÊÍãÒåP dŞ¿8gÍ÷;ögb“†ñğÓıéuWvS¾š¦°³Ø¹¨UãŒÖ)øÄbNqùô/.n*ÿL¾m•j½½«ÃíŞğîğ/½{}ïø†üøşè7ó|¡ÓÅ{]~†3íİAv“wø³ü5Ş|)ù‰L”Pu•ufaH‹ÍJ†´Ò(^%¹54"¡…
­>qKQòq#EVN*_+¬¢ÌÄ	¤Á]ªe‚VµbkCPóË0x|Éà yş,+˜M3©b`.†éü˜	Ohš£ ¤*,Î¢…é€ù°™ÌxÊŒÍšÅ•4û–$q²xıEcœ˜\ëÆ·İx‰{­{«›q{›æ}ãœçZ²c™¬NkXlúênèQ 9è~±1=vt§gbÓ-ïôlgÒÙé‹!š9ïW’+BÏ„ˆKÓşÕ±@—¤,ftªÕHmm¢úßdWl×ïşúÎç³}¹³ÏâÄ|q=0%!Ä/#	”Ğş¥qÀK˜F ê	jÇ¶’Òt(*´ş44¡£#ë*B¤]Õ¨ÕÆ¦m"*ê4±MEZh7H°B.ûŞ9a•–èüìwïî½ï÷}ßïû}ª´êóGÁƒÇ+ËS$9+òéˆIk*x¦æ—ã“‰O.ıb¸Í²¾pzxzÉÉÜÉ_õ—Ë¶Ô¯ÆßœÿEIESÍ²Ú2“úëœc³»/XÃ/¿¸,\pÔÕ½Ô¼¯><«8¼¢¶ÊúD™§éªÆy±Š’ ù.ˆ†ƒvö†Ññ¤LŞ3uVV„‡(¥‘k}z6|—çÊ™*WUAy¨–©wÕÔ†òGQ’RQœ0Äò*ñEÓéF¢?êvDpÄ§è˜{ÇM	w .Ø/P˜Éãİ	²b"ı÷'!«ó9}ƒÄ;äs'Ô†EM¦³kÛ|mz{˜ÍeQ.A8 S€¾ 0C+€„xÈ` Ív}dY#kÏ˜Jêñïç^èŞ¸áÇì{·ZãÖ¬[Ö•µÙ^ê‘·–wôıüü‰ã$Vƒíë§lßoÎV²\VÌ*y‹€y÷¡#Ò¡Ò)i¡–
,¥k¤¥ZMà¨ ¨¶ÉNb¹);yÙ&úã²+†‰µn7
¾Bì:…MiÛ`R;ïä­¶9,ÏÎP
;‰½®v®]lWòs¹l4ZN"ØxÚZÿ«æ2ë­ûÕgš/@¥ûhh'L(Éšíë_êŞøí]½k³ØÀ,ãÀAÊó ãíe›ß:yáDØ[öù*
ãŸŒ øºÎYyT8æêñ°§Ä÷…÷]ÃA‡CÅK¨Å\¸<2à:Ï^-ıAü£t¿ër…İaÍ„(×LÙ›rkj—4Z#ÙèdìQöÃHí3%·¬4È­2%ë
†ç¡.Sˆ9[Xœ²Çñü˜˜õ°=šn „~ÒÆzàØ-Š0ŸeœŠNà.qò(Š“Zt9ğl0i‰l‰ôE˜ˆ;ê0]î >•Ñ‰¼ÉA"“R]¦©êf©šÑÍˆ>€FtÂ7D„f3pŸÄÿèYX¡ÃÀ"eŠnÈ84½¨Â®ön(•äĞC~2Ä¯Û?«£™"ë¯ÈÙÛË& $“Me²½lXÈ~©-¯·‚Âi3>D<f!Šä=¨l¢£6ÿ‰Äs~êK¬Ïÿü´õÛ±zùV¸	“Ş¹şÍılãºtã•Éc'ÎøÄBÂºh}ğ£½Kğw¶ïX´è»$ö_‘ùÄ>éHŸA€ñŠSh¨.aPÆ„›[$´
;„~˜`i‡v•†H7Ñº
Oæ ÷9–ã‘âc˜±;ŸhIŠ	82ùOL5®vÅÎu¦iÖC*Z·&Hc…áz4V8ÀœÇŒõàşR&vÿ
©ÃO¸j±ğî89ÛÀR]ì ;Ê±7Y¶ˆmew°ı0ÁÂah$ß`4}hçşï$S{—å÷eßû²öz!îd†«FPÎÁ^€¾¤q>)E§)=5³†ªuÔê53¥b:_%´Æ»â}ñ“Ü)ş§Ò9îœ4‹_Ë(Œ7ÀãŸÅ¹¸§2ğ»Ë¾ÉòQ†úyˆ<©nf„á=^¯
‡cè>Îí‰)^³¹¼Õ‹· 8ÃTé†b…a˜ÛÆ­a†¹wgAñ'L3„a'Ÿ!£9ÎmÀRÃ¬†+W‰‘2Ì…¥’Æ%ã3ƒvEF—A#£Ø˜kLŒ(ı[zº æ2ÀÊsÃ3‘™ ‰uµôxà<òO˜CP#[Ìã­	RÚp¢ ª‘Úæ·+œß§Ä)ƒĞgM}Ó{GÛzæÖ½¹nÛ›¥…Öx¡±¢jÓk<’™_½i¶5ÎÄülõš5«[ÖÕ™ÈR-oÌI/ÙÛcQTİëÍ_«ë>:ñ |v tg|æC}¦Îøš›Ì0ƒÁ[GûsËˆ½¼ìâ$§(šÂ12‹KR§„—u‚šoFIj¿Ş¯Sú-º©c]tÆ$™àërI6!Á#ı¾ª"àŸŠ)Àk
©'‰jKÜ±'l¤Fé‡ìıªñ^¤¥1Yk¼dEåãßK@ğ³{/ç-/¢"ïlXĞĞ=d1±ŞwmêşÉÕ•ÀÛÇÀRhÒÃæ’ëxÜq·à®Æ\¤®ƒÀ°Êz}Yı0u„;â8,ŸRbÿ,|*A“Â]wyN9~KıûØñ+‰İæØÍu;h¯…N?Hexµ’¶†:BTH¢@°©ú+Eëa+açN¨VB»§jU»Î`Rœ1´
˜…4ŠsIl–ú¿ZµrÏDïmœ²~óÏW­»{pqÏæÍ‡mŞÜCÍxs{¬‹7o[wO¼10Ğß;0 Iv!DW€½4`–f± ãUl»¥“J“¼IîPQpKEõŠ4)Qi¹DIÃÔ3fœçÁÇ4Å‰¥Hğs…‚;”>…jQv(§•1…Q<(†iR¤Õ…ûAÀ¼™FÓ²ä¡KïäO\Cz¾Vƒ‡+çf‡êı«êËW47ç-  ¢¶_?o;Ú‹û‰W=]Óš}jñcU+“LìğÓ5åÿSı¶ul,š¼N`ƒGoÆ¡!À3Å¸{¡¼TÎºù€†tÚ§!¿R b¿B©X§^ä%}cÓüışA?İ
Ã((ØaÌi˜’³Hãx[‘HN!)&Jâ°V˜¥:ó+k´ŒÚ§VéVµKİ¯©·T©µX«2j ølÿ4ÔV€…U`áR'GdÓO< €.Åó¯ åiÂÈÒk@Ş27üt°6Ó«’BUáç¦ZïÌò²òY^jû¨ÓKõoıpÙöJ§ğüó8ÈÄ®Z«w&Â¡+”­¨}ô¾tõòIk7à³b~ƒìî5ıOy7z{XZà\šJ{ë©zï8Å»‰©^ÆéC¢¦ª¢Àı—óªªºâç¾wß{û>6Én²IvH`$İÉ**±J°`©”Š3BÅ_vÊ0ı
JÚ:mÇ†ò‘J$vš*ÓğÛüEÛ2C+FHÙ¼şÎİ]b§3íÎşöÜï{Ï¹¿sÎİÜ¼’H„øj³ò•ç?_äÿ·wœ; ®DànçìÙ³¯Uå|É·§i%%ü§,ïßÿÏôÚÊ_?»¢í19·ºæ…ñ"úfİÒ¯·µh?(<¿lúœÕ—D’ôtÅBOWKDŒÒØÄ
‹Lş	ğŞáŸ9©ÒkQ¬²b—¦îçFDDë1;æŒ¢r·Ûõù®'òñºrÈpó(ê¡ñnUºMd§ş¥´;"è©µ\» B
²…IUWWáË8¨Ç‡%Â.9Òul[Ó„‰²òŒÂ{J+ÜàÈà¤`"(ƒ±§Ú™ãèN‡6)áJ-îÊj9Gêò¨6	áuc"Û›J¢H$„.¢Ş1p+Êä*+œ}m1|lq´ö¡eşEÕUváÔ¡³tÙb~©ŒT,ŠsøRn±GcW˜Y9'Eñ ¬—¼ğ«‡òËËµ)›ÚÈæ_M=mlb2,ë©9–a£|m„1+Ïá„</\¦—™£İ¸7kô³Uo5í,Ötİ„Y0¡+¥!m×‘Ş0ŠÉ|#Ï:ÏM¥r¬Qn—:c½É4Í˜a?L³´YFõˆ½–ÖÉµÆ:{³Ök¢M²ÉØdorš¼³tVö½öY§×»BWä%ã’}Å¹äİ¢[²Ï¸iõÙ·œ>¯Üèğ?JØÃ*+d	~ìÿœª9\ó2}Ä5“³~´’éÑuÒMà'}ÅxüU¿]¬úÜ×\S'aA6_:gôP¸ §n¾ı}WEşìÃ¦cC>–¸W'¯³t4!=İp\Ë˜Ë2)™¢31«O}"p¿-²¨6_I. ]dµ‰hğØ»"–Š²±èìd¬0™ŒE“…)Pêú«Ó/Œœ*u |Cê—Bê”à?—S¤(C**#~X·»‰`ß<ŒCá›ïãnÂã–ë‡<naÚùC.×Îtã”~ë”5pDg~åòWëºh8 BİGDöÁS"2°wàGÚÁ±­ƒñÏsÚŞd²ò­	68Š÷sLÌˆ‡Å˜Ğøğ´¾Ó;:ÖWzÎ·=}³Èû¦£ÿÀÙìípôG]‘pww¸º
ggY$ór¥–è­—‚cK
fq¤çd'²r*²÷‡–„¹ŞŸ‡æC€İ¡µ2>´P{‡>Ô``]ıóÊ©ĞßÓŞ õˆB:§¯lqÕä>D®¾²¾¾ô3Ÿ$Ç2w/ÔN%v|V­×ÅâHh°GhtH­‡DoRÛÙ'„¾£Eèol9 5i?Û²%¹HŸ’<­UÜîÑš“ö?"C{ùÖ÷~WüTvÕçh€øóÖÅªá,?Ïoïï¿Ì¡@DùªP3 kÆ@-ÍÌ¡şşşsRëú§šé&-Fuè§èyÙHaàak85İ´Pü•Dß
`¦>œî‘û¨ãW£ŞùŠ÷“_¼Lf%À"`~ó€û1çĞ†5âu”¼HË­º{Ğ|xÕ¨§è{ÍŒÓRnÇ^?Â£QŞ‰ö=fmC¹ı<VI_O_Eÿ”_1ê}ßj&m„ríùØ;Ÿ²û7ÊFÿÊã±ö#èo‚¬ƒ|"}ŞBU¾Ès”®¬ãK\†}6 }0Ø,‚}xş$Ì‰z3Ê.ÎeCz@–$…1UÚ}t ²ûÏLëMJoèqG'œ_é?£Ï78ëuèş0èlCÑ|éA}Šº?Ö9L×zèØe€õ2>ñ¿`€wg W'`È§ir€ü6œ³Úh§VÔïªIÈİôœ~wĞN/š-ô´“6è£1Ú§3ÇĞ4ØoÖŸ,Ãš(><Ígğ?…)?A–h¤%Àrì}"c'¶ê5¸×{›ıvı>ğ,lĞ
¼ÀçÃşÙæ¸÷/DıÀ/0ö<öy”=G*@÷Ô½ÒjÌ_…µ„Ú'u)	 9lºøğ[>CŠgi¨µÚH×ÚüÏ sĞlc¾K€8ÁşÆ;Š¯às“ùÁÜ0ºWçñÙS:(_Øœö™•˜¿ˆ¥æ>z2RŒeû,eÎ²¿dÖfn1g2Rqz…âıqÖ“95H¾jtÑ×øj_p+#Ùï°îz–zDi—ŞK[™³Ì·Œd»0×ØÙ'ÒòñAºNHûÈÌ¡¸.fdÆwäïiÖ¬7·§W©V£Zı4Õë!·C¿wÑ}d/bXÍ	tÑ8ÜåÌİ9D¶2¬^±{½,÷Â½´GÙµW%{…aìõ/$N{µªü%9¢+ÕÇ’1¸ïmÿ }lì¥gP¾bôú>ôÙÎ>a]“€¢ŒDû!`#0>P&Z+D‡UG9&Ñà9™ J#AÓdUË%`§1h¯3g©¸»ëw‹«ÔŒûú¡¡ÑúeÄFì¥}Œü ğú³ñè.ÎåRFfø:T2g8îBQøİQ 8—ÆŸàc0‹sÇg•£æ_ıkwøy‚vCnÉğsOÇá§5”—C%çï*·ÀOqæŒş9ÆqŒä8Ç¹/3~¨4bÇŸTî¡…i¿L&b÷Òq¤o”ğÑ¿™ùVµß©Ÿô;ÍşÏ­şq³İß½ÇİÉ©]©XÆş”É¥l'Î‹™<j”Ğ3éx¶KÅş*Ö«8@æzøßrZŠuOs^e?ÔwÃï`O¬÷]ù6}K^ ­8{¶şËT»œGµå”Ñ˜Îı®¾UõÏ•ŸÑ9å·!_§iÑó}ã÷¨¶‹©>n3ÒkàİDùıÔ8Hø®Xmª’ï>l¤=Ãh—ì‡Î]Ğ±[É×Ÿxîa¿Ÿõ³¦S¡C?ğc¥íÑ¢lÑ¥l´Cq¶à5Í?ª÷g0şMúNÀ¡]±ˆOŸSÌB,Q{¤ù„²»Tùúïğ«àXm2òü[Šÿû|_ïÿ÷åœEuğó}»ßn­ %˜„ò°<JlbhŠAQ1¡­8<ÒÚ0õFÇÁ–ª£ĞR"D
j$RMHµZ‹Xcu
Ê€­%cµ£`©5Uj…©’Çöwîî&Ÿ>¨ÿtg~sîû{öŞ{Îåµq¾”u™’h“:ÎRµ±/—ëù±Ú$S÷ë+3ñD{|£Ìw¥ÆiaßµâZùom¬åV¹€ôJ»Ñk§ídÆ›ò™&>Q?UìıIÏ‹Û"Yn1óÓFu0ñóZGßURÍ]21­Mu†ÉÜ£Cà>&¿B)ëïK^ «ä-ß(»Ğ".âÅô,Ø¿äìÕÉDk³dØsˆŞ“ÅñYjMcß½Ï°äÍÛy2Úz_¦Zÿ³4‘!ãL»øñwe†]Aÿ¹ÁşµÜ`y¤³àAö#ıOÉÕ‰ë‰³*' ^DŸt™á,']àmÕvf½Š}§š~I]CTçI:?Èª~Â~P}I'ë«ºvëèx,ıÌ:u\ú™6“‰ØééË®™ñû¥ÖÇ_'o‘…±‡¼íØuJ„o'çí…±j˜¶½Pê‘ùÈ÷ ÖÂøÀ>_–0ösÈÇõ] ÄÏİ…¤~#<o†uÉè<Ç*OÆ>èmOÎ'
åB%Ç÷é:Ó¾^ÆÚwpñ¶+ÖÉPœ3$×M“Üø~ÊËéÉ'FËÃö\Ú–ŠÕ—NÇƒoL’‹“×şäÀà$9L%ç+_ıógÑïTàÿ.‚›Œı×Ëyf½KLîzÏÇvHeì-ï(÷¹£øyÉ1ö¬—3ÃÿDyµ)ü?öJ‘Ú<ZNúb%ÌGÿk_yÆ­J&Ü!n¡+ö›´‡hP¬8ºÇòzç»çME™ŒÅNSì2tÙß;ïô—%>|-õåkJw¾Lrm«`Ûá
¶Ş®Ä÷Ë9ŠUJ]©i?AI²ëUjW«Eûšşæÿ„û<úè+öÜGï3—INT&ŸÙè¹–…wÉ±ÚDÎÆ˜Tcş?ÁÙy	vÂ¿ĞyØç1a¯B!¦ûñF3±ê£¼1wËı"Õ"íÏ‰tÌæÂw4Q6‹ô(ä‡EYoÔşéyÔíƒ=°Ş$wqe6ùÉ~ßÎMÁx#ışÚï(ÑN{‘ß¿})Ô‘Şì²öç‘«‘GhßL¿
$1@ÇbäXò3€ıĞñgò ¿ß1ş	èÙAÓQ@ÿzX ñÈ1Ş¡Ÿ¯Lñş8Q‰·À÷LÌ‰¾Ñ7Ä	Ëğö!£oğÿ÷%Ã·D/Ø˜ï%%éísÜ7N(ùŸŸ†Cö}^'1¥kâhbYsküHo·šx2fbÊ@bOÕãt5~E®5ï¼—Ñçv¹½Ê^¡Iº[ãyr#àŞ“Ú¼‚>ÿæîé‡=Bl¹Bÿ«ôñvã»úqç>ÛáAî!?_–ú´ğníuÇööi_hşd}ä)øÔéUÂò9Ñú‚€¯*Q_|²ôå»OÙ—§ğÑÉ~ú³æC?’>A
·½‹{Ç¥Ñ8 ¯|_qîÉæ£qGR~›rœz“Æ%a>J¯úŞ{Ïgr8o!‘sw²pN'Ùs½×Âóê=Çİç-È;‹ä2˜ÊØÍ=’5Á»k8i| w—ú·´)Lk’BòOÀ“şãUø¾Ï«‰ı†Xú¿zåt-!ïÚ{LÛ«*úÚÏÑ}«ñ¹‰±™Ñ}ÿâ°ÀEplƒÛºÿ5oHæŞeáyõk½ãa¬#©bÁT’wŞ|}ï‘ïG¾wñ g›I´Hé¥Èd÷{|Ÿ;{Vb§×é<nÚ\K]™ıºLãŸ“°d®}ÀÛÊ~]"‹§Æ|ù™úNpéû}ï#=ÙÏ=$1NıPàfá?’YÎDBÙrõÃpm¯Ç¶WÇß–!ÜóC©Ë
d¾sóà¯œ\ãcÎ l -¬ë€Œ‡
»HÎ…©û&\ceì¦ïòø%ÒlµK³İ$åŒ÷TFƒ¬Nß)«ÓXOz¹¬s¿"ëìù²*c¼Ôò~«%¿RıUèW±}W˜&vkpËUºnÆÈ²pÍÑ˜ÀèWÄ½z¡·!yŞ°_Z	¶)eı;¥–üÊ¾bÆùpFçSßlööøR~øø›º}~¹\Î8cHçÛÖËyv®™ï!ã«ñÙ‰Óçt£»±qT—p.ìÒ™*
c˜löÍY¬{ŒüX”•™¸`¢\ÁÿšY‰¥’e/“Òxƒ÷Bwb&İGö^³g—©Šî¯`Ï­ŠoáŒ¾&4mï“Uü£%Ù§›Ô¶v›ÔáìcOJ±ÕÁ8[İxíFæR°—êPgÏ4û3;Ø›ƒìå;ö³gÎbıéF×• ¶›Ç-
¸ûŒ3Jc«6ì¾L¦›5SYì[ìcÕ_kÂ¶i—J™{ûõ1öÎbæ"CZ8,YÎùÄ‡ËX÷dú.–êø‡R¨ÄğöÇmÒ(¢X"…6‘9wÄş!×Z»eöª…ÂjÖó‘¢íLÛ­2;à\%Ş;‡ú§!LÙO›²—>
Ø”í¼·¡=ş>sŸÃøqôúÀ×ÉêÏ^@Ÿë,ŒúUö•ØêÓ”D¡¯Ê‚(”«%(Ï‰B¹ÊIQ(Ÿt=RµK¥GªòQQ(õ9è‘jÜáQ(~ı¦F¡|êIè‘ÊÎ#¢P>â8zL‹Bù´¨ÜOÁ³¼QŸPÿ‰¯¾¹y	r.üŠ4ï^oNß´»¹ı¼¡—ÁlÚà½ÁZ˜ÙƒÎåeú}Ây¼[Iÿù-.íÛõ´?·!˜³kS ëoáwIyÕ¹»öûó™¹Ñ£k»Çxk‚öónöõî:ù¿½ÖëM¿Í=x?{¼S×öİT÷®fÒ¿ğc¦®§[nğçíäèeC~P_İs/È.Ş‰+¸¨¯N‹‹¨Ô»ÖÜ¹U2 ÉW™ƒôÃzß9hc_,ƒb8ÆÈĞ¸AïpóäŞ7ïÉW‰Oˆ#ğ#ûÈ¿ÍëÙ‡gpoŞ+£uûCâÆV¿«1‡µOf*&Öh1¾z¢úƒŒK¤ÂN‡%‡ñ¹{¥Æ©ä>õß²§¹7“¿‰¸ãN)w\YV/5î_©·d
şª$,ß¶ÎÏKäÉi¡<m¼T¤?Cù½ÄR92UçsÏ—YØl\8w·¶ê;×üwµ4‰t|®0:£/òLä ã‹5vR›¼(Õè“§ş»iÇäKÎÙœ«í¦_<)ÕéqyÄM;ëç×uÛ>ßj“LçÉKüT2­7Ê|çuìz±t ñ5îErvb+ëZ'kì]ŒµN†%2%ÛÄ­fl_†c4Ï´I{"'×„qTw|ó2{‚X {`=*Õw&­ßÈ¤xÃØ=±M®´o•ì£A|‘¡Nn«¬sZÍ¨4ñ×©tïÂ·6Éç)I”§_.%i92Ìİ(ÙŸ¹sØ›¯á£a’Ÿ¨Î¸WÂÿyù#hÎwypæ^…­ÁİQê—›³IYçš ü¸ªüz­óùéÎCşø¦în¿}§ŞUœµ'ªëP@'|ò?öË8ªêŒãßŞ³d%ÙBD2foŠµPJ/Ñj68Hy…K#Y`5î2›…bm%S©Âğ’Œe #¯ 3Ò0ˆ»3V#Z´Ø–¶Bí`Ği­Ò¤Ó:Øæöÿ{6YòÔÊt¦“Ìo¿ïÜ{^÷<¾ó?jÏ~Ä~Î8o–š¾¯UºSºupÛKdycGçèaGOöµ3`oÌ¦±?ãÀZÎ>šÕÑ½-òn“ÚNZûÏÊTö—¼ÖXëõ¶9ºº_;~íÑ±jŸe­£«ÀÎÏêë¡l·şÀvëõ¡ì\Ûæ8•µ¾õäcšµ*ë±J—÷ÜŸzÛè´SJÇ²~ŸŠq_=7c0xİ1ŞN»ÃÛ™k#øÎè~ğ–"_)‘o¿İáÛßcù®8Ş(·çKÈîÈåZ*bĞçGìgÀap
¼2àpÙÂ…v6ÙĞê9gÇ&y?©íï6´»íÔ¡=DqßôQ€Ï»Á€f'_Êİ-¿±“ÏÂA9Šv òF;£Ì´sAÚN&;îÙqÌ¾í¬œ¯lŸ³í«z?ë<¢Îuƒ1ğ¼ØÌ¥úîÁúîù™ı8É>öÒ	u/µ;™^}Ş û}ß|óx?#o‡¢ãú.ø#Ç(ÅËàyğ¯-5À Úé½:*Í{‘ñ±ï»İ>Éû@<kÿa-Õßøø¢ökXƒ'}›a¢Ì=òÄÚëöªŸã;£b_Yş«8¿à›|ÖçÀÚ&ÄŸ—hÑÅšÏ£bp+ê!Ä‹ŞEDÍó¶án;1é·öm­RQlr´Ÿı
ø‰3ÎòùŞ\D9•2ğo@{hÅŞ¦ô6ëØ¤C×YçyO¿²±×%Œ».áÛê1ß©_¶¢o[©šgëyFhª{9m€¦,dıÁzAî…&ª‚.¬U”a\"îèÆÓ4GrùÚìÖDrNÓlïU4Ûı@|•qqR¼	:Pö}hÎ:Zw#Xûp¬Y‰ÓGÄÑŠ;.”³Ø[çà°ß&Ë•„F=ÿ (ÅóÏÁ~¬€5ì·À`Ÿzş Y"ÔåÏ”!ß3•Æ1a¢<7~|«¨ÊèÀ³)À¦*8ÏAh<~W#óYÆ9´ñUò‹åOÆ»7@×çê]6OMOÏ_è6ÿhª‘`İî	Ûí®sTêPsZ 0“]|ú‘ÒQØ­öL°éóÆ‹cÄrô9d·‹Ç²ŸÓõ²¼Åô]Ï4w°7€søk4ñg"´ts'êâ»İw“ıOÌÛ*ñ:úñ–äieÛ½¿¦òüU¸÷Be¡ë”µF€uÕÉ³“°¶ÈÅê­ÍQdwíğ^Ëê\ß7h½o´ä.ºSÅ"ÖZ|–çsşõ¼v<ã©5áô±koó~˜ƒØÀû7¦öpÌ½†àµ¥´ çß'Šé;°_6¶`¾B¥ªì0<¨ÆğvÔ»İcaŒ€ñ%œ şMüv&çı%I»·c­@l©„_Ù7ùœ©¸hn}U3îSÈÇD¨J‚ ÌÛC§½Aª`Œ¥Hoé']Hã}y4^–;tÚx›ÊQ‹1®í›Fû73İß=DZ<Nc™ìzë^Ó}ÿiû%ÖĞG}W²o¿^ğ¬eïŞÀZ*C¾‡ŒóØ³'p>|L!'†#Æº{|$×ß#N}ĞçŸGÌƒF¥|F°æØ
íºˆu©h·sœc­(õ ô—•@ç#ÆÎ”÷²›i¶Œµˆ©èËaÖ¢|O“1È/ñrœáä:O~@gŒ¿"BºÌ‰KìË±6ÀŸ…÷S8Å1H,@™xvÁ‰Y2frlã}ˆx%ªÁ×‘ş“1Èxˆ~ï‘…½ĞâÀgN×>›dì4œzĞ|¾»È};—Jy"_x(½¤ôeVcîJ"Ï‘\z¿ï`"4çM%4Í¿Ğ¯bÖòİ÷®&Ëg¶w’¼¯È¸ƒ¹,éÖù|æñ9ÉóÄóµ††#¦”ô¹JğÜz¶‘ÉgÆé§àx]à ÏiÇ³2Vºè.ÙbœZw^©kø~Çw‡Ú¯æÜı²w¹bµ¶ÆáÛ6ã\íyf¨óş êîR<Áp¿ˆKŸ‚¿c•4÷âè¥«§·ÕƒgE?ïÁ{*f__òÖ}:ü8.Ûì0j¹°åbU9ì$!q3ÑÈòŠF8ŒB¿‹Ç]'ºâøÿc>Ğh4F£Ñh4F£Ñh4F£Ñh4F£Ñh4F£Ñh4F£Ñh>.¢‚k©ƒn¢ä%ƒ‚TAuDŞÆËäAš¨öãWÿİ#Ù÷Q;R.rş®u]¥|A#]ó•ï†ß¨|/ü•Ê÷Ñ]®ät¹ó¹N×‡ÊwÑÕÆ|åTh¬T¾ÀóõÊwÃÏ(ßÿÊG›ö’IUâÿ:xZBQØé” 8HÑı´T>™ŒT>ÿÖãyLæ(Ç›05âß¤Z<[Œò)j’©(l¹—ã·9Ãğc(Ëyc2O=HÉúç>Ø$İ‹g	Zôô…kËruHÅâÖMš¯^¦œ–ãxZ!k0eİKd_MZˆÔ2¼MÉŞrîò½¦UYyY5§'â‰ÔıK£æäDri"YŸŠ%âåf¸±Ñ¬-^’j2k£MÑäòhCù”;æEæF&„“±úÆ‰5‰Æ†é‘OöHúf¬É¬7SÉú†è}õÉ{ÍÄ¢›7cq3…wuñX*Ú`ÎIÕ§¢(o¨H$ÍŞ$Í…‰eñT2m*ÿ/N÷ºƒæ¡…¹`BÎäO¤ÔÕˆ<Óñ†Ë-Æ€7ÊÉÿde.e®ÿÙE©ÂÙ_ ßQ?OGšÃb=£ğk‚@PµØ—ñXÕÏÂ(’6]<ÁzÎ>ç†IòùÄÇ¬æƒ¢Ğ$<nK×ñã¶Lõ­–´“ntlÅ5Ò¦óœ×¾"+ƒbÀ €òf‚`ø1ğ¢Cmô&°OŠÖôm!Ô°ÂEb"[5~ô~¾e}¨¸Ñ«İ™üaÜünYªDìF© ~ƒ <%ğ»Ø@ÀkÅ»V2D«Ø•†‚a¿ØN+!~@—‹B¨}K&(Çfk&0ÒªÅ÷i0è€˜N‡€j7¡Ø&2}Zzâ5r§eü…Vù×¢ÓkÑ‘µhr'~]2]8ÿÚÌÈb®ş¡t`¸,÷@º²Êq2ÁÑÖ,ŒÂ
r‰¨ˆÓX
‰aKaÂ^	{·h ÙÏêL h5£½[ı1ŠÆãuXcŸ‡Ä­b•ÈlËÒ…N;ËÒã¾há‹'‹Ñ2K@Plğ¥­ù¼¨–ƒ¿:“÷ou:8ÊzA|Oø¨¹š‘ëòPàáÇÌúå—D2ùÖ£áa"‚ÏŒ`XBè£ëß¤—oh›ÇÇïîQôÈNlËNâ¨±İ{lER"U±ìÅUB‚õ<ª”²êE”8-R“R%¡eĞ,Õ,mm'˜]âš¥lVóÂ²Ö-®;DW(]ÄÆ˜;Ó‹ìÕRÒcï†÷½“ògà7e²¿÷=İı>÷»çîôHVùM9Ğ›2:•¸ÒKºÑ÷}¥ì†W–şå9ÿIÉÛË««Ê’ú‘éGGk´ÔÖ>\5Z”QôšÊ<6`^&_(yÃ«ì'!ˆa§Q›–‡~µ9ìÚvj;5‡IÍáôe=³ˆT.’¬2I EÔÅ±ÚmaA+²²oÿpEyJqaaœ«XJŠÖ½¥–v13—ÕµS†¹J;Ú‡#·•	œó	Œ©+¹Ò×ğ…UÅ//å™’«G YÇõ¶²§±5 »Å–ÜVz±baú”§­İÜ48Ş‹ƒÌ	e¿c5±HìOìÏb»Ù]¼şû¦Ùô?4|³Êjû£ğºÑËşÁ^e#‹¨1¶ÊÖqóçì¯¬,fÁ¾boàı÷àøwà·¬ş/x™•K0Ìı#«­[\,[·ƒÍ
÷4+{zš•®îaÃÃ~Ã>#½â/ğ}ğÏX•ÀïÀ]ğ*Ë‘/à7Ù9
ÿuÓËÖÄgŸ²r^²ÚÅLK¶lÙ…}b‘Æ»ä _cŸ°d/B?¶¼{Ñz½äİÇ;V1e?g9«w­ìMÑ!¨@6„“.ö3+,Y°Ö4^alAw…uÔ—”'-)šGjamI3œl7E†Ï/{e˜h§Ò¡6kÙÂ¦ñ\“¸.FfPd-ƒ2+k¥óQï7²aWÈ	ˆaŒ)hš.áÛ»½½½+[rPšÄİ$"""+‰,ˆ,ˆ,ˆ¬$²2{DDDDFIˆùf@d$‘‘‘‘”DDDDRIIIIè t:]:„B—„B¡K""""$‰ˆˆˆ$B B B’Ğ@h 4š$4„&	„B“„„„„SNNNNI8åşä!AÔAÔAÔAÔ%QQQQ—DDDM•šñ9šDj@j@j@j©©©5/='ƒáØLAÓĞ$Ø*Ø*Ø*Øªd«òxå!Áš L&S&„	Â”„	ÂaJ¢ ¢ ¢ ¢ ‰ˆˆˆ‚$
òàæ!A|ûCù­·†]¢)¾kÙ= }šÜ—>E6¤¿KŠÒß!KÒß&—¥_$aé“Ä+ãIÏî wİ¸œ€^….@‹Ğ2tReí.ôwh“è¶õ„º¨.«wÔmËj]eööEû²ı}Û²½ngšÑÃÚä}·ò¾,§Q>€ğ%‚2"kvyá>;‚¿CìŞùµöÀOïúé?]öÓ÷ıÔhaÏS›¼Ói$Ì0qšÒwxGùöúFqgš_¹¿‡[Şgy™®5ì€€ß‡ŠĞt
CÃPò@\¶ùŸÒšC®A>¨ÒD
Òİˆ]½ÂÚèRéó6Ò"òøöƒ[µ|!XÙò€}jùÎs£…®ŸøUDobçnÀ—-~İ7ìW_…]·ø!Ø+–ï ìŒåû’môEÂm=İô1\·ğS	a'-~ °|^íG"zĞ¹÷4©}Ln‹…XüˆˆvŸØxj'A9½mp¥„	=¨Ğ”êÛù×ü~ø?±°8_ieì®§L_Ò[ùZğ§6¸e´Šx|?›n
¿É—<³ü#ŒE=+üC~ÏË4_Å¼ge
‹_ÖÊì†¾“ÏğÏïñ	ş?ÇOñW<h·øY¾&¦IÒ4Ån¬ğ$ü.®Âcñç=e9Åãü\ç>~D[ëK7Æ×Ä
áFög°¾~OYœñÃeÚ©ûÕoÔõŒUªnu@}ZíSw9ºNG»c‡£ÕápØ6sÇ®òf]Û]v§0»M”6Yw2Q¢@Iu0ò1w*	–‹Ò„Y}$Îkæ¿ÇÜeÚzòes›;JÍ®Iœš‡‰²ºyÊ¦š<“*R:ŸF«É~X¦ätªL7EÓ•³ë9t’+W{*„Ò§®\M§‰«û­ˆ+Ò5Úyäxl‹"Ó,_®'«}æc)ó—}isXT6ûÒ	óÒ˜v6Ua¬-«°vaéTÅ–eñS¢İ–¥vO†á4·#Œø„!Ì%šÃı$*Â°G8/pÄõC\kñÊ8ok›Œ³QWÜĞâ±¢¦É!2fÃCˆÁ‰+z½2Ê­Ñ”ˆ¢)·&'v@Ä9B‚\†Pü®“q*“™ƒC<Í‘G!#2—BÇğFÌ®ıcvíGLàÿ|G´4”ŸZ»ãw|Ê˜ï½õºËœ9¯iÅ©¼èĞLÅ›9ÿÚëÂÏ›y÷xÌœrÇ´âĞúİë¢{È+’õøéTq]YCúPÜ}.–.E¥ŒÿÉ5û(WêØƒƒ¥D®ˆ±E·!º#"—!r"WDÈ\ñ7Ä¹O¦ŠM?w¶á%¶½g8ÓÓŸv;³£â@Wö»¦znÙ½N¶ÒæwÔlƒDWĞ¢Ÿ3ÑÕæf—kêhÏ-z½ÙåDs§;J.-A	sädÂì{9%Š©ŸÛzÏ&ÄKv»Hüşñ>'…¿'#ÉÄ–¯ÜV¯|>?!Š|`‚„éK˜ÏÄLT©2±4Ú>lSÙVli‰—7«è`4'Ò‰Z€°‚z+ºTV°T&r¥½}Ãnã|Âs›´‡äSÄdiÀ#_r¥Á‘†ãqU¸µ·Ja Â=×;ƒ¨,x‚á‚§,„íh]YB#__¥Öà’Br‰‡j.ÅÆ´D¾kVoŸL\•À¥©]Ì/ÌÀf„:<`‹¡¦ƒ/ED¼j0& ¶—Â´•B5%KÁš †@xp€<    ÿÿ   ÿÿ ØJJendstreamendobj16 0 obj<</AIS false/BM/Normal/CA 1.0/OP true/OPM 1/SA true/SMask/None/Type/ExtGState/ca 1.0/op true>>endobj41 0 obj<</Metadata 46 0 R>>endobj46 0 obj<</Length 5767/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="ï»¿" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c002 79.dba3da3, 2023/12/13-05:06:49        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:illustrator="http://ns.adobe.com/illustrator/1.0/"
            xmlns:xmpTPg="http://ns.adobe.com/xap/1.0/t/pg/"
            xmlns:stDim="http://ns.adobe.com/xap/1.0/sType/Dimensions#"
            xmlns:xmpG="http://ns.adobe.com/xap/1.0/g/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:pdfx="http://ns.adobe.com/pdfx/1.3/">
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">bms_logo_cmyk_blk</rdf:li>
            </rdf:Alt>
         </dc:title>
         <xmp:CreatorTool>Adobe Illustrator 27.9 (Macintosh)</xmp:CreatorTool>
         <xmp:CreateDate>2023-09-25T13:28:08-04:00</xmp:CreateDate>
         <xmp:ModifyDate>2023-09-25T13:28:08-04:00</xmp:ModifyDate>
         <xmp:MetadataDate>2023-09-25T13:28:08-04:00</xmp:MetadataDate>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:OriginalDocumentID>uuid:65E6390686CF11DBA6E2D887CEACB407</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.did:5b0707f2-3331-4669-a1f8-b3bb5fecb5f7</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:e9ccb478-a5e7-984e-a54c-e534a8c2b689</xmpMM:InstanceID>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>uuid:db5659f3-6411-f742-bf8f-b16bfaa386c3</stRef:instanceID>
            <stRef:documentID>xmp.did:4edd90c1-b301-4d0d-b22f-f129dd224159</stRef:documentID>
            <stRef:originalDocumentID>uuid:65E6390686CF11DBA6E2D887CEACB407</stRef:originalDocumentID>
            <stRef:renditionClass>proof:pdf</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:b521286a-9a99-48db-800b-c0dd2945b62d</stEvt:instanceID>
                  <stEvt:when>2020-01-02T15:36:11-05:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.0 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:5b0707f2-3331-4669-a1f8-b3bb5fecb5f7</stEvt:instanceID>
                  <stEvt:when>2020-01-30T11:01:24-05:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.0 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <illustrator:StartupProfile>Web</illustrator:StartupProfile>
         <illustrator:Type>Document</illustrator:Type>
         <illustrator:CreatorSubTool>AIRobin</illustrator:CreatorSubTool>
         <xmpTPg:NPages>1</xmpTPg:NPages>
         <xmpTPg:HasVisibleTransparency>False</xmpTPg:HasVisibleTransparency>
         <xmpTPg:HasVisibleOverprint>False</xmpTPg:HasVisibleOverprint>
         <xmpTPg:MaxPageSize rdf:parseType="Resource">
            <stDim:w>415.562183</stDim:w>
            <stDim:h>104.989900</stDim:h>
            <stDim:unit>Points</stDim:unit>
         </xmpTPg:MaxPageSize>
         <xmpTPg:PlateNames>
            <rdf:Seq>
               <rdf:li>Black</rdf:li>
            </rdf:Seq>
         </xmpTPg:PlateNames>
         <xmpTPg:SwatchGroups>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <xmpG:groupName>Default Swatch Group</xmpG:groupName>
                  <xmpG:groupType>0</xmpG:groupType>
                  <xmpG:Colorants>
                     <rdf:Seq>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>Black</xmpG:swatchName>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:tint>100.000000</xmpG:tint>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>100.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>Dark Gray (CMYK)</xmpG:swatchName>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:tint>100.000000</xmpG:tint>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>11.000000</xmpG:magenta>
                           <xmpG:yellow>7.000000</xmpG:yellow>
                           <xmpG:black>77.999997</xmpG:black>
                        </rdf:li>
                     </rdf:Seq>
                  </xmpG:Colorants>
               </rdf:li>
            </rdf:Seq>
         </xmpTPg:SwatchGroups>
         <pdf:Producer>Adobe PDF library 17.00</pdf:Producer>
         <pdfx:CreatorVersion>21.0.2</pdfx:CreatorVersion>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj17 0 obj<</BaseFont/HZWTVT+ArialMT/DescendantFonts 47 0 R/Encoding/Identity-H/Subtype/Type0/ToUnicode 48 0 R/Type/Font>>endobj36 0 obj<</BaseFont/HZWTVT+Arial-BoldMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 49 0 R/LastChar 153/Subtype/TrueType/ToUnicode 50 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 278 333 278 0 0 0 0 0 0 0 0 0 0 0 333 0 0 0 0 611 0 722 722 722 722 667 611 778 722 278 0 722 611 833 722 778 667 0 0 667 611 722 0 944 0 0 0 0 0 0 0 0 0 556 611 556 611 556 333 611 611 278 278 556 278 889 611 611 611 0 389 556 333 611 556 778 0 556 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 500 0 0 0 0 1000]>>endobj37 0 obj<</BaseFont/HZWTVT+ArialMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 51 0 R/LastChar 233/Subtype/TrueType/ToUnicode 52 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 278 333 278 278 556 556 556 556 556 556 556 556 556 0 278 0 0 0 0 0 0 667 667 722 722 0 611 778 0 278 500 0 556 833 722 778 667 0 722 667 611 722 667 944 0 667 0 0 0 0 0 0 0 556 556 500 556 556 278 556 556 222 222 500 222 833 556 556 556 556 333 500 278 556 500 722 500 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 222 0 0 0 0 0 0 1000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 556]>>endobj51 0 obj<</Ascent 1006/CapHeight 716/Descent -325/Flags 32/FontBBox[-665 -325 2000 1006]/FontFamily(Arial)/FontFile2 53 0 R/FontName/HZWTVT+ArialMT/FontStretch/Normal/FontWeight 400/ItalicAngle 0/StemV 88/Type/FontDescriptor/XHeight 519>>endobj52 0 obj<</Filter/FlateDecode/Length 535>>stream
H‰\”ÍŠâ@…÷yŠZv/šüİº·… Øjƒ‹ùaœy€˜”N`LBŒß~êä4=0‚úiRç~u ’n»CßÍ.ı>Í1ÌîÜõínÃ}j‚;…K×'yáÚ®™?~-ŸÍµ“4.>>ns¸úóT•KÄ‹·yz¸§M;œÂs’~›Ú0uıÅ=ıÚŸ]z¼ãŸpıì2·^»6œcĞ—züZ_ƒK—e/‡6^ïæÇK\óïŸ1¸bùS¦Úpë&Lu	I•Å×ÚUïñµNBßşw]•ËNçæw=%U›³,~E~%¿‚WäxKŞ‚wäxOŞƒßÉqhU2³Df™“spA.À%¹YÀìÁJV°‘LÏå†¼‰,œ%˜%œ%˜%œ%˜%œ%˜%ÌäóùÂ½ö.Ì—%Ÿ=zö èAØƒ a‚<{ğèÁÓÇÃÇÓÇÃÇÓÇÃÇsï{÷tópótópótópSîW±_e¾"_™¯ÈWæ+ò•ùŠ|e¾"_™¯ÈWv«èV9K—YìAÑƒ¾‘ßÀìDÑ‰²E'ÊN(;QtbìÄĞ‰Ñßàoô7øışFƒ¿Ñßàoô7øışFƒ¿Ñßàoô7ø¯0«Èrü¿Â=E^`î÷Ç/œ‚#Oºû<ŸÍ}šâÑ\Ë™ÄiìúğùÄ‡ÑÅUx'  ÿÿ   ÿÿ Ù4endstreamendobj53 0 obj<</Filter/FlateDecode/Length 32536/Length1 64686>>stream
H‰Œ•	TTW@«úÿ_PVA±ûÿnøHÃ(ÃD‡\cfÆH¢3‰KD×D%jpÃ]pßEAQ#¢âÆâŞmƒkÔfĞ83N=¯ÃdÎœœÌ;§êÕ«WuŞy÷ÿª—:uz,¸@p1lø»½ m˜˜DÅ$E§dñe 
àöyÌŒT¹mÛ}% ˆK™Ô¶öy 4NHœ¥î?@{ fk|lôø›ç–,˜Ã‚Bâ™£-~Á>¦üã“Rgµ¯¯_KL‰œ
^±õ­¤èY)mûiLÉ“£“b#öa¾†\ >(%yZª- r ^TÙ÷S¦Æ¶Ç¿xàT—Ù €ƒ°NèÍnáÛ6sÕ§rwTNÄ«ìƒ¯‡ Û)˜5€¥:ÚóG C8È¶&¡¶åì-†áp@›ÍÆÎ5¥öÓ€gZØz 'ãÇ,ìÆ„ İÉf•Êóßƒmr¼@¢ƒ£ÚÉÙ¥SgW7wO¯.Ş>]»ùv×h%Y§÷óWo½İ#àÀßô|7è·½zÿ.ä÷ïõéû‡Ğ÷Ã>ï×ÀÀAƒ?òÑÿôç¡‹øäÓá#şò×Ï>9jô˜/"ÇFEÃ¸˜ñ±qâ'&LJLšœœ2eê´Ôé3fÎš=çË¯æÎ›Ÿöõ‚oÒ.ú[Æ·™Y‹—,ı.{Ùò+Wå¬^³vlØ¸isn^ş–­Û

‹¶ïØÉíÚ½gï¾ı:|¤øè±’Òã'ÊN:gÊÏVœ;¡òâ¥ËW®VAuMíµë7nÂí;FÓ]sğ®aì¢Áìª"Ã<´©dÕHÕnÎÆ%sÓ¹y\&·˜Ëã®p¯y~¿HğÎ	Ï„WÄ‘ù’D})’lb’&A3IsFS©±içk×kÔ¾‘¼$4H*}&”FK_Hs¥CR¹T+¥çÒ+©Eî,ëeƒÜS’ƒå¾r¨&”#ådy¾¼R>¬t:o^gĞõÔ}¬¡‹Ô¥ëVéŠô*=é;ëİõ^únzIßCÿ~ˆ>Zë§òsõÓ) ¨gÅUñT|”îŠ¿¨+¡J¢’¦¤+Êbe…’§ìR(%Êq¥\¹¤\Un+¡†pCC”!Æg˜dHLœÙÓ»°[¡Îª²†XC­aÖ~ÖÖıÖ§V[Ó¸æš_67µøµ4ÙšìÿûÃrU Ò©F©öpş\—ÊÍáÒµ¥Ü®Šû‰ïÄGğÂ2¡JxA@NŒš–tNQb„µDM¹¦EÚ4m®ö¥’$KC¤ˆvjc¥4éˆT!İîJ/¥×2ÈîŒZ £ÖKîÓA-QË–s[©ui§6T7\7šQËî æÆ¨uÕkÛ©EéÇ·R“ZDµl%WÙÑA­’Q»Å¨õí kH`Ô¢S5ïBÙŠVõ=F-Ü:À:ØZkmjŠlk¥&·¤Ù©Ù°ú|Î¤†õ£÷™ô°\ËD»æYh	h+Á¦ª¦‹B›kşS–! ÏùçC,ó³ê¶xY<,n–Î‹³ÅÉ¢¶8ZDYgQYà™ıAıB&«˜¤×¿¹WT?³!ÙÅ}˜Î¬ŸP—P7»¾ÄrùA`ıRËšº¢ºs9ßœ`.°ç×y›§˜Ç²U9ÜÜÛìold
5õ1…˜z›‚L=Lz“¯ÉÓ„ÆF£ÅøÄøÈxße¬04–‹™uÖ¸Í¸×8ÈØßØÏèoÔuFíÃµõ'ê˜Kã¼ãÜ…2V‚Äõâ:qmÛ=é)…¹Üq©v~& ÓÚµX×çX—çÇ0b™¤	L/²hg&!”/mËvĞ2	rèå0Ş!×Ñ îb÷ªİÛe0üÊP«?ešõiõŒŸy[ûv›G½ásÙEÑ¾Jÿµ³~–9FÙaú?âC;¬8§P§øÿ	à`¤ÃB.’½>a,…,ØÛa+¸B&Cú¬€ğ#,ÕÈŞÓç°	vÀ?à%¼‚|Øç¡vÃ8ˆl•çà\‹p	.ÃÕpª`L€FX× j!‚¾…˜“ 	a2äB2L˜
Ó`:¤Â˜	O`ÌÙğ%Ì…¯ ò`>Ìc¯ü×ğàæàjT!‡<
`…&\ƒkq®‡fhABÀ†p#nÂÍ˜‹yèˆjtBgÌÇ-ğ~Â­¸°‹p;îÀ¸wãÜ‹ûp?ÀƒğO¸™˜…‡ğ0Áb<Š.Ø	a	vFWtCw¨‡{èXŠÇÑ»àb<exOáiü½ÑöÂ>ìŠİğ–£/vGjñ,VÀøÜ‡(¡Œ:Ôã9<°/â%¼ŒWĞıQA^Å*¬Æ¬ÅkP‚oáÛØà!<Âë”IY´˜–ĞRú²i-§´’VQ­¦5‚?­¥uP@ëim¤M´™r)òim¥mT@…|?‰Šh;í ´‹vÓÚKûh? ƒtˆOä“è0¡b:JÇ¨„Jé8 2:I§è4}Og¨œÎR£ót*é"]¢Ët…®RßÄ7ó-¼M •À	¼ $ˆ‚ƒà(¨'ª¦ª¥ëtƒnÒ-ºMwÈH&ºKfª£zºG÷é=¤Gô˜~ '¬ÖŸ‘…èïÔˆ7ğ&ŞÂÛxNî¢«è&º‹¢§è%v½E±«è+v5¢V”DYÔ‰úÓ\ßAZIÀßéùz¦ûíù`Éy…Í»°KP‚äœsPÑCäŒ„*D”œs–äİ‰‚€ˆ€u¢r
ˆdœsÎ°,°7WW÷Çü555U]¿šy)$…¥ˆä—ÓrFÎÊ99/ä¢\’ËrÅ=tÙ.Ç=rİ—ëºgî¹Ë‹Q[ÁV´ñ6Á&Ú$›lSl*ÆKQ)f?±#í(;Ú±cí8;ŞN°í$;ÙN±Sí4;İÎ°3í,;ÛÎ±sƒCÁi;/8bçÛv¡½ùWl‰]j—ÙÏìßìßí?ìçÁÑàXp<8NÚåöû¥]aWÚ¯ì*»Ú®±_Ûµö»Î~k×Ûv£—RRJIi)#±RVÊIy‰“
RQâ%A%)2+2›D†QCjD©	5¢fÔœZPKjE­©µ¥vÔ:PGêD©u¥nÔzPOêE/SoêC}#s%YR$UÒ$]*IeÉ«rM®Ë¹)™REªÒTšFÓiÍ¤Y4›æĞ\šGói-¤Oi-¦eQD1ˆU·ÕuWP÷Ô}õ@e«õH=VOTªÊUOÕ3õ\¥ùl€š !,0„*D!ä‡( ¡V• U•UƒâPJB)(e ÊúŒ6Åç8•©ª@U*B<$@"$A2¤@ªdI59.'ä¤Ü’ÛrGîÒ6Hƒt¨•!2¡
T…,¨Õ¡ıNÛa|Ãá#Ã'0FÁhcéãií¤]´›öĞ^ÚGûé ıIé¦#t”Ñq:A'é¦3t–ÎÑyº@é]¦+t®ÓºI·è6İ¡»tîÓzHÙ”Cè1=	0c° åÒS,ˆ…è=ÇÂX‹b1Êã€Ç¬9ÂÈ†-3‡,ì°$–ÂÒXc±,G9çç,‡å1+p.È…¸0á¢\Œ‹s	.É¥¸4—áX.Ëå¸<Çq…¨áxNàDNâdNáTNÃŠÏé\‰+sgr®ÊY\«s®É/ğ‹˜€‰\‹ks®Ë/q=®Ï¸!7âÆÜDîÉ}nÊÍ¢6JQ†Q‰:nÎ-¸%·âÖÜ†Ûr;nÏ¸#wâÎÜ…»r·h4š/š?Ãİ¹÷ä^ü2÷æ>Ü—_áWù5îÇ¯óüîÏoÊÀoñ@ş+¿Íïğ»ü¿Ïğ ÌC`*Lƒé0fÂ,˜s`.Ì“‡0ÀBøÁbXKa•lÉ‘GònÈ²\¾”²R¾’U²«Ê¸·õH=ZÕãõD=UO×³õ\½P/ñ`¹^©Wé5z­^§7êïõOz³Ş¢·ë]pGïÓõQ}RŸÕõU}SßÖwá.Üƒûğ B6äÀ#¬‰/à‹²F¾–µ’+Oå™<—<Àcx¹ğÁsÈÓV´Ö¸¡“0kam¬‹õüéØ›`3lm°vÁº,öÆWñ€oãû8D'â0ásÑ(ƒãpNÂ)8gøŒ4çáß+ëT\ŠŸáç¸Wã7¸¿ÃMøşŒ¿úf³÷à>ğ0ÇÓx^gâe¼·ñ>æ`.æùŞc}†Ïo
˜B¦˜¾nJ˜2¾•ó‰>ÎT4	&É¤˜4SÉdèj¦ŠÉ25}CªëÓ~ÓH“ilš˜¦¦™inZ˜–¦•imÚ˜¶¦io:˜¦“élº˜®¦›énzø²NÖÿ>:Ô¢İÿæcz™¾¦ŸéoŞ”œq¡Ëç
º¢®¤‹uq.Á%¹—æ2\–«éj»z®‘kæZ¹v®“ëæz¹¾®Ÿëï¸r*Z<ZBT§ÔiuFUç8/BB¨ÃHˆ¡	mH!‡a(¡£a¾0†…ÂÂê¼ºÉäDEGDre·ì‘½²OöËùSÊ!9,Gä(\«p®Ë–`]ğ-L2[TV°1ø.øU]Ö‚ßdk0*ØŒ×m|ïìà;T{5UM“mº³î¢»ênº£î>ó$ªË¢TÑ_"#‚Å·b%F
¸İnÛëöÁd9,nÿ–³ÔKÁtU_Q3Õ,5[ş©†›Af°
[å{Ù$?Èò“üK~–_d3lƒßa;ü;`'ì‚İ°öÂ>Øàœ†3pÎÁy¸ á\ö:ëx±vÖeu9]^Çy“¯a?|İ;m‹í°½WÚûâ+^nKl…­½µßpnõŞvâ.Üíí~€ƒp°Wü¾‹ïéD¤“uŠ×ü!Ç¼ä‰Şóxïy²÷ı±NÕi^õL®+éÊ:Cgê*ºªÎòJàCÌöboàM¼åÆx©ÿ{§wkx«o™úº¾æ×ï²¾—ÙĞK?ƒgñœ×›ì'zÃ©ØÄd˜Lo:Ş{N÷Šk™Ú¦&c²®¦«ëûúnúãUUqÅï|¼İ°$aùÙ$(oy&•lV$”B–lv† ùÒİ4ÈnHJ‚­	DHx|h9H…Rm‹
JK_Ò@•6RõØ£!l+¶µ G$ıƒÚ
ìëïmBLúGOwö½wgî™;wîÜù]JÃ“®ì§4™E."óËÖ7Öh^¶øÖ—
$ŞÙÿ _°F`êßÑ	ÖK~<
x‹R©˜öï¤²Q5Z6S9Š‚ö,Íì IÀÇO7dïN>Fc™Ëü˜y£8ƒ^)‰&Ğ,Z¤½Í3WR—hÍşnbëÌ¹İÜa¾ ¯8*Ş2oÒpJ²_BİæçÊ{æßÈ‹ÏÀsÎ³Ã“³¬ƒäÙ÷ˆE’™KÍ/¡È½›$•R7ëâŒ^O—˜‹5?FÙgæëG‹ì¦Êfs·Rc–šİ4s¬Â¨»©'àlrœŞg‰J¯ù‚ÙKi”Cs±:ÉºDìæúØLXL•&Òtp–Óo‘œv~/W•\ÄÅÇÌwiM¦*h»=ÿÎ¾ÀM»\¼)ƒf%Ã.?°¬Mo Ë§S,`÷ ),çÏ‰)3NF©C¦²™Åèç€Z ‘ôˆ}ò ¼n»-vÁLÆdÑ;½†ÁDÿ{HõCîç‹q¿\;åËò´=ŠUß‡|gDö1Šå±2ömÖÀšYNßnàşSì2ŸÅ+ùı¸iÄ
q\¡TÈ‡äxøÛåX(özì±/Ì\s•ÁÖCûg•uÀOz€%ÏÒyºÈä9É(VnQÅÖ <˜ñ³x¦ÓYN±‹ìà±kì:poeX˜	EãòGqGîÅ¹¶Nögüß"ULÀ™š*
DX,‡V-âi”Ãâ™.{€òsQv)ÏãÎ8¨œPzm‰ö'(áûnfß<£XklW¬=Öa~@)ØÃtXa<@û(Ê2ì÷.xÜ/é23v ›²y°Ìb¶Œ­`«`É'‘Õ½×ıò¬nd W¡sŸ¥ó]ÀjE|Ê}¼¯À=¿ƒwğ?ó/…wÂ‘"²Ål±HÔ‹‡Åj±KâÜÅÅ?ÅS:äx9AfIœ-Ë•ò9yI^Rj}>¶9lß³mBşóû7ì…ö…ö2û" ü#öw"V„Fœş5ú±Àq˜¶ó)2±ñ$üy1Õ‰ROåX+_Ë:øÊ*Û>ƒÍ§^™[¿ÉŸ
˜!JY	« e|rßh¶1ò|
äïéŠ|k;‰‘WÙÙãüª-‘Úñé˜óq·ôˆ·é}qÙåOé¯ÒÌó
ß/ÂËB%Dn±—‰l-æ"Çõ„­ğãùìÄ…J–Ëş%L|>¼hšø6Ğıü=ÜR+ıÕÉ¥´¦°fºD/áTLT@LaàRç£Yqù2V7«PÆĞ“l‘Øc»ÊÏÒJê‘:'~í{ø!Q*{•rÖ€°–6Ñ
s=­VBò4[ŠkûÊ”İšE®tãû}D•Ä´#8İÇf‰R´¸à9óàUˆ{PEœğ Fœñ{ÅNR‡­’wÒR%™!êÉ·cåTm¾D»Í¥ô€¹ƒ¼ˆ-f3F<@ÓSt€mŒ­¡&º'ç›§y4½\çgyß5taíLæ¢OQ¡R¨ü†tùª ™æVóOğî;awS-}‹>Â*?ÇsDM‰ÍçmfP4a½ç©ÌÜogj0¿KèUzÑ®PÔîÁì4Ö»†êy¹ù°¨5ÂOÁ
>Xk%âÏfŸ¿ªr–ofá7fäOÏ›6õëSr'ß=é.o'{â_ËÊ¼C›àVÇß~Û¸Œô4WêØ”1£GtHNJî–`·)RpF9-Q¬ˆ!³´9s¼V]‹¢!:¨!b¨h
•1ÔH\L*éƒäwşKÒ×'édNµ€
¼9j@SîbMídÕe!ĞÛŠµ°j\‰Ó¥qúé8ÚíF5àj(VQFğ‘=)ÆpmÃ~Í_ïğæP›c8Èá ŒT­©¥²8ÁSùmœ’ ”‘®Œ4­ØÒÀ™h±°,(Îp»ÃŞƒù—hµiEÆO\„üñi›ß°Ç§Q­ÕĞµ-§KßÚé¤Úˆ'±N«‹Ö„[sŒô`Şb#õ±\_U1ø(¨e07CèW£jUu½E5~RÌu[ïpc /ÏFô ¦Ş
#–T¨˜o‡¶SªÖJ¬Uõ­¯^X-‘eª1L+ÒôelMºnPùjw{zºï¨yÒª^ÒÜÆÌ--×6†ôòÕ¿Jó©iC9Şœ6çÈ>Ã¶%è'“õ¼8·¨’òË2K#m.ÂP—¨Ğ$¤aMyÖ«>ô%yÃ/ÌĞË¨Ã4Ãüİ™oµ[ı%Ó©©ú5‚hW>Úío±e:¯‘EZ~2àjàß¢ÇÈÎ¶\ÄîÇBÇÂx}ª7ç‘N®iMN˜Â¶Ñpş$˜ßí¶6xK§jQ1Ö•…úê*Õf´“o’'lğˆÅéºÅI©²8ënqºG4xr1#!kà?Â9vt !ß`cÿ»¾_R¡•”U‡Ô€é·mIåZ?o€×O£ı!‘Áû)!â\8eÍ€°U	%2[Ü©ë:í	ğÊxSƒ†32§ïv¸İÿg§N³×êÿ|Õ­_M#ß3´>cH}ˆz‰º€Â¸*K*«uİ1„Wë›pnÿO•!·ê7¨
'3ÿN³+ÏzÂ†&ó[ğ¿¾¦şêÁŒ~:ŒŸåŞœ ®55¨Gôh§¹®VSš~”Ÿà'ô¦@ä–ãtšÇ¶dÁ­aØªåãPp*jÓXkY›µVT‡:‰ÔÖÊP;gÜ)
[†äşÊĞàİ‹‰°—8‹Ã[…€—íDî‘î‘™x1\y7TÑuÃ§ĞuRe®%j•ñˆr†şÃvµ 7qœáİ½—uºÇŞI²%Y–e«È¸
Ø ¿Ôˆúh‡iKqBRL0EqS(Mp:à:¥@x„bBhq›òÊ@1)4u
¡äGÚ00xÆM[3Ì”ÌÚ1”aÃt\S"¹ÿ0™>îæöööövÿı¿ïÿş=ŠæXr™5¥<JS8vÖòànÒaíiÄQøã¸ãÆ¡]Ş(Hf&Òt"êõ‰Y•8‰#Ä¨ª­©‰œŠñÇ{şĞ°tpËº²9á(fŸÄ÷°6v5sÿM;÷¼›-Î†şcşïXÊt2‡L12Ìù0‡áŞƒsOkÀ‡JI#Tîõèº]íQU»rÇÒe™4êZ±F´ãæ£pü—®02ªÊ"pÆò!ÓQ’Ù‚£ÑÒ9eë·.mø0û¾ÿ:Ø·wçÒ?ßÏ\Ëş#›V¾½†_¿=Ö+ƒS#¦ğB+‚¹!XÆ	$X'}áqØ¹­†}H' Ğé<²,OÒt‚&P=+išfÒØ0ã³*cÕ1[”ÊjjjÏ/|jv¼†n}-Òà{æ›0ï\œ"«È÷ ÇG,ß²†#¸¦#âÖ@¿æÇŞèct4Io¢Š†ô¬JÔ
‹¬.ñÌ%å8ÕÛË0î‡¢¬çĞ4ËK˜±‰œ‰'ß	ï;yÛÊ‰dü”ÎÕ?<<Ì¾…¿N|8ô>ÄM^ëvÇIjòšrÇ÷q˜p‡¹“áÖ"ì†Ş@<ÉÜ-Dnn]09z=Œœ ãišÃ ]˜Mn¤çÑ¨Ç0îêÈ.ñ	wş#Ô8ùwŞÎŠpã)Â(nÉş /¸ƒªZàHMŞ²±gËÇÀwHa-(_Q TXª à‡¡†õ°ÿw¤qId#İÙ•1ËçtŠlHÊZUV²¶‡C~6fòÑ Ğ²›„œïAŠÌ‡Ë„KŸ¼n}›ÛÉçı’&8$§—Ìs-ğÌ÷}¹p‘k™g™ïÉÂ©Å¹Üõ¼§Å÷­Âuä‡âZçz½]Ü/í¥—¼WÉñŠó#İÿĞÜ6‡U®ªt`ä âè(6Ú(¥Ak6zu/¾–#=ğ=ÙM?0'[QÕ±ÃÕÔä¢fMlv~¾	äÃ¥eÍÍ®1h$\*‰-#k»_øÒª‘#—×ı´¯kÃ†®®—7ÌO’Ìã9Ç›Og'¯f³ÙNì?‹e÷}rşCW=·qåc ğ>`'£“Vˆ³T£ª…ßDv“yüq;(Î!`…à!Ù¶^fkB˜é@jòºİP¹m6 PÍ¼lù\S˜ØøøÁRõ*aÊ•	–@Ÿ³'ğP.4Z£à—hî€‡DC±¾ 8óJFKÂ†(JÕ…1r¿gîÈ¢}«xé‹ŠßùÊP3[[¸,ÁÚ‚øâ.9ªz].±QeT2»2f9(…ZĞ-EX‡`½4xT˜åÁ°"„Š©AH¨Ô âò0+‡QEšYZÏÊó³yÉÃ	Ó$ö„–C7ÈÔ<×-§é"A7kccwÃĞ,TœNÒXÀÔÑöâÿ›ñ™ÍÇf³'³j„÷ÅébŞ¥€ô5¥IY¤µ(+´õæz×«æ yÃ£ğ®_yßyÖE
i€Ñ ß›¼‹$ Ü€–?(Ó<Q
øİ€?/àµÈó85HSäèéÇl¤°·—­ ÙîĞ1Qä¶‚ğ6ã: [PQ\g)Fo=i&«É&Â“~ò9TŒwŸÊ‘te"ÊäÄ%“¨Og’£†É…¢]›Õ@jrJ‹¦" %qòûMMÓ<%‘Z@¼¦¦º
¨o‹0ÄÈ1$0Qâ¥OkIÁ´_¾ñÉ¯¼´õ îsİûÓÈÄWßúı›Ë‚'NÌM,?÷òù+[^?¸Óõá_nŸXòöàÑÏÌ¦,¼ÉçS¢¸épNŸ×bş÷fT*ğ€ËÃ²ª+zP–Ë=Á ,åjXU¼>H!ÊÈ’"EÖ=RÁÔg¸‚ÈŒ××CI~éô‚§ç£³ÙÅğ›.¨ùê<u»ÊÏ32ÖrOæ?OW¹Wäÿ@]çŞ®ît¿ZxL•…góÆ©¨/a˜3X,XÀ üª–#W÷(Š‡÷ö“£ÈGµÊÀJÌTÍ¶æĞê	y“C›¥¶ˆ­MŒ"4BÀâñ³ìM¤c†7…ëº}#¸×A"9g9?S«GRøg§¦ËF‘iÖx4™Ó­Ì(#'äI†gNU ¢·6¹jó™fÙÀIµ«S2%V¢pidqOñ–M'ßÜ[à6m©í«Ûåî)¹ıÎ‹C-+WlíÈŞºò»IüŠ÷@ûo·n8âşyqãò­Û¶…z/~·{EóÁ™Áwr.ûÏ›`´4€
ı o*X5æåYå¥K¹¤¸êÏyÎ#Eä$AvrR Ø‡8ŞÍq<§"¢¨¼Ä”[´NKF<]ĞÌ§ÈÊ³‚ [EÅUò”Ê¹ÄdWÆì%§p­¥JVi¸JÚ\R-uè„ÑÉ©º«¡$D8Â>fß@eôû†ôj)¼ËöôP?[Ç™¼$èMjë OL$Œ8sr<Ş>3ÊCÈèºî†}zR!ç›qœË–3çJgÄ9¾¨(Á†h0 åV,g\Ù¼0®X‘¸R€ûŒ¸­¶M°í¬Æ1#æ	œÉŞÌ6rèõz²Õ¸ùwæÓùÇ²G ¨÷dZ€x,÷—¿]œ‹œ>„a}*[hrĞã	˜L*œ:Ïª†‘ä…|aïìŠeLÓX”0‰2ç!2X`”›¶öêvùuÿº¢E{]o¹>P®(æ9\^íó~ÎQ)T:ûAÇ8ˆê’=¦Ë5¤énÍåÖtBÄr1C,­6ššnyğ£Îê<aáªf…˜yF3]M7Ñİ”§$^;H¼yÿÍx• 7qá÷ö^k%­dë°l­WÈ‡Àø(‡Á	Ê@Èj›†Øƒb®ØCÁ’	9¸ŒÍa‚]$e€&` À1`»îpÔí$’&CJÚÒQC
ğÒÿ=I@ÚÎ´­öißJûŞÿß÷¿êfÜq’¸›u{¬x€jT»åø#KÚ÷Éòˆ.aâ(#t£a ıRN‡,"*|Tóp-¸­ïÑ¸’èsøXàr$‰àe¿rì\¸¦£­iFSæÁ7˜‹'Kë[NciÙæ›¿À«Ô›z÷íj/ëd¾û…ñâLãÖÇçZÚ¿"®­2ç Íó¢l\S½4+NÃ•˜Å)™ZÈŒÍf(U)|º–dNĞ0¬’"Fœª¹T’AÕ<up®˜İêû´OıM<“áˆÚ&™Z“ŒÇ‹!Çøäñz…}š^ÃÎçIìóôeÒòÔuRCêgÒ§N›¨“gD9!”ù©à‘‘Nˆd"C÷ë>2a#«œlf`)øB%I$ˆ_3øÙQ!;:>¸N¥‰„E–Â.®Ÿ$Dm’@2§áÂs¬«ÒµØµÒÅ¹œdÎå$su2ƒŞFM01ò0‰1Å£J{ŒeŒĞ‡¨]9¡[!ÖL‰¸ÙIò§#›:’HNz,¥ì½÷ÜC&ÖLªlóTOuÇÀKÕÿÉèÿÙ†¯Û.Œ,}£dé;û^Yqˆ›jY[œûäß¿œ;Ë¸ıÉÆÈëx~<Ózöş¥ğ¡òÎİ; Ì½sò-	YzÍ˜ƒ7#q2haa.ƒ9Y1×±,CBRJK4Ëx¬Rü7T
¹¯dØ±pZŒW‚yL¶ÄP\ıPmQñÍH‰z‹¸1Òê]h+Œ–j +é`Ä
¢„İ>r6{¼ÉˆLaíb×ÜØÀİmkÚfØ{_´áoğ¹·IŸ;˜t!?ÊePƒ
JÑrˆF‚cÊrrì>Mà35»Y“6Òœ ]DĞJúKCkÜ8‘´ºÙxóÉÆïbÂ—äPÈíú
_Ç£náû­q\‘ÂÂ‡ÉIº!¾!º~Ú™Xã{>¹ƒû¡tr‘<–üÒAåÌAwúhñ‡Á³ğ°ØâaĞÈáNœåœèœ¸ª\Ëåå\üz¿Ê-“jMK•åæ®Mh#nâ¤Õ¦z¥Á¼Ùõ¡íıD{:0¥=U÷“®#§¡z€ĞGËÒ¤¹‘ËØ“ƒ‹tİ)ËLuHÖYC:pÇŠ‘Uµ2ÖNÜr"ß]w”Å,Ì·ªs<li!ãhÎ{ØÒÜîßŒJ^$¶·0İ)Z1ÆP/­Eµåå8şƒ˜‹;W“cËãÔÁ–,¼zêô75‹7·.^4nµÌi¨™¿nCUõúÑ›§®nm[³ò ›’µcÁ?\ŞSõfÖŞõ=Æ§·œÁÓæ×¯­œÛXÿAqséşUkµUì+ÛÀ "5G‚(3BÇaK`Š F!†t?{¥½;`§°CÂpvt_tk‰Ã,]}}}ly_ßı}}ˆy0€_^DD\}[¬*-úÿèˆîPÉcJË)À(Xxú9LÍU«¥ùò,u=Û¬ş_8­^WM_§3“Õù¦£êå†ù†EæÎÌYXS‚Ìs8EIEÆ’ ˆAWv'd¥]š.*I0Å°,¹æ ×XS’àW²Æó’&°B'³$$#I¹b0ÃtcÏ²+:zAd§LæÎs—9¶™Ã\'Æ!Ódå´xYa›¬ïªU</2+ÅU"#nµ~öy4ZÉpÀÛó$«‘r-òDÆö©x7ò9Á ÔÁÆ7=Ó ‚ÓiT{{-½½|ôğ™tÔ4uÒQíGÏupVV»¡‰AîD•ã¥¤v’—`?ëc}l CY¦àcæ¹K‡ŞÚ{·sBzjß}wî1Æ3x{×K›7eÚ*z2e£Õ1±q“gL&¡Œã&ø§û«üur½,üØ³œ_"×™ÖòkMB†SfİÙšÓ+Ë‰v-;;+¥z5ˆ[4“Hr…È‘ 1T@ôH°İyA"ÿ.Ğ\IÂ´Á%•üBI ÷)r—ââÕtL@¨“yÈé-*pt@î…Áİšäè@ ƒë¡ò¿(33ZĞÈ+*^B¿GnF/c GE`9‡Ù
‰§Zz¨pÁ›ï1ÏnaüØ—mË~0ù#Ÿd¢ãíL õƒºªêu[f¬:ÓdlÅO¬õì¤	kv_àEÏÆUŒ¶­Éhã»Ë»^x~AFÏªêc³òØ)6gUñÄÅY÷öˆÊ¨š	S^Îb¢ªå_ä/@V.ŸË,ğ28*üt_‡*ÉHGùæ¹h	Zæ]…ê½Íh˜}×ÜÅv˜Ï™?BıŞ^›Åîµy½l¶iËNÕÓ1OOšá˜<Ÿ¯ñ¾bßdßÅî´ìJmÅï0­¶ß[Qò¨Iª‡fş±=³öƒC3U+Â\J¢¦°)'«ë³( cŒ=i®€.aI!«‘’µ¹3iı†‹Iõ„Ï˜{°Ñ`BÂµĞ ^Š]çO³*Èç\b€¨ãH²Íã:Î>aüúJÄøü­#xÜÙ/ñ1§
În=ø—™‹®6üüÏ“÷í½3ø'Ÿ\ÁeÇ¾ú`èŸî3¾mù¥qmcÑµİ =€h+ÄîJh˜†ÇIQtÚTÍŠ$X²ŒÓhË+SPÉ	Q²›^¡Ğ£’äIóªÿ7ônÇ¡w'=íß¡‡A./wÜË¡lŠ(	/q'$»=nF0% XÁáLr&:Y!…uù°İn)Õ‡	6‚(ƒÙğZÃ¡.§Ë	æ‹|öåˆœ™o7şçáŠ×Ë—Õ•¬hé[gÃ…-ïæ=]üæÂ’6ãC¾Ûáıáã|ïÃ88;¿mDŞÓ×ö_½­Á®¡Hpë 2Ú

¼&I[D,ŠˆåH,‘$¾­3º‰a<&NşŸq
™h ”€ÿ`jÂ˜vâ+¦d÷Gí1Ÿ„Ÿy¹°[‡­ì¥ûW˜£“ùî6ctÛ@¬ağ¦x3ø_”WlS×¾çÜ‡¯}}ŸvâWì\Çöu¨y„`\²qUh6R²V¸¤‹h'ÚlJWØ(îÊ#°N-lJ©Ælš´NÒ¶A#´2Ú­h«(Z»•M¬lİŠP‡*ÄÙÎµC&4©s¸ç|÷}ÿ×÷?òÙáˆ?R;Óè!Ñ‡6™dâF §˜¦‰m’w@HÄô€!+Jš,v¥;é¸z‰ZB;Winı8í\òÿñºB¥£–éA\ğ„¬®eĞªå¯—ì—'zBh5ÑsÂ5pa	É°€KDªÂU¡*VğZZªÂª¶Äg%RA9g*U_öûLœÕğ©8ª’ +ü:,1w<Î$YX*Î3­IkÊ”?$O˜<šÒÿ«ò*®éJOp	P|_£Î.ÂİÏÏ¸PÜ?8€ÚŞÛĞëpüËC_Û6úõøœï~úêçñ¼WĞØÅuë£‡.œGëş^İÚBë—¶.îİºx£ğp#Ò!'Ì,b™·‘¬Á<¸~`Îç²tŸ•uöiuÎ^;ÅÙ)gÆœ=¦»}—¬eMşş0Q‚ÿ<s€y•áfÀ ÚÆ|À\exÃ„‹/0,}\¢é,¥å?Ëiy¥œ–×mÍÑ4-Äï˜T²óW.;Z ïèY×4–/;fÚy$	gé'GICÇ/³ÓzÈÖVãG…'ğ¡WîÕ7Í´A‰$Ú0
ÛSİnËã-ixü#*Ú) /$9uACõäŠM‡4)oúé³}m¾NçCéeòù¨\Mï—ª©Å*[ò±–ïq,"š’ïã¼>“÷5RyÙ0¡#›5÷°km×Â5µ£¯ëõß ÁşoÎ_ÿ4ûÉ­ĞğÙ5"=‰h…»ÀNé¶½slŒgD“H"ü²­º0û™éòút)ÜA—æ¢tœ¯èÅ¿‡ÿëgğ{FPáM4|É™¥3"D“’Œ¨È:­P3 H„+v-A^ƒÜæU/ëfİ’Âˆnì‘­‚O‡h4x¹K–Ü([rË±äöèÉpê”vîÜ)C&C»\†)Ovµ‹f–@W–®]yºŠÀ+v‚ L‰Š0Šr[{èê*f‘8¬š ‹G^ÓcdUºğ^–AŠÄˆ"Âb8ù6
è—œÀíŒ¾j·åe÷Ó¯eÈ–¹6È\>¯©É1&ïXC?”S2{ƒUÑ#"÷¤w»÷¸Ò»Ğ»Pe§p)yª²Œ]Á=)?¥ìE	óbNnPãvË[å{Ï^üÛçêûÙ—]‚UE©ã±Ÿç±cb/½¨ $¸(º=T°¢h$NFÁÀÆîgd4ó(oŠÃh¦íñº=¦íİ"!iŒTwğ0w7Œq¦ºVCÚ0nÍä;ù¤€ûô¹P!Ğç×òMAÈ3ªÍ‡'N.åA©ƒ´IaĞïD±ïØL;lPE·…ù/ïøMÈÁó0üœ§º¼åU/Ü«…{ÇyüÆÅC®©Ów†â9ej<'lÌ)õ›W§å—w€²gzòÀ?ş¨2ĞĞˆâzBG	¤ïEI´¢®24­Bü‰bûáâ2~äæ'»¿Øö}öÖ§ÍÜ›7gso’bÜj¨štq´ùˆ!Rôø*²bĞ[	3Q’q‚DL—C’ˆ],+º9Œİ.‘cMAàËÌÉ“t¥”Ê;•²ÇÓtÎ›2¥6©SZ+$^A0äÇdø±Ï&¸’4¸SIyæN¢åL4N 5ªˆ" )£"³G#ä”ßq†¿øšWÏŠ&,Á3ëHc„ŠvsÌ?5ÔœízÖç\5¡‘¾C!€õ$WÚR"çRüpøÈùµ!À¨£ +¼q¤¢¿šT:ÂYhb·ï¼q«{†ÛÁ*Ü,İÚÊåü;ŒÂD˜³v[XE~Íï"Ó8¿"Ü¡Àò+…‚lFm}±oqÀ/ã—¹—jKôU¾åUÁöğÒÈ·/a-cY#&¹+,„é$®rÿp•ò±‹tâ} ×(!¸HXâ”zÂ…(Šª‰¡0‰:BUe­ïˆı|™¹[ÅOf'Ğú ø}¯çˆ4¥º£QcfÕ3zƒàgºP/jx5ÿt°8tòíâHÿ}÷=Ùø÷İ¿-¾‹Ï¢nôƒÑâOŞÿ xàØ´ü—ÅßFY@Òw‹u´>7Ù-3Aæ¨=uµş˜·h-şÚ
?'ycÀ0L èèUÃét)j%î-)81l†üåÿWÆŞ9p†&·±ÒÄÙ“wfÎ	!K¥?‘cT¸Ç`ìÁñ¸xB³ã){ZßÓq¥øëb/úÆÏ˜_4skq'?¢«‡ºOÇÆ^aÑs[V>[!“Ì95c%ø İ²ã†¤ £¡jyõ#bw5Œk´sĞÕE×$‘$Ä™Ä› oHe`ÿeÀga¿:P“Îêä<šÎj¥]-ípÿÂ@ÔrîÃóZi'÷í… RÊ}U÷™J+«º«Ö¹ŸR6ªÛ<½ê‹ò!uXı›rYÕ Û™ºê×uUW½n#‚ãáJ`èšìåƒnwe Š•„ˆÓ&^Cãªª"Æ,eŸ@R›„J(‡
ÀE»†Ø!Äb!o&×&I6Yü¬1ş'%æöß1ª”
 t)HÆ;Ò0J±ÎÀ½¦Üh¨Häv(Ó3üfí4	fò‡))NÛ#ÚjNÕîÖ»	m Ú1`Ÿp(§?p(vUN«ñÃQÇá>Q_YYá\0|	v:†tJĞÔ"¹•ˆÄ»N¿µéìï[k—,¿6ºä«K§Å[şŒnë»ÿÅëø‘Åg6î;M%ïßPìA3·>7Grm`g5nüÂW¶¸rü2÷˜¯êp…îb»¸õì—JÏfsUóÙ…®EÑ{«$›Ó²®•Ñ¥µ;}J‚ŒOÄßÉ2H•Ué2HĞP8; UV¤‰ro&¨V¶’8É¦Sj6± uïŒåf{bIêqiü˜òˆup£´IŞ¤nÖ6$×§¶³»¤ò.õ;Ú¶ä³©=rŸÚW+)µiqËˆXa·5¤53%lü‡êrnâ8ãøíŞíùîtwº;ëq’eI6²¬Æ6òKØ ƒÁ¼&…bL‡Wbp¡”4¡…É„GHƒgÚL“fZš2“ièPãBfB)Ó„IS:L')´¤êĞâ)nfxXî·'ËPinwu:éöv¿ïÿıÜÔÚ(ÓÉ¥T=W²¿—Tx”ª`eª BµÃvf$X%ƒÖÖ¼$p\6t´Ë"j£ª‡óï«ª"¢*R(–E<ÇbUDÊáO‚%U~‹†İAĞ¡aSeª]e5Fí¨mA}ˆˆ8nWÑ[Ò[ÃŒˆQ&âTÂU/Ó©)ôwqÿTx&5hù¦_… 7h,;í,_FsÁW;¬Ù¶!›@Ï¿²¥|$/æĞÏmFèAë´ÜÂ°“’Dï£(Í/nâT>Ú*£‘Êh´¾®¡!Qé-Š‚äez=œ×R€HtÕeõ;7ùZûªæÜ3K7¬ûî—?<|o9ë<úÎñ·ÒMèjÇ®ïìyğ“÷swß@Ÿh=ß_1këìÖu“¼k’‡»7ÿfí†ßïV¼º{å’TjS¬ùôöo]ŞºíÔ¨gA‹˜ı–Bpœu'œ8ˆ·öÛØ‚Ğ>Œp5‹XŸF¶4PSä°åA×†/Ør£ ¢ËhúÂÀ,'¸“¡ìM*yé¯­)ÓËêËÜe:.Î•r/çJˆrôèı»t¶oAõ/‡Ùº˜«–uvpÂ%óĞ0ğ€‡ªãš…9Üa»ómò…³Hf°>ˆÏâEWüğgØÆZLU0`ãE6ìAaO»wy¶xvyXKH*ØAÉ–C© ‡R!R¤	9”¸q¤ÈË¡4!‡RÖMíÙ#9Lf‡Û´ì8tæİ€]í’Ljæ]€M6€ê\×…µ¹úCîş–sîüx€œ}xâzîááW‘r‹]òğä{§Ÿº€\tD¨ss`$4#O}–A#ØÕ]bˆ(„Iõõ´ëé©¬yµ¶¦ÄŠT”`bl…T-×È]ò~a¿Ø'Ÿ—ïÈ°Ü.c;œW‚3"’¤à/3Dã~-‰bX .A „&.Œ‰·º–€LºÔº”Xº]@»„>>#d)ØŠ¥WctÂÓ3z˜´\4ÒGÎ“;„ ‘ìëwtı"O$½CMô05ÈB($~ß°™i¡ÜEƒrt(O. ‹“Œvâ?'EÑÀÌ]“ı¢ ƒËl aÆÎ7uvÚ¦lGgJåy"…ğÌÑ® SBåUè•ß^ WúÉ®-;vpñûsèšû¦h;õè/V4ÎDõ¸5ÓLƒ6ÌùÌ\}¾1×ì`VèÆ
S{]xİ9¾VJC~_Ò]GêäÙd¶¼Ğ½Œ,“Wº×’µò&÷6²M~Şí$nJ®† ©†í}Ìdì]óÚêI?ÈrÀ‡|,¾‘(*ªÓ)»ŠÃíñš¦{p¬¥Ÿ0f˜ö²¡ÓŞú†ğƒ!ƒ¸bL"A·ér»MCÅ Û€¡¡ËNgXÓ]š¦¢,˜nâÔ5È+˜aMÍéEAÀ0'Ó0tü^¯_›)¢¥L˜‘¡uÃa1-‡B>ß :p"o²~_Û(àä¨ß7j.ní}sÂp’úx>½p º´=—ÿßA&íUµ‹¡i¹X=ŞÀf;a³u†dBşæ# N&EÀ8°ªp¦_¶ˆÕ”Šof! ŠóQl@WœÈŒVòEı4÷üû‹ø›$äıç•%“U7›ë9—û°²ÈëÊ]‚\ÍüèµEØOGı¹Ûwœb@“}%Ü=÷ÁaŠã+£‚8åšÅÁ±Ïûo$Ìç–
ÎK‘zI³Œ~õg«\#ÊÅ…„T­rëÑz~½ãS#ËòB‘Èó"ÏŠ’Ú%†%‡K’<Ë‹,µz–cÉŠxÙÁ#äÄ>K”$‘Å ê 6-QŸ°¤]–ÑiKq8ä0Ã>±´Sö´%B¹
nÑrØ%A/7Æ6õBMãäWy.ÉBÙÌw7©ú·À¸EÏoûŞ)É¤ ™LèöÚ£½*l¤ÍÂã^Ø  lĞ)AeîìØPì²SšV[d»DQ(ÀÁ—ğQØ9Q…ËôGé­ãæÑo£²öÖYO¢ÀÑ3øY¶-7ç…¶ö¡cûG@ùaÁØ\€›ÁÄ˜F\eM1áSü‰¸’H¤•wcÉ´ÄüDVÉ&6*]5/+{â?ö¼éGqÇ¨õ¦•¡’VMÛ¡¿í;ğ‹]ô]]q_	³=(H]‰N‡aØ¶É6Oõ´>-§£7d&''êÒ\zò|nŞä¯É§…Éíò^ù’|O¹—ÔëTÄiÕ‘:ïÔ2—¹:¾9ãj5£T©c*9¤Sÿ­²ªL7H¥vˆî™JoìÖ4~¹*Ój¥òN'´j€õâ#æk®@ ˆ¡ùí‚ŞZ)M°ømÃÛ›\Q¡õuÜ¾ŞÎ××G÷>ÁÃÛƒ{`ğWê`dß(Rp
‘A¼ÒR+-&ªEÃÑšè±(IS
£¾líÇö –³”à¤ºšôù4şY¥½tn3é?z+ÌòêÈ{üe‡øyÕF;yÓf™N†·á”WmîÑèÍùÚ¦GDÚ¦.©A‰¡ox¢h·Œ&?ûŒÖê¡dfxtH§ä2~}oŞÒ¦m;KCĞvz½Ğ1½ÔÄÙ¯Ñ~××UR“WT9ÛÏãv»<ŞIQ–/RsiÁ‡‹Ø–µ¿Şxìİ¹[çÕoº¶¥Z÷}ï¹ÒãfÏ÷ï;Ò®‰ŞòwŞ§.n^5õÙë-}qùœ_¾´x÷b—ªø#ROÕôÎ^³÷ÀBkÍ‚);î<xizºh±¶êy]+—Lÿ6DôˆèèÆ”¢]Ö›ˆÈÎ©'­„dBÇC8*¤³[B}!~Zq‹§Å¿È³ÈŸ²J‡3ëyÒ¿QxFYïìñôøÏ‡®Ê×¼×|7Šo{oûşQú÷ĞXÈ&ÕÎjWÉ8-²ÈÙN&×JÿËİ×dÍ­rÿãºêƒ£(ïğûî¾w›½½½İ½ÛÛÍ]6¹|	Ü•¯»¤YÄ„jøHË"ŠĞ’B? °¢Rgt¬h
R´(A£Ö”–´0üaaGp¦¨…™†u©$éï÷^©3÷ñîŞÎí¾¿ç÷<¿çñ
$Çéô…€’]Ü«P]q•F¥Ua1ÑRx*Ù|VÁƒÅ ï!›	›çyóàw
â©l FŠğæ#ŒÏ”„n
Ù vĞÊbt6]DEŠÖ›×İ\l/Ê[…rkHƒØ*”·
\ñ]'v¿ÔÂ[Ól¼/5ñ4’7oÆÿ<ìŠæŠúœXpó$7{ğ2ná¾Åª©™4Ûƒ'„uRTX"B€FÀ<Zè¥?ø]góáû5¹ÃßüéÈZ!]ÿ«–ƒ¯ol9èéúöùEÏôóáËÃŸ¾F_:ZÿÌ©¿õ8S¥fä¢Øz¥ËG}`:°E£šB]RCÖ‘° £HÙSh ,eáî%¾{É»—tÜ½Ä;üÔé™Œs¼a:¾Ñ.Î“ı4æÌÍµëBuvc¨ÑŞ-ì_Q÷éû¢ş,5â[#<$®ñlô¯W[Õış÷ä÷}ïùı–›ÿŸ‚(¼W[§mÑD‚Ä¸O%øPğX»H;9OÀÆjšBn>£^ÈâúT˜û+V1˜:à*\ËÑùÇ$Ê1¹Ã	÷H4&Í–)€I>¼Hâò*MËIÍ"€J†üÍÕuEÕÜPôıÍWıÍ|ï@vã–)zC¼x¢Ü~Lmä61ÒAŒo7Ò"'VÎ½üöÙáÿ4ùô[ŸÇE¶,ßñæ¾_¬y>eĞCs©ï ¶Ú“³ö'Ç>ùô¯OàŒ©ÌÎ#`d½»Ï'05®¦ÕÛUO™Yæ,–ø›uÎƒÂıUòJ³Ñéöœ	}¹º`^¶¿\àÌ³b±DéZEîJ“…bu²5K(S«…JµÊ¼ÃYæ[ª>¨^ğşÛ¤W:‹E×€‘Šd ¤¨d§(‰Z\×{ª®Ñh´@Mì‰A 2ÇàC©jx±ƒNXƒ‡,¬¸ÀŠÃñ%ÎR#Ñmˆ±!X|Tê‘ÎI#CˆI¢”Ç[ë´”—iEKŸ>R$/]3iMú‡Æ“®BGOÑÇ#¾oò\}SAj1ˆq0à5oòLœ¹êø–3×œ~²ñ¥)ïåÜØòúG7íÙö›×ö¶Qñ—µs„À`•<ùÑ_Nœ=y1«Í…³:×'ªÁÓ ×+«Äµuò*%+ŒSoîb\å:øYü»gĞ¼eÓ‚³"Óœ9ÁÑ9NmğîÈbgEğ§ÑÎ&ï¦ğUáj¶N,ª©¶]ca:-GÛ¥·ë‚®³Ç'‘.áMìØ15ë6@İu`Ç‹!`íª0uy\U¼µŠóKªâõrÉ¤t‡JÕhŞOHã·;ÇlŒÆ¬”^,¹Å“ÒcHåCÊáHeæpŒ, 5^†úêMàşšnÄŞ!˜}œ\CM<Ï \´PÚÔ<F1¤¦Ã”
,Ä‹LàCT¼§+yéÃ/‡/Sóó34@¯_ô½óÔÊCg…ZÿÌ¥O?ö]jïí¤1{?-şÇğõüC]«é‹Ûæ®Ş*[=Ÿ›ªn)S-2%25âFÖGvû_UßP³¢j©Úé°Ö£4Kçf©¢_s|4,$Ì½Ä×fRs$ä2;Îˆ(¼ ²„Eœ63ßnÂ‰¥wq‘&WšŒšåRn”‘8$9j—8|t™XO’ñh|ñ/>ğ`1ø·a{³#Gh) W©Œyê1pwª_ïïoÈXë! d¨iSç>ìšºá•%o8$]æÃ«åĞMLÚº•&€'Í)£¨,U–Q4YCU§ÂEÆ;mm¡è“-óïÎ™9}ñí==â+;›Ö¦«–_óU5Ş·óúÀˆÛ†kÅ¯€yd]ç6*ŠÇL*qs¾RizåÜHnR™`&‹nQÊÍ;•*s©t—²Zô}L.J–ÜZtkÉü’]Éö¤T^P>qv²J©*¨œ¸¤`ÉÄ‡¤•+'6&[“gK.\*º\bØ–7üápg©’ø$ÑóÉT>GZI7é%`[…Íîtãh¾ÊBÇï³Â©xÊÏÎîµ©n»v£İj³$”\¨OrY³¹¬Ù7dÍæ²f[ü7@##kx•3²f£)¸›ŞŞ Ñ8)ŒÕz´sÚˆÆbÚlm:Î-ŠØj…øošƒÿ¤qmÓ¸¶i‘DrCÊ[bá8y»Ò¯Oá†ú®V yú?}ø]Œi‚¡dÛ–1%À!£svYÊ0¹	»)ÓçnØ¼#;@[:>øÙÇÏydÿªÏÚÿüÕ¯÷o~ìÀ[l:pW´6>ışå3:¡_¼LéÎ—[¯¯ù®gÓïÅIw=yìÄ1ÚNˆx¦–IW|H,hü0dUŒ-Ü^ÇY™X)v©ŒŸšeGÒv–á7LÑC‰æx$Sñùã²›*OÈ´[¦Ÿ1–‹0È¥üÓDdNæŞNâu2Ï›XHÙDHd0
ŞWö!]ğ÷÷±¶òB¹h§ËÓÖ€%¬·Ú­kÄb–`Æ9_]a öCò¡sÎ†Tëµƒ®ÍYš±•YxkÂF:˜ñƒDà´¸å\W3j.FQƒôP‘bœCä§A+2vS/ggÀâ¯?‡ªYÀKÄLl%@jšHe\¢e…"ƒÃèÛ;ïny»ºsãÚšg+À~óBÃ¾W‡îöl´î¹ÍCNî  à'p}9åŞ#—ãÉ»äv¹Cî–ÏÉ²Dä˜¼^n•ÛFO—Gd_L%1A”½âã”x=^æóJqam¬u°nvy»Ù Ëg½pÄXÆ+õìFİ¯óá]W66¦lM8ÖŒ!‰|XC¶0ëûÕk†ê¡ŒÍîç#ßØòÍM‰PY*,BUvtvv²¯{z®…Ù„kgAÖG~;\Kgñ=É·’yâ²”g›Çcgy<có„UA4ıìlWlÇŞÙ}ïİíŞsÏkß}>Óp	|àØ¸½Kyã`'!‰0øJ ·8¼‹HIIpÛTÄAH*µ1	"UÚ0”(–
Aå¡šiÓˆ—ph(%E*rÃãÎıç?Û¤¶µ3;·;¾™o¾ïÿ>KÔe¶B]’K-O'(z(¬t%4­S'Q=­7é‚ÎVTÃV¤›˜L0(è˜)õ&ƒ-JW0“ ·õ°ÏÿAùôbV#‹!Ô7šSO¹ÜÎ¥g³L «òÖ¬Ïª®î0•úÂ‰PLO•bjQİ²ÃNÉ²µ“¤4ì€_ŠoîÉ?_11Z3±§ú‘m3é•“'o®Ë=s+m¹İuhö"ÆW8Â×°/:ÿıŒ#¼•ô´4O<®ÿˆ’ =‰e,¶<m¸£w€Ê_fLöâSÂ÷J1_yJp¶×;*¥²­WÄrÈ¼#¥"•jÔé …ô6W[#¬Òş.\’ä‰KUrB©•VÓ®&W3m–æÊÍêºN|KıDúıTê—®Èÿ•n*¯¦‰‚@yI’UUUQ²ä—eI 4!j~QÔ48°T!p,EIV€±œF÷OF)ÃF¬PØ]yÓ‰¶¥¤àødE¤¹&`ÏÌ8ä>"Î!âdÎ‹
€q‚ÃhÂ…×ÅòéÏcPCë3Ì‚œ#åMø…ã\o…j;Ä1IºÁ<­tCGØ•z¯{$Ìn®•DÕ—^µ]V
´ ½Îÿä–¹M}°¬VUÊÊê°sİeµĞœîa³§¼¿B38_ğ¿\2	oà¤ÁŞîòZ ±·;Èšsİf­ThğÎÀf^x9Ù‡½˜ñ¥Dñá¿ùıõx·ºmöò¿ö8…ÇI¶­ëµ£^‘jBâD†’÷¯ä—Ïå·ÿD<xçC²;¿:·ˆş8?ŸËMp©A¾^Ú'¢@‰ÌFÕ<œÂ65¡ĞWh+ØfPn<bT|[</Ò&¸\…¨¸\Ü(ŠÔ\ã…‚À³™PèàlŞæH/ÄL¾Xí¿¾«öeEj_ÀºàÇ”!3V,è¢àF´‹k¤÷j¯d² _X¥_(³ÙÔ#¼5m¨†JUà™âäÈÎ4cÓ+û‡:À ¿efë®T‚öÓ~õbè‹˜xFˆñ!%Wm'¦
B<R*˜¥‰/	›Z_‚t&º|tÌè´ˆE1±Ù˜ÖX5Õ1±ùÙ"-Æè[¨ÅcnC[èÁÌrk$½¥’Ív¢Ó!NçŒLçàtpÿUÆbÓ9X%Mç0.aqv61ÜßÁ‰6_ã«ã	ÒÇ÷º8>Ê1ş	È¿²oğ—Uà;ÃùFÆ¥¸ …»@ÉÊÄ~²vïı
ŒE‰Y4r­¨8gs¨Í/pÌ<CéA]	ÊtA–¿¯ÊoXñºÃ…z(º ¾‰2Ù¥P®ÑGîíãw.Y½-úâÑß¾¿7Şòİå¿ê™»èÑ—êhÕÏ,œ{p×¾Ü(ş7Ë©{cGnß½víc¿~=÷Ù°çºç%H6d|¢ ùøß™ûÍKÂ?|×…ŸD™äÖÃYg’7Í>û‚=hÓ˜âwûƒ^ğ\D
º4—ÛpWÚè³lô\:º-İ–>â¶t$^O°F·¥£Û‚û›@ut[:sc(‡::ÀŸŞh3Ò•0çe_·ùåv—½Ûîµ©-ğÕ rs Ç²
Ìûÿ†K»ÏpYE†‹1±7ã½ßÀ5†Ìlû]L…7Ğ„İ3
?×@™ƒ<âÂ‚’¥jŠ&k‚dVY’Û!Í;òè—˜İ†#„(3?ºâwV]°ı1Së½tÆŠ÷hÕ¶]S—Ï¿!·‚ßüÃ¶G¶Ï}…›2ø%(º¸0Yº/`³•ø€‰H2£ä
Öã^YÓ¥ÊÓR³ò©UQRf·.8Áj6x‚Sí±E}ÂÌz³Á'ì6±M]d¶yÛ‚‹ì5$ J¢k¾ğ¤ø¤6ßX&,kË-TJe$Ã_é`öqğÈ,å`ö‘m6*›C£×{Øşc=ë0°ƒ”à«L¤ÆÊ„“M9&ò¸ó l|f$}w%g¸Yìõ"Ä·ñu#¾Ö¢şpAD8S29à¹q%©&®Ù»È™íÉì@6[„%$£ô5ZÈ±í¬l©sÄ9êBq¡JYmbøÌ `(âŠCÑ”??ü9	®¿úêùüµİ›»÷¾ÒÑÍûÈ¨-«ós'®ş”Dˆëø±ã';
_¨#ßJËA/!3[ó!ó;fƒIÓ±İ1>{Àˆ—Œ/û^ÙòXgL©Õ9³B³œfe¾Ñjq–(KV³-´ÔéòŸµÏ–œŠôûû#bƒ±`œ&Íd`­3§ÑYæ<óıjYŞÔ-·,-e*,uëœ;\Ù§SËh´!„1„|ÛåŒÎ€Ôì¡û[Ã†î+ÄƒPcg-Î6[[I|Õ|µ7Áq½à‚HÙM®%iÒDÂêª1A5&¨ÆO1Ø”„‘™a‡b0"›$p%áèô›$Íû„ØÌİè¿s³í€b=1j-—e…“k÷‹j0àçY e	Eèuì¨ÛúüÏú–¬:¿~Şkc¬«×şş½•+öä[Å~ñøã¿|óİüíW­Ëİvœ8tìÌ±£e,œ‘o. †&WJ&f¶è|’mOâøu†”¤ÃáÎHWDLùRN:2Å7Å™ã›ã<ë{ÖYÙ9-ñ^–®ÿ´Íø
#¨å'3ùiÆ<¾•ÿÌøÜ¾¼¾ìÜá=„ºü%¥ºì–ü¥€¹«¹„iöyˆéÉxx6zh$£ÃvF=—)¡‡).’Ñ#±m÷ñ3,¤lë=A¶×L*øxÕc¥Uù±ügù¼<(Ó(˜Ü& c%2¹„½(W ·ƒã‹|—EV–§Šªd¶}öµ\²§z@©ş›ÀpíÄB&Y)Nhx¾"T„Go{ê£ü¿têÅÃíïäÊÿ°vÅÎ]«W½›oå•Id‘»ò›vn¹5YøàÄ‰?9ıéVá^h>T,îO™Ißö“’8MÑÉt}®¤’j)ª¢º|–êâ…èH	NS¿Õ©üìjâ8ã3{ûš¹İÛÇ··w~œÏ÷âÖ±‰}Æ1Ü’™@Á‚ÀGQËC84€ƒ
hŒJb%¤	ªH¤TIHÒ4j!Ø`hQK¢ò‡T” ¡ ÕJŠ¥(¢¨
2î7s>×¤º½™o÷vng¿Çïûı°šJ†qXHYâç›?lÓ¸Ş|kZ£‘9İÃ(x#yÉ_jw]¸WBg5Ë·úFÁ9Ì5pp!‡Ì‹¡}˜£úp¹Ê	…ùEFñÜÑ‡6—Ö¬}èá‡ç®Ô‰Ùw¶/œs,×UZ×7~™y¡4q#p¼0+àø{ÄT$5‡,"Ò+SR{É!r ı~øMèÄ‰ÇœY‹›®8RBxBÌVLc=jé¡=Á­GïU{I/íöj½ú`v0gä²é\zæìôjº*¸>»>¿£qGº?}˜¾©½–?ÒôÛYïÑßkïæŞËŸÌ~’æ«L4U5«Fºjä+êpòf4VtÕ¨]áÛu«Õ\F£b<™!›kãÃÂ‡~ÊmbÎ¯wKn·û÷Oîg®l¸õîV÷+W¬w_q÷ÄfäÅ‡CT#ìvûX0ñ%zØÄf<?-böUÄ¸¹§vK­P[3CÙ6Ø"0¾æf†fkšƒõqO»~8VleË[XÙ¹±ÊÈªÅ²q“l¥›d«\.İ(ïÒÃÂš•t–Õt^*à{
[Q`åÉş¦P­S0nb‹
qş¨†\¡¸®õ|«PjíoZMŒqÅ*|—§\²âe€vf°0ÃwÙ&’iƒ°Á·g$'â{?Éq#ÄAã úª*kİûY'†"Ÿ„â1øš0õ-å‰]Úî-™Æ‰Ç€³›JcÛíÎ–Š²Ğæ$;óN…=ù¹ûê¥HSÖ2m3lä”L ’WXº†ºœ6„(Õ¨kêLšÀù¡²'&P½YËx–g+«Lzoÿşıhárßör¸#Zš\6×,´gwTÔçb¸™S'Tš}¶ô±ñÂ½»Ú3‡?}£{ş…Wßwnµu\{fóŞŞh´%qà/GVnştßg_âkêÛ°àÁÆX¦õ±ıK»vçë½…{6Å–÷,ïh¬©ÓtÛü½=«ßúñG¬NÓß	éä /Î 
9Ø˜-Ùù`ô»aM§8€¢&ñ
­;4ÌJaİÎhxBQ%®S¶)ıÊosz[9®œW.)²Âš5Ã*¥Ò¬¹ñİ Ã,¥¢Ç&ê]ád¬÷ƒ%OR³
«TÎ
½(†gŸØø‘
íwø±9Ê~¬&Cx«­Í¼Èd«çeæ¿l»ÕøŞHÖhE˜ë3ş£y?İÒtàÀÉ¡¡°—¯{ç-ó¡G…Ÿ½„•-w_~iüğ’¦8óÑ¯Ë®‹Yxz÷ßNQH†£Eƒí¶Í½0N«á¨†ÃÑ €¹nBmÑLÌar"ÎµŠÃUŠc38\v28¾)}âp}â0xçúÄá‚ÓaúDgş˜pğy;Kã,F3˜4‰¶ÅßOÄÅ¸–!Sƒ`D’ä¹NDRmdªqşdBÙS	ûŞ/×&D`Ï&K]¦=§¼Å5öÿ":ó{i^¥sğ"Š‹fH7tAVTY•T"¢–@ºj%“!…Â~è¿°¶¡‡&Ái³ áYAÌfv ´÷óµïv›ÁÁ õô²e‡æ¾9¸ğçİíÏ¯Ÿ|ùş®e¿rPè¼s¢!
Ü€èP|ó„ <²âIß‘TDUËID•° ¥YúI-ŞµóÚ¤ëvl«‰ÓíF)«“2|×­N2³¨²A ¤;	3œá/|R×PDy8ï$©LEa€³«ş¯òÍE”„ÁĞf¢<ÉÒNÔN¢.º¯V©O’x£°YİLv¡x§°[İEvÒ< <xA9¨¾H~‡^'¯ÒĞQzVNĞ‹èz}N¿Aÿ¤wĞ-Ú¯Cc(Jó(K;h7ò)‘|;Z” UŠ'dşîŞ‡½:bÙ7X)âÊ|Á®q:Ë¼Â¯
’¤!l-×<ğ|G¼µ”J<”	¿ƒ*ªš!4BEA bÁ6B²¨ª `Y¡$€°Ô¢a-¥ú¾Oú‰@†qbÈ—ú%AË'IÁÇ©àÍ°l‹»ãåñr<66ZfTƒ±Ò<—%(İ©ÙØwa 9Æ¦U@@<ÑtÑ‹Ê«p[8êÌî·aüÇ»[ş<š©yßœ¹û´˜?°iëŠ_!9 ;d„¤Ó¶X[É3ÈfÌ”£Ì•<©1.j:o±7€¢‚e%µÊçC&ÿZ+³,ŸŸS+€‘lËxC×dVPš…‘Še'Vè,è:##æ•ó²7Â²9˜uœÉ¶ÀŠ!Áq&Yk¬CVÀJòøO\ç(V‹Á©o(š5µ9×ßú§ëÓEQÖHXN×–D$ÊA©¶‰ÂˆR£&‚µ `3JAõBEÔ®ÌQç†ºd_Y¢.>btY‹ì5Ærû)e½ºÉŞ-ÿRÙ¡‘Ï§ìËwH>håQ^Ï…òFÎn‰<€:ìêóêë#Ú1üğAğ}m’Ï†ş.^‘¿$7ÄÆ¿ì[ò÷¤&(³k|4ùâ£ÁG{2m4dˆ6²TEÍ(F&Äd\H	èXËèÃWü†R:d_k5GÂ2ZYêY+Äå´ÇÚbíµ^´¨EEÈEJ`şçê2§µ-Ş-8Ø¹9Ê>•îGÂ$	 K‘¥*hjZàûâ“²³<æo¤F(ù7KQ“ŠeÛ¤D$I	Aœ3z(¢ë!äGÕ,GÒT¥ +¶¨–ÒùölÀqUUV:¶a„BˆFn›:^§oÓûõ€>Œù4ÙMñVú,è°ğ„Oº-¼ÕzÖ,v4%¼NÚÅ€â:6„o‡ooä”È]r«\¯ƒY9öõTe™“xu<Yu–L/¸{'ÈÊù_ª«8ªò
ÿ»÷ıÚ»»Énv»yu“iHÂ…E®`’Á„	RYy¨H[1Úhv†‚Z[©L…2!,Á2<´Rhé0¢` …¶éØ6¢€»Ûó_´wçìùß÷¿çÿşïœsTĞÍ$VfÒ´kdëœ>-ªFÉ»ùAˆi‘?İ‡jŒ¨Åã
Oªi×ØV¸qbşôn¡»±Ö¦]µ3çº­ƒ»…èVZG¸­°P?„‚°6°Õé^¡†­Ø‹Æ‘;oº·ø½yÅî<o~på¢ˆu mà)óÜÕÎö[6|·Ï†/JœÙJF%,V„TĞ%—O|ÅŒTFÑ
Š›r¶Oâj·ïÿuİÄş\ßíUç€`^¿â}Ÿ|?»ùƒÉÒÛçIçŞ¯şLc€ú70‰?)ø¡€#Oxi¸¹QpAé-vıaa#²yæZBö\c·IÜ¢¿fòâ	’áÙ%Ô'´³WÃ?QÄjë»\JH)sô_âÍòfeÉ¨'”÷õ?˜çé_¤3ÚÇæUÙº{¹Y^#¨A`Á3vÓYÉàÑ,¸#Œx	@CL…¥<OQ’0ÏKBÈg€?×°ah¦AÑªš2oC6¡c1ËäGH¢D;¦a­L¥~U¥²$QJxÈTÉÍ¶¦këÔ¸l,ä¥uaŸÃ·ğxÊgÈGÒu$Ş¶œîítÕôğg¾Â¼jı5ıxf¾"]@kúæQÄ¶o]¢‹Ò;ÿ t“b² Š>=Xj+ÌŞJ©­Æ‹m
Âê½1Ûd/lÙ’±ïzœTº%ÀPÀáÔ3×Ó %€	6ğó¹-—~{_dLÙs¹ŸãîçÇç®“Jœ»ùPÍäÚÛ95{
7¦riø®Xn&ı`¤QÀH©ì7¨B#!ÃâŞçXFTqÔh+¡êDÉ…’à‡%!“)œ!×m„÷l°X±+ı³™:š­¬k²?A•¬"-hU(j…V¯Ökuú¯RiUú¦¥¬”/Xf-ó-tğÏhŞ5ş5Ú½/[/û^òo–ßQŞ5xü—ÿæÿ\Ëš7ıùÈˆ»ˆ*ò)‘0g<h<oP#toûîşàÒ5†jWBäòû|e–ì‡Š¡–)²_QdŸe©ªÂ³PÄŒêÈÁ‰dÈ¤½ØÂñgÈ,G™d9™o´ˆ•Á“ûGß	Ë¬Ëµ–UkÔf•¶¨y•¨0bOµ¶!“úÂÑN F0^¶ÒE ‡‚æğ•y%İ>T4‡Ü
²Äá.¢D@è`B/@ªËÅ°l¶9€Ôü5¤ä¯áor?±¿Á–ã¶·loÀöÆv=À4Ã ||,Æm`¿¯CpU¯÷O“œVì-÷(¹G.$â#—ûrË]Ó9{lîñífåèğ“F)W™İòôsÏ'oŸè™œjeQN%pÏYÀ•{ÍÊ“"±ğ·­â±À¡§	
ø~ˆZ¡vÄi„B©”ªMÛòt<•L§KÍæ<<‹ÌçJ-ær¼˜,ŸÖâÕâZ©o_’nâa‰å¸JLH¶¸M<‡v[ö™±è‚³Î(ËÆd¼$Q–Ë0÷G0øE,ô$àå…ÒX*¹Ş<¡Ë$ƒ>p†ş y!$@gëâÚotŒtG_ oĞ?Ó=:›7šué«‘¼ã„›QÊ#Š‚¬…suŒÑFâáa`÷äsÈÌ²Â•„9Ì7iJ"i^…ñª—ùüB¨iêGp†®'pÃ18Í½U¸\$ø®õDfK¨ÙÇ¬ÈLéÄí)œvÏ^ú0˜
êÚ¾°-‰Eá‰,8ë-¶İ´K.²‰¤¤èkb©­Ãü¨X],€…úÚX ’¼½jN®™~/{¸­ã	üW©È¿úlö±µÒë(ŸGMùkÜÏR¦Á±èô_°ZØÑÉ`ì³‰ÉhZ‚àØ~GU,ÑJ×Aü.‘nşÏ ½áŒL+ØöÖYŞ©¡¿¡ˆ³¼¦Âù}ñ‹¼¬W‚°,r ¦•%iº©EÈÀz½;­<ùÉ¢^Q”2ÄÓëÙ&°±:ÚF¢´†. ”†íÇ÷!—Á“ÃÙá`ü7nÁ) Ã“…ær€ËŠY#NCJèe–ˆycŞZŸ¯Ö;ÊKGQ/¾û’¼–»—œ8uühçŸÖ~LºIGG¶‘VgŸ&İ_!;³³H¶‘İ„‹ÜÒì9¨X²Â…{ŠC,•;Ä4eì^…õxùÓ6º­§´µaÒŒ[[dRB»0‡3dA/dfÒº…¸~çÆW3²Ã ¢l:É¶ ì“^ÜøÏO¸8˜»Æv°œ^Ç='‘‚V;å.d·ğ@ş#â_ˆo‰d•øC‘<".ÔIÄ¢B‘ø{!ƒ[œ˜Ş„PAIŒM"aœXPcRÕá¾>˜¾–ƒ=0@¾‡˜ñĞIÈ#V¶ÃƒÛÛ}uµ¿Àõõ‡G&S_G¹/Ïl{aÂÌª‡Šæ»|IùééÎ7’Ÿ‹a±gëåŠo1ı÷ÔÏnõd7‘¨BU‚ñlˆpîa4ÅD·zn­1ï¬óG«ãMÄ¾'»È9ô·
@¦¥èYÏl4w¡¹dêdBK‘ÃíD+aì¨? z€Í…ñ€|
’™RRh›²¤•Õaì~6ÖxŠ­ãêUh®8µyfç³ğ¾Mãh)È›PŞÊ]Fïğ6Zõ·aŞA¡6ælâw ÍĞşô/†¶7AÏú[Pój
eIx…˜á¡½
Öé.|o=Œê¹UùKğ-)X³äxGè© M0Æz2H>^ÄÇó[¡4ú¼¿ëÜ—{pÕÇw÷ìŞËË„GZƒ€‚€„0P±HRË#€‚€I¤5c©[_u,„FŞÄ±T2A¡¨Ğ"C+vª[`ê4´VÚiEfŠ´¶e€†dûù»/0@í?½3ßùŞßÙ=çüÎïü^«ã`dÈ…¬³çùÌë‰\ÁÿÎèáÃY èãl2‹ìƒrş’ô¹Á™¥gn<ú‡:5EZÇñ™`ÏŸ‚aÁ	¸E†nqTÄ0Ö,åpè&9‡d¶¹SØëï„¸
üNíô'p»)•	È	ôœâí’5*ƒ»,êÍ:Yï‘[yö”_Å9J±÷ pN:“ş~/™dı š5ÿjı¡Tîaÿğ`sÂúĞ"°‚½şÙImƒ¼€{Ì^4˜?Œá^ÊÁÃªûT›ë½'Š†ñî‡¼3]Áø-8»ú¤ÎÑù¬Õ+ôÃŸ²läJìúgØ€Õ!‚õ³<{›u:tÀ	°”ÛÀxĞ‡½…}]ë¯øŒú¦õ|Ã;€ÑÍúlúÕö>Ó1³!\K÷éáo“²=tMõYtÙ­­1¥>±õï2ë÷ë9Õ§™Ø3§dŒê`cßŠXã5ªœ"Y¯Á+ÔgU¿ˆÕ.êkÖ&ÄDÈÃ3ÎškcvEn}½"âÈ<K6±æLÿ~rÊz)4OH¡û}¹ßüSFº}e€—ËçáİÎ)™œÚ/ƒ¹Ë‰È/Äxµ"Y›xÈÛÏ9k°g­¼ˆM5µÎ¦6áy5ÁIO½gıß„ãHìO?SVd>»ÚñksÔ«!gÖyµAÀyVjL$O%rA÷ˆÿ(7§ú%V§Ê{’E’í‹œß2r›W _2û¹Ÿò<±Àx‘÷yÃ­”¥¦6x/Q.åN­,JæÈ}N9½œ£R¡ĞõáogøÑE>÷¥ˆ#³æüĞ§ºÁ>ñw8Ä‡!Î³øÑx|²“ÖÍÏ¶>£Á¢´¿Ÿ4úçAy^ùgÌOËbşÙ:î—q¶µ…üÅ)z,Î¯ùQsœæHÍsšg¢÷ãœ1™³?Ö<|H¦…q}CˆqèøAûäaî»$üÑÁfW°Åmlñóøÿ{à›9÷ÜÆš:5hëiß¨–¦Ç¥UTG½Á2;Ìg›l¾9-ÏÛ:Zlõkáo—ù^÷N´ú®c{¢w™™‰Í×È
ÎÑÉ]L<2¦«Mì]ˆtÔº 5Ñ]…µUJ…û>ı‚Î,mm½È—t?hÇ¨©Ê:æ•ÈFÿ”ä™"rí~)Õ»Òs¨>z÷©'¥M*‡<Q+ƒÌy'GZòŞzkƒÙlıBç–ÑPa‹ä’Äg'ğ®·ÁÎ)v¡=6Y[Øùô"êÃjÖôsd²í'NÉK^‘”C’å²¯!.¶°ÆËÌ+R]˜×ÙÖëUr/ñµ„Ü´„œ#Öÿ§unç™K^n96ª‘^96,³giÒ9v±Æ»UnRñW‘‡µŸX%ËL?å—I%c•y’}—3öñ›Kì.e~·0o{/e\çæk/£=‚ÆK²@Úûå¶«ƒö)ìï”î8Y‚%µ
;,”ş¸´6×ƒAiXy^ˆiØ±ì4'z¸Ùò]wË»ìĞJ$ĞúºY ß4Å’ç"vÛJóbõ¼¬u³d†yGÖš=²BeÓ^ú¸;8ÿ.zK?"wë¸ó.òj™f†3‰<bfÈãîN|ï·ÒÒ<È]3Ï{?éÉüÓ¬"q\¦¹ÅÄÖ"şŸ¶é{v]A‰ÂJ;/V×1ñœŠÏÕWÿ_¤/º6êéx	ıì9u]æé;f­ÇNÇ@¯47Lr*¥¬wş _uï’ï$¶{±ëè
3e3$ñ4`†ÈOÀşßÿlOËônCä}°µß„_Óï…s‡Uf¬¬¿ŠeB÷¹Ôx&¼.ÁŞ‹äİÔ8ìUÄßÇÎCÙo¨¹=Ø«ÀÇ)üùÒ!9G:¸½¿y1ÙëB<í–®ÿnN§Ï¿Ü;d1ºøW€cÜ]9¬×¬Ûµ‚û¾fíû±ä¤}H®KÁÅ‰£’í>‰äşÈí#{F÷ÄøìxìşğQ›ÇÇãrü^›“×dF&"?hô‡•2BaòyÄåÔA¡ğßâÙ[Me³¹L“›İ5ª>Ø»©ìO”Ş
§'ºvÖ9Äh”#€¾kç·‘1
]…³‹ï5Ğø|ˆŒRdØu¨ÚÕ]“~İOt/ñûA¿sXÆÂ7ÁÃà)ğ¸ˆ3c6·ñ±(—\êXlä^nÍÿ';ï€àíÿõ^	ÁWA6ğÑ‡äÓGÖÒŸÜ+"õä’Á+ä¡{àß1FõnèÚğ¿-cß€_©;ËÿÇ¯M#pLYö•ûq87®7%=¿î—"ŸœÛÓóë¶‚‡øÿ/@=¯û#ü&¼š÷?bŞ3ğÏÓÏëg ÏûO!?¦òÿ98¾´í˜_¥Ğ~¤ÉwèçÎ—şş¸R¦gy =»Á{á§ãßWÌÑ}6Ãñoèş›c/ü–hÊi;ğÍô}ßÌoŸÏúÆ‰˜ûlÈ„)
êé)[k­½¬öÏ¶Ù~¿Ù>–}E:DŒ>-´ÕŞYûWX×_ì{VŸ"ôšiõ
ëFfnMœ‘jº„\Æ;çŞÁarOş}–o£M
äë@qÁjWµîòîYørWølTÓ¢ÜÚ$Ç6SÓ>oùjkä5ÔÔ¼3b¸Üx„[CŒUÄkñÕ¢¹Ú}Íµü25:³Nÿ·rTç#´!yŠdA°WïK›ôÍÈÍõ¹W+Çû«–c}I$ÇÑäyÜ÷¢~¦³tnD,î®úmavÚûG:Äã¸1ŞBÊy OXC7’/èÿƒ®€¬dl^ê‚ä¥^•<äİ€ºÙğw¸TŸÁ/%*EœsA=ò÷³Í!ûîÔ¥ÍùsÜoµ?·ı!6³yğ9Õ_‚/ƒv`'˜İµ~C²÷{UW¿sÍ´à¬9b=`³<D¯"g!g‘‹;ømÉÛ²™ÿ‹à–pKòû$ğ ¹ünï@Pï?eßÇ³Ñæ	)$Ï?bjYóxğrúlÓ YÉÖ²˜ÚYAíÆó*æ.AÎ;&»Ë&ÖÙÃüåZüÓÔÁêa­ì[,Õ Œw'šÓò¼ÛJF²NOs\:„œëÕÉ}Z¯üÌ¡æ1Öîcù¸2Óe$Èg½áZkÜ|äs©?NÙçN}f›<Æz;Zn•ê¤:U*£Só¥Êß*Uî:©`l]òYYç÷“ÅºFTWµ&Fÿi¦É®¶æÏFîòÑ™ã=ÕoºÜI]Ş˜¹o4/5šZzšó³·êÚ\oC_J9‡ÏÅ÷S9[ƒ_§Yf…5~NcÍ/–éè™¯6µ¶.“Üy|÷iM×ı_Ê×Í"Ú8®K´v©¿\/õ&ü/…zÏ"íÕ¯¬/¥Qä´÷5VïÌkCgéı¯«},æş‡õ²­²:ãøÿ¾Ÿ´JYÛA«£–JÃ‡EDT,PŠµàJ…Ğ	aAR3±Î!*	ZÜL`|“ns"à‚l±Ñeá#PÌ`F)ÜwÿçœóŞŞŞÒ6FoòËsÏyÏ÷ÇóüË[Èp.!§Àó•AÖÖŞÑ%¼+<ƒN5S-ÖX6Ø©ê-RõÆ{¥dÇUÉ~jƒ3-`mÁ§Ï)¸^²V¯àíãÖûìkRÔú-å˜ª¹Ï?¥2¹2ït'ùr>$Üòk¦sÔÜUk5–õRø®“9RSÙƒ ~ëb}Åu3eı(òÇò¼vE‘»9ö£Ô/¦¯ëÃ½+æ¾¦àû4²œ»1Ïî
!Rœˆ4ÑR©ÖEæÿ‹v#ÓU˜e}„Ù\¯ÕdyónV§V ¼/æVmäV~?Efšÿ}õæÀ~EØF-vÆÁrÁiÒl½Ä¾Qad[9öcßÌû— ëÌ5ä™~&8?âkÍ½‰°®ØÁ‰0_ìm‰˜üÌD˜/¶0æŞ`í•koíåç&ÂüÜï`íµÛ/æ÷ë`|“aşäo0öÖ9'æçt0©‰0jâ8èŸøáÛtíÇ&Ş_ BËÓıÿó}TšôÇ¦ÜïÈ&ò
¹B
ôyÁ–©¢ıœì$Ó[ˆ£íõû	jÈ R®û’ºÑÃºo…é3ºW×¿ş¦o\:Ú›œÓı©¾Å÷ÖÓö#›Mùu¦ß·ôØ£5-åå»ÌQÕ{«…À&ğ{6miÑ?i‚whÿ@>!ï‘£æ–Y™ói«Å/àª³Õâ%Vûµ€ŠÙO`Šò¹´ŠUJc0ÎìRş. ï…¯uÈë(İ >Ü¯Êop+›@}B­ ôÂgpw‘áÅg	ÆÛû©‹'Ğß²ç·xHÚ¿-šÃ^ûI‰Ä0úM‰…“és«’÷)ır3ËôrÎs¼¯ o¶uîtîbúÎe~å>]£Áû‚cmD%ãU¶7#Ü§11|Ûz‹‘äŞD]`l×æ%õa~-ãî9ŒOª¢®;‰®Ùğ°ïØ:øèÅ|Ù3*½(W.Ê½¿–O¦¨1s¼Ôa“O=FÍ¤âõO¸&j<S%~:»áØ«÷c÷$äùIÔ^ƒ±.)[½/9}å‹®‹­ı»¹ş#¸Ã­B®[Æ=Ê§n>Ãu~É¡¥ooğçÁwgÍÔnÛœJ/ötê®´cWÌ†mÔb“»Õ<ƒuM¨£bšÂU{\ö›­ÄÏØüÓjİ™_ì¤!ßMãÙ¡îhcÍ˜ü4ìbÙ¡õPìÛ´;Qé=‹R÷~®K*JıwĞÓŸ€tÑg¾¯tİb‰Ñî×Ô¢¥ÈåÙ¿×Ü÷_¹KÌ_ÆüÈ}å~I¾º›Ì»¾ÙäÿŒ¬$õwù¬Òÿ¯_Òí«o+uùë¼‡A5—Í=jøT£Ş!·ÄëT¥Gµ¶nmcº^Ÿ¢Nm‚şlÏÊæIéáPO¶µ5´Â4uŞ§¼£/²î-Äut¢eÙ—©QÔViC±;Œ}CÎšh½DÓÕíØöôkœÕ÷,´ZW¯M°³Íõug6¦¿[Ù 0éî1½Ş™-G’ÒÆúÏÓRƒ†Öä§ÄY¯Íû)Şª=mt¬è÷bÑ×ÎVjÑs'xOó´¦\°7bîğIQkŒÎoï7¬Gºd'\8æ§4Á«†&Ãï;ÎÆD‚Ë
y»İ ïuöKºÔøÇ4Jÿw × >op—Êz;„*Cğ/6„®{¸áºpnç8ï±1‡ı›v¿í>~Û}ù®æİÑØãá<KBë	77÷GqY#ş‰eS×õ0©#Ç5ïJ&ïíÿìù<O$¾N›sğ<ß¦‚IË]<*;?]ß¾‘.j0óFëãÏ×çÏï¯×ÉmÆÃF{å<º‰ŒïËI*Á6åÊ‘-¾…qWîùç/¨l­ù‚R›¹Œ“.Ë÷p—¡Èz?xÃ]AŸğEpÔ]E-@Ø×Ã1ÃV­ı‚?ÒŞ£ÖyÑî‡oÛ,AÊ°¿¥d‡ÑÛ¢c×DÏëü–q…¾×şŠóhF†èg,2”~Yˆ*’a7ñ;õç°Î~ã$fØwQ[Qˆ^PwHuNÑjºq]Jì]q÷;kœ2®M¤öéc€”?¢êg¿˜'}Ù?§ÿ7²­&–ã7Ö['m¸û°Bt‘Í…;çb:ËNşao¢høŠ,áxË±ĞZƒv%
¬“Ô;iÌÿy”ÿÓiSÈLòY;T~3ÏÉU–'¶Ãôßi]TëkCµF¾G
QaíG5qÛÓåU‡ŠÈ_U_v!Ûc9‹/%›ŠÂN3ÿ=~_ËzT l/Ò¤ÛRßÂ2I-eÜÿ (¹E^*YÔ»ã‚úÈŒrf¡÷´Æ½>aŞ¢£> \­`ÓÇ­½˜#ØP¬ØÔÛı‰±î›XèÆ@÷:õÁ'<Ÿa”û%^uÇ Ï+aÛ9K#‰¼í*¥Á5»R«18ÙÅ±ÄáÍ@ZÒ»˜À=ïBkÕÚH™ŠGà™FDÔ[Vd|wØæ®)ëÇ3¼ÇEDû"­µz±n²Ü=şŸ¦bìôÕ:NŞPQ®V ÷¡”¾!™u¦›;<çi›œ-£Y5ØcıSŞµÁp+3¨·Jeê>¤ß¥Á“ä%RÌv_ã;æ!r%xYˆK×ßuÚy
w9ÃÈhşİ6Íı,0´Ú[ïEüPpÆ°œ0ìÍRWïugioúVûÈ¼AzßuËù6”ºY§­}è'¨óÖ¿mšsºOˆÍ»³t7-·Ø™noşKÑÈEŒ+^mĞÈô²‘şu»à øíÑkëí®¼ÛËø„íÃé—"‹ş+Ë©æÙ£î×í!•¾©P|#ıü5‰&şU±İfÑ¥v:ı¿ø2jEÓ¾¼“&J}Ñùô{“Ä÷¹w¢L|­øT3¨EåFS!¾Å:†¡Ö5íƒ"
ˆ/²{ĞwrŒ…ÊªÿÖ ãS
‘då\j4vJpLù¤îÚgÙ`{ÅŸ1şjÕ×ÎÔşËúPû ëË„\!QÀ»ğ¶FbNt·ŠMWµŸT¾~ZşËÛÅ¼ŸRäÒ_ŒëL/mY—`‡¶3]hêÔ™:mËÏB©s‚çd+÷Nbò{¸İ®±w0TÖß=§Ş+ù]4H‹Î—˜'qRí÷¨Œš¨	‘ÄwÓˆRÙ[w,zJìâ:!ÆÙ9§eÏS—%3îNQ}ĞÇ±ı4Ó+fœò>Éà9İ{û…o¹ğ­Œt¶`»ıµĞL4ñşí¸÷ívAÎ™ö¸ğ¨å©*‰ã(W¦;¡o´êéÑ—Óƒ?@%µH*’÷7=t/"ÿz<k8İ>©Õ@ZĞ{6ğ½šôŸk2Oß?¨éC_ŸÍ—Í­½pıJ4·q¾yŒQ·÷â°ïò÷ /j¿Ğ1s;ÇÃ® Ãw#şÏ~ÙÆ6uqü9çÛav<HBq|oŞLÁ,NÍK€ĞÄIDiBBœ‚I	¤1Š¨“Vnµ!u%ˆIlcÚ‚ªiR×u8Î”9€¦lİšuu“è[ÚõÃú¡MáÃZ>eÿsì•"±jª¦j•Î½ú=Ïÿœó?/÷Üë{Œ³×¶×^ó(~Î˜3ØMT‡ëÙúÑ#ø^4¾K´ël:DÔŒmzÔJ´ÿ™´½BÔëï<MÔı1Ñ7Qo‚(Òó?äìË~|ûèKÀO
…B¡P(
…B¡P(
…B¡P(
…B¡P(
…B¡P(
…B¡P(ÿ§0¢Üõt›¶ĞÉFœœä§N"Ë€¥ˆ¡L´„~‰¨‘8É(´.¡Ä(s¬geY­ÑÎjôÁ¬¶BÍjíaß†“YrÄ˜l.«¹ù¬æ´„Èjõ‰¬¶@ŸÉj+ô/²ëá çÈ  UâÜ ÕAEn¦ƒ=NGdÍV”F EŒ ~P:*Ğ¢!œµ¡î ú'(.KQä(ÜÇûáA¢¯ğJO$äxığ<†<B‡Q£Ÿc-bÔa9b¦ß.”Q³Ô‘¥ÌÌÃ¨õË9ö€\«A}(EkB®V¸+3••Œ¨Ñ%?5¶ÆFÄF"‰ÁØp…2Ú$âF[49í¯ØÖ½»£³ÃŒ5w|VI&c0nDŒÄH¤?úXdä°;ğç3‡Úv&¢ıF{"’ˆ¢óp¿?6bÄĞ2bôÅ'F£ñŠ/ğşn£nÚ:ïSw»eá>ˆ}’÷ø³œŸ·íKûteß´°’ÎÑ})êĞœğê×¯h«hpmUÊW¤Oi+µ¢TµLk¥®eGèëš7‚_F1.‚i`¡^Íƒz'â	`‚‹`\V¼ˆ<²Õ 10æD‹V¤¹S†î­Ô–£ïr¼iZÍƒ ‘è- Œ‚1`•>Q'À4øP¶µ‚ÔÙµX{Aêi™&d1’)öì‘Å‰İáLnŞ™ÉõÛ3¶ÍÛCë2Õu™¼rM&»Ê¦È‹sWCùZ>.2?‚ÈøoÉÁétA[FIÀ5k¶&¨¹&Ê¼±iÍBLãÃÔ®j,•›-æ|\¤óøû™şşÄ’¼ÀXh‡.‚i ñwp¾Íß¦|Nì9b-Óà˜V>‡ó-œoò7ÉÁß ?¨½`Lƒy`ão :ùëâ{ £Ğµ€ó×ü5\Ökˆ~ê&¿‰¥ı%Uµ)0%…ÏŸzyV¬È
W~ Í_IİY…'Ê‹;'ê²VB5´V+I•?¤§µÂÔ–A=Íÿ>aøô¡Jş*%¾tˆN`€V°V¨P7ÈgÀxÊÀà³àepƒ*A´;¿Â4i~-å­ÓCùüÏü÷T€ÿ>V"¿Ì_”ùüw2¿„ìAå/¦<:…¾‚vB'²ÙöEü7e.}!”Ç§±w:¢Ô‚ĞF•Oó’T¿îÂ —iÖNp¦è=™FÏÚ)xHz·â4Dğn~
aÌóò ÷ÜQÁ{ú,”Şï|Jï7Ÿ„Á;tJoÿ!(¼İ½P"x[: Òü'¿.[©WµfFÈÁc—c—c—“…'İ±ˆµı(µz5vì|Ğ·jµn^bæf¶1óYfF™ù3Ÿdæfîe¦™nfz˜dæe¶[a²à¯î)n
2s–™/03ÎL/3Ë™YÆLƒUÓ¼8µ}­L2M„Äùá¼}¼;ZŒg¾ï„iÄk`A–‚0%órÈ%«k3åŠÍXhŸAÇÜ†zXpƒfğÍ`à@¬½à*˜À
w	>*£ÑjA/8æU.gpŠe—xQ.ÌŸ]t‹(ñœ%8‹yq°ÈévúœÛ´Q7sxX‹gÁÃ«(?odW=/Ír'?Êıø£\Ê	åğÓ|”Šp#ÎdóhêN‘f?Hy/ë¡eìûä±à©c›ÈËÊ‘7R\–×“Û.ò:üUö<r åîD7GÊ»F¿Ä–ˆ^“ú÷»ú{î4‡ü‡û²ş7#ma)ı¯¨y~RÕ}JÉŸ¶£æŠ7Í.Ò:åŞ¨¿0+­O¢á|JB¤Iı[îFı°[6D3{ã(z›·[ß†ñêİûõ`cNêµî½ú–Œk½è3©Wb	¾Œ\Å®rËIK=rÀ]Ui6\c;gë²µØ6Ø¶5¶b›n+²­°-µ»ìNûûWí‹ív»Õn±s;Ù—¦æ‚>Â­[juŠdµˆh‘ÚÉEP‹—³sÚAÉ¯iM¼©½5%¯öQÓ~#ùÏöÒ4[¼³;¹¨´%]MÔÔQ—ÜèkJÛÚ’U¾¦¤­õ]ãŒ£6ÉŸJ3êèJ³QurEÒµµkŠË;ùÌ
‘<ùL8L…ùÇjk]5y›©¿OØ—¾»Gá=º(y®©½+ùó¢p2 ÄBQ¸)ù½v£§kŠİf6ÔO±["…»¦´v»¡MÔk5õápSšuJì|xbnIŸfá#ÃîÉøÎg|åè_™HğåäP¹ô•çäHŸ…	ßx¼¬¡~¼¬Lz
ŠKO¼Àø´g¶òréÉ7iVzfóMáIÖH‹Û‹Ç--ìrK‹›= -w-ş¬åÔ'–Sr&İõ¸3Ü¹{rçàñı·G´ÎçcÕá¾†hiÃ¾Ò†(Ø—|úØ@aÒÜoã}aÑ`$5ï¾ı}"G¢Épi´>ÙWZoŒW÷Ü§¹G4W—ÖSOCG×xO0ZŸªV7”FêÃ­ëªî™ëÔ's­k½Ï`­b°ub®Æªû4W‰æF1W•˜«JÌÕl”sÑ¿Nã9œ"c ôf&n.`zMVŒt(°'^kE‰:é]ÀÖÊ
níÈ<ÊNx$¥ë¨ë’æ)P˜*%Qg­(½‹qTJ (,¨ìÄ ]RZ\Ê ášéAÅ@ *)8„Ô.Æ€r®]ŠK¼7h{o°ŒŠØÈÎM yiƒLŒ›ÛuÇÿA=  H™®$fãä„*ÄŒÿR(íÊL»73:È1;'‘Ìä¼C˜€EAHĞ¯1Q»€m)PõP	ô`1£6c1Ì¨³µµ |Ÿa¸¤Ê‚†E	”†èj)†	€Kb%ÚÚ    ÿÿ   ÿÿ Zv!-endstreamendobj49 0 obj<</Ascent 1010/CapHeight 716/Descent -376/Flags 32/FontBBox[-628 -376 2000 1010]/FontFamily(Arial)/FontFile2 54 0 R/FontName/HZWTVT+Arial-BoldMT/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 136/Type/FontDescriptor/XHeight 519>>endobj50 0 obj<</Filter/FlateDecode/Length 478>>stream
H‰\“Ájã0E÷ş
-ÛE±­HO5˜@›´Å´e2ó­dÙ(Î"?ºº¥…1Ø:FÒã\ñTnvÛ]U~Ä©ßûEÇ0D™®±÷êàOc(j­†±_>ÿò·?wsQ¦ÍûÛeñç]8NEÛªògš¼,ñ¦î†éàï‹ò=>á¤î~oö÷ªÜ_çù¯?û°¨J­×jğÇTèG7¿ug¯Ê¼ía7¤ùq¹=¤=ß+~İf¯tş¯)ÓOƒ¿Ì]ïcN¾h«ô¬UûšuáÃğß¼]qÛáØÿébÑj,®ª4$~$?‚rŞ7à-y~!¿$^=eNCâWrhM9‰5YƒWäØØ’-XÈvd¦§§¡§§y&?ƒélàlèlàlèlàlèiàiyç`éfáféfáféfáfécá#Ì(È(Ì(È(¬#¨#¬#¨#¬#¨#Ì(È(¬)¹&3
2
3
2
ÏYpÎÂ¼‚¼Â¼‚¼Â¼‚¼Â¼‚¼Â¼‚¼yò::;8;:;8;:;8;:;8;:;8;:;8;z:x6¨£«>!Ã§Á]k›ó³Ñ¦é6©¯;Ğ_cLíŸ¯\î{tüü×­œ§Y¥]x‹   ÿÿ   ÿÿ ‰fêendstreamendobj54 0 obj<</Filter/FlateDecode/Length 26870/Length1 56288>>stream
H‰Œ•	XW€«¦»«a”STœéDÂWY6º„à¹îa$ÑİÄ#"‡‚Šg¢’xá­€xâ¢¢FD.Ï<£‹‰ëgÖdöğ±Ùo¿|Ù7_UW½Wõ½y¿ªN›:=\!81òİ>Ğ6ÌL"£“£R³ù²& pÿ4zFšÜ¶ì±@›—Üæwc1Bb\ÒìØ‚^Š¤Ñ !Nñ1Qoz¼06ŠÇ³‰¶ø±«™òON›ÕîªOJ‰âœ•
€œ¥Ì¿™5+µmı\Sòä¨ä˜U=ê™ÿ5 —š2-Í 7 .69ÖS§Æ´ÇWvbÿ·8®^upÖ	}Ù)|Û\Äª<œ•FäUÁ7B€ı4ÌÄRù£†’ıìÍB]ËGØWÅa€v»íkJ»Ï´
°uC/ÆYØ	Aû${ªT˜ÿl‘ãœÕ×NİÜ=<½¼»øtíÖİ·‡V'ÉzƒŸ¿b|ëíïşª×»½İ§oĞo‚û^¿ş¿y?ôƒ°2ô÷ÃşğÇ?ıyø‡#Â?úxä¨¿üõ“OG;î³ˆñ‘Q0!zbLl\ü¤„Ä¤äÉ)©S¦NK›>cæ¬Ùs>ÿbî¼ùé_şí«Œ¿Îü&+{Ñâ%Ks–-_±rUîê5k×Á†›6çålÙºm{aÑ»¸İ{öïÛàà¡ÃGJ+=~âdÙ©Ógàlù¹Šó.VV]º|åj5ÔÔÖÕ_»~nİ6™ïX€webG!æ¡]%«F«öp~Ü.…›ÎÍã²¸E\>w…{Å»ò#ø…‚§p^x*¼$¼É—$êOd“µ	ÚDíYm¥Ö®›¯[¯ûA÷Zò–´Òi¸ô‰4Z+}&Í•IåRd’K/¥¹³lr/¹·$÷—CäPy°!§Èóå•òa½ ÷Ôûèz£¾—şCı(}„>C¿J_dPÈĞÙàağ6t7H††wÃQ†?•Ÿ›Ÿ^E¥¸(nŠ—ÒUé¡ø+J¢$)éJ†’©,RV(ùÊnå€RªœPÊ•KÊUå–òÈb34F£±ÆDcJ`RàÌ^>…İõ6•-Øbµ°¶í·=±Ù›'¼ùàÍ‹7Í-~-ÍöfÇ=c7,O*½jŒj/çÏ…siÜ.ƒQ[Âmáª¹ùN|8Ÿ),ª…ï	HÃ¨éHOa)†kQKÒ–k[t K×åé^H u•di˜ŞNm¼”.‘*¤ëÒé…ôŠ]vF-€Që#÷ë –À¨åÈy­Ôº´S®©Ë¨åtPsgÔºtíÔ"[©É?C-¼ƒZ’§ìì VÉ¨İdÔúwP‹1&0j‘iŒšO¡lC›Öö£fdj«³57G¼	m¥&·¤;¨Ùï³ú|Î¤–õ£÷™ôt\Ë$‡æ«™ĞV‚ÍÕÍUB>{Öş§,›‚óÏ‡Xç<bÕmõ¶zZİ­­®V«Æª¶:[E+Y+gUYá©ãAã&«˜d4¾¾[Ô8óY³Kõc:«q.@CBÃìÆRëåûK¬kŠr-¹–K6€e»#¿ÁÇ2Å2y½-a–¾óPósˆ¹Ÿ9ØÜ×ÜÛÜÓl0ûš½Ìhj2YMMM÷Y¦
Ó)S™©„YçLÛLÅ¦!¦¦&“Á¤7é¬m<ÙxÄr<Ö'ÖC(c%¸A\/®×¶“P¨ëm×—§pÑ­]‹u}uP~#6˜IºÉôrá(‹vaLâÑ¶l'“ŞN}œ&:å9[ Ô]³jv
¿0ÔAê™f}Z=ã'³­}»mF½ágs:DÙîeüÒ^?É§è°Çüñ!V¬&Dÿ?lXÀE@.<‚…°²a#ì€­àYéW°¾‡`1¬†LDö=}›`'ü^ÀK(€İp*`L€hÈ‰P	1p.Â¨‚Kp¾ƒX¨«P{!š`ÔC-ÔA<<+|	0	!’`2äA
LT˜
Ó`:¤Á˜	aÌÙğ9Ì…/ òa>Ìc_ù/á)<ƒc˜‹«Q…ò(€šq®Åu¸Ş@ŠèvÜ€qnÆ<ÌGgT£]° ·À+ø·â6Ü…X„;p'îÂİ¸÷b1îÃıx Â?áfa6ÂÃxKğ(ºb'<†¥ØİĞ= î¢'záq<ŞØáI,ÃSxÏà·èƒ]¡öa7ìg±}±jQ‡ç°^Ã¿àÜG	eÔ£Ïã¼ˆ•X…—ğ2^A?ôGx«±k±ë¡ßÂ·±'Àxˆ×(‹²i-¦%´”rh-§´’VQ.­¦5‚?­¥u°ÖÓÚH›h3åQ>ĞÚJÛh;ò	|"ÑÚI»h7í¡½TLûh? ƒtˆOâ“é0¡:JÇ¨”Ó	:IetŠNÓú–ÎR9£
:Oè"UR]¢Ët…®R5ßÌ¿á[x» 
*xAH'ÁYPª¡Zª£ktnĞMºE·ÉDfºCj FºK÷è>= ‡ôˆ¾£Ç¬ÖŸ’•Ñß©	¯ã¼‰·ğ6š4¢›è.zˆ¢—è-v}Ä®b7ÑWì!jE(‰²¨O—Æûß4×wp—EğwŸı=»Ïó>ûƒj(é	$ŠR¤Iï„ˆŠ¢g¥Ì ¢ €ˆô.
Ş¨ˆ8'ê©§€…t!ô–Ğ!È­wsì_;;;óÌgv¿_)+yr\NÈI9%§åŒœ•srŞİr…®Èİvw\±+qwİ=wß•Fƒ¨Š‚­cëÚD›d“mŠMµi6¥’T¶¯Û‰v’}Ã¾i'Û)vª}ËN³oÛéö;ÃÎ´³ìl;ÇÎµóì|» ØäÙ…ÁA»È.¶KüëµÔ¿bïÛev¹ıÀşÍşİşÃ~
G‚c>µ+ìGöcû‰]i?µ«ìj»Æ~f×ÚÏí:û…]o7ØREâ¤ªT“êRCâ¥¦Ô’Ú’ u¤®$J’$KJdndµ‰Œ£¶Ô¦öÔ!2Š:R'êL]¨+u£îÔƒzR/êM}(—úR?êOh ¢Á4„¡¡ô(‹,TI“tÉL©'õ%K.ÈEÉ—¹$ÙÒ@ÒšI³h6Í¡¹4æÓZH‹h1-¡wi)½GË£:‰b¯®¨«êšúC]W7ÔMU¨ŠÔmuG«tU¢îª{ê¾ÊğÙ* 4ACX `U&8ˆB(1Pb¡<TPõ "TRõUT†*U¡T‡5}F{Çç•­@ÕêB"$A2¤@*¤AºäH#9"ÈQ¹,Wäª\£­™PêCdCh9ĞCú™~qğ
Œ‡Wa¼¯ÃD˜oÀ›0™~…)0•~£m´vĞNÚE»ií¥ßií§tÑa:BĞQ:FytœNĞI:E§é¥st.R>Ğ%ºLWè*]£ëtƒnÒ-*¤"ºMw¨Ş‚iƒå¨„îb,–§{t+`E¬„•©”VXãXs„‘[&fYØaU¬†Õ±ÆcMr.Ë1XkcÖárËå¹WäJ\™«pWåj\kp<×äZ\›¸NÔp"'q2§p*§q:g`]LäL®Çõ9‹³¹7änÄ¹	7åøALÂdnÆÍ¹·ä‡¸·æ6Ü–ÛñÃÜ^®ËîÀ£6JQ†Q‰:îÄ¹wånÜ{pOîÅ½¹çr_îÇıy@4--á<ˆó~„‡ò£<ŒãÇù	ÎOòSüÁOËMÉÏğ³üW~ŸçøE~‰_æQ<šÇÀ˜	³`6Ì¹0æÃX(·`,†%ğ.,…÷à}XËy¬J‘Ü–;P É
ùX>‘•ò©¬’ÕØPŠá2\Ñõz²ª§éz–§è%ú}ßVè•z•^£×êuz£şJ«Ğ›õ/z;\Õ»õ>}HÕ'ô}A_ÒWô5¸×áÜ„[PEp›âø ¬‘Ïd­”È]¹'÷¥ÔpŠ¡îÂ=¸¥:ĞJƒÖ:13°6Ç–ØÊŸnƒí°=vÄÎØ{c?¤kâP|ŸÂ‘ø¾„ct2Ã	>MÂ7q
¾…oã;8gûŒ4âbß+ßÓé¸?Àñ\Ÿãü7á×øşè›Ío¸wëLÜ‹ğæá)ç0¯à,Â,õ½Çú_Ö”3åMeoâLß‚jùDŸ`êš$“bÒL†©g²t#ÓÀä˜¦¾!µôi¿i§É<lÚ›¦£éd:›.¦«éfº›¦§éez›>&×ô5ıL3À4ƒüÎ`Y'ëÿ?jÑîó1CÌ03ÜŒ0OËFÎ¸Ğ•q±®’«êâ]‚Kr).Íe¸,—ãšºæ®•kç:º®®§ËuÜ7Ìw#ÜH÷¬‹V‰Æ©£ê˜ÊSÇÕ	u’KÃ T!„:Œ„šĞ†r†º0–	Ë†1a¹06,VP§ÔéHa¤(r;r'R)‘²SvÉnÙ#{åwÙ'ûå€”Cp.ÀEÈ—ÍÁºàxÛlV9ÁÆàËàGu&Xl~’-Á¤à‡`ªîî{goß¡z©j¦lÕ}u?İ_Ğ}tnx?,• ¸¥Î‰PMDK¾L¾ÿİŠ•)çv¸n—ÛÓåp°$¸ü;XÌU³Tk5FÍQsÕ<56ø§/lF™Ñf,l‘¯d“|-ßÈ·ò/ùN¾—`+ü¿À¯ğlƒí°vÂ.Ø{`/ƒ<8'à$œ‚ÓpÎÂ9¯³…×Øs±¯®©kéÚ:Á›|‡ã“Şiì‰½¼ÒGq>æåvÁ®ØÍ[û	7ãïmnÇŞîË8
G{ÅÏãø¢NÖ):U§yÍ¯àx|ÕKæ=Oõ§{ß¯étáUÏÑ™º®¯³t¶n ê¯ô&ŞÂB/¶ /áeï4ÆKıóNï4ŞŒôVŸ1Ïê|}Ñ¯ï²µ—ÙÖK?'ğ¤×›ê'{ÃéØŞd™lo:Ñ{ÎôŠ›™æ¦¦bªn¤ëú&n
ªÿw}T$ı‡ïªªºÂçÜwwB ËoHôm‰4›€P,Én€¦@B wØİüt¤b¡Jø8ZA‘Ñ‚ÔÒ"şÜ@*ƒ:B))RTAÉL*¥P„}ıŞ&DÒyoÎ½çŞ{şÏ=‡úYï}#ÕÖEgÿ‹«è]úµ~Ûİ¨¬ÿJO§=|›é*È!4‘$İDÍş6êÛ—¨'M£¨@PošNQ'±‡ÖğFk¡u…FÓ´ÅÚËË­À?*ı8øL2 ÉX?•úí­ßR,ÕQgES¹7…Q±œ¦àáEZO‡øë¨ö„ÿ½@¹4ÆY‡­;”AkäZÇ™NBE€V¹UMı)•Lá±N[ŸS:ÑY¼<Ü$'Uş*z™“´¿ z	ıE„ãÅl-ßñ(M¤¨ÿŸ&Å‡Ü‹g-Ö¯¬Ëä¤4<UÓÆ“ÄVo±ÎÒLÚG@^ûm’3å6ÇÌÈXëUë}êE{Qã¿Ë‡C¿¹»Ìú½õÅƒŸ!ĞÈdĞ)COsÊ¿èQkÕÒ*å#¨ÊuÔÚù4j‰%b‰v’AÚÙàö)ú)Xd? ƒĞÍ?Qó_BÅŸÂ?æ2ÄÌ7¨N*Äqm£Ö ’,w@ß¥AG]ïDû ãìÀùsÏáyèY^åóB‰kâ¦Œ•+ä·ò®#=r>ò­5ÙºA}(™~‚®§ºıC4şÿJ£ßºNÿAÏ‘ÍUèc²Ñ5TG©bŠ¨ÄVñ&rÃ:í°&óäãò˜<‹xX‰Üy=òbäÍÈ	k¯u¾Óç§S4º^±•ŞC7ö1*ĞOé‚í?8—òc 2ŸŸãõè‡ û¸
))ú¦ŠQÂªóÄ/ §åÑÛt+2€ÎŠOÅ×â†æĞROâNTZ£ö7íKé’ér"§ÈRôCñGFØîØåxßÑ‚¸©pÖ8¿BM½2öèİŒ»ŸE(RQ‘=ğİXxÒbhb3ºÍ·¡‹è1B#ŸÀ
ÿ†’Ñ;=¾Grò$~”gq%/ç:ä²—y#:½· d@=™*<bœ(aQ‰ú­UAŞıÈe§ÅÑÎ5¹cˆ6Q+ÕfjO@†Úm%4»NÛ©×Nj—µ¯´fX-Qö—OÉÅò¹M6ÈÈ ?Ç»÷d“ã„ããS8“}ƒ‘S¶;/Ä8c†Ç¡O8s=¶]`8×é¾G$!û‹¢§¬åfLôcI	Ü;” *®ÓX-»tµñà­—H’=ìN¯TØ¿€Ğ0>BµN¡1‘<O»ùœ8/ÿ,F£‹q’Ü¦=áøP¸i²ÑZñ®8ÀyÔ rÅ±I#¾ÄÛéüı—´çù´‹›9‡Ÿå\K§Do­„WR®µEHîÄ¹…À-“ô=ğá‘t®D6Ë.òä§FÚ ‹¾AŸóºÍë²›†lF–Y_EvÖ›8«E<&!ƒÌu§vÅŒp‘‹©…şKWûáQyÈ¤—#Õr³üÂae!Âe´qWEã1—à%1¶G³éqÈ%CÕETJô,²Ş:KY›¬Ö"k}„½·Ñ‡Üæ×Ø‘Kà}>áÕˆÃñ–óûH5ÑUîÃi<ñĞìXˆ›i'êªCcÎ!ĞöJÚ¾ oƒåt‚®ÒM…m’(“¿Ùà=@sEP;HùœL5ˆÙÈãym’ÌÇ)Ë¡½Mˆçƒˆä‰YtˆÎ°àDHTú±8§zş)V¿®à=˜©@ÖÎ ¯!wWÎ@Ï‹“6 k5§sô%´mEùÊD^ğñœu“¥
PNE\¼C#‘Y}ÚQè{ »(SùØB„v¥~4ÒñÊŒL¶²EµvwŒ…ù×p{¥Ğh~\$@»Ô‹§Ğ°ÈTğp’5©øïQ.^•Vötd.}D;`¯\ãó›æ;ftî¨œ‘Ù#†=ò£¡C<(+Ó“ñÃ¥§0Rİúú÷ë›’œÔ'±w¯=ºws%tíß9®SlŒÓ!5Á”é7
BºJ)™nL˜e0&Â÷M„”©‚k”Š.Ó;®ôbåÏşo¥·u¥·}%»ô\ÊÍÊÔı†®ù½‘K‹€í3‚ºjÂ“¢ğÚ(Ü°Ûº¿O•OWÒıª`a•éùp\}ç¸|#¿2.+“êã:ìH%5õœ8†£€HôçÔŠí¦T²áó«$Ãgs ´4¸Bü¾·;˜•©8¿Ü(Sdä©Ot	åGÉ(g¾Š‰’Ñ«mihµ^ŸÙd®itQYÈ_aT„g”Ú4ºy@×§_ìóİ‡wÏÔİMÑLŸjİšf®šŠ÷cİöo0ˆ3°W¤„Ì^%–è &VŠW¤nKbKÕ*_¥á·gBstÕÉÈ3ªÌ9!˜&ÙT4u‘{wr²wŸu’ıº9-`¸ÕØ#öõ­ïIæÔE{’¼zRGLVf½«[«bë»&´ñ]î*ÛqQ(ºÜ†
§¶k–mŒ‰p¥—ëà$`@¦lû§2›Ìòl,ÃdìR°Hµê”2]9ö¼½_9Ò\†nŞ x€Ñ|­ãL¸mÆ™æºA6hûI»«VÊÈ°]$&6c¢ãaY™Åp£Æ¥ãê£"è6Ìõ»İ¶W7z©µ´8Ğ:Ö©,e7y{‚J„lLÓ=L¯é6fé=LûöOn \NÔKÅ¦·\½{ø«r÷~ º²_Xb—t¿jÓmá´£V|v;®R=òZŠhƒDŠÅÂ)gµ/¶x%ÓğqFºBipÊèëÊšĞúŒs»¿wOcLì}›­{Wôï»mm\ªOÇñ¨ãÜÅ›ø•é¢pZ©iÆuÀ ™f¡˜!3Üh--3t—aîÛÄ6³ÆºgĞFkÿêU°&!ª8Î*(¯ŞàçŠë½ü?¶«¶©ë
ß{ß»ïÇvìg;ş‰ÄÏ	NŒIœƒ‹RF(„¿¤}ü“P¨V‚HÖ²vÍ%°1•‰¿1*5Óš•] –dP¢´tê$ÔjEÚ¦¢‰Á¨êR•,Emü²sE­„Ÿß½~²}ïwÎùÎwÎİÙÔ²lHAHİ¹hY?ÁdæÊúææÉˆ°xP¸ L‹¨şÁ† ’´æD”78dy£I áÎâ2$CwêEŞ¨2šÊ¦æ)#©Æl
¥á³2Ã”xĞ´‡`ÀPñÇTîÂ˜FÑ7Hå/@¯€6Èzú!RĞlÍ¶½ÉIÆHVC:‡KŒ0ŒˆìÓLò]Ëa•ó„$ì½Ùz&;’Q2(VR
ì…u\ZFªgMm!®|‡ÇMÖıåPÏš%Û/ìj{¬ºÔXpyzHrıœqÕXúùÆ‘Ã­ÉL@¢åü@ó–“rSi3±Š²¤ x;†	Å9L§¤»ô°…¡ql˜ÉĞd²7¾Æ9«N®Êípå‹„{¼iÖÔÂÖ]ç¾YßpÜXĞÿö½O:>ÇÀÅ÷®Ş1FŒo’c÷bÖ¦OË’Y0‰ƒ¸Xó¯á:³É´—‰l(€TXÚ:½Qp»Şx#{7fF²ØDödrJÜtå‚X^SS[ºD:ZjÏ!;qÁ•­¿Ü¤n)\½˜í7w“gHÄ»RÆ±]D-D_áT.ÎñÜ,ªäöâPßû,Ûë†Ş¨ÜÔQEF‡- º3Húïã[m/Ç=‡&h.R‡L¤ì;hù‡h³ë”xü/;×±8¨!üohW÷bšŸ«Ã‚PÇ›ä>¡«4N	í“>8–‹>#Yj¥3éÌ}$î+l-8yæ±yìî·+o€y½MH mÓ"‚bu&¨¢8S½S4ºØÕê;&
²Û‰´‚@‚A&¨¥¸®Ğ6Höö+¿8oÑJœ¸ĞTˆh9¨¸U7qû‚¶ ¢`¥@íùÀ¸Ì<@×˜q$+2Œ@‰ìÈ%{S:X\Q«˜šêDYi‰ †j&TUò/Q80ƒÜÇG½¡mÏmÜã73ößü?s¼9šwm­µ¼Øó^`Ê´…[_R¾ÎÑÿêÜÃ‘3—°F&ÃàE1„Äñkš\›LaÄÁñš®NğtM{2XßÁ0Eø›*,u¨–¦-Ğ²k¥ë¥6Ó9Û\³åL²Ì‹2†ZÌ‡F]y^¥B>¥‚dÒ|EÓMl³¯(a
xyŸÕ¬‚H(Ïc$Y<$«4s ÖÀqÜ…9<H&hr@Æq¹K&ò0™€xø…¬RLÌË×|K›‚Q½}Do÷fç=¾nÖMğo:Õ˜±ƒ³SÙh4ÕMcÑî—.uÇ¼l•TªûÒ¥“™¹hÙ)9!ç%P´’³á„¹©áD1¨ğâÆ~‰7à©±“_Ç^Í¸âÄ^Á :97ŞîÊyÁ¸L¦ádäıË¸Ñ Ãc?'jö:ÓÌàùÕày'P~º¦¥Áë­ÏGnò£</]²¹×|‰»ú\ÄåÊ/-	9œ’šÂˆøË7	]pšl—÷Y°<9 ›À¿İ1-ödlelS¬+¶'Ö“ÔX<Fbù%*Rq'q’_LÒtßYL‰½}4Ú² grªÌn{²Bo‡B6„\ã]ıEIlÒïcS×Ign†ağ(‚û¡¯là«“&ü¢#İ¬,&Œ­nwNcÄöªÊÚÆçò²R ğƒ‡²Òdîu·<·bÇı·sÿy8|ñ­È—6Ìtõ(vôDë›´Ş§ÃEOZÑv<Z~öåµçÚó$Â_6Ş¢òÒ'f-–ivÈx^¶èóêŸ0Y5~‹.½ö¡¿kóvÈ»òw¹_G¿Ş•?â>2ÿ“CrØÎ›˜?ÑİA;äT¢Çãôx&’¢b˜¢å+Ü;fšÆóAó*_‡sAÌåvo"7›€/Ğ´kïd^²jVGÂÚ°Â†çÛ°Msy¶AÖJ“Mœíu	ºƒrKùâ…¸ĞUŞ#b›ã"t÷€ÿ§âÒÎôAg11ÉDõöQ6³:“¬ë:¦_ª"»‚‚ªÇí¡eL&ìŠ»ª²†Oã@½ñÁgÆ?x+Nà¼#k+øz;÷×÷z:ÿS_ÜÆ¯âü#¼ÿõå'foŞş©ñµñég˜î†®†* q/kUaH÷'<ëøuñ$=sÜÍîõnšôÔø»ı‡è3Ø-M‘
ÊûD,>à$³Jsv±ŒIĞî *q…(Œ…ê#Yø‚ÌÊvÌhäqçÊ£À®Òû$šNo€EûHÑŸVşlpåäÚÖÆm«ßÈ~ˆÃÿz±vÎŠTêÙ¦é§épaÙEãÖßNoëYÓ	ğÇª­%ï=z¦ÕaeÙšÿXjF{´Ç$Ê‹RHp(Ó>(#Tæø4>&9dFpPlàÈ2c³OÍ‹çiy\/«˜. Xdù®E¹ ¦GR#©G¤…|*JRÈ'H+ú½´â((R®î¹‚îı|zì6¹U¹*:|ÏøóWFûW€ş  ßèe´YKz†DUŠKç¥O$¾BÚ#IB÷MZ˜ª±ƒøTsÜLÌßÇoz~Ágàü£ğä2Ùidmö5†­÷^öWÌ³«!ûÎAö© p³ëŠŠ—ˆR§åi»åÏv¿,x¿Ããğ‡íaoØ.–æ˜ŸâÉ-æüOø­Ş-¾3Ö3Ê»y—••[Š•+T–mZÀ—„âŠşOvµÀFqœáÇîÎÌŞÏçÇ=ì‹Ïw[œmÌ±.1˜zS;.ÄJâÄà¶n¬4®	j¶HìTŠ1MCpC+R©Á "[iÚF$Æ.Áv@1	D*”D<RQ9âeUuE”$À­ûÏŞ™@{öÍì®F{óÿóıßÿ}Ê/¬Ğ¸_œ¿éş”#«-GVÛ¢üŠ,º0z—ú×â¢h”@È±ª…J‡ÊE¢J!«®¸oè¶ª“Áû®Ìv¹ı"]}P|³Ù²{t%j]ÂsUgCÆ ıË¾µ4J35˜çóC.«&u¸¯Í:xÉÙ÷úÔÄ¯>@Ùhi¹óqÑkıï\œ9ÜöV=.ø25ş½£¨óÃ‹è±GV_|ÙO¹ú…sİ¹¾Úš„8e¯Xäâó÷v	§ª ˜‹êßO!Š¦ªp”:c€N•Eµ²òğvÌ6›Ív“l2ûM,¡:lN™ÔÄFú°§ 	¥áúäíØ}µ-£Íİ–	ƒ<s¯ÄÅ+I·9ı^ç!qóï%T†P™s&uXL½ïºÖˆ·¦¶@L; ˜ˆ²Ñ­ƒ±¤e©’0â%îl×å,EµÕfµ_VÕ"µ]İ¤~®Ò~˜…ar<Èˆ2­)ÉÇ2¨“pG•'è’ùÃìÎ„Rç
í®nØ­ÜßT¦N^k„}ì†Ü¾+s‹^´ÃLC~¿*Á„B³â‚3¡rÆG‡ì„®åêºF¤ˆ b„à ZáÔ·¦ƒf)†Átæã±QuƒÉöë.Qà›™Ÿ§‰}“÷„\0Mô7Ó‚¼CwÔ(ğ¹LĞg|ÇÜ&/˜¯–#r¬Më–ƒ<j˜œËû£¬ô‹0Jı:;´P+å;é 6LGèÕ¡½JgèUôÖÜôØ²-.¾ .J´•b3ÙFv“İ|ØG&Éq"’“ä† +Åwî­ƒ]m­.´¹™1¿Q§ÏÍØ9YF­2óağäÖÑ¨á¯ƒœË
¥go =Ã
w†EîœY7êÍ©SÒ2
¹#ÈyRàÁà_ÏŞHZ‹~:ƒ­ÎO®SOâR½±üÇ¹Nr/ğàÔ7À’®´ÃÍºD	…®0ª†ÁUİš{mÉÄ­çH„Ü›Ê€ÄÅoŞ^ø½iõë«¿”<d¦… %´ƒ,d°<6ŞoóÂå–ˆ._a¹ÙÌÌö+…•ğ0tÿ[€ª"R/q\N£|1˜Çõ´ƒo=¸—¾Â÷‰ƒ|R\å×DşİÉ‡Ä{ü¸8ÏĞSü¬¸ŒgèEş/aöğ^ñ,ŞAŸå;ÄN¬¯3:ğÚÉ×‹§ğÓToÀM´7‰‡ÙÃ|Ğƒb±×ÂË©ÅWˆ:¯N°‡jœ‹<¦®§acA¢W=ºÔ¼¤kê0kf¦eÈÁÒÈb¶·Ô2ä ~gûä…ÁR(ğP˜Än]­Dlú Ûøšfåƒ‚ñ¹vüJ”2Î“„æB1øÔ$Áp‰á5ÄC1ö@Qqy‘w™c é$¸CIßoKC å!KMê¶¾…!vdœÂ#jxğ8¾Óö#Ø°P±a‘’,’Â^cJó]éšM$|µŸújÃ!_ª+ÕUúÀ
Àß….Ø¼Ï­¼t±İâ2> §Ïæ¦Q)úÛÜË(	*`HM#6ûEôHG‡YçœsŞù'Hÿ ™¹ÖH~½O~SƒÀ<qÙ·Ñßm/'‘ £~à5È®"ëJ2¬[Îö"ˆˆ$uÄÃX'ò¹"TFLeÄ4© $Ù?dÍF»A6ı6¦œîõŒg^êÖ¼·¥ÅâÉÛú¸¥€M‚0ßàÎeR©ø“jj¯”ÁC†Ò8’ıaÚæ€
Mcdê—¨qÍTÂ¥£zwUÿ›F5ë7ªİÀV†+-ÖƒJòI’Ø„6’ç@¶³QvhÇÈ	ö1#Q²˜Yd»Ÿı†±a²Ÿ·™‘6©K«-l/uMê´m.NZ8*=·ì²yq¥…‚Á]İxGî``X×ƒ˜ôr\ª¯ÀKõû°­ÿ ¯Õy..ĞïÅwë{ô×ô¿á³x_Ö¿ÆF).ÓïÑ{õíúëX“İ¤;1ÿQæ¡Ğª¸H‚²Q¯C9ÎéÔ @ùğZ#9|£AªëVPF—Ae)ÊËöš]ê.6èôR†t/ËÒƒ¥Á^Şã×{²{ó¶Ñ6àÙæ}Î?»=o{`{p[Ø£û	á<87Ìë9&Uè$¿t¿@Šğ‰hZ×ØÑªˆilŠôG†#Z4òyG|¥Ã
ÊY_åù±Â¾woŠWƒ·¹|¶nVb[ø8\šT7i£¡ \)n@~ƒĞi­Oş¹s`5 çœ>çˆ3áô¡%—8îĞ¡iüÑôà¦ÑÄrç	g³×Ùvcı×ÎÜÜÜ¯®Ë<HíıTÌC]¢©¹Aò]uª§TìÏ.1½^¥À'Õk–ÂòÿÏWäEª2ñ©_Ö­,_x»µ¸é,22öwÖ)cPãñ†Ğ2şô·èÈû`ß¾Gwİ·áøÑ—÷?UÿÃUÕÃêd~ñ¹ıÏ?—:MßqÚ+½«y½) ªï™»D¿€s-G'í•Ùã‘7ËŞ+§`*óÀTæjGÙf­×Ü\vÖs*îik¼kb­ñõû;‹/ë,ï‰l‹¼TìñÇe7¹£È’³İ
[ÄˆÓ®XW|klkü“Ø'q-!™bâ5¦oMfC¬>¾Áìˆ?mş,6`ş2öGñ'óÕXHS‹iñ™ù1=&EµA;µ6ÑÆàP'q‡R ây]€
*r‰²
É’YZUÈFÍ¨íDÃhM!†>¥v¸ÆG­XÄƒŸÍPÀÎ	X&½ta¸²¨tØ7¯	}–>’PÅ™óhjYw@±ïl½Óbû*Ì‰niq»WÚÒswâ0qº¬\±ƒ|D¾—¢!=ŸÍ©‰Az`‚»ã£~ywÒÎò×ü—îòmâ<ãø½wç;ßOÛçŸwg{vpR’KBBÚ*	¤1ÌTªdÚ„˜¤]KèZ¥¤b]ùÕ21H
$°Œ*Ó€MšĞD)+BøÑÀ²VSaË÷l(ûcqü>¾»×òİó~ßïóy¤˜RÅÛo>÷µ)‹pNªâCøí­J>ı—Î•A5_-•ç•Cë¥çóê&ä?Îã‰LúqšdE_h¿ÊŠïpŸeü¾`€¶UDOŠ(¦íëŞºıÙùÆÀ¿–woüæcäCAÖºâ]¿şµúTñttìâOŞ™ ÎZw¬ËèZxûæuz]™:£eİÑ?¶ıû/RçKåyUF~ªíÕÁ·7|ù
B˜DŠa¿À~a¡Û›”âJèG3×ÁuqÛ8–A2Ÿ¦H–prÁ FoÄµ M1y†¡b#Şpè¡äf²ƒì"·‘4©:Ç›[•…­ÇIX»Û¯aöªY7rû¥ÆF#0µrÜë¡ëV#½ÅZ@=|îj¸YîJ%~aNg,ÇºƒÎ 7Ç9‡c_àZÜ»Ü»=ïù÷¹O>÷ßdî1‚$Šˆ Ù|/'
1é".øvÓ¢7ëËuªCïÒÉ˜^¢ÿZÿL§utSKÔÏTJÅ[[û¿MËˆÎ6ì{ãX’€½™Áİ29)¯ ¯Û4YğnıÙ†.M.yíÊÑK_lğEÀ oN_òêê]G©ä#Ë»º+½bïâ÷pÖY‚`ßÆü‡&L%I%™˜P&ĞƒS«6€»ú ROÅ^µ*ìm“Ó"¯Â >>"ğ‘ïêt bĞ1X@2FÔ?WDäsì0[¼Ï=àï‹ó?óçÅ«Äß€ /‹wˆ›w„şÈq„? ¡ûgøâš›Jç9R|LÜKïpìå%:³ŠşÔ‰d‰Án)Ç³ÁÁ ¸8¾å¾,Ûõ˜~Lz+ñ‘ÀPbç8›æ —ßÑœ]öõO‡ÚëŸ(éc æú'JÍP„#(’Œ!Â"å¡!-xŸ ğÃ²1'çs:9ZÅöÁP"A"Z¤¼ÀrNÆÉ²Ü>ÉÛ H8eĞo
ø®•˜|ŒÍæm8c f {Uz1×AijãxFkêx&´ d{ë	Í¹s/ûîáßc„C^ãÓ”÷¿!K+6äuæ*<:3q÷áyã¸1A«¬ß Ô5$‚/¢¯Ğ3VuÎúÒºZòPß<‚VˆoîÃ~Øxõ_ÓSéçˆID)ê4_f5gØ	húÜp}şßİ×=\…Z§¾PĞ¦®.ØTğ®ºC;¨èçµºÈ0’?À¨B¦ÈŸV×’›ÈƒÌ	æ#5¾p“‘Dé4O±”0“S„™75b¬I<J‰º^ôÙe<ADÄ9y¡#‘bTF˜p3 I,›aOmÜÔİ0„4#ŞOşøÍŠ_Œµ×ì—í3Ša†iú„è´g7YJOÜ'’@Û Ü¦0D­É@ÆrØ9¿,4•Å—Ñõ j
.®	RAµ¬}f8~îß9’YàÎÜKfnØû²è´kÔkXˆ¬¬{SÔ™y	ÀL=b,J¬L™d:ß€µ¦dwÖ´:3Ø¼ÁªKÁœ)_ ÇîÍ0`ØÁ++*³ƒpõ÷ûÀ/àTE9Z5‘¼tñ÷ıó(=ßº#¸YjîşÌşÁ–½ïşi~óšy‹Ğ‹w•­³æÏ.sä?¦¾¿3ıÖ)«ÿ7ç‡+Ug]]ïæ%[æ…ócá…³gX—”ÒPaÍŒ–Ò‚ÊÄ*Hy7¨a§M=aâƒB™3§	U•úTZ˜¾%ĞJ‡ï³L9=Cšá-×gÓó¤yŞÙúNvÇ‹2ÈŸĞ`z¬¯…W\Œ;µ(Šº‹HªÀÕŠLu]¸öFj³ùî¬i¯¹µ h(ËB#Ø1¡ÀufPæùVShcÚø¶@[¨=ìÈ Ë&<:°Vè÷‚¥>!¿n¤¾Ş;dYãK›ŠQ¿.óó7V¯Úä8=şíNë¶õÀúÖºº4İC>s ©cß‘“~€½t1<{-ì•øÊ\ØêJ+éÀË®v¥=°>´NİMîÏ¹Ï…>w_3ÃÎaï°ŒñN÷N÷7(ºPZlÙj¥2P¢Ö:Öºº›\o©‡•Cåd€“m…ê'Ÿ!—IøŒ5ìèòÒiD<äLñ„	S	æeÛ@§§Á¾h¸²ŸEq"%áR¼	
”¦³qŸªµfSÙˆÑ%Ó8’I»Œfn€bÇG“IˆYb€œÚlUUE¥‹4H‘fİ•_jj_¿ñ•æ6?ò%Gÿ:lİE‘¡›ä?K¿¿hû'ƒ=K×¤ş0„
dş!LË‹ w+rºÙfNQÒLšO+Yµ¼Òã¸hW”¬¦±Úo¨Ô,±Á?KİÃq>[.V)¬ì‚¥àƒE²T€°R\.BÛŠµwª‘Öš'OØy/«»d;"OZ‘Ú™v¾]Éª…É¤ãñòÜBo„şçi©Ğ+¬‡3/9e=´†z_Gê¸’šõÓ›ßX½²»giOÊHİIºu|2ÿ‡öŸúp<ïLxŞBĞŠ£7ì“:¡j÷¾´Ë}Øqˆ?Ã‘ú5§Ó‡æ’s˜:¾)zX:ÉœÔÎóÄËüqŒ½/IaWØo‚CøMÙc¸ügıı”ßVC´Ör"¹Å]²Ò,/—I9¤`î=©ê*S<'3ì˜W”É)Ù
ÛÑtBWEn¸íeŠiî£%„ÓX"Rş¬ˆRÑeÑ5Ñ}Q:êŠ;MÉe@Âsn˜ÄÏ`Qâö°×ô…ÌÉ¾ÚuÁ Â^mSkí¸Å
ÜÌPğÍÀ$%gÕ8ö>:š+bö¸ Tá›îâp¬ãŸ³gÆkí2—¾4cÿ¼lB–dü£2şyÙ„dÙ¥0T2	p¥µÌæ-p„%ÄÂ'¨¸M_Ş,Éÿ PÅğï¬»o¶£ÿÒ]-@Qœw|¿İıöyİ{ì= áÜrœŠx‡JÅÜ*„j4R¡"h+¢I	˜šØ¦F©/R‰É(Q‰ÓF2±ÅhÁ6£3Ik:v¦6;Ó´ÆLk‹™	#i#ÆÊ-ı{œÆf
³÷İîİí~ÿ×ïáù`¹¸¤ÁìX» Ng¶Ö¬.+ChyQÏ«g\ƒ^ˆš—Ì··u.DOşàùòò§	nøa ş	ÎJ£™³XTÈæ(9j-ÛîÇ{ÁO{5•ö¸4ÕávRŠÃ(…öˆ‚SFò„LË¤‡T§†&4¤‘Ó)
ÜwnÍ¹=’KË„*
”"µA¥ÕAÄv‡;L{¨>í¢Fk¤'D[\ø¶Ñ©TÍ RÇA!×ƒdÜ ü0&õmeI8ğR:Ó	“<äYa¦·PÁóæ¼æú{K_Ù²õépù£óJŞßîeÃU»:Vä½«”V/¾6şKf‘5ûf5Ûh)ˆ"´ÔX÷lÖî,Úe³·ï²·³9(—Îef cTN—3ßrÖzjók"5Pª'œ_¨_¸]sí1mnAl*ØDmqAÅÔQ[Ò'íÎ–mv¹Ğf×šÏ;Ín#ãÏ#pÖš «ÑªÕ$gd[j-(L@n~j-§AôfXÄß€	àd;u²8¤i$á²—÷¸Âˆú	èˆ@0ØUŒŠ‚‰Šå…\÷ÑçóIüQF”ä4Y%?ßœdiş§¬ÍY€âXí‹ˆl¥ˆä#/(iŠk³pË¹Ñ³1C¤)º±ˆ#,çÃš/Íû% a“ì+®!„‚Ûó Ë¾æY5-³óİöíÿ´mB~ÓøG[Õeşëoã;7ìßÓ¼~g¥>Ç;%¤ç®9rêl×U$£àÏı×ç7•íwĞ;_?úê±Ÿö…d½®®p]£Œ¨e£RRHeZ ~„î"‘ÇÎ£W©Í*Fˆv{T—›ñĞÈI’šÅğ¢$y¼’FQ²D#'/ş¦ˆ&D$Bš¡$Ú#yñı}~ºÕ?ê§où‘Ÿò„5¯[ğİ>/õ"oÀ—H%¾ms”x©¥ÄVEÇ&ÏRn õäÔgÉ+Á²YÀD L¡½ĞÊq‹î8ò½±çíµ½Ë²Ìáœêy•-1sdÁ?/lİÓ•<@Ÿ¬+©Ø»+ù)½ı2â)xË€Ózvˆag	UJb•H·‹§Å‹âñ–ˆ³ÅFñy±.`†ã)Ì2Àbu…ú~YšˆÃÏJ4œiõb(/Î„É¸Ä‘°Æ“Á
‰(%7GİdÓp¼Œæ0
°çkßû¾÷!EOœ0«ÑkÖ½T§±DãÃ|oNÀí>Ä°˜òzìŠMÿwG¬—kP²_t"O˜V0ÂÁ.¢ƒ‘ÏS`òšæ;O?A…èM¿€mZš8°ä†Ÿdÿ¾§­OoºY=´o²k¯ê±ä¬>;ívŒ%İ[
×Î)öä:£³]©`^¼wïòÉ5Nç(‹óã;˜ÛU÷Bç5@\2õï!Š™¸vÆ®&,«¸-0-Î3
ãæt±‰{Sº ½'^–>”¤L#CÛy¿XÉ}Sx†ÃçÄëì;ÎŞæğR~©ĞÄmc_`°½¸‡ëá{)›uqQ6Š¹B¾P(²/fc	´¶(‰‚„%‘áX³äŠ’e—I’ÙAú»F	¥Ù<â×Ûi9ŒÚ)”ØÏMZ’€2Öæ¤ Ju(üÃôï¶)ï
ei”`&ŞCq*mëÚ¨Íàˆº%F.„xu/
 E¨Î<ˆ~dşÑ¼½LÜzÆüarº¶×<~Ğ¥+†(9ŠÅU˜nÇ§ñE|ßÂ87âçq\ÀR“	#*İT€ıJ7Nö_,Õ{øü*áYÛ)Š;h¯£¹CT~]Ïvµy9ÍgâBÜÏ­ óWäÚr˜¢È
±1Ò9ù	w’Ív–;k;¹ù8â "E‘*øàBäz„‹ÁÌxÎÛ­1bù`¡Ã‰Y¬ÈòŠªê™™a]‚‘r*a—jÔ•4ªè)AºÒp3ÂY™pí©LÔ˜‰2áÚ[ùá°N”ä Eé–¸d5fÁ¾uøªnÌ‡£<=®_›/Òÿ _×§­·ë¥çè3ô	Õ/K›ÃÔGSP6:¨v¬­,iHR,XJŒ è[˜ùÜ%t‹¢î—ø>Ÿåş|šQú}ˆz€VÛÓy±éĞŒÊ«·œ( ÌÊÒ«ç6O7‡§$fÍof³á¯?¾råã«+'ké†cÓËv2iºòHİÔÊW’ãP³Å¡fuÜğónŸ»NhØAAµ”
¡Âù‰‚9²UŞaçl²œFa² ›Bp“ÿÙ’¶9H~ívÛ}ä¶¡Q‚!!·•©¯€wj0Òê=ôT[I gkÍá¼êÒEß‹ âÎê{–eÓSN­ŸSÕ1`f³áŞ·Ê›;#x½tyDj×m,¼‰†…;î;^ö}Ó® ˆt­Rã®Ñjıİôaî°Ğm¯ÒÁ¯Ú†ñ0wÓ®œ.Ó¿çŞ~kÃ[„½\‡À¨VÊ>’"Ë{Jù`cFkáQÙ®”yM™‘4«‹•&ğ"ı,"”êİq„¸Æ5/œÿ%ş^¾/ÙûŠ›¿ûô%óÎ>”s¨¥åàÁ––Cô#/ nŸyéÖgæ;ıÇúûûzûûI¼æ“l7Ä«€ïê1¦Ïq/tÓ®8Sj/uÇ3*˜EöEîŠŒ»bWsßñw3˜Ÿ e¼xâ¿M–§Ã‚­àµÔˆÃá+ŠeÀäVªÈJ¤âl[2R…Tn¤ÃMÉŸ4çÓÄ5}Ù¾„J’˜Áb: ìAÔˆ‹ı|Ó¢Íñ¡U]Ë ÄÚş¦u;v}{Ã(mÕwÌÌ¤9fş¹reòfèÌGÏœ<qr7E1³­Øû‚nŒDZ›ğÌ¹V9š­.Vÿå»êcÛ8Ëøû¾÷ŞïËöÏ>û’%ö9şHœ,nc7ušÕ×¯´kš6íÚ²Deešª2²j4Lˆv€–¯¢k;Ú?RÓ$Ğ¤€¦J…Uˆ‰­ÒZ!¡¦ŠŠ0…ĞŠÆæyÏé„àä{Ş{ì»ó½¿{Şßóû©*9­VURV÷¨D!ÇİfQ„úæˆ g‘”òÒç$*Ù'Œ6N—wjQsŞü	9‰/b‚czy××Äõè”ó2ë‹¼$ ºKkkPŒ¢Ş	ë©Ş‰âŞ§^‘×®^M,´_d½åÈÖ‘ÁÛŸØ°¯¦ÏÙZüÇã›.UşsÌC=a-ä-wNĞ…¤/céVòœqÎ<›9Ó"‰fIŒŸk³ş‰’÷µeGhÖ´ÃÚå¬ñ#gV7%İ¦­éçœgÓãÆ¸ùªó•&©3½MèQvj{=‰Íè4eÒj1QtŠÉb“(È¼.%¢ZFu')69në1uÌüBøóÍ/µœ
µåğ™–ig:©Ä§­oDÏ·ü¸e¢U°7‘,DÜúÆBcÿ¬L‡/ÑŸ:")7úX!e·2v°€uû[q¾··âÖ†D4HN UföF8¥Ö—$úRnl†AşØ”÷è½UÉ²xøªµR·(`,àN;ë=‰ıxĞz?o-c[„Ú	‡dCšJ²ö0Å´'«ôÛØî	‰à…àÃdù£}h´n9Õ›ÌI$fj£3SŸjhbùüTcS-Ù^îÖÁÁ¯szœsÚ÷œëÎ{pTR­zÔÁ\Ë”ÕVÆ«ÆÖËTîcĞûÎc÷c:‚OâEÌ!„lSïÌPÎÄØíCÓEJØ".Ü:Òa¹p_Ë…›Zn±³`¹¹Ç!¤š!À}V£5l½`QkÀv½6î·«6Yühni¨ÖËr,]Ê­v·…\ŒÚƒ5§8
ÛĞĞ–OpiªşÆ•£ÈB şú3­¤šj‰Nª%@èî¥„ØÅ®>¥"™)B«Ë@Ñçdİg„/
aÜ´B“)Æ<¶Ï~úhgÊ?YùÉ'¿tçƒ;ïe+ÿÔ‡¾×§ñ¯.ıíö
nÏíÈÖ·ÇÃ¦Ş»ñç¿ö‹o}}ÍÆÍ‘dC¸ş3;{_ıîï'`5V?$ßá =á·ns%•›]şşÁ€£(	#Ë™Ø2ˆ‰£œ$Ê¢epuÑš°¸æ,ÎšÁt2ŒeN¡° 2êô«ŠÔ.·#Ô‡%à7åÒ–1.›ÌË&7b4¿m¾c.š<2ƒfÜÌ›ÔŒÙc‰‰Ş‰Nà‰À³È¬Î­ìî{:bi¨;¸cÔô
Œ§.xB; ãNê¦‡©Å@K¤z²ØQLéäå9%SŸÙ=ôÅ]/—é•W°MÓó•ı_ÎÕ×İiéØ»mÍü»ùwXyğù&°ÌS4úàû®u@Nç$!&t“n½—ôê!¢çètªD6MYBf:FŒ ıO%DpÖüÿQ	’ïcyàÃ‹>ìûßÆ®ÖbşK%Š›€I&jÓf"¡s»»~ùü‘K»p¬q_yÇ‹-8vaàĞ3—^'+ÑùÃö¼´€çÀ*Á<ĞAOÃ<\ç†ù¬İ^YXğ± ãı)=“·»
oP,pŠÏ'«
8Qbp¶dËjSn(*¬íE7òX¼ #^1QLI¡¥€º”q$Õ(iZÆšêİK‘¬ÅHÂ’Q¹ÌüRÉÂRk(H¦Š,I„`¥’Æ®ˆÖgŠÖ¨å5W£šeÙA¹,ï2Cò®BII¡eº‡rôÉƒ@;éÔ"Âq ÇÔëP[1V\¹hß½!èTC±İÛoı³—{ú”‰S£„á¼¥ƒ†ÅÖ)l	œYë:×u†À€\­ìÇ™_wY‚?ø6NT ½•?ıt[¤­4Ô0•À¬LU’q× ²2ˆ,òRŠªó¶hJ²®ªFË	I¥Ä•„ÜáwNül¦c­ÛB…RJŠLÕ:dÓoJ19¬ªI”¥¾MÊÊuêä7J=h;ÙÎïŸ”£1zœ“Æäãê8:EÇùSÒ)y\½nÓ[ü-é¶|K½‹îÒ~Aº+/¨ĞºÌß—¥ò²ÚÆÏTßu¥º®MCfªw¼Lf™úè7Ä21p¬‹•ÇÜUÂê+öaPÌìw0q?Ãâ²L€ÄE¨ ‰½tæ	£2>ôŞüô[
åã3Õ¾)A–`Üå®å‡«8LU—Qò	>QäyJY}¨2
’Ûıe?ñCQø6IØâ€ùQ¤Àî"û§ã8¦]ŸÅvM«Ø±¾;º²bÇV¢µ"@µ×_^õ(Ánïà£{éŞSB] y{ 1æŸV\­3¾?©•`Â÷öWeß,ísµ²ùI…eóš€×E˜.bõbœà8<X™Àú«8på&WŞ¬|tujl™aû¿î7W Êü•½tTY¦,C¬ïFÕ@ÁÑ‘>ßöaõ‚-¥šâ‚…"ş„ohDÇ¾K/ µû³(Î‡GÂÜ",q¯+§ltú†B@¦%ÎÆ
'8&3®D¼Œ`Â2—[¿®Gy¦’Íë«¬ë[‰Ad+pÅC=—}±/¸´ ş`¨½=¬>İs†ô¢?ØÍ ¯>Ô;„¦ĞMa’Ñµê"¬òÅ+\¯‡mĞkÁ|õC×¯éåP0ƒ`DËPÓ‹S°qòÚ½kp‹~.éd2Œ8;ı8W¹“•×¶¤¶8Ñ¿wwlsñĞ31€ŞO>zHf‡=áèĞ2—ñ>‡
¼†Dd¢·İ%§ô£SçÎ«×õ›wT=öoîË?(ªëŠãç½{ß{Ë²À‚ÂDÅ Xğ7F×ÚSGâ@Á˜XcLÔv‰N5#IÓ¤â ÆñgS[ÛL‡‚m7µSÅJšN»iÆf2)jTítbHJ…×ï¹»y®¦IÓé?eæÃ¹¿ï9çsï[ïÓ>±À»Ø÷˜W¼à­öÕzÅìX-;7¶6VÄ&&%Ä[$$K}€§I«øbtãrœÏ#).ßÙ$B Ş?!áXâÒ$.$€æOL“^wÂxÃBí§ô†N|8"§õC”BmÚ „¹¿;{IÁŞİx7º³»»³ÂÏG¿›½|İ"ó8Ê#?ÌğW^®á±†'åpObf¢È‰Z¨WßÛ­•j¢¶N‡×½¦oÑlßŞ»XŒï½ O¸Ù¦×ôV0ì™çÅ“b«q/Ë@*Ä›^+)59Á§ùòv$7iC1I	ßüØ‹k™f™dİCŞuºKÚ:—|/u]|ÜÀ¸¾¥iOümÁëWĞå¿ìïîå(™ƒ"ŞÖµDıc;”)Ú0|BMÂãoZão)ì»šıTÙä¢õ*-„òúRUO¶nªY›ñÔ]Ëô]m}z[¸Èv¬¥¢'ÌvT¼;LÍT6X±ù”¤%q-;¹c`¾Èç²#ßmG~†/Ï÷7üä’øµ5õä #Ø¦%Ÿß(|šÖH“é.ë‹´´°!Ú–¾QZÚèõe“‹géUFóùMÛÊ3ÖÃ-­¿§ú‹#ïıÎÉG
>ò¤yˆÿ_*ÌòŒ\»«§çf¯Ÿ<)êÓÔ`İßWH3üÔÓÓ³É¯ZÜqÍH“>%B5‰ßÒZYAI`¦5˜J³T¦]¥‡Ñ·Ìƒé.y”Š1~=ê»õ)v/Æ—€Ã`<˜F€Å`a„`:æ´‚¬ñ(¯£ä%ZeµÑ}Ø‹@ø:xÉ(¡Zôí1§Ğ2nÇ^Û°F&Ê{Ñ~Ğl (×£¿”Ç*ÉóKèkèÏAy·QbÛVYh#”{ÑŠıw±Î#°…¬°»PµDÿÈbÈ¢ˆ¾ƒTùÏQ¶²[¹ÿT¢}'˜ªÁbø‡ççaŞPÔkP…^1>/‰îÆ˜ı>zröŸ±›”İ°£ß&è¯tº3Å¬ŸèÄv]màM—nÑÔÜB}EŒWçÇ6Ç©z}~éc»Œ+öÇâîmØÕ¹œÆzÈn€ÓŒSTú8P ¨ M 5âÎàm2ëèûh'},è¦áú”n§Éğß"¬¿<5Ï¨xXÎ:Ø@•WğıTAKÁ*ìİêø‰}ƒú,œë"Œ½Éù ¿>VÂõ`ë‡ısÙç8÷µ’¾W1ö=ì3›ÁC°=|®´óË±–¦ö	ŸCXô¯‚O_‚×YgÔZ$ôûCÈdÚÀN7°Lá1Øß‹ñ^¯ˆMã¬ŠÕ¬{Ø•Õ‘œù&æ/i`”y”0
cÙ?Ë8f9_œµ9¶8f©bzµŠûsl'Ç”K¾dië öEl9’óënd)R”NûDˆvpÌr¼9’ıÂ±ÆùÈ9‘s]¶æDr$ó‡¨XG,:ÒñE¿üíÃš%æNÄi'Ê‹T(.P¡±rìûÚ`áË¦‡<AÊÂY>„¹{£d=c…´UØëEÙ_„è òkH¿[†4Ãh´¯¤µz¥*ß&£Ñ‚á>–Œ»ï?mÿ"èo´å#dÛ°gç„Õ©åG¢ıxŒödkõÕZ“UL~“èX#t¯ É2HÓd
à§áh/6P÷î¬Vë¤œ×w­Ê×q7b/ı-¼€×‡œãŠ£[b.:–éÄk´ä˜á{Ò€LCŞ5ƒp1Â_@;âqx€ß¾ŸÕû€;Ô„ãÕîêÏV: ¹İ‰Ï¨8ŸVt\FK~[ø~WoòzÔ8öóıÈwß‘|ÏñÛçŒ–®ùµ¸;ş¤îá6*‹äuÈ¹XãtäiÁ÷ãäè5óv‹5Ínçís¯ı#kµ}Î<e€İYıoj0|—q>9o)û‰ßEç5FĞŠÈ}¶OÅşê-Q÷ ™‘«hÖ½Àï*ç¡8€¼ƒ?±Şsòú†l§Ğ=Aü$Ü.P!ß‰rÊhÇÎı±b‡êŸ/?¤2åW ÷S¢iÑóW<ÇnSm—Â}Üf”ÑÄ]®ÜJ?4Ó">+¶CŸhŸç³GÎ§{¥ƒ!†ÛiŸìÍAØxVÉı*xîI»‡í³¦Ò@CÀ>xq2"ş¨S¾*Õª†/xMóê{ƒŒ·1ş{´Ùã¥}‘¸Ÿ>¢tw‰Úë8-ô”ß¥z¯ÿüèDŒS•1Àş‡Šÿ£¶-zCÈ/FC_
¥´¹T¥ü–Õœ?¢“R8F`_‘úèDŒ¡uf#m3ƒˆ»Ş‚Î­¶¬¦|”wÊFûŸûU¬A¼7Úç©ï~§ö›œ/VYì1¬ƒúşÃ¾â
ôİMU¸K¦{:é&ÿ2$?‡€±aTıP	¶…Qmş°Ô†aÍÜ®?Nç …NdkœòUäŞ~š.~L^¹ßôœK[D!â®o† Í\—94JtÑlñ‰z¶^š¬Æ¥â¿Fse)æi¹<AË…ò P‹xÄ<£‰ÊŒÇğõÖ‰ OÂœškV£œkåqjOìTFn¤qj¥«ë|Ø¥s-¬ú6âõEÙ­/ëÚ¯gDÇ;é§ìäu1Où3M‡ŸŞÃÃ²o^Càeı"¾ÃƒT©ÕÙÍğëÌ(f¹ë²R«s”•trdà4ø«œH/`í×!OòïFÿî.Hô?ï:}nxŸ;µ»‘ïÛÍîº1¦0zîôœ[ûÔøC4A~÷pİÌˆäeÌxÊ²<”¥·£½ó¢êÆ(Ú#×`ì|Ÿ¥Ó¿y.?Ü6:ç™ú9xÇ%3X"¿Æğûüßè÷EÀù>Pş™¾¤bè¾É-ûŒvšÑŞ³{pŸ›L¸NéÊŸ‡(Ñ9'´W©ö¨óC¬LbŸG·£\À8õèsı¬:Ö]éÆ‰kù.Æƒè:Şƒ crŒåÜ^ïß÷Ó(¢	ğÓLY]Úo¯›~Êeôµ¨×£ÿ}Éô×‹(‹á±|›ÉÀ×ÍŒŞNÃ1}óÕøû—_±_Eçªùê|œ8>Ì%ùkÜG—ñÍ\DéÑÒ³ÑyİæÜ%w•yŸ¶æÿÈóà,øÍÿtÄ¹FˆUğ/ÚË¸ªâŠã'ïŞwo¨Q
H	 È¨é¤ˆªU"¶(I0ÕÂH+
£Z´Ö©Š‚”¡ †Z‘ò¡a¨”V;âG£…úQ±jZ(-%©’ämgïŞäyÃKÄ7ó›³»wïî¹ûvÏùïé‚¦ûz£­úwÌò HË<‘¦Eš§‡ÈÁÍëi« <{Ši›%5½Gùvíğ¸_"w:]Ù‹ú¨èİ–Un¼s¢÷õ½¨¦aÑûMsa9å]À.kz»{œşu¼W…E4ÏÆ¥ş]`?4¿FıR ï7‡ƒ€ŸÍÈ˜æ!¼¿f©9É=ôóµ9îŸÔâãø¾Õœø›¼C|bÿŸØä]#şÿ;³ñ]¢uë€æ{UÉºûtxÇ‰-ÿçGcpÄ¿ß´ )C«£Ñ²Vs«~tÖêí½VOæYMé,ë©~tUí¬úû˜½çíÆŸ™2¿*­_qÉŠ­©Ar#œé îI9}^ÇŸÿ{ŠÈ¯ÇÑ–‰~“#ÌrW1÷…¼çÍqìNê}ÈeqN‹ck»Û>§}¡õSÍ‘Ÿ"§sLO·Os$Ÿqœ¥$sñ©ÒYîşÔ¹<GÎÎÓŸµçù˜‚K¥L	/ÃïËÚëÒ¤è¬Ş™Î=ÕzRwdÕ7(<·õ¤.‰ëIÚ=o¿÷"=Ó›ó“8w§
çt¤›y+>¯±ÉsÜzŞ\=¸G®€Q±Í[-çGÎƒwï:›29ĞÜ¥ù-¿YÊò×KõgaSsLU”ûLMŞoÑÒÿÓ“¹—zèï´}¯uTu¶Ÿ“ûVõ¹Õ‡¬™õ}!ÿÅ1# l€[[ÿkîÌ½Í#óê=×û‡9ÎXÇsiÁ\–{^µŞ÷¨Q/"—¤4½E–S‹-Äß§ÃÄìŠôVÓl´}®çÙDÿmKœŸ–öä6¿Ş¬#¦OMsÕ¨–‡5wBÈ»Ëx÷~Ê%Ø¢ğˆ,aœõ¼¿@s@XLl”Šàr)¥íÍÃğCúş€µı^ê})%Î÷åY±³ƒƒÌC¾
Î³9æ4ÚÎô…ïª—áPå“óáb}®óN0öJûî©K¤Îk’:½T2ŞæÂ5²¸`«,Îç{
*¥6üŠÔúÕòHápYÊım)õEš¯â¼ÊÚgâ2ÚmMØG®ÕïfìÎNŒ¿9©	¬Ãˆ«›•ÙóÆïå—³6øş­²”ú¢Î´ã\ƒáìOÎ§¹ÙëcvFV~îrüM­9¿R®bœ¯Qd×v…\àŸgç[bs59;İ•qºZßí'}‰çb]Zri¡X›À(»oêe¶î1êC¡»k›huÁå2†ÿk§çJ±?_&¤Ö˜WZû ™tù»ì¯~*º¿Ü{$µš3ú–t×²¿Gá?º×ñ3öé*][ÿÔX×ÂKìc#X«ımp¶Z1ûıµÌ¥°^êc¹?ŞîÏ^no–øÊhµİ3İøşëë"Ğµ»=:Ì1“xÆ™Š­]«C¬û|g¿Må­eß²>Ş
ôU½\÷Íÿ–Lïg¿>ÃŞ™Í¼WJß`)“âàBôá|¾{ïÎ–y©£R¦ä-0¤|Ê8¢x"e>ÊœØ#yäzo‡ÜÎz-…Ãb¾§QÑ~¶ï:™â8_I­ÉëÏóç .9*Û¶WUYĞÏ¼M©3wÆOá×"Ÿ¼ÓÙ«	xgªÃƒ>¸?İŸÄZ}œò$¼«vHÚÕ“Äµ÷NB»Ú‘Ihy?rõËåG®öIhø9ø‘kÜ³“Ğ~vş]„ö«OÁ\ë< 	í:ğclÚÇ&ı >=/pG}Vó'¹úNìì%ØÛàiÊÜ{Í4WßæúİÜ†şL_Ç0…>äcsƒñmè\¦GôN<¹…röÛÑ\únæ¹hn‹›3³Êùú;ø}V]}gîÌÑ|vnüÈü!Ò1æQ×„›÷©ÈïLOì¢şú\¿Ñ¾÷T†ãgˆã-úm×´¡¾gê(ÿ:ÒL™Ín-WFó¶pO4½`°{>¯-.È6î‰‰‡³4Wç§DÔj¬µ1wºtÏÊUVcPş¥Æ» oüoJŸ Ç…ª4†Ûû$qßŞ'ß@Ÿ ,È#{¨¿Ï³O#nÎ‘suÿ(z…±5ïªæğöÈxÅj-6W_®ù ğ©
†ãÓ1éÍø%á.©	&O£»l—ğfê7¡;~"•A(³òWHMø&Ï=¹’|U·ÇwÛà^cÒƒ¤Kl»—ª‚?Ò>-Õ[®ÖùÂ¥‚5»(»uÖé=×şïºşk`½HóWaŒõ±g`Kl.Ví¤k²]æáÏ ÍŸ¬Û~|)èÉ¹j–sÃôÅ&™W’eáúé\¿R]×ºöƒ½CÒ#x]¥!=ìZ?)ÕÁÛ¬ë­higÉ5áé™^ÇwÕÊ£ş6Æª•~éÒËj‡½vìÈÆc¬AÏ’åì‰ŞI]ë¨V}³›=hÃ}ZÍYßom–Ş°ëŞ “ü[äş	§6ö)Ü+µÁ^»&[ıu©Lï"·®—+ƒW¤<]N¿JÊó{K¿ğIé¥ú,œÆŞT½FúÉàôráŒ›rşŸíØ; ÎïJwæŞ€u.vLˆÚíÙ¤­åQ×>î†éÑs}fî‰Ê-G¢ñí³»£ş-«8kyœ¨ÌG|äÎì‡ZÎZç%VÓ··N×Ëb§[;¶	ı™Ëêæ.ÎÒÃ‘loÇbGÄuÎçëªåÌ®XG'-}k­¶³ÖrvŸ³;t¯©ÖKÚ,]}R›K¿¶éXwÎbéê¹9lU¬¯;³­ú;‡mÕëÙJc4NÅ6|PBÕ ±uq¬k›uº¼íş”´£ÓŞu:VõûhÖıAÎÜØĞ}§¦!hÌ¶ÄHğşL>	A)ıJEÂ§MCøt›Õ»bGñŞCä—¾¦!¿o¶•î
>/Œ0›àxÃFØâå™/y™´z–%w,²÷“	'#¨eŞZæ©`>¢x¸‰šï:Í.a†÷¦ÚolÔ\Ø!»˜µóÜÇ;'˜ç„µJ¼îñ:ÆëÂ·°ÿWìs<¿÷³şŒYÓ¹ÿÓ¨|^ßİ‘ïé­æ5Ø§eÎÒ;î^‚5JÂçÖïı|#„“"ô<Ó·ÁÑÈºşş¦1Êñ<ÿÒ½å±æq0Or4:\]Ï¢ì7o†W™}z¼Íæ˜¢ZêdëŞh^cî—`wñÎ{GRíõgµPã»âb_ÿ‚ä/bå~šëóëØÛBüyQ¦}\ó™k\^É8B¼èl”‰^F&k¹Ûv%&ıÕìW˜kc»cQ¤ıÌŸàåhmûo²ñ.R…òpæcSëô¶êØêˆÌ¨½Í¯8öú(aîºÂ·İÀÿ]dõË2|[&%hÕ6GÉh–,@S¦úCõ‚=3e(ºp‚£?ë2ÑİX/×XÒo­iRTÙÿ©^Æd¼ÿ_m\$Nz‡Ş=Œæ¬y<ë¦ÚGÇP=¨ºÈ«g‰)ŞJî¸(gï	lE„ïaï–²¼j4ê»”ë ”ö³°wÀ”bï‚ë`kÿ©”¥»3Vš²ÒŸ~›"kIE¤vGxı˜ƒöÔ«ô›#CS´}
a´Cû<ÆÓg#m¿²ÔAæ#…^‰+ÿŸırª:ãø·çdwIÌcIÈóÚK!1yx„†½`,¥Ğ°ÁGG1%¬ÄİL²PíC2ÕNI1ÒÇĞV	¡ØPÀ»m%	hPêP[ÓJU¦ÆÇÔvl¥L§íXeûÿÎ½ÁTt@ÇéèÌÙßı¾sÎwÎ=÷<¾óy(;Æ áö2ÀY·lÄfîÛ6Ş¿Òü¬-ˆ©
@wzĞk¥=¦òŒ0§9 3yïCºqvkz1ØŠôñÅ¹}`†ÓƒòàJï1šéİL¦/H_ó^Nq°|y8‡o *øŸjÄÒÍÎèßíVgt¦ßÄ¼İ#O¢§¸rĞw‚j2ïÁ½QºN#RôHO³:;	k‹<½õ;™÷•ô¿x¯Ä¹ş[é^ÿvÄ’Ûéó®/âX‹Ï’±|®CŸÉkÇ;™æ¢%œ>é¹NŒŸæı°¾÷oÌİÃ±Œnzˆ×–²ı^¤¯B6ˆ-‡OR¹[w¸Üåá§ÑîV¯‰1b*Î@ }6}Uş¡¤3¶bİßR½îÂ4æs±ËÿÌ­ß¤0“ñØ1š&‡‡GPçÅ‹§}ªeD;Ò[Ş%K“ıch²ª»ìâiñ"M`dÆ¸éÂ4ŞßÈœÿî‹¤å4‘Yoç×ô{}ÿKé#C³õ—±>	~&¡3XËi”ÂZš »»ÅìÙßá|ø…øÖİğoµş¾á´‡ø¼>ñ4lÚùŒà˜}+b×•—ÊÁôQös+ªxñ×U Î‡]¬îeô9åkáSÑ—£‹ò=Mù ,…ıû ÏÊÄ~Füé$Ò¿ÄºX‡İ°	ú”_çø)öAr9ê,GŞÏR>“}ïCø+· ıø ñ2$9ı¯’‰½°ÙÏœs}|6)ß)œvÅßğè|wQûv•ó„u±xÉ/GbÌ£ïL_,.„ÍÏGóÎrù2æ BÅ8oêÓ¼…~9–?ïê¤‰|fûêÕ}EùÌeÉù8ŸÏ<>'yx¾ºi,|JÉ÷I	[ïƒdğÙ…qz
<;J.wPç4ãŸ”¯ôĞÍêğqîºó©¸†ïw|wøaú™Qw¿‘»\Ğ][Uø¶ïàÜà Ïºçı!´}Îå!†ûíx\j{ü«¤kX¢|å}òÛ‘G°È·ÉiœOeÂWgM"ºì6¢l”e?åÛ^#&*@ş¸ùD…Á·P”^s(©¹4Êf•Ï 
%‰ŒVi;ÑDPñ¢J+û
¼¿ê,Ñä[ˆ¦äƒ7‰¦âÕ¯:Ôü’ÈD~=öÉ´b¢éq¢†gf6}¼¹¦í£Ë¬iD³Çh4F£Ñh4F£Ñh4F£Ñh4F£Ñh4F£Ñh4F£Ñh>âxˆr¦ÓYšM÷‘¨–š‰|oˆ'È‹4Q.íÃSÿnSOÖı4ˆ”‡œßtÏ$W—Tà¹ÑÕ3 ·¹ºúzW÷ÓÍÍ°ôddr›×]İC•âFW”+Ö»ºDş½®=åê>è/¸:ú#Òô0dRşWC‹ĞjŠB.¢ÅA’î¤v•3©èülA~LYÔ Ä¢6üjBŞ*ÔOR§JE!£°^‡g+,-è1ÔeÛ˜²iIÕ^+ln‡ì 5ÈKĞÊĞn5®Ztê5#CŠßnĞRh-*å¼9ÜZÕ‚¡Ú^­újĞ
¤Ö¢4©zËÖ5f]İÕFduÔX”ˆ'’w¶Gy‰öDGK2–ˆ×V[›Ñ[µ:Ùi4E;£ë¢­5nº>²,2Åêˆµ´UÏM´µ.Š\Z–ÒX§Ñb$;ZZ£··t¬1+ßóõF,n$QÖ%£­ÆÒdK2ŠÊñÖÚD‡‘@I‡±"±6ìˆE;kşÓ½€n¢ëñ†e`Ê¨É¯¦¹h«6‹PÂõVaÀÛÔä_ZÓêc»(]÷Bé+è9z—ß#‘.+Gî¥ı >
Ol’ÂroÊŸc†BæSÒN1ÒÃP®©WùÕß2»É~ZNõÈî·›9»?¾ÖT²~–#k¯RÒãûÇ™!«Õj <W[î}àqàC‡úé ¤Ü#wØóChaÊ³ÆÉ]ğla<ƒ4èı.|Ë.zİÍÉ@¯v¦2³ùõ;U­¹µòğ€.°^JàÙÒ@BÛ²$ä¹İ„V–ÜJëß£<‡Bh}K* Ææ»©¼3lä·i	t@.¢a Ğìı¨v?	˜/´«¯RC¸0••k`¿ŞˆlÄ+·áéQé0`û©‚ 7·7VÕû²]7ÍQR"s	FáòÈ¨ŒÓD
É» Ë!W@–A~A¶Rêg8•0»ğ¾90Ÿ#i2Š-Ä>Éke1•(³µv®óµvÕ•&¾x,R&y2‡¦A‘~ÛC2¬C*ó2îß;Ph–_—~«.Xå–Y˜Ù,õ%‘TfÙkeË>3‚a	¡Œr\5·Ñ5V~J–RekdBÎ—åJş@n§ù¦*KCÃCò›ªÖfn¯ot–Vc*'×¶2e#JÈM˜€Mêå½©Ê&Y•²Šê€À¯‡¶^-úh=˜µÌTfªêÁê#Ù’nØÔÊ/Q»ü"õ‚>è¼¬
mè€R&U™òrY„	a(=È-NeærÏŠìüeV”ÊÎ5ç–Xçh3,“©ñEfbH^©>ejª¨„+´ÛX®‡åxgjP1ÈSrX–b x`Êd¹]:`…æ…"xZœàA¿'yºÅq¤YşÂ•Ï¸òWL‹Î¦¿fyÚ*¯ ±åâ÷ÔMˆ!ñ$œHœ¹â1@s ŸGºr ²rĞp,tPLA ïß·s‚ü±âI{J­«„*\e|‰«äM«B<!P)šxrä1LŸ€|²rX$éäOÄtšùcW‡x‰‹GÅOidÊÎå.°ı,öÛ>ûlrRKjC‡Ä>ÑOÅ0ı‘]YŒÜ=©ÊI¡¼!´ç»DÒ.å[Yb»çÏ?`´gIùb‡İÀôÚ‡ŒĞ€è½á¢†pE¸:¼[ÖUÔU×í–F…Qm4»+ 6Áô	ì_±Ï2Vƒ^Ñmg4°ŞÂ7ñw	êÂs›Ònı/éåÓÆ‘Çñ™Åñ.$CGËq³à®¼ubÔÅk×nÕú'¤ÕºIuN"¤ô©–lõH‘.:%E:é¤ÓIßŠš;1^«Ô´TAB}¬âGúT?ä­‰’§¾ÒïülHNå¥º5ßùg~Ÿùg‡ıƒ²H5†2°ßû”j	í›…4Œ±-AËĞ5<°­hŸ@ŸBŸAŸSKª@¸šAAA‰(‚(‚(‚(Q¤ìH"
 
 
 
D¨ù@ˆÈÈÈÈ‘‘‘‘#"""G„Âá€pˆp@8 „CDDDDŒˆˆˆˆ111"L&„I„	Âa‚0‰0A˜ L"   D@@@ˆĞù©@ŠhhhhÑÑÑÑ"¢¢¢¥-ÔºšÉï444	iiiiÒÒÒìüô2-††m³-AËb·Ànİ»Eìm¯
¤X	B‚ $„!AH"$	BQQQQ%¢
¢
¢
¢JD•6nRÄïß”¿ûÔh×¸kà^«-ó	ò%öˆ|‘íÎjäŸ±UòOÙuòOXœ|…È1y™	ƒ{"Ş—Â%`ú3ô!tZƒîC:Õ@?A»ÚŒ3îëÓgõ;úš~_?´¦·t­Ï?ë¿ã_óß÷Zó·üš™Ñzé:ŠKû‚Ê%”O ÜDP&¨–Ğ¦‘w×Ù|¦µi§ÿ±ù$ÂDøı_‹ğ/"<Ù­½É}t¥3Y\ÃÄ¹ë	;P<>ƒ+ÓíõG^èUÑà›m›plø#¨­B×¡84E!ÔA¼ëŒw†Ü„ÂĞdªlhˆı†³¡õòÕú÷½¬[å	÷­Á^xöµ¾,’İ|…ÕSÿ
gî|ÍÑıß¶ıÇßÂîzbö¾>»à…É^ş>…ïø~·òsxag=1³½pHEGÈBïwÙC¸Õ¡^ng
zâlÜ'U´ÁÂêÄs?‹ÒôAÊ»ê˜Ğ“îú¸sX<€ÿŒ…ÅöøÑlø`¬×é›Ñ!8)¼dŠÇı¡Öq©ü+±jİÿÄXÜZÿÇÅíhÃ@ó-Ìû&¥ğÄu³¡İs^Ë"&ÊÑ‡¢$Ş—Ä9ñ¾…vO\›jš,Ï]íŞºÈaÀ·ğ+,O¼i5hŠoˆ…#Ââ¤¹©Ö—½Ö7İT+À¦ÚÙ_ÁúF¬†ÚãïÄ¼ß‰èOõı‚ÒOéA}\ÿ“>ªFÀ8j1zÃğ>C3˜1ØØm96Ã¶ô”ù}ªôQ= ©J¦qCco3ùBWVËÎ¥xVn]aÙË¦üe.Øà=gß“‡‚).²,{>%_³³}÷œŒÛY©ç.¸5ÎoçÑ*µ¿48;ï6ø®jº1"^G'»qkdƒqşâ[ù<ú(1œ8ÓòôE¡SÚÏáç«£òïÙ9W~9š—Sª²;šÏÊksæEwCëÓz3éí¨²¼»á+j}™sªİWLçöÂ°›"Œ…•!ÌH1S…áz’Ra8Gí¸pÄ)C\O/Q\¨§—â|\ÅÕvÌLºfšc1¶C1;{.;lº
QTĞä®ŠânĞ¤‰MĞ@B $*(„ã¹œ’ÉÏB¬NÈÌ~ÈåêâÏbD;fğØ^Ìà1ÄØÿç1Ÿ²y}²²¸™f
ÁÌ<Tıèê°\¾lšµÅŠê0eW¨pùÊUå—æe%8Ÿ–‹Á´Y›Ü> {[uOÓ5¶9ïÖ¶ù´7éLf‚—Òùzâ´›üŸ\7÷s¹§ì´ÌU¹Éº“ª;¡r%U®¤Ê•p”+óÚ÷9·f°Tşõ‹m¯k‡{°‡#cùÔP xFmèScÃ‹#ßø¿ËÛyy$˜’½êŠ&£IÕ…ÿ3ÕuÍ}®áÅSc#ßğ»® šûƒ)¶·´LeåÌÙ¬›{ÏU[E:—>g%uP÷0Ë|Æ¾—Iø<ÉJåƒJ¥RREÅ.1–•‘¹¬|õ,f¢ëHUHçÑv|¯­«‹Újİİ™Æî:mL‚—U:U³¹tzğÖ¥kUU×Ô«B¹şÒèÔ‡ßá¾á=N[ğNLÒ[ÄB}ÜRï/åú‰™¶ãuU¹÷ÒØ2Ôã@•[mwú£¨¬X+Ñ•xÕªF«q?Z×WÑ(VÕ­Ô;±ÚÅÊvio!P-ç±Ø˜–Ê÷oï£”¸ª*¶·KœÖë·‹Í÷}aKQK4|yï„´ÛKAp&ÚÙ+{X¥Qg… ö íoûÅ³ß~  ÿÿ   ÿÿ @Ú+:endstreamendobj47 0 obj[55 0 R]endobj48 0 obj<</Filter/FlateDecode/Length 341>>stream
H‰\Òİjƒ0ğ{Ÿâ\¶%15µZ»‚û`n`“c'Ì¢½ğís\(üHNü›V”çÒ´#°7×«
GhZ£ıİ)„+ŞZÅt«ÆEá­ºÚFÌWÓ0bWš¦²Ø»ŸF7Áê¨û+®#öê4ºÖÜ`õYTk`ÕİÚoìĞŒÀ!ÏAcã7z®íKİ!°P¶)µŸoÇiãkşV|LAÇFõ[+tµ¹a”q?rÈ.~äıo^,e×F}Õ.,ßúåœÏÚ¦A2	J’ ]L’$AÚ‘¶¤=I’¤”t"íIé@ºŠ ÉIgRLz"	Ò…D©SJ-)KJY$ıCJÿ )Y’Åéüu!‹SĞ!!ÑÅòõİoÓy®œÃQ.g6ªï=<:¦îÎùf…º4÷§5ø¸C¶·à«æ'ú  ÿÿ   ÿÿ §§Œendstreamendobj55 0 obj<</BaseFont/HZWTVT+ArialMT/CIDSystemInfo 56 0 R/CIDToGIDMap/Identity/DW 1000/FontDescriptor 57 0 R/Subtype/CIDFontType2/Type/Font/W[3[278]55[611]68 69 556 70[500]72[556]74 75 556 76[222]79[222 833]81 83 556 86[500 278 556]192[500]380[604]404[604]3032[83]]>>endobj56 0 obj<</Ordering(Identity)/Registry(Adobe)/Supplement 0>>endobj57 0 obj<</Ascent 1006/CIDSet 58 0 R/CapHeight 716/Descent -325/Flags 4/FontBBox[-665 -325 2000 1006]/FontFamily(Arial)/FontFile2 59 0 R/FontName/HZWTVT+ArialMT/FontStretch/Normal/FontWeight 400/ItalicAngle 0/StemV 88/Type/FontDescriptor/XHeight 519>>endobj58 0 obj<</Filter/FlateDecode/Length 42>>stream
H‰šÀ Œ|;?70 p€Ñ( h    ÿÿ   ÿÿ ØOÜendstreamendobj59 0 obj<</Filter/FlateDecode/Length 15998/Length1 42470>>stream
H‰\UxMWş×ŞûÜyŠ¼”sÉ›	õœ77tQ‰	î%WEB£zUÕ£·^õa*U£Ššê‰	JGŸc>(¦èÌxU‡ö«ÇÌ÷©ÖãY'1†9ë;g¯½öz¯µ×©œ9+€¼‰n#FuMCÓs€_ß¤ç*õ¦-µù“+J¦5í€v­dêìÉs"W²LÔx }eiÀ_|êğ¥ ÷qfz²”	Mü)aüéT:­²êş>èqrjù$?-ùù6`³õ8=Í_UÑt¾î4ôéşi‘5EL[÷ ºUÌÜ?¯îD|)—ÑjhÓªµtö2¡i•_b²h¦‰‡ö£Î#Ù:„*‹6³åós<:2¡[wµ¡\JwfĞîLeYl'IûÀ¶¥íG¿ñÚ6Ä©$ÄÖe~¯Øk¨ÌºbŸÛ«øùëî¿Àv¼GexÂÇtƒ¥ŞÇ>Ôâ0b…˜‹µX
Æ2åä1hL_KqV-ºb3×a3ê™wæc?ÚR¬õ`±<ÁR‹…ˆ‘(Ç
fÍBÎ©Eè…a˜
zÑ*°VZk¬·±ûäaëW6“ê­kÚiëïHe‰uØ€s´¦ÙÎÀ®ü>ù&f¢ZSd•X·ÙgrPO‡„›µp™bi®ô°–-–i}Ê\í0¥¨Æ~êIƒ…K+²r¬z´eU¬uvc/CâkŠÔnXo[7‡<ÅñÔâ(’¡{C8cg©úğI9>ÄŸqŒúH”k‘Zš–©½`DktÇhövKş“n‰ùäç*Û„æœ—×ìlã3\ xêJ#èiÑE”‹Mr&ÂØbw†b”q¾_gígÉM{E¤h[ÔNuÇñxè¼Õœ+’„7ğ&>¢(T§gé%úŠ¾1A¼!.Êµj‡:îôsÔã1+°·¨õ¦\ú5•Ò\ZJ¯Ñª§ctEùâq]–Êò Ä0J=«iK´WWB¡OC_†nYiÖär?,dï×aG¶8ÃpI£jÎ “‹FÓ†ù´‚~GÛiÕ²•ct‘¾£ÓMº#Àà	Â%:2b¦x^¬EÃ1ñƒøYÆÈÒ-{Êş²P–³WKåj†=ò‚ŠWÊâ<§iëµ·´íÚNící†#ÒùRÂ¾¸»å^ò½³!„–…Ö‡v‡j­hÃ5Œç,t@öŞÏ0…ë½;î}œ HÎ]<%SãÌL )4ƒª8“/S5mmô}à,¢ëìs”h×èó¢§$F0Œ1C¬kD­øJÜ–N![È62Y–ãd@VÊÙr½4åòò¢üQŞe°T¸ê :ª$åVƒÕ5KmR—Õe­H;¢}ëwLs,qÔ9şå|Ò™áéÌus®rîuóqw~‚=ø#zè¼\(½rVŠt'Š£ÜÏP,swªØNËÄ<ª´*G?Ñ†ã†Jâ\.Ş?Š~2‡†Ò(Lİ›´9Z«wyé¯>ÁUu€c;Êš«‘4_\wDb7Aôa›ŸÉnÊ-àkyœj3ş¦Â)†®Šmr$wÁA•¡À%7b—œAó°Gxğ;aË¹‡Ó»<ò)~’¤Î]ÔK~ƒExFœÆU¾ÇËğ*V%X‰tš‹Ëx‡oEmº#ÙÑ†ş"ÊTP<FµjG×‡:‘ÔZãe'«×ÅÌBƒ
ÇYù{ö¾Aì’9ê†–G¥|æa	fX1[+PÇ©’F"Úµ˜+Ó”‹×<UŠx¦íåÛ½ŸçÀ@™Ã”XîœaÜ£yBT3¼ÎsBq•ñÃSì(jù¢%Zsâ©ÃóøH(c­w°Á*ÁtkRy,µæ²Æíø«°‡æ íùæœ¥aZ¶hĞ²­TgÄ(±şÑúr¶)ß3ìâMÏú :…Q`-·şÊİİ™'ìLÄ¯p‰£¼Æ†ÈCH5V¶¬àxÏ!×Úfu p”ZS1‚ÿ•[üN7×Ø¤ãïDU)¡2ÎÃ*ÎB&gkÏŸW2=£ófÈøeÿ~}ûôîÕ³GzZ÷n]ŸHMq'wéü‹¤ÄNFG—Ş¡ıãíâãbcÚ¶iıX«–Ñ-šGEF„7s:4%!Åkdût3Égª$cÈT{oø™àˆà3u&e?Êcê¾F6ıQÎLæœüœ™Mœ™8)Zïş©)º×ĞÍú,C¯£±¹Œ¯È2
uój#Óˆ¯nÄ£w¹X@÷Æ–fé&ùt¯™ı\iĞëËbu5áÃOMAMx£Œ™1FEÅdP#"b¼}kÂ¢Ø)3ŞÈòšqF–í)½şbsdn7+Áå*LM1É3É˜hÂd¶p7²ÀÓhÆtxLg£½Ì¯ê5)‡‚Ëë¢1Ñç,6ŠıE¦ôÚ6ZºÙn–óÂ¥ØÿmYy+OÁÒ‡OdĞ[¦ÛÛ`p©nş6·àáS—ı-,d,+³}Ál6½œ“8t”ÎÖÄâÂ“³IİÄª)¾€áµ)¾)ºÙÌd”§ø¸4ñAy³]»ãã3÷YçïÕƒù†Ë`ú³ÚÕ´F0oöâ2õ¸GORSj¢[6%¶¦y‹ûHdÔÃHàÁY#ÖÈncCód–lŒ§¸!L}’ÎSoûèà¤ŞÌÆO!±”YÌ)3›y|Áè¾6İ–7µÄhCŞw€qõ‡G)şûGbôMØ¨İ'ZÏÿ‹›n·™œl·ˆÓóÆ«=¶©ëŒŸs¯}¯ãûğµcûúqkÇ“ØN‡pæâYÂ#<’£„âÖÒ…Ğ+£Ò$è6X0Õ`0iESÙÆ˜Ê`14P“15b¨Ò6!ĞHè„Út¢)¨Ù $Ş9'	4ÿL³Ï=÷ûÎãï|¿ß÷{¦ÈÆ%Do¬‰ì)P~ÿ.É‹nÈ} ù¶·§9ŠÜïóa€4°)ùıİ³ºlvŸZ4Ü“§2¸gt¾Ç–Â=ûç{LÏø“‡DIÃ–7Ÿ“d/míkÎCûÿèŞ:Ûß¾ŞßŞ¹±ÛÛšËÌù¶½k6Û¿øIßœ”/mé¦İÔœD¹iÒ‹H¹éÉ`¬tóy]*!õKÖ€XIZ ·-/eVÌÖ=FŸïÿœT(ŞÇ³Èíé´93óÍá…ú7èÌãs42•í]s9ã‚>DµÙWÎİãAW·ÏÛ’)™¨Š£‹ñÕãÎkÈe-x âßlÓœº` {NîA?ÌÎšHJt¹\›ßÛ–ËäzÅı›ı^ÉŸ»D]¡®ävµfæ‰S(vçÛŞìA¾êƒÍ(((°ìœvÓààúİ—$ôu0ØÕ}‚TKfYv$ÕÒÕıuôHHôÔ 
’×[=ú(, >³Ï\*ˆ¼Ç^zô±¦_¯nK u#è›‚E§„ §ÊPª$å—¨İïzuPW€ğ=Æ©(i$_€Ğ‹æŠw4N’¨0˜L¨.¿æy"|<,DxŒZ,Ì , '.şÔ–¦Âä—NH“èšOÿSJH	L&¦uµÈÖFŸÍg¦Jg<ºÜŒ[/œ=ûè_èU¬*ŞÑ)º%è¼\DÕh‘¡$ä\¡j!ŠM¶EîæĞÊPZH‡ú…m¡LmN8Xı–ı¸ëÁV…æ8&U‰-wbé”ótÕEçïª®:¯WıÅöQ•á›vXV(Njfl¶Å‚k=ëÆBñ¶–Â’*«p$‹ëâ‘•º‘†ğË†má=üù?ò…‡aó¢˜uR4“ë}VÇ‹Õ;«©j%*&Å#âÛbQÔ¿-‰÷DZä±ßÄBñóaìF/l“$&%òØY"c2¡ZTh¹@¾è8fUàA.âÔÖJc½BsÕ½R/`ˆ¿+|Bñ.y4·t¤£Ía’x	·0~H"æÑ
¨ç5±RA)èÖ‡‚ú8¢ô°(R©`¡xó"êp›&”ùcµñÑ8u"ã2¶m)~¢\á(Şg®3”Ê$ŠñNÛÃ8°=Á5“bD¼]FÂ‹3u‹ç©Ng'&'ÂR:F-é‰É¹æpb:üé§ 9‘''¦ÇÍ–xt~|)¨Ä¡Ù"ÇëjA·Ã,ºlÃøËƒ±¦¦Eäß«úË¶r	ÕPo·£—›Õ.ûƒ4ÃŠêñ :ñÒ¥ş¡ËËw¯hÜ>ö-ØĞ:¸ïuOŞ±ãÆ¡ÁÓR‰\~Y‘7_İ¹©şÕm}¿z¾ŸjûÍµo¬µŠ‚+PaÜQólOÖ‘=Ü®õ®zfïı¯<»~T¥HUk¢+2Ï¯{ö;ˆÑ£UğÀıÚq¨çM}£¾U¯Oªy•RÕr¥AY¦ìRªLsiÂp­¶¯v¥i¡Û”¶¿àê7¼"ô™vØw¸FÕù1yÌùqé]ù®óÏmµ¨:½ú¨)j­Õ'Mš~µ©Cÿ²~Ìó@÷Hâ%›¨c(àVmŠÈ978(q—áös:UÃhq„£œƒÈ…â‰p$Ü'â0™0yp›·hQŒ'÷mhn „|@G‚¿® ¨QÂ0ïC
“p¤!N˜´Hx¬y0½ ¡
”ğlhÁT„*hÄ†1ÃÈP;^:ğºĞŠ—€Î²å‹áµÒ®`V$ÖHÓ¨e\š~Ú8	„Šó3¢ ëó›ÌMõe”MşòJÚ*c"4Æ0U`Í¯‡ÎmÊj3_şşòv*–úñ3¿zmÏıÈôƒ#ëüi÷Ì½™›?ƒ?y?uøÚŸo|peÉâzå+ÜxÂéZ‹‰ûLĞÄAt ¯è,
Ç:EkÀ»gÉîYï•ğîYÂğkû [=!]M×ã«®Ö­-/á¡ª´”¶ÈëK×Ë™ÒŒ|œ:N¿%œ”Nºxƒà4öSÛè~ıkü.a¿pŠ¿PrÑxçíüAşŠË_4í4í3Ñ&ˆRŒöz-ÀFeYGÁ	pÜ%ÀdâÀSdz@4üTîFûpaB !Ô@AgÁÄE0Y©Ø×Y¨²I–bE<ˆ5âA,I¯l;vuî<@¨Ìz`îP» >L'&Ãdï(ØÍñ¨”GÃ–E¸õ@Ç60Ç,:»Ì1Z³!L'ÎyîıvlæßŸ:{KrîÛ8xúäúÈï]‡h<©7†~îŞşÊşzóÊ÷ğÓ"²afC¹^“U Ø¨Ö§KRÜVz»~gÉVÎ`ÃoĞŒí9,y\WZ>Ô?²N¹tu–fg²Ô²ÆµTé´lr>§ôZ^uõ*{™½¶)jÊ!;4	²ÜaÏØwÙi»b:*(IÒ¹#F¨Óx÷ó‘1Š<‹¼&!O+EHÈš€289h‘ğ1EÀg	öª€Ç—T†by
.iïVcø®-Å)[…ª½A
°Z ÃÀ¬ciÖKˆF²3«Î‚¥˜ìøù¬³,öõøJ‡×L¯•²áğTëkpTM£l;N€J'¦³	ˆó11˜&éfæá’@C=0[YŸ#}A’éF"_\úlæ´Şú;áã;Æó¶¼9=Fuò‹7úî;pƒüËa¨¢ÄÁÃª™Ì<”¼C#}ğØÁ–¾S½e3ôç½2‚;µÇé­®Âºškµ2%§'Â­œk²®âÚ¬Øn®{d|`ŸñG*—ø—T®®<9a›|MÕÉH×æk­îòuUoc·ø¶Tÿ—íªmâ<Ã÷İ}wöÏöîÎqÿ¦$« v`DÙr¤tP(mÅ3
Û¤K °´4(¬[ÃFK36›ºÖˆ²¢ 
¬]­ul?"¨ê~ŠX¨š24M(b¥÷½ŸmbĞøŞûîøìï}ŞçyŸw}M_ÍGñ[³î„ÿWuMğ°'ÓUåne$v
øÓÇd˜Qb©FØ^³–//wJM¡rYÒ¼‰hBŠÆ¨İÔ×ë}:®1m$ç5TouÀM;©
Ê« ºFŸt	É&ğ– ÷w(Ú:ˆá Hïv¢(
DŞs^q9sNp6:[Á)ºÎ2@×‚İœå°““Z'uN_uM÷¬är£ºº¹p×2ÒƒgtVÀ­M§61XÃµĞí"dÔuMÏ7Î8A˜­£„Ôëª‡6_·gFL¿yÂV»°»wá@;†¯M>õµw^<ºñÚàïÿõ³£½/ûÍ‹=ÇV•­ˆÖ¶­™?¼5\?„Ğ«‡ú>o¿w¥ç87ûjæ½Kïÿé}ğ¯ıÄäŞ"ıÓƒ¾q–ÑH¥{õ$vÚŠ(®ãš¸svL—êu_R·ª²êáxÄ8Ëy‹Ç&ÉQÑLÌKæD”‘fB¢4`«è§ ÁP©8‘ö4±Ş#«SyHD@Bîïí"‘Í	ŸÜŠÍOOÎKk“Û©jÃZNÃë‰‚—&ô&¿a&¹ ©œÄ©ä>£ä‡ÀÔáGÚ©¾šÁğµôíƒK]!K[m³wñò“¨×Ô Vª¤3ÒeÂØ†|\€€¥_0‚Ãu²Ù­N?bªQuõn†U'òİQÓ¼jX¥0
^µ?½+³ã·KÓÛ7/­´Âÿìoz#»=Ò¿så¾Şìï'÷ È#:\6¿.Îƒ´ˆâ 8,fÄ1qR´0b@ìûÄÃ…¥bN”"é-Ìr¢ÀíBŒÀX,QÁ‡ñ Æ|<‰Yñ(¹Ã8ïØgñƒ¼aš7,Á·bäç]7ò³	ICÜl}4{[Iö`6iœ rÿ ä·vU»ë^deO:Æ·¯\¹ïÅ±ûA]¾L>æÓ3r†§æA‡ç1I¯ÉºüuÎÜü5¥W3JÊ×ÉøÃü[ÈÇ$ÏøN¾Ïñ˜T‡Ärù‚háxuÉÃÊvÍ–VÏ½™ê©(©š†f±B
JÆ³\®8°rÁ4ã‡sÉ é ¬ßš_†Êx9ÍŸûì‰'…Ñà0úóYÆNL"lo)„3—ÙìÉ(ÇãâÇú§AşC~*ÈêÖ`X4üA‘ãÂ•å‚$Ê‚„p™O‘F£h :e£º^æˆ¨HÅp<Õ ™Té¸‡T=pHF<ª²pPU†ƒªtĞQWp6R”ïà¨Õ”è€ùévşÛùéväş©Âv~Ê:?50du:Ov¿û‹”öÓ6¢Q—bL#ÓBjşO…ÎlÔâ2tb´£?O`¹kz(µóPP=c|‘èê9=kq©N}nv¼Äú–ŒLä&ÛÜ´qÑMâqH)/S&”	U‡QiA‘ø²ÇóÈª¹ìŞ"ñm›àëGİ|äéO]V©©=Ú¾ã``×…_¾}:œúrçOÓ«ÚÚ]cš×mXuîÄ™lœıÅ–uõ†²ÙS==Ëşãìß‹~“Ô‹†zM7Ï	nö˜2¢|ÂıÓ=ÉM¹ÂÍI³Ì
:¤Œ7ŒœƒVÃ£¹ˆ†#A³Kv‡ìˆT·ªá6ªŞ6ªŞ¶êm£$°…èaªŞ6ªŞäş¿y@mRaª™2©KµÑaCä¯­Ù Ò•’“ÛiÃFÆÀÇ&¼åæTZUóÌûÿ.="àj‰€ã3¦ëÑ†Ğ¬+S­]3˜Ş¥¢şĞ*ù3Ñ 4€®7NÌ¨º&¨¢d•,'(1Upø‘Sr@½Ú7)!Š2è»şÄı¿Ú~}ı‘åŠ”½ùÉmoáØÁMËj{³ÛØWïøÊşKÙwÀ7/"¾9NP´3>´ùŒ×€“¸	)Éœ@Émùè—EòÉ‹…'­Ï	«­ß6Y­I¥ŞU¯ÕMÊR×R­ÉHñ)ñi¥ÕÕª=mtğb›ÒáêĞÚŒï"¯(ğöµÜ3ü3ÒZy·‘ß(m‘%½[T"ˆŸz)?-¸&ê¥,tŠ-TÅ–ÔÛB 8Ğ€z^ Á‰&çXcQ,Ab’ç€õ¯&±#ÂÈ²9ã¢t¦3SNñ¥ö¹ÀZª?ŒF6É– ,3·ì4u9b¦[§Z[K°¤c‘Ú®V¦kaj•)®äWŠø"F­«xÅ­Ì' 1^j²˜R“µhè‡ç¯!mçí½cÓgOõ¿rêôúO±nß·cúãìåÛßC•È~éâ¥«ç/^ ?¨zEt1•hƒ¹OV¾ |IYªàÆàp“ÃµŞÚŠ¯Vt‚Öz½Ş¿D_â_m]+§ô”¿İºYŞ¤tè›ı™àëÆõ²*Ç=ã•7‚¹ ÆÕJµ·×+Oà%ÊåSÛíŠiÅ¦:ÈàS*¯•;lŒÃ•"™Òz©OÂA
aÂ)änš6 R2
÷ ã4¸C±” Á „ÔZ’-u#w‚M¸¢“Ah ¢a4‰p 5¢2@@Ÿ£jŒ¨#ªÆˆV’é<d¦#-¼J’épë¢Ã­/°x¾f&¢¢+Ù»ã3¶™¶¤]NP>™VhœL—»(ªš×Ã‚A«\	zıCõû¿½g´}ûØÎ5¯?®İÑsü­îm'§7ñïşhÅŠWs‡Şœ¾¿÷©úì}nèò/~xñÂ_AKs·¸“Ã9œnîÄ!O¨^\".Š<ÚzIÜ'~?rÔ}¼æœ]ÔË}ÎÒš¿è¼Ÿ}–e•Z$)kJLI)[JNÙÛ­íb»Ônk—ÛíéX:îŒÇ"ñÈcó"k¤Õ¶¶X[Uw¸;Òù‰ô†¼¿ê`Í9CÒ¯å7ãCU§cçcZU±Û‡ŠA¸DŠ}²*áb)#¹˜®Êk¬ñ¨,á²`Ì‹mW”Á¸òÕ T_£¯Å·ÎwÂwÅ'8}ßw|c>ğ½îc}ï"z‰8½Í ÂZ¼® ±
Eìÿ8¯ÒØ¨®+|î[gÆËÌx™Õï6cVqjâ¡e_LØ)JXB‚!,nSšÆ–)KÁ–­ŒK
(8Ä„¥pU	ÄP$0MT©I¨ÚÚT¹±§ß¹ï1Ã¯óÍ¹÷¾»ûå’ğEp.•å«2	O÷V
1taîê\%7'ÛÔx2mû	ãßb™L-ghÊÀc™Ê
>ŒéX¿Ì¨ Ìã‘Á<ôğ©‚>é	Ï+ß9cE0ôlNõõˆˆğ*<"Ân“§‘Âçïñ HH.•_©\RÑY¡ÔV4V(!D¬œBºœ<KË0.ğ¸ò&òŠÜ’än¹=w|r$Êã5İéò9h=>&Á©‹BÁì­@u¼
mºß<êdâ¦õåÓúå÷op§Ú{ë3ª‡YÙ#C
$øüÃoE¨Xé…zÖà¯'Ã“éQ‚´¼09ËÌ°Ğ‡àg@ªùé…a*(LKur…EY©Óe”kaèÉåXVîAä³~/)ojj¢~¦É9û¢ÌQ>ËÈJKJ‡â‘ŠçªôL+Şeñ+Ö?@±jIí÷öW7m¬*ŞsùÀô1OEŞœõÚû¼í©/nZåóo¾´oî‹—_ûãGbtNı†cGŠ+&5ÕMøaÙÀò‰¯®Ì\8sTaNn¦«(:fÓÂGæb;-ŠßW"úòÓ‡È–T:ùfÇ ĞÄ»'5Í%TòyœånÜ£šâöPHË(NqÓ1Î9n‰¹Îl4w™!:µšíf§yİ4Lvˆœx˜–C”…ûìçL+çµ|ù¦•¥Xqı+J†ş¬Èm^TVQ@Œ|çù¤‡ \Ü=~VŞ~PÃA
EvoŞhÔs•ŸååÅ~Ö_I•·°*êgWèÍbÕ+ĞÔš¥«oŞüîÙ³™åeñ<³¢MY¶S˜«{[vöì™68$ßPğeŸh%X}ú
A7N¼”¼L_¥›wÍÈª,ÏEL_ªÈô¥äòBMõüœ²…d>è—™ ?ƒà—©=kÀ/s1_è—9 êÿ¶r@¿Lêıœ¦±>â~Ñéşº|sqúú2¤¬µ†ÚCñJ-–·çá¬¯Vgó:Ş°š3ñãBÌË{pÊ•.^ÕÉóË¸â”ùŸS‘/¤ºàcÏ.×½'½šÛ¬÷Úšj™ÅK#
iô4wšb˜Ã¡;ìi©aJsxÃÄ©^$Ò„àƒ±ùUòjJq9Q/Ï1’Ëjí¦®Å¿šîIéHñ¾4cÆO¿Ñq¨câšéUÊîw[FL˜1ëmJ5¸
˜Kjƒ~ş5(rcŸ#%Mu9?r,!”r5ÃëÕ4ÕHËqˆ ÏGÙ.¿/¤Îİœ©§óM8\§°N2O
pÊ68Ú8¸„T_„Â»\í.ÅU–‘‘ùÛ,×›••#]Ó„ İŠ¢ßîHÇ|(|!é­2áyF•éÍ®ÎşdÈO1Ï®C›<
ŞÛÈ§ù¯Ç¨İ^Tçy¸>ñ™Ÿ½5øÂlï×±¶ÆòeÖ+*İm˜é¦'Ln#-, ô¦¦([ M´>†]L6ÛB>Ô}®µuÛe³sª/{íš˜İ¡şbÇÊÃÇıû“7Ûñõ
ıb÷xÎ­ÏĞv­PíFn‹2c ${˜s¤Ÿ_‰´¡DYµöæË½½ïëí}ùæÚEo/½µo_×Ò·Õî77 M(çnl˜º¸}ñ¾[·öAÀÊÍ4³RÿÒ£¹Ÿ­³ß¿V]WŞØ¾ıFà»îš¯a‡üÒöYi„å´u»ºO÷¬ô#U'úóÀ|¦·¾å¡îÓİ¯x’æ%J«2ì&¥ºíÊŸh±Ö@ÙÀ$3—~ Ï¥ùb+-@œßÄPs)¦¢è{õ1y,úÏ>j€¹@Èn›<Ìâ:ú^à±˜cÏ#e-p¤µúÜxÖÛ«_¡çÃ(·iŸÑq£šÖ ~ã.iD£¸Æì5NĞ~´Â÷eh;9õ£(/Ä¸ávÙi¶P%` }æÙaŸ·Tı=ÔâŸâ,ßÆœ“-XãYÈñÀôÉ„ü&°U\¡mâJ¼ß!©ëoåv`¬-'bã{-Æ¡ŞŒrû0 İ@>P¦œ¢j%‹~9çŸg¸B/ğ™ûÎ„ıÛ{zÖ§ôÖ|(Tªãw ıö–Œæ$LR£ÔY„Ê´F›Jú: ß!•Ş±şŒÖ–Sêûœ¥wĞA®Ó$â=Ú!jUĞSøöŠ±çX}ƒÌÊC¦|ACŒbzü‹ù›€Ã˜óï’Ëi6Ö
ÕîHmvb­%ôÄºA½	÷:k}Íö€ñ³€	¸—F`5ïëcó½‹¹½Õè{}2Ğî—ÀÙ™“<†Çc®b›‡m$µ¡Oôú	¤dó<³o—1O0€\`(phê§)@Ö&¬«J¾‚3ÌMÉpC¿bo’³ÖËû´læ¨=¯“oœ¢zù<'Ûs{y'17Ûs&!%¿ë%ïÿÉçdNõIØv—&ğ¤‚[	Év‡=³=ìEF¼ò xÜÌœåı%$ë…¹&u›°eM¿³—6©Ú\oNÈ„.úäts.1–Â§´ÒDí{4Q}“–j_ÒXuÕ‡£çAßvå.ÍttRw9õIr?Ãì«ôNœó$ôÙE¿„N×k]JÖ%tıdü:‰«úIåG²ü„L†è´¾±dôÿö¿¶ÿ?Pné'á3OÆ?×»âqœg7Û„yWòíg€F â(ûõâ¼‰WAô X«Åèi=F£´NÜO6ü<lísôOé’Ú‚XÖÿH4R£ÒE[ÌlzNÙŸ†µ”[ÔÌàù!×õãÑcœKæRB&øš,ÙçÛœiÀş®Ù¸mã!ğx4œrl`ÿ,ã|4°Åâk¼»ŸWé×;üLâi}?S“y™,elOØ)ö±=q~öìãØG²Ÿc?“èŸ,ûÿ‰r<f?ü-°íºÀÆdìñ¯¶íÃã¾çÅãÆøø[FGü¸š?nT ü! ÇßÂ¹7öÅÔùñ^;JÄR«RqTÒÛŸ“şæ>ıLÆÑ¹rNã4½®ÿ÷(÷ÛjÛ ô‰}×kK óƒ´çª[ah²Nä]8.pLT=s,j¡fõÏÈxl”¼2^ÔÒ<ìıªlCLeÉmú<j3îR…6¾¶“–ó]ñ9x?|÷ï#Ï†Ÿè¢ÚoĞ'›\è×*uû/÷å\Uu…ñuïÙçŞ$€	8^:Æ€F^é@e¤FŒAL -mÚjËà£EMx9V„"*‚c‘^¤âğN™R[Å
­S|´´Ó´ƒ¶µeÀÆÜÓßÚ÷œ›Ë	!‚öŸŞ™oÖYëîÇÚkï½Ö·å{.´ïl±ˆÏ”8gv"mt¼u¶O™tóãñ´…íÑ3¬±`ÌX\cùÄ‡ò¤[%S¹Cëâõ².VÅ+ŒñSúU©/ô+´õz…Lç~5’›É9bÏ×ìld=óÉëÀ©'F¥‡[OgÛµ1©Û ÷ÇIH±‘Ø
ò°ò‰²Ø”È±Ù²Û2—<É¼K°İÇıÂİ]Dÿ~~Şæ^„]ûV.£AïK¼LºÇê-ëƒòæwÊ:§R9Ç_ÏZAî—i%}SÔÔÒSÕøXš‚µå¥dä|'O~¤öèWäfè$âiİeî‘o›j)u†rw»Ê@ó{îê'ò˜“+µfŸ<fvÊRÕMwàlfı[á–j? “Ô}}•Ô˜‘ôo”¹¦VnsçìıArÌ,öš~îƒœ“"úc\‘ÃRãTs·àûïYmgçØêMU˜±2ĞöË€õ5@ÈçèxVUÉâ¯~Ÿä/¾¦ı|<…v:.ı´yLF§CàÂ”LN.“`môr¹s•ÜÙà5×ŠÆfêfXä.0È“à¾/Aş<—ÒánÃäOà~Æ~¹EßŠh¹W‰mX^şË„Îs*{&Ü^^ÓIú6jˆ÷šáöÄy8ó7_óšœÅJEìnÉÏ“|§?ö¾ôén/îÓ6)rÄûOG>ü†dÄ±,sÁ~ Ïı8”!ÏSé×†³öílÁşŞ®³ñı§¤ÎœyÓ;„¬¼)yÎ9ƒ } z÷ Á>a_ní¡ıã¬ˆÆ<lëá}íHn‘ÚLç }–Q
3šö ¬g½*£±—øï¥¶ºy¦ÔÈÅÎjõ‰3Ø¿­»Zú+¢EøZ¨}¸s ­ G mkûw‘+zwÑ­¼×@úÿar…"#®Ã5®ÎêÔÿÁşûŞü+3ûe²99YÈÌ;¾·a[KNÕ&t7†´7æÿ¸;ûÀ^ğòÿz®ˆpVAˆ‚‡Œ†G„ŸL—…"-ä’Ïƒõä¡k‘oa£z'/]øîŠí&ä"Í'ø¾ûÁ¼¨é%k}^ÙÛv¿o–?Ş”TÿæWD>=KõoN€ïğıo@=oş3òä*Ú@¿û¿NıßR‹>ìFÿı0ï‡ÈK@wĞş+ÊGÚ¼C¿tyê÷Çç•p–™øÙÙ„¼+ü†øÜ2ØÏdø­ìGÒõßme*¼™Ş…÷mÎ|ûœîHö3™	SåµÀ);+V.«üÙòG_Ú÷›å±Ì+’HüÉVşªÜYù+RÇoˆ¹ÖŸ*üºÁúå×ÌÜ9.k@èåËÙ´ù$ÚßÛOîÉå|Ÿàmô´ıP‚w€Ú•K­ÛCŞ=|½òDPÓ‚ÜÚ&ÇvPÓ¾lıLkäYÔÔRµ!´gp©qŠp->StT»Ïº–·S£3ëôÕƒ: {””*âe^“"ÌKÛğ€ôxî™êaŞqÆzˆ—zmşŸ½€ÏJa¡{w¦Ğ·…ÙÖÊıÂ÷8}ß|]‘	òÀ ¿†>E¾€ÿ{} 5Ê{Û‚¬Ï¤4k“”¢oÔÍä?uúòÉÈ2‘èÇ^ú½èyæuÛvšºÎsøÜ*?·ü˜Ù<øú/ƒÁe xÌ	öZßÌıN”ª«ï\Sã0ûAˆv(‡É÷Á&ô\ô\rq~¬+y»Láûd2‡ü>Ì"—Or÷z-±;l›Jş«0?±äù¹æ cö^$§Ï1IÉw–jçBjh?ş_IßFôdøyò4ãì¤ÿ­±cÔÁ©ÔÃl­Ì[-kÀlÚ^mÉ#N'Ã8Eæ°äûrˆÛ,ßÔzDj¶‹¬<,CÍF3ŞH­5ÎFÎÈ{ô¥şDóe·3Qv›gåVÆÛœ“5Ù{eMVTdİ-+c	Yé<.±=P•HƒÔU­‰Á7d*ïckşôB_–ksëß™@]~*sŞ _Vµôëgnõµ#nC_êX‡A~OcMx¿MI¹Ù¯ñóÒ5¿Zfàçh©í™ì,àİ§5]ç_|S®7 ?Æa_‚¹ˆKK{\(à&|OcuŸ-Dºë¹²g)…*÷¨İ¯qºgnîp®î¿·Kãc1ŸöQéi>œ!õSÁùê	)¢k¸£s¹+œA³Î”û|ĞÖ[oûİbû‰M£ñkó$¼#­û[á1U²Ø‚xéşEó½]È[£¯1×Éµñ»Ÿ–²Ï7À‡D
‰£®»‡€]Ïçµ€ı·£ÙµûÒÆªŒ~¹¼ëtp*gÿe9—)¿"n~Ûø©ˆ—q^;I…»EŠœïÂ_~E®ëÍŞU²¯¹²ĞyWúšKe¦ÓUê‘
oäC$L]ı û;È£7HMô-¹xÕƒ[ÀbÖİl±® ¸/ßóq£"šˆœÏÿßğ¿û¤¾±íÁ	YŸÚyï‚æè#Ì].uÑÌ±_˜ÇÉãş…@ŸoùàÏs¥™Ê;—‡A_•ƒÃÀ®òÂ0|{aØU–‡½ü~´×®=?Ú³‡½øKğ£½q/û§ño|ØÇŸíÅ¹(ìE§ñcbØ'†ı ?ñM¾ÌÛôYäÛ~½?Šœ€äô%_ä›÷…7Ë×ßöÛı¬‚ã Ü9Ï«¥Mòï`=˜ÜŠä«ÈŞbÁ<Şrp1¨NÍ¥}“¿HÍmáÏ™Ü’êß²É÷7COŞOÍgçÖÜÛ„¼ ¬öÛ7úónNù\ŞÚ^ÿ×5Ú~›[á9àşï‡œÒŠä¶¼ß ½àÿ»¯]ó«5/È§fµ,Õ|¨µ:±5ûN™`sî“j•åÔ™6ßyä¾‘RëyBÊ•7hwo´í—¸uÔ&ŸÀ,_ø«¸æ%éé¾'µf®Œq¶Ã‹¯$ß2‡Y!ÓulÍÛÊ9œEr˜¤5Œ¼©µp<9·!g«å/y´É7ÃßGeo¶FwštÒ|„şkY'óİ;å¬9²'ö/|=(³¨Wıbµ2Â½WÆoÛØÉv;Ã|Ù)"3³{cOPwß—1ÙğºßÉ$böÕ`îtâ’]÷¦—$rIöş³0ÁúŒ¿ğ0cJàcp&[¯¯#&uÖŸ‰Z?ÍÏÄ8õ"îGÔîq2 ÷,Ù=dmìcÖc®åuéØqR¿I†ºRìV±G%ğæ#ÄùZÉ	$¹}O|¦Äİ¯î¶ÎÜlùb7³QzXî@íJË`Œ„¬rëe)gbP˜×<*Í)\»ÇUÁéõ µ~¦×ïË¾aã½ÒH‰[ÀÙw´‘¾OñÙ@Û%ÿe¿\€£ªÎ8şİsvï’Ø<H ”$w*’à"8ò6Ø2ÍğÈ¡µLênÈBÈÒd¡£ãXuÀZ ãtğTèH¡¥“8-fb_Tl©•i¢3êCãÚ‘çíÿ;çlØ$„LÕ:µ½»ó»ßyßsÏã;ÿ“Ğ³N*HØSı=ªôW`\²©2ğÊ
Ì¥¬Ï¥ëVñí?-ZIc°öç˜ış]À{i®Ùãq¤ÿìÒû‘÷§«½‰´Ë[Lú
p?ˆê|Îs[tør·n_åİ¯Ë_Æ>t7`ØëQÃIº‡8É:UéQ­­{Û]¯ÖOé ¶şÈòÆÉîÑÃ	=Ùßn†­OÄ¡óNbnB]Ø	İ×¢ìÓĞ(h«´!ÛíÆ¾Äkµ^_Û£«°é×$«÷YÂj]ıhû-cÇ$ôõ`¶G÷²®kâé=z}0[C)Jwxş4aMzF’µûİŸ’­š’FÇ²~/g}íÛ
-zxİ1öÃX½©aäFúöµ°q’0†Ş? öS¨†ôÅ=Ë ÏiÜg§/2Ò"b|ûâUğİíØÏá½`ÈDMà Féÿë€1  vğ,em>¯Tè6¬OàºLbÜã˜|Ûûøîú>'ŞoÚı´óøiçå³úîëõ=ìÉ÷@ÂÚÌ5ûùQœÕ°BÙlƒqİv‚×›ì•‘Ø·ÿ¬'\§ß:xwSÆÄy/26”]`„Ş¸#ÒĞ’kO ¢×_ P“ÿ"Õíõ¾#ı;c|ßè”ô‚ò5TÀ¾ç.ïóI¾_Q]oÍçVbİäòŞÀ9éGù¡ş8•Š?¸/ùïƒOøÈ}Íß- ğ®u†ƒ†­Zû¹»a§©q¾öÂîHwÛ|†Ëà}Í`»ÑÛ¬c›4W>ĞéWû•ğ½òc|ÇEÊeİà›M¹J¿Dé1+O#zßğ¸¬¥Ÿr*´ôëµˆ²}'`5i—òå¤ı=Öùª1N€5‘š§8¸üU¤ñ‹cù]r%üø1*§Qy¨÷8·á…îc]$q£ğÏÇºXˆ²İ?ÉÁ–>èoEÅ:š(ë((Cïä ı; †ğØ°<ÖÒ-*ı"ÖÉ”Ò‡øaıAqŞ°AÃùV	…Å/(MF{ºÜUGcSØúµzWX– =”¸)I(
™cÂ6òE½N(´gÖm©¼D™”«eüg¨4µJílğ„Ûá¹Ö‡4Ã·”†bNÓÀÌõ!s`õÀh¹Ï#şºh§eŒüÊ[ÜYŒõÿ”¢ş™4Ñúà8ÖAÍğÿ“ñÏ¢±öœc»ˆ×ÒtÀw»:_³{	ë®RqY/£/IØwQNÊïh.æ°?(aÅN kU«óˆ°¦Ébõ¶S+2Ü;¤ÙkJçî¤G°KöEZk}uSyï!<_±Û)Oë8¾C]Áh¹¼*áRQg¡ÙÃ±^àµe´ ªº»Ä›|¯uo#İ±€òMİoè{©û ø!(G»Ïâ3±Î¹O3Iñæ³û¢©¾)`&Â3ûÇ1ŸAC¯¹µ7ÑŒoÊ1Ki¼ÜÂuõ\·çS!#Fã#¯oÁ½n-î†\7ğ¸x…ndÔz+ìÇ7}éùîÁâiX[ ±ŞzÖô@ßßì²F.Å¹ÒiÿÄ=‚ø/ÁFø×mŒ\y{^{BŞ€½ÇtÖ>¾±™òá¿ò}°ö ûu{”ßTÂ¾~şŸæü{í^d]*GÀÿ³/ƒV4íó=©Œë³Î‡ß›Ç¾Ï+U³¯eŸªÎhQ¾§Áß„Ù·ˆƒ4Y\Ò>È:¢ öEr(|G	úX¢¬
‹ñÆ§”PŠ˜ŒoÙ¬‘îAå“ÒµÏ’„öö°?Ãù«ıU©ı—xKû qeœ§(ˆ½°_ÃgÎ•êlº ı¤ò…ğÓæ»‹¹?eğ„¿¦—Œ¶ÜÙÇîKØÁt¡©³ÓÔé_~)UúalÅÜñ™ü{ç¿‹nè¹wMæñ÷¿¯î+eÈgrUçó™Çç¤š'ÌQ54Ñi²úŞ|G¨’çÖ?›²øìÂ8 o%ÙeuNó8~ ]–Šs÷ëêğqh?ëôœé'ßOr±N×÷Üıw¹Ä]ƒhºïyÚ&—CM¢2sŞïOºßncxiKãÿ‡ùë¿T
ù16š!4©§ˆ¾ô}¢´‡¯’³!7¬8¤©D9®’û"¶<æyTØã¿™¼Ãÿ?äßü&ìáááááááááááááááááááááááááááááááááááááááñ'îááááñ9a¥M¡¿Óz$(“Š©†ÈWïË#?âDéô3<%ño…zr8@ˆY¤S¬Ñ&,)İZbÂ>„—›°ğĞİÖ#(iùR¸M«Ë„-%ÊMXPº¨3a‰ô¸	ûş	Ûï2aôG¼F;È¡ MÂ*BUTOØ
ŠQ#ˆÓ½´Z¥ÌA¬	a~Ö"=ªJ!'Dø;´iËQ?NÍ* ôZ<Ã(B8Šº\6ªÊÔ‚¸j/Œ2«`›h%ÒbT÷	úÂ­6ªu½jÄ¢ˆñÛªD¨VÅô›‘Z¬ZpTÛõª¯İƒØäÆUo¹tÑ'8iÒT§ª>âTÄcñ{WGœ9±¦Õ±¦Úx4ÖXä„œEÑåõñfgQ¤9Ò´6.*[º¸ª¦jB¨)ZÛPQu½˜2N´Ù©uâMµáÈªÚ¦•N¬nÀ÷9ÑF'¼êÆh<v*ãµñ*7†‹cMN9MÎ=±5ñ¦h¤¹èsœß2ZJ‹ñ†0!i¶+çÒË1®j¯Wò“æ}aW×^ª’cÛÇŒ(8¼_£. ä¸¶	y{e¡Ìk›^0{¼±=+'˜š(ìøbõtğŒİ øh™ÌGz&-àA°t‚ÃÀ†£ÉW¹ˆVĞÅ92Ojs
2C…2usáI2äpê.T€g1˜–§@+°U9N‰Ğ	>R9³åğ¶M“Ñ÷ámë•i_ÑTÑZıæİ*Ú¾x‰¶µ½s.6M»åV\T¢máÍÚfİ|mjZğÕĞ099_§%~K–E´UæĞÏ¶I™-³ÚG	¶vJYRHUà¾*­¶´¡ÁPªpE7eQø›8£sÄ™öô¡ÁÖP¹x—vƒN Å»ø¿#Ş¡ÑÅcç,Ğ
:Á Ø¢ÿ“øŸ'(C¼MÅ`XZA'èñ6™â8û{õäğ, Äq<3Å1|Ö1<3ÄQ„Š£èÚŸÛn»=¸W&›@ÁM&0ü+&5,¸G¼Ùv~VÔÌ4VÔ>ùUºƒ&ÿ‹ñª‹¢ŠÂ÷Ş]º³”²ÛŠe¥ÓÙnw”P¬Å-mig·»İ‡–¶’ÚĞÒ²	?&lKëHb£P¢	*&Bx0DBœš:mIÀ4b¨(> >J¢ò„ğ ò´~wv[$ÖÄÙ~ç;÷œïşÌ™;?uÕX‘ç%Û°ZH6ûuZV¥s±­ì1¼É`ı€tCÀ Şmx·‰œÎ&€]ëd¶Ü n“­€tûÑÂ46»i)q)VÉ~`ß’õ¨ø÷xq¾Á®9üûÆáëà x‘]³‚‰•"OĞÇöƒë‘_Å¾®­ò±rvµ“`ëv ¦€v…ÕXû¤
2O¥Eî:ü9/í ¤)Ø€27Jóx0gå³
Ó”Ó£Érò}xÜ(o¿åcğ¸Q^?
eßAxÜ(ıƒğ¸QºúàÁØìÓ¯jŸ•¢]‡¨ó±qTiUG•Æ‰›óyäækûÄª«CÅÎhêÆ:É˜£ÆejôPã<52Ô˜ Æ1j´Rc5TjˆÔRC£Æ<mB)ª}ùDs» Æ"5.Q#K…jÔRC¦QÍf!ëåJ:4ã7xG>>BECØó!<®ÀŞòNKƒH®)ˆŸ	r®™®k/´·47ídè¸€Ë°@~Ü¸@ØFdø`ÛAà*pÈ%P×`áSõÁÖíÀ ğp(q–s`äpq‰_8«/.º‹·Ø~5ø…XH«ö‹~Õ¿Ó5%R_vóA%••ø¼ª(ÊmZ6ó°ì¯‡eÄó²“lŠTãBœ*ò”õ¨Z²éG–2/Å¦’ »n'
€›HÖio#¢À¹_]Á–¸İ|–²Iš£ky¯é‘ø›tW´ÜßÅyégÙvSKú	‘‹3Ò-qRº^oˆ\Vl
š“é¬Ø$]Zt¤Ç8cIœf¤7ÅNéè$2…Ä,ZšOêQú¥/!KZcÎHíâ©µ ÚÆûÌH[±µàÖa±EgÒpĞğÕ¨M÷k›<§=iO—çEOƒg“'ä‘<Õ*Ï:¡Bğk…5ÂjAJ·À"¬³ów4•àÒ­+ñs*qsëv|?ã–0ó‡y…˜O¹R,Õ§)óêIËæŸ½a›®ŞÕo®
Ç©Y‘"©¾¸Ù¤¦lO¾ÇŒª)ÓÓıZ:GéIQ“½cSÒ—¶i‡W™éYBiùñUœŸ;~B×I òh{ ½¢­|ûK‰ÌPÑªÀ~µy:Õ›6?¯ÖÍîä«õ”ùA¯<¥èÉÄ,½ÏIOÏºÚèƒd»Úº²énGGdz:ì˜ûNÀ‹™ëˆ,º3]ı¡«å×K".âõ::7åº\¶6™ÈÕÖ:šõ2É:šìzùŸšÅ4‘ˆ£©4È¢£Y¬4¸Æls$¢IPt$t‰H78’İ%õEÉä²dÒ™ÉEkÄ‚¦ìÎ’¦ì4êÿ=2qU¥Ó-úÈ@2N…“`È|÷èş€iËrnDç	Ùt)CÃ#û9ïÍ˜z8“0GÂ	9×2°Bz€§[Â‰Hö¥sZ&aµh-ÉğŞ„>İÙİ}b®Éå¹»W¬›ÖÈçêŒ®òt'Ÿ+ÊçŠò¹:µNg.âìñîtN q½c ÀÓ¬t5öëPUHWú´9›·%˜¨šÃ×ÊRªêæšpÜ,xjslsŒ§pOñÔZ„}ÅT`¢%T5G/S~„ËÃq¢eÇH y QøËâ@htŒ¼`ÕìÈ%Mmo";JHÊ¬ëM™í»úÓ9Ñ!~JfóR¬´4iç¯‚[læA—kYÈc­<æõ…ÿ¾şcEîàwÁæ§©¤øçCw™ÁTÃ£ ¯ç:ĞŸÃ·=duœ`–ª4»4FqÙªJ
mÂÏy	£cE¯X‹Ñ"z¢Kv©$Ë/–º\±QUı  ÿÿ   ÿÿ ÜÎ§endstreamendobj21 0 obj<</AIS false/BM/Normal/CA 1.0/OP false/OPM 1/SA true/SMask/None/Type/ExtGState/ca 1.0/op false>>endobj39 0 obj<</Length 14147>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 37 666.8857 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 550.7797 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 325.6894 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 228.2013 cm
0 0 m
538 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
-0.023 Tc 0.139 Tw 10 0 0 10 46 715.6797 Tm
[(G)0.5 (etti)0.5 (n)0.5 (g)0.5 ( )0.6 (med)0.5 (i)0.5 (cal)0.5 ( )0.6 (treatmen)0.5 (t )0.6 (ri)0.5 (g)0.5 (h)0.5 (t )0.6 (aw)0.5 (ay )0.6 (may )0.6 (keep)0.5 ( )0.6 (th)0.5 (ese )0.7 (p)0.5 (ro)0.5 (b)0.5 (l)0.5 (ems )0.6 (fro)0.5 (m )0.6 (b)0.5 (eco)0.5 (mi)0.5 (n)0.5 (g)0.5 ( )0.6 (mo)0.5 (re )0.6 (seri)0.5 (o)0.6 (u)0.5 (s.)]TJ
/TT1 1 Tf
-0.013 Tc 0.052 Tw 0 -1.502 Td
[(Y)91.8 (our )0.7 (healthcare )0.7 (provider )0.7 (will )0.6 (check )0.6 (you )0.7 (for )0.7 (these )0.7 (problems )0.7 (during )0.7 (treatment )0.7 (with )0.7 (OPDUALAG. )18.7 (Y)91.9 (our )0.6 (healthcare )0.7 (provider)-13 ( )]TJ
-0.017 Tc 0.033 Tw 0 -1.214 Td
[(may )0.5 (treat )0.5 (you )0.5 (with )0.5 (corticosteroid )0.5 (or )0.5 (hormone )0.5 (replacement medicines. )18.5 (Y)91.7 (our )0.5 (healthcare )0.5 (provider )0.5 (may )0.5 (also )0.5 (need )0.5 (to )0.5 (delay )0.5 (or)-17 ( )]TJ
-0.023 Tc 0 Tw 0 -1.214 Td
[(complet)0.5 (ely )0.5 (st)0.5 (op )0.6 (t)0.5 (reat)0.5 (ment)0.5 ( )0.5 (wit)0.6 (h )0.6 (O)0.5 (PDUALAG)0.5 (,)0.6 ( )0.5 (if)0.5 ( )0.5 (you )0.5 (have )0.5 (severe )0.5 (side )0.6 (ef)18.6 (f)0.5 (ect)0.6 (s.)]TJ
/TT0 1 Tf
0.139 Tw 0 -2.564 Td
[(W)0.5 (h)0.5 (at )0.6 (i)0.5 (s )0.6 (O)0.5 (PDUAL)0.5 (AG)0.6 (?)]TJ
/TT1 1 Tf
0 -1.682 Td
[(O)0.5 (PDUALAG)0.5 ( )0.6 (is )0.6 (a )0.6 (prescript)0.5 (ion )0.6 (medicine )0.6 (used )0.6 (t)0.5 (o )0.6 (t)0.5 (reat)0.5 (:)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.581 -1.538 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.124 Tw 1.8 0 Td
[(adult)0.6 (s and children 12 years of)0.5 ( age or older wit)0.5 (h a t)0.5 (ype of)0.5 ( skin cancer called melanoma t)0.5 (hat)0.5 ( has spread or cannot)-22.8 ( )]TJ
0.139 Tw 0 -1.214 Td
[(be )0.6 (removed )0.6 (by )0.5 (surgery)74.6 (.)]TJ
-1.8 -1.646 Td
[(I)0.5 (t)0.5 ( )0.6 (is )0.6 (not)0.5 ( )0.6 (known )0.6 (if)0.5 ( )0.6 (O)0.5 (PDUALAG)0.6 ( )0.6 (is )0.6 (saf)0.5 (e )0.6 (and )0.6 (ef)18.6 (f)0.5 (ect)0.6 (ive )0.6 (when )0.6 (used:)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.581 -1.538 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(in )0.6 (children )0.6 (12 )0.6 (years )0.6 (of)0.5 ( )0.6 (age )0.7 (or )0.6 (older )0.6 (who )0.6 (weigh )0.6 (less )0.6 (t)0.5 (han )0.6 (88 )0.6 (pounds )0.5 (\(40 )0.5 (kg\),)0.5 ( )0.6 (or)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.43 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(in )0.6 (children )0.6 (younger )0.6 (t)0.6 (han )0.6 (12 )0.6 (years )0.6 (of)0.6 ( )0.6 (age.)]TJ
/TT0 1 Tf
-1.8 -2.564 Td
[(Befo)0.5 (re )0.6 (you)0.6 ( )0.5 (recei)0.5 (ve )0.6 (O)0.5 (PDUAL)0.6 (AG)0.5 (,)0.5 ( )0.6 (tel)0.5 (l)0.5 ( )0.6 (yo)0.5 (u)0.5 (r )0.6 (h)0.5 (eal)0.5 (thcare )0.6 (p)0.5 (ro)0.5 (vi)0.5 (d)0.5 (er )0.6 (i)0.5 (f )0.6 (yo)0.5 (u)0.5 (:)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.581 -1.538 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(have )0.6 (immune )0.6 (syst)0.5 (em )0.6 (problems )0.6 (such )0.6 (as )0.6 (Crohn\222)18.3 (s )0.6 (disease,)0.5 ( )0.6 (ulcerat)0.5 (ive )0.6 (colit)0.5 (is,)0.5 ( )0.6 (or )0.6 (lupus)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.502 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(have )0.6 (received )0.6 (an )0.6 (organ )0.6 (t)0.5 (ransplant)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.502 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(have )0.6 (received )0.6 (or )0.6 (plan )0.6 (t)0.5 (o )0.6 (receive )0.6 (a )0.6 (st)0.5 (em )0.6 (cell )0.6 (t)0.5 (ransplant)0.5 ( )0.6 (t)0.5 (hat)0.6 ( )0.6 (uses )0.6 (donor )0.6 (st)0.5 (em )0.7 (cells )0.6 (\(allogeneic\))]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.502 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(have )0.6 (a )0.6 (condit)0.5 (ion )0.6 (t)0.5 (hat)0.5 ( )0.6 (af)18.6 (f)0.5 (ect)0.5 (s )0.6 (your )0.6 (nervous )0.6 (syst)0.5 (em,)0.5 ( )0.6 (such )0.6 (as )0.6 (myast)0.5 (henia )0.6 (gravis )0.6 (or )0.6 (G)0.5 (uillain-Barr\351 )0.6 (syndrome)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.502 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(are )0.6 (pregnant)0.5 ( )0.6 (or )0.6 (plan )0.6 (t)0.5 (o )0.6 (become )0.6 (pregnant)0.5 (.)0.5 ( )0.6 (O)0.5 (PDUALAG)0.5 ( )0.6 (can )0.6 (harm )0.6 (your )0.6 (unborn )0.6 (baby)74.6 (.)]TJ
/TT0 1 Tf
0 -1.43 Td
[(F)0.5 (emal)0.5 (es )0.6 (w)0.5 (h)0.5 (o)0.5 ( )0.6 (are )0.6 (ab)0.5 (l)0.5 (e )0.6 (to)0.5 ( )0.6 (b)0.5 (eco)0.5 (me )0.6 (p)0.5 (reg)0.5 (n)0.5 (an)0.5 (t:)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF00A0>>> BDC 
20.429 0 Td
( )Tj
EMC 
/Span<</ActualText<FEFF0009>>> BDC 
-19.843 -1.394 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 1.8 0 Td
[(Y)92.1 (our )0.5 (healt)0.5 (hcare )0.5 (provider )0.5 (should )0.5 (do )0.5 (a )0.6 (pregnancy )0.5 (t)0.5 (est)0.5 ( )0.5 (bef)0.5 (ore )0.5 (you )0.5 (st)0.5 (art)0.5 ( )0.5 (receiving )0.5 (O)0.5 (PDUALAG)0.5 (.)]TJ
0 Tc /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.43 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
0.002 Tc 0.104 Tw 1.8 0 Td
[(Y)91.5 (ou should )0.5 (use )0.5 (an )0.5 (ef)17.9 (fective method )0.5 (of )0.5 (b)-0.6 (irth )0.5 (control )0.5 (during and )0.5 (for at least )0.5 (5 months )0.5 (a)-0.6 (fter the last )0.5 (dose )0.5 (of)2.2 ( )]TJ
-0.018 Tc 0 Tw 0 -1.214 Td
[(O)0.5 (PDUALAG)0.5 (.)0.5 ( )18.6 (T)111.3 (alk )0.5 (t)0.5 (o )0.5 (your )0.5 (healt)0.5 (hcare )0.5 (provider about)0.5 ( )0.5 (birt)0.5 (h )0.5 (cont)0.5 (rol )0.5 (met)0.5 (hods )0.5 (t)0.5 (hat)0.5 ( )0.5 (you )0.5 (can )0.5 (use )0.5 (during )0.5 (t)0.5 (his )0.5 (t)0.5 (ime.)]TJ
0 Tc /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.43 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 1.8 0 Td
[(T)111.3 (ell )0.5 (your )0.5 (healt)0.5 (hcare )0.5 (provider )0.6 (right)0.5 ( )0.5 (away )0.5 (if)0.5 ( )0.5 (you )0.5 (become )0.5 (pregnant)0.5 ( )0.5 (during )0.5 (t)0.5 (reat)0.5 (ment)0.5 ( )0.5 (wit)0.6 (h )0.5 (O)0.5 (PDUALAG)0.5 (.)]TJ
0 Tc /Span<</ActualText<FEFF0009>>> BDC 
-3.019 -1.466 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.048 Tw 1.8 0 Td
[(are )0.5 (breast)0.5 (f)0.5 (eeding )0.5 (or )0.5 (plan )0.5 (t)0.5 (o )0.5 (breast)0.5 (f)0.5 (eed.)0.5 ( )0.6 (I)0.5 (t)0.5 ( )0.5 (is )0.5 (not)0.5 ( )0.5 (known )0.5 (if)0.5 ( )0.5 (O)0.5 (PDUALAG)0.5 ( )0.6 (passes )0.5 (int)0.5 (o )0.5 (your )0.5 (breast)0.5 ( )0.6 (milk.)0.5 ( )0.5 (Do )0.5 (not)0.5 ( )0.5 (breast)0.5 (f)0.5 (eed)-23.1 ( )]TJ
0.139 Tw 0 -1.214 Td
[(during )0.6 (t)0.5 (reat)0.5 (ment)0.5 ( )0.6 (wit)0.6 (h )0.6 (O)0.5 (PDUALAG)0.5 ( )0.6 (and )0.6 (f)0.5 (or )0.6 (5 )0.6 (mont)0.5 (hs )0.5 (af)0.5 (t)0.6 (er )0.6 (t)0.5 (he )0.5 (last)0.6 ( )0.6 (dose )0.6 (of)0.5 ( )0.5 (O)0.6 (PDUALAG)0.5 (.)]TJ
/TT0 1 Tf
0.293 Tw -1.8 -1.61 Td
[(T)74.7 (el)0.5 (l)0.5 ( yo)0.5 (u)0.5 (r h)0.5 (eal)0.5 (thcare p)0.5 (ro)0.5 (vi)0.5 (d)0.5 (er ab)0.5 (o)0.5 (u)0.5 (t al)0.5 (l)0.5 ( th)0.5 (e med)0.5 (i)0.5 (ci)0.5 (n)0.5 (es yo)0.6 (u)0.5 ( take,)0.5 ( i)0.5 (n)0.5 (cl)0.5 (u)0.5 (d)0.5 (i)0.5 (n)0.5 (g)0.5 ( p)0.5 (rescri)0.6 (p)0.5 (ti)0.5 (o)0.5 (n)0.5 ( an)0.5 (d)0.5 ( o)0.5 (ver-th)0.5 (e-co)0.5 (u)0.5 (n)0.5 (ter)-23.2 ( )]TJ
0.139 Tw 0 -1.214 Td
[(med)0.5 (i)0.5 (ci)0.5 (n)0.5 (es,)0.5 ( )0.5 (vitami)0.5 (n)0.5 (s,)0.6 ( )0.6 (and)0.6 ( )0.5 (h)0.5 (erb)0.5 (al)0.5 ( )0.6 (su)0.5 (p)0.5 (p)0.5 (l)0.5 (emen)0.6 (ts.)]TJ
0 -2.564 Td
[(Ho)0.5 (w)0.5 ( )0.6 (w)0.5 (i)0.5 (l)0.5 (l)0.5 ( )0.6 (I)0.5 ( )0.6 (recei)0.5 (ve )0.7 (O)0.5 (PDUAL)0.5 (AG)0.5 (?)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.581 -1.466 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.135 Tw 1.8 0 Td
[(Y)92.1 (our healt)0.6 (hcare provider will give you O)0.5 (PDUALAG)0.5 ( int)0.5 (o your vein t)0.5 (hrough an int)0.5 (ravenous \(I)0.5 (V\) line over 30 minut)0.5 (es.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.43 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(O)0.5 (PDUALAG)0.5 ( )0.6 (is )0.6 (usually )0.6 (given )0.6 (every )0.6 (4 )0.6 (weeks.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.43 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(Y)92.1 (our )0.6 (healt)0.5 (hcare )0.6 (provider )0.6 (will )0.6 (decide )0.6 (how )0.6 (many )0.6 (t)0.5 (reat)0.5 (ment)0.5 (s )0.6 (you )0.6 (need.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.43 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(Y)92.1 (our )0.6 (healt)0.5 (hcare )0.6 (provider )0.6 (will )0.6 (do )0.6 (blood )0.6 (t)0.6 (est)0.5 (s )0.6 (t)0.5 (o )0.6 (check )0.6 (you )0.6 (f)0.5 (or )0.5 (side )0.7 (ef)18.6 (f)0.5 (ect)0.6 (s.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.43 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(I)0.5 (f)0.5 ( )0.6 (you )0.6 (miss )0.6 (any )0.6 (appoint)0.6 (ment)0.5 (s,)0.5 ( )0.6 (call )0.6 (your )0.6 (healt)0.5 (hcare )0.6 (provider )0.6 (as )0.6 (soon )0.6 (as )0.6 (possible )0.6 (t)0.5 (o )0.6 (reschedule )0.6 (your )0.6 (appoint)0.5 (ment)0.5 (.)]TJ
/TT0 1 Tf
-1.8 -2.564 Td
[(W)0.5 (h)0.5 (at )0.6 (are )0.6 (th)0.5 (e )0.6 (p)0.5 (o)0.5 (ssi)0.5 (b)0.5 (l)0.5 (e )0.6 (si)0.5 (d)0.5 (e )0.7 (effects )0.6 (o)0.5 (f )0.6 (O)0.5 (PDUAL)0.5 (AG)0.5 (?)]TJ
0 -1.646 Td
[(O)0.5 (PDUAL)0.5 (AG)0.5 ( )0.7 (can)0.5 ( )0.6 (cau)0.5 (se )0.6 (seri)0.5 (o)0.5 (u)0.5 (s )0.6 (si)0.5 (d)0.5 (e )0.6 (effects,)0.6 ( )0.6 (i)0.5 (n)0.5 (cl)0.5 (u)0.5 (d)0.5 (i)0.5 (n)0.5 (g)0.5 (:)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.581 -1.538 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT0 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(See )0.6 (\223W)0.5 (hat )0.6 (i)0.5 (s )0.6 (th)0.5 (e )0.6 (mo)0.5 (st )0.6 (i)0.5 (mp)0.5 (o)0.5 (rtan)0.5 (t )0.6 (i)0.5 (n)0.5 (formati)0.5 (o)0.5 (n)0.5 ( )0.6 (I)0.5 ( )0.6 (sh)0.5 (o)0.5 (u)0.5 (l)0.5 (d)0.5 ( )0.6 (kn)0.5 (o)0.5 (w)0.5 ( )0.6 (ab)0.5 (o)0.5 (u)0.5 (t )0.6 (O)0.5 (PDUAL)0.5 (AG)0.5 (?)0.5 (\224)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF00A0>>> BDC 
38.103 0 Td
( )Tj
EMC 
/Span<</ActualText<FEFF0009>>> BDC 
-39.322 -1.502 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT0 1 Tf
-0.023 Tc 0.141 Tw 1.8 0 Td
[(Severe )0.5 (i)0.6 (n)0.5 (fu)0.5 (si)0.5 (o)0.5 (n)0.5 ( )0.5 (reacti)0.5 (o)0.5 (n)0.5 (s.)]TJ
/TT1 1 Tf
/Span<</ActualText<FEFF00A0>>> BDC 
12.124 0 Td
( )Tj
EMC 
0.377 0 Td
[(T)111.4 (ell )0.5 (your )0.5 (healt)0.5 (hcare )0.6 (provider )0.6 (or )0.6 (nurse )0.6 (right)0.5 ( )0.5 (away )0.6 (if)0.5 ( )0.5 (you )0.6 (get)0.5 ( )0.6 (t)0.5 (hese )0.5 (sympt)0.5 (oms )0.6 (during )0.6 (an)-23.2 ( )]TJ
0.139 Tw -12.501 -1.214 Td
[(inf)0.5 (usion )0.5 (of)0.5 ( )0.6 (O)0.5 (PDUALAG)0.5 (:)]TJ
ET
0 0 0 0 k
/GS0 gs
46 148.153 260 -13.04 re
306 148.153 260 -13.04 re
46 135.113 260 -13.04 re
306 135.113 260 -13.04 re
46 122.073 260 -13.04 re
306 122.073 260 -13.04 re
46 109.032 260 -13.04 re
306 109.032 260 -13.04 re
f
BT
0 0 0 1 k
/GS1 gs
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
10 0 0 10 69.8567 137.993 Tm
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 1.8 0 Td
[(chills )0.5 (or )0.5 (shaking)]TJ
0 Tc /Span<</ActualText<FEFF0009>>> BDC 
24.786 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
(dizziness)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.214 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 1.8 0 Td
[(it)0.5 (ching )0.5 (or )0.5 (rash)]TJ
0 Tc /Span<</ActualText<FEFF0009>>> BDC 
24.786 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 1.8 0 Td
[(f)0.5 (eel )0.5 (like )0.5 (passing )0.5 (out)]TJ
0 Tc /Span<</ActualText<FEFF0009>>> BDC 
-27.214 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
<00C000580056004B004C0051004A>Tj
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
24.786 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
[(f)0.5 (ever)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-27.214 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 1.8 0 Td
[(short)0.5 (ness )0.5 (of)0.5 ( )0.5 (breat)0.5 (h)]TJ
0 Tc /Span<</ActualText<FEFF0009>>> BDC 
24.786 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 1.8 0 Td
[(back )0.5 (or )0.5 (neck )0.5 (pain)]TJ
0 Tc /Span<</ActualText<FEFF0009>>> BDC 
-29.019 -1.646 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT0 1 Tf
-0.023 Tc 0.223 Tw 1.8 0 Td
[(Co)0.5 (mp)0.5 (l)0.5 (i)0.5 (cati)0.5 (o)0.5 (n)0.5 (s of stem cel)0.5 (l)0.5 ( tran)0.5 (sp)0.5 (l)0.5 (an)0.5 (t th)0.5 (at u)0.5 (ses d)0.5 (o)0.5 (n)0.5 (o)0.5 (r stem cel)0.5 (l)0.5 (s \(al)0.5 (l)0.5 (o)0.5 (g)0.5 (en)0.5 (ei)0.5 (c\).)]TJ
/C2_0 1 Tf
0.023 Tw 37.198 0 Td
[<0BD80003>-204.6 <0037>0.5 <004B0048005600480003>-222.7 <0046005200500053004F004C004600440057>0.5 <004C0052005100560003>-222.7 <0046004400510003>-222.8 <00450048>-23.1 <0003>]TJ
/TT1 1 Tf
0.181 Tw -37.198 -1.214 Td
[(severe and can lead )0.5 (t)0.5 (o deat)0.5 (h.)0.5 ( )18.5 (T)0.5 (hese complicat)0.5 (ions may happen )0.5 (if)0.5 ( )0.5 (you underwent)0.5 ( )0.5 (t)0.5 (ransplant)0.5 (at)0.5 (ion )0.5 (eit)0.5 (her bef)0.5 (ore )0.5 (or)-23 ( )]TJ
0.098 Tw 0 -1.214 Td
[(af)0.5 (t)0.5 (er being t)0.5 (reat)0.5 (ed wit)0.5 (h O)0.5 (PDUALAG)0.5 (.)0.5 ( )18.5 (Y)92.1 (our )0.5 (healt)0.5 (hcare provider will monit)0.5 (or you f)0.5 (or signs of)0.5 ( complicat)0.5 (ions if)0.5 ( you have)-23.1 ( )]TJ
0.139 Tw 0 -1.214 Td
[(an )0.6 (allogeneic )0.6 (st)0.5 (em )0.6 (cell )0.6 (t)0.5 (ransplant)0.5 (.)]TJ
ET
4 M 
36.5 36.5 539 695.96 re
S
endstreamendobj35 0 obj<</Length 15758>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 36.5 667.3805 cm
0 0 m
539 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
-0.023 Tc 0.139 Tw 10 0 0 10 258.5375 714.8154 Tm
[(MEDI)0.5 (CA)74.4 (T)0.5 (I)0.5 (O)0.5 (N )0.6 (G)0.5 (UI)0.5 (DE)]TJ
0.023 Tw -2.29 -1.564 Td
[(O)0.5 (PDUAL)0.5 (AG)]TJ
0 Tc 0 Tw 7 0 0 7 290.1945 701.5005 Tm
(\231)Tj
-0.023 Tc 0.139 Tw 10 0 0 10 297.0311 699.1705 Tm
[( )0.6 (\(o)0.5 (p)0.5 (-DEW)20.5 (-u)0.5 (h)0.5 (-l)0.5 (ag)0.5 (\))]TJ
0 Tc 0 Tw 7.933 0 Td
( )Tj
-0.023 Tc 0.139 Tw -14.687 -1.114 Td
[(\(n)0.5 (i)0.6 (vo)0.5 (l)0.5 (u)0.5 (mab)0.5 ( )0.6 (an)0.5 (d)0.5 ( )0.6 (rel)0.5 (atl)0.5 (i)0.5 (mab)0.5 (-rmb)0.5 (w)0.5 (\))]TJ
0 Tc 0 Tw 15.302 0 Td
( )Tj
-0.023 Tc 0.023 Tw -9.613 -1.114 Td
[(i)0.5 (n)0.5 (j)0.5 (ecti)0.5 (o)0.5 (n)]TJ
0.139 Tw -24.088 -2.465 Td
[(W)0.5 (h)0.5 (at )0.6 (i)0.5 (s )0.6 (th)0.6 (e )0.6 (mo)0.5 (st )0.6 (i)0.5 (mp)0.5 (o)0.5 (rtan)0.5 (t )0.6 (i)0.6 (n)0.5 (fo)0.5 (rmati)0.5 (o)0.5 (n)0.5 ( )0.6 (I)0.5 ( )0.6 (sh)0.5 (o)0.5 (u)0.5 (l)0.5 (d)0.5 ( )0.6 (kn)0.5 (o)0.5 (w)0.5 ( )0.6 (ab)0.5 (o)0.5 (u)0.5 (t )0.6 (O)0.5 (PDUAL)0.5 (AG)0.5 (?)]TJ
/TT1 1 Tf
0.127 Tw 0 -1.582 Td
[(O)0.5 (PDUALAG)0.5 ( is a medicine t)0.6 (hat)0.5 ( may t)0.5 (reat)0.5 ( a t)0.5 (ype of)0.5 ( skin cancer called melanoma by working wit)0.5 (h your immune syst)0.5 (em.)-22.9 ( )]TJ
0.06 Tw 0 -1.115 Td
[(O)0.5 (PDUALAG)0.5 ( can cause your immune syst)0.5 (em t)0.5 (o at)0.5 (t)0.5 (ack normal organs and t)0.5 (issues in any area of)0.5 ( your body and can af)18.6 (f)0.5 (ect)-22.8 ( )]TJ
0.121 Tw 0 -1.114 Td
[(t)0.5 (he way t)0.5 (hey work.)0.5 ( )18.2 (T)0.5 (hese problems can somet)0.5 (imes become severe or can lead t)0.5 (o deat)0.5 (h.)0.5 ( )18.2 (T)0.5 (hese problems may happen)-23.1 ( )]TJ
0.166 Tw 0 -1.114 Td
[(anyt)0.5 (ime during t)0.5 (reat)0.5 (ment)0.5 ( or even af)0.5 (t)0.5 (er your t)0.5 (reat)0.5 (ment)0.5 ( has ended.)0.5 ( )18.2 (Y)92.2 (ou may have more t)0.5 (han one of)0.5 ( t)0.5 (hese problems at)-22.8 ( )]TJ
0.139 Tw 0 -1.114 Td
[(t)0.5 (he )0.6 (same )0.6 (t)0.5 (ime.)]TJ
/TT0 1 Tf
0.108 Tw 0 -1.744 Td
[(Cal)0.5 (l)0.5 ( )0.7 (or )0.7 (see )0.7 (yo)0.5 (u)0.5 (r )0.7 (h)0.5 (eal)0.5 (th)0.5 (care )0.7 (p)0.5 (ro)0.5 (vi)0.5 (d)0.5 (er )0.7 (ri)0.5 (g)0.5 (h)0.6 (t )0.7 (aw)0.6 (ay )0.7 (i)0.5 (f )0.7 (yo)0.5 (u)0.5 ( )0.7 (d)0.5 (evel)0.5 (op)0.6 ( )0.6 (an)0.5 (y )0.7 (n)0.5 (ew)0.5 ( )0.7 (o)0.5 (r )0.7 (w)0.5 (o)0.5 (rse )0.7 (si)0.6 (g)0.5 (n)0.5 (s )0.7 (o)0.5 (f )0.7 (symp)0.5 (to)0.5 (ms,)0.5 ( )0.7 (i)0.5 (n)0.5 (cl)0.5 (u)0.5 (d)0.5 (i)0.5 (n)0.5 (g)0.5 (:)]TJ
0.139 Tw 0 -1.546 Td
[(L)0.5 (u)0.5 (n)0.5 (g)0.5 ( )0.6 (p)0.5 (ro)0.5 (b)0.5 (l)0.5 (ems.)]TJ
ET
0 0 0 0 k
/GS0 gs
45.5 552.476 173.667 -13.04 re
219.167 552.476 173.667 -13.04 re
392.833 552.476 173.667 -13.04 re
f
BT
0 0 0 1 k
/GS1 gs
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
10 0 0 10 51.3067 542.3154 Tm
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(new )0.6 (or )0.6 (worsening )0.6 (cough)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
19.721 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(short)0.5 (ness )0.6 (of)0.5 ( )0.6 (breat)0.5 (h)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
18.113 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(chest)0.5 ( )0.6 (pain)]TJ
/TT0 1 Tf
-42.073 -1.655 Td
[(I)0.5 (n)0.5 (testi)0.5 (n)0.5 (al)0.6 ( )0.5 (p)0.5 (ro)0.5 (b)0.5 (l)0.5 (ems.)]TJ
ET
0 0 0 0 k
/GS0 gs
45.5 522.025 521 -13.04 re
45.5 508.985 521 -13.04 re
45.5 495.945 521 -13.04 re
f
BT
0 0 0 1 k
/GS1 gs
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
10 0 0 10 51.3067 511.8651 Tm
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(diarrhea )0.6 (\(loose )0.6 (st)0.5 (ools\) )0.5 (or )0.6 (more )0.6 (f)0.5 (requent)0.5 ( )0.6 (bowel )0.6 (movement)0.6 (s )0.6 (t)0.5 (han )0.6 (usual)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(st)0.5 (ool )0.6 (t)0.5 (hat)0.5 ( )0.6 (are )0.6 (black,)0.5 ( )0.6 (t)0.5 (arry)74.6 (, )0.7 (st)0.5 (icky)74.6 (,)0.5 ( )0.6 (or )0.6 (have )0.6 (blood )0.6 (or )0.6 (mucus)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(severe )0.6 (st)0.5 (omach-area )0.6 (\(abdominal\) )0.7 (pain )0.6 (or )0.6 (t)0.5 (enderness)]TJ
/TT0 1 Tf
-1.8 -1.655 Td
[(L)0.5 (i)0.5 (ver )0.6 (p)0.5 (ro)0.5 (b)0.5 (l)0.5 (ems.)]TJ
ET
0 0 0 0 k
/GS0 gs
45.5 465.495 260.5 -13.04 re
306 465.495 260.5 -13.04 re
45.5 452.454 260.5 -13.04 re
306 452.454 260.5 -13.04 re
45.5 439.414 260.5 -13.04 re
306 439.414 260.5 -13.04 re
f
BT
0 0 0 1 k
/GS1 gs
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
10 0 0 10 51.3067 455.3343 Tm
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(yellowing )0.6 (of)0.5 ( )0.6 (your )0.6 (skin )0.6 (or )0.6 (t)0.5 (he )0.6 (whit)0.5 (es )0.6 (of)0.5 ( )0.6 (your )0.6 (eyes)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(dark )0.5 (urine )0.6 (\(t)0.5 (ea )0.6 (colored\))]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.069 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(severe )0.6 (nausea )0.7 (or )0.6 (vomit)0.5 (ing)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(bleeding )0.6 (or )0.6 (bruising )0.6 (more )0.6 (easily )0.6 (t)0.5 (han )0.6 (normal)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.069 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(pain )0.6 (on )0.6 (t)0.5 (he )0.6 (right)0.5 ( )0.6 (side )0.6 (of)0.6 ( )0.6 (your )0.6 (st)0.6 (omach )0.6 (area )0.6 (\(abdomen\))]TJ
/TT0 1 Tf
-1.8 -1.655 Td
[(Ho)0.5 (rmo)0.5 (n)0.5 (e )0.6 (g)0.5 (l)0.5 (an)0.5 (d)0.5 ( )0.6 (p)0.5 (ro)0.5 (b)0.5 (l)0.5 (ems.)]TJ
ET
0 0 0 0 k
/GS0 gs
45.5 408.964 260.5 -13.04 re
306 408.964 260.5 -13.04 re
45.5 395.924 260.5 -13.04 re
306 395.924 260.5 -13.04 re
45.5 382.883 260.5 -13.04 re
306 382.883 260.5 -13.04 re
45.5 369.843 260.5 -13.04 re
306 369.843 260.5 -13.04 re
45.5 356.803 260.5 -13.04 re
306 356.803 260.5 -13.04 re
45.5 343.762 260.5 -13.04 re
306 343.762 260.5 -13.04 re
45.5 330.722 260.5 -13.04 re
306 330.722 260.5 -26.081 re
45.5 317.682 260.5 -13.04 re
f
BT
0 0 0 1 k
/GS1 gs
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
10 0 0 10 51.3067 398.8035 Tm
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(headaches )0.6 (t)0.5 (hat)0.5 ( )0.6 (will )0.6 (not)0.6 ( )0.6 (go )0.6 (away )0.6 (or )0.6 (unusual )0.6 (headaches)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(urinat)0.5 (ing )0.6 (more )0.6 (of)0.6 (t)0.5 (en )0.6 (t)0.5 (han )0.6 (usual)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.069 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(eye )0.6 (sensit)0.5 (ivit)0.5 (y )0.6 (t)0.5 (o )0.6 (light)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(hair )0.6 (loss)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.069 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(eye )0.6 (problems)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(f)0.5 (eeling )0.6 (cold)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.069 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(rapid )0.6 (heart)0.5 (beat)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
[(const)0.5 (ipat)0.5 (ion)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.069 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(increased )0.6 (sweat)0.5 (ing)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(your )0.5 (voice )0.6 (get)0.5 (s )0.6 (deeper)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.069 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(ext)0.5 (reme )0.6 (t)0.5 (iredness)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(dizziness )0.6 (or )0.6 (f)0.5 (aint)0.6 (ing)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.069 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(weight)0.5 ( )0.6 (gain )0.5 (or )0.6 (weight)0.5 ( )0.6 (loss)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(changes )0.6 (in )0.6 (mood )0.6 (or )0.6 (behavior)55.6 (,)0.5 ( )0.5 (such )0.6 (as )0.6 (decreased)-23.2 ( )]TJ
0 -1.1 Td
[(sex )0.6 (drive,)0.5 ( )0.6 (irrit)0.5 (abilit)0.5 (y)74.6 (,)0.5 ( )0.6 (or )0.6 (f)0.5 (orget)0.5 (f)0.5 (ulness)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.069 -0.204 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(f)0.5 (eeling )0.6 (more )0.6 (hungry )0.6 (or )0.6 (t)0.5 (hirst)0.5 (y )0.6 (t)0.5 (han )0.6 (usual)]TJ
/TT0 1 Tf
-1.8 -1.655 Td
[(Ki)0.5 (d)0.5 (n)0.5 (ey )0.6 (p)0.5 (ro)0.5 (b)0.5 (l)0.5 (ems.)]TJ
ET
0 0 0 0 k
/GS0 gs
45.5 287.232 260.5 -13.04 re
306 287.232 260.5 -13.04 re
45.5 274.191 260.5 -13.04 re
306 274.191 260.5 -13.04 re
f
BT
0 0 0 1 k
/GS1 gs
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
10 0 0 10 51.3067 277.0714 Tm
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(decrease )0.7 (in )0.6 (your )0.6 (amount)0.5 ( )0.6 (of)0.5 ( )0.6 (urine)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(swelling )0.6 (in )0.6 (your )0.6 (ankles)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.069 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(blood )0.6 (in )0.6 (your )0.6 (urine)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(loss )0.6 (of)0.5 ( )0.6 (appet)0.5 (it)0.5 (e)]TJ
/TT0 1 Tf
-29.65 -1.654 Td
[(Ski)0.5 (n)0.5 ( )0.6 (p)0.5 (ro)0.5 (b)0.5 (l)0.5 (ems.)]TJ
ET
0 0 0 0 k
/GS0 gs
45.5 243.741 260.5 -13.04 re
306 243.741 260.5 -13.04 re
45.5 230.701 260.5 -24.04 re
306 230.701 260.5 -24.04 re
f
BT
0 0 0 1 k
/GS1 gs
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
10 0 0 10 51.3067 233.5809 Tm
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
(rash)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(skin )0.6 (blist)0.5 (ering )0.6 (or )0.6 (peeling)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.069 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
[(it)0.5 (ching)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(painf)0.6 (ul )0.6 (sore )0.6 (or )0.6 (ulcers )0.6 (in )0.6 (mout)0.5 (h )0.6 (or )0.6 (nose,)0.5 ( )0.6 (t)0.5 (hroat)0.5 (,)0.5 ( )0.6 (or)-23 ( )]TJ
0 -1.1 Td
[(genit)0.6 (al )0.6 (area)]TJ
/TT0 1 Tf
-29.65 -1.655 Td
[(Heart )0.6 (pro)0.5 (b)0.5 (l)0.5 (ems.)]TJ
ET
0 0 0 0 k
/GS0 gs
45.5 189.251 260.5 -14.111 re
306 189.251 260.5 -14.111 re
45.5 175.14 260.5 -13.04 re
306 175.14 260.5 -13.04 re
45.5 162.1 260.5 -13.04 re
306 162.1 260.5 -13.04 re
f
BT
0 0 0 1 k
/GS1 gs
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
10 0 0 10 51.3067 179.0904 Tm
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(new )0.6 (or )0.6 (worse )0.6 (chest)0.5 ( )0.7 (pain)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.023 Tw 1.8 0 Td
[(t)0.5 (iredness)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.069 -1.411 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(irregular )0.6 (heart)0.5 (beat)0.5 ( )0.6 (or )0.6 (f)0.5 (eel )0.6 (like )0.6 (your )0.7 (heart)0.5 ( )0.6 (is )0.6 (racing)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
26.631 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(swelling )0.6 (in )0.6 (your )0.6 (ankles)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.069 -1.304 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(short)0.5 (ness )0.6 (of)0.5 ( )0.6 (breat)0.5 (h)]TJ
/TT0 1 Tf
0.082 Tw -1.8 -1.655 Td
[(Pro)0.5 (b)0.5 (l)0.5 (ems can al)0.5 (so)0.5 ( h)0.5 (ap)0.5 (p)0.5 (en)0.5 ( i)0.5 (n)0.5 ( o)0.5 (th)0.5 (er o)0.5 (rg)0.5 (an)0.5 (s an)0.5 (d)0.5 ( ti)0.5 (ssu)0.5 (es.)0.5 ( T)0.5 (h)0.5 (ese are n)0.5 (o)0.5 (t al)0.5 (l)0.5 ( o)0.5 (f th)0.5 (e si)0.5 (g)0.5 (n)0.5 (s an)0.5 (d)0.5 ( symp)0.5 (to)0.5 (ms o)0.5 (f i)0.5 (mmu)0.5 (n)0.5 (e)-23.2 ( )]TJ
0.084 Tw 0 -1.114 Td
[(system )0.6 (p)0.5 (ro)0.6 (bl)0.6 (ems )0.6 (th)0.5 (at )0.6 (can)0.5 ( )0.6 (h)0.5 (ap)0.5 (p)0.5 (en)0.5 ( )0.6 (w)0.5 (i)0.5 (th)0.5 ( )0.7 (O)0.5 (PDUAL)0.5 (AG)0.5 (.)0.5 ( )0.6 (Cal)0.5 (l)0.5 ( )0.6 (o)0.5 (r )0.6 (see )0.6 (yo)0.5 (u)0.5 (r )0.6 (h)0.5 (eal)0.5 (th)0.5 (care )0.6 (p)0.5 (ro)0.5 (vi)0.5 (d)0.5 (er )0.6 (ri)0.5 (g)0.5 (h)0.5 (t )0.7 (aw)0.6 (ay )0.6 (fo)0.5 (r )0.7 (an)0.5 (y )0.7 (n)0.5 (ew)-22.8 ( )]TJ
0.139 Tw 0 -1.114 Td
[(o)0.5 (r )0.6 (w)0.5 (o)0.5 (rsen)0.5 (i)0.6 (ng)0.5 ( )0.6 (si)0.5 (g)0.5 (n)0.5 ( )0.6 (o)0.6 (r )0.6 (symp)0.5 (to)0.5 (ms,)0.5 ( )0.6 (w)0.5 (h)0.5 (i)0.5 (ch)0.5 ( )0.6 (may )0.6 (i)0.6 (n)0.5 (cl)0.6 (ud)0.6 (e:)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.581 -1.438 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.234 Tw 1.8 0 Td
[(Conf)0.5 (usion,)0.5 ( sleepiness,)0.5 ( memory problems,)0.5 ( changes in mood or behavior)55.5 (,)0.5 ( st)0.5 (if)18.5 (f)0.6 ( neck,)0.5 ( balance problems,)0.5 ( t)0.5 (ingling or)-23 ( )]TJ
0.139 Tw 0 -1.114 Td
[(numbness )0.5 (of)0.5 ( )0.7 (the )0.6 (arms )0.6 (or )0.6 (legs)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.403 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(Double )0.6 (vision,)0.5 ( )0.6 (blurry )0.5 (vision,)0.6 ( )0.6 (sensit)0.5 (ivit)0.5 (y )0.6 (t)0.5 (o )0.6 (light)0.6 (,)0.5 ( )0.6 (eye )0.6 (pain,)0.5 ( )0.6 (changes )0.6 (in )0.6 (eyesight)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.403 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(Persist)0.5 (ent)0.5 ( )0.6 (or )0.6 (severe )0.6 (muscle )0.6 (pain )0.6 (or )0.6 (weakness,)0.5 ( )0.6 (muscle )0.6 (cramps)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.219 -1.403 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.581 0 Td
<0194>Tj
/TT1 1 Tf
-0.023 Tc 0.139 Tw 1.8 0 Td
[(Low )0.6 (red )0.6 (blood )0.6 (cells,)0.5 ( )0.6 (bruising)]TJ
ET
4 M 
36 36 540 695.596 re
S
endstreamendobj32 0 obj<</Length 80676>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 0 k
/GS0 gs
36 732.96 252 -10.212 re
36 722.748 103.68 -21.412 re
139.68 722.748 74.16 -21.412 re
213.84 722.748 74.16 -21.412 re
36 701.336 103.68 -12.192 re
139.68 701.336 74.16 -12.192 re
213.84 701.336 74.16 -12.192 re
36 689.144 103.68 -12.192 re
139.68 689.144 74.16 -12.192 re
213.84 689.144 74.16 -12.192 re
36 676.952 103.68 -12.192 re
139.68 676.952 74.16 -12.192 re
213.84 676.952 74.16 -12.192 re
36 664.76 103.68 -12.192 re
139.68 664.76 148.32 -12.192 re
36 652.568 103.68 -12.192 re
139.68 652.568 148.32 -12.192 re
36 640.377 103.68 -12.192 re
139.68 640.377 74.16 -12.192 re
213.84 640.377 74.16 -12.192 re
36 628.185 103.68 -12.192 re
139.68 628.185 74.16 -12.192 re
213.84 628.185 74.16 -12.192 re
36 615.993 103.68 -12.192 re
139.68 615.993 74.16 -12.192 re
213.84 615.993 74.16 -12.192 re
36 603.801 103.68 -12.192 re
139.68 603.801 148.32 -12.192 re
36 591.609 103.68 -12.192 re
139.68 591.609 148.32 -12.192 re
36 579.417 103.68 -12.192 re
139.68 579.417 74.16 -12.192 re
213.84 579.417 74.16 -12.192 re
36 567.225 103.68 -12.192 re
139.68 567.225 74.16 -12.192 re
213.84 567.225 74.16 -12.192 re
36 555.033 103.68 -12.192 re
139.68 555.033 74.16 -12.192 re
213.84 555.033 74.16 -12.192 re
36 542.841 103.68 -12.192 re
139.68 542.841 74.16 -12.192 re
213.84 542.841 74.16 -12.192 re
36 530.649 252 -89.412 re
f
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 441.2374 cm
0 0 m
103.68 0 l
S
Q
q 1 0 0 1 139.68 441.2374 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 441.2374 cm
0 0 m
74.16 0 l
S
Q
1 w 
q 1 0 0 1 36 722.748 cm
0 0 m
103.68 0 l
S
Q
0.5 w 
q 1 0 0 1 36 701.3361 cm
0 0 m
103.68 0 l
S
Q
q 1 0 0 1 36 640.3766 cm
0 0 m
103.68 0 l
S
Q
q 1 0 0 1 36 579.417 cm
0 0 m
103.68 0 l
S
Q
q 1 0 0 1 139.68 689.3942 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 213.84 689.3942 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 139.68 628.4346 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 213.84 628.4346 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 139.68 567.4751 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 213.84 567.4751 cm
0 0 m
0 11.692 l
S
Q
1 w 
q 1 0 0 1 139.68 722.748 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 722.748 cm
0 0 m
74.16 0 l
S
Q
0.5 w 
q 1 0 0 1 139.68 701.5861 cm
0 0 m
0 20.662 l
S
Q
q 1 0 0 1 213.84 701.5861 cm
0 0 m
0 20.662 l
S
Q
q 1 0 0 1 139.68 701.3361 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 701.3361 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 139.68 640.3766 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 640.3766 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 139.68 579.417 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 579.417 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 139.68 652.5685 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 652.5685 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 139.68 591.6089 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 591.6089 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 542.8412 cm
0 0 m
74.16 0 l
S
Q
1 w 
q 1 0 0 1 213.84 530.6494 cm
0 0 m
74.16 0 l
S
Q
0.5 w 
q 1 0 0 1 213.84 665.0104 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 139.68 664.7604 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 664.7604 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 604.0508 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 139.68 603.8008 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 603.8008 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 555.2831 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 213.84 555.0331 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 139.68 689.1442 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 689.1442 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 677.2023 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 139.68 676.9523 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 676.9523 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 139.68 628.1846 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 628.1846 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 616.2427 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 139.68 615.9927 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 615.9927 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 139.68 567.2251 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 213.84 567.2251 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 139.68 652.8185 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 36 652.5685 cm
0 0 m
103.68 0 l
S
Q
q 1 0 0 1 139.68 640.6266 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 139.68 591.8589 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 36 591.6089 cm
0 0 m
103.68 0 l
S
Q
q 1 0 0 1 139.68 579.667 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 36 542.8412 cm
0 0 m
103.68 0 l
S
Q
1 w 
q 1 0 0 1 36 530.6494 cm
0 0 m
103.68 0 l
S
Q
0.5 w 
q 1 0 0 1 139.68 665.0104 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 36 664.7604 cm
0 0 m
103.68 0 l
S
Q
q 1 0 0 1 139.68 604.0508 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 36 603.8008 cm
0 0 m
103.68 0 l
S
Q
q 1 0 0 1 139.68 555.2831 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 36 555.0331 cm
0 0 m
103.68 0 l
S
Q
q 1 0 0 1 36 689.1442 cm
0 0 m
103.68 0 l
S
Q
q 1 0 0 1 139.68 677.2023 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 36 676.9523 cm
0 0 m
103.68 0 l
S
Q
q 1 0 0 1 36 628.1846 cm
0 0 m
103.68 0 l
S
Q
q 1 0 0 1 139.68 616.2427 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 36 615.9927 cm
0 0 m
103.68 0 l
S
Q
q 1 0 0 1 36 567.2251 cm
0 0 m
103.68 0 l
S
Q
q 1 0 0 1 139.68 555.0331 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 139.68 543.0912 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 213.84 543.0912 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 139.68 542.8412 cm
0 0 m
74.16 0 l
S
Q
q 1 0 0 1 139.68 531.1494 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 213.84 531.1494 cm
0 0 m
0 11.442 l
S
Q
1 w 
q 1 0 0 1 139.68 530.6494 cm
0 0 m
74.16 0 l
S
Q
BT
0 0 0 1 k
/GS2 gs
/T1_0 1 Tf
-0.012 Tc 0.06 Tw 8 0 0 8 36 727.248 Tm
[(T)74.2 (able 5:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Efficac)10.2 (y Results in RELA)55.2 (TIVITY)74.2 (-047)]TJ
0.012 Tw 7.6 0 0 8 160.6762 713.4362 Tm
(OPDUALAG)Tj
0 Tc 0 Tw 7.6 0 0 8 192.8438 713.4362 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 167.0124 704.9362 Tm
(N=355)Tj
8.997 1.062 Td
(Nivolumab)Tj
0 Tc 0 Tw 7.6 0 0 8 266.6985 713.4362 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 241.2974 704.9362 Tm
(N=359)Tj
0.06 Tw -27.013 -1.569 Td
[(Progression-free Sur)-17.7 (viv)16.2 (al)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.012 Tw 5.32 0 0 5.6 111.1509 695.0482 Tm
(a,b)Tj
0 Tc 0 Tw 7.6 0 0 8 117.5167 692.3842 Tm
(\035)Tj
/T1_1 1 Tf
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-10.726 -1.524 Td
( )Tj
EMC 
0.592 0 Td
[(Disease progression or dea)-9.8 (th \(%\))]TJ
16.387 0 Td
(180 \(51\))Tj
9.774 0 Td
(211 \(59\))Tj
/Span<</ActualText<FEFF0009>>> BDC 
-26.753 -1.524 Td
( )Tj
EMC 
0.592 0 Td
(Median \(months\))Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 86.8322 670.6644 Tm
(c)Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 89.0336 668.0004 Tm
( \(95% CI\))Tj
8.724 0 Td
[(10.1 \(6.4,)37.2 ( 15.7\))]TJ
10.242 0 Td
[(4.6 \(3.4,)37.2 ( 5.6\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
-25.944 -1.524 Td
( )Tj
EMC 
0.592 0 Td
[(Hazard ra)-9.7 (tio)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 73.947 658.4725 Tm
(d)Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 76.3452 655.8085 Tm
[(\035)-47.8 (\(95% CI\))]TJ
15.055 0 Td
[(0.75 \(0.62,)37.2 ( 0.92\))]TJ
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
-20.364 -1.524 Td
( )Tj
EMC 
(p-value)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 61.172 646.2806 Tm
(e)Tj
7.6 0 0 8 63.534 643.6166 Tm
(\035)Tj
-0.012 Tc 0.012 Tw 18.504 0 Td
(0.0055)Tj
/T1_0 1 Tf
0.06 Tw -22.127 -1.524 Td
[(Overall Sur)-17.7 (viv)16.2 (al)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 82.3153 634.0887 Tm
(f)Tj
7.6 0 0 8 83.8899 631.4247 Tm
(\035)Tj
/T1_1 1 Tf
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-6.301 -1.524 Td
( )Tj
EMC 
0.592 0 Td
[(Dea)-9.7 (ths \(%\))]TJ
16.387 0 Td
(137 \(39\))Tj
9.774 0 Td
(160 \(45\))Tj
/Span<</ActualText<FEFF0009>>> BDC 
-26.753 -1.524 Td
( )Tj
EMC 
0.592 0 Td
(Median in months \(95% CI\))Tj
15.457 0 Td
[(NR \(34.2,)37.2 ( NR\))]TJ
9.25 0 Td
[(34.10 \(25.2,)37.1 ( NR\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
-25.299 -1.524 Td
( )Tj
EMC 
0.592 0 Td
[(Hazard ra)-9.7 (tio)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 73.947 597.5129 Tm
(d)Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 76.3452 594.8489 Tm
[(\035)-47.8 (\(95% CI\))]TJ
15.055 0 Td
[(0.80 \(0.64,)37.2 ( 1.01\))]TJ
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
-20.364 -1.524 Td
( )Tj
EMC 
(p-value)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 61.172 585.321 Tm
(e)Tj
7.6 0 0 8 63.534 582.657 Tm
(\035)Tj
-0.012 Tc 0.012 Tw 19.101 0 Td
(NS)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 216.7655 585.321 Tm
(g)Tj
7.6 0 0 8 219.2286 582.657 Tm
(\035)Tj
/T1_0 1 Tf
-0.012 Tc 0.06 Tw -24.109 -1.524 Td
(Overall Response Rate)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.012 Tw 5.32 0 0 5.6 102.6984 573.1291 Tm
(a,f,h)Tj
0.06 Tw 7.6 0 0 8 111.7209 570.4651 Tm
[(\035)140.2 (,)37.2 ( n \(%\))]TJ
/T1_1 1 Tf
0.048 Tw 7.015 0 Td
(153 \(43\))Tj
9.774 0 Td
(117 \(33\))Tj
/Span<</ActualText<FEFF0009>>> BDC 
-26.753 -1.524 Td
( )Tj
EMC 
0.592 0 Td
(\(95% CI\))Tj
16.525 0 Td
[(\(38,)37.2 ( 48\))]TJ
9.774 0 Td
[(\(28,)37.2 ( 38\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
-26.892 -1.524 Td
( )Tj
EMC 
0.592 0 Td
[(Complete response ra)-9.7 (te \(%\))]TJ
16.621 0 Td
(58 \(16\))Tj
9.774 0 Td
(51 \(14\))Tj
/Span<</ActualText<FEFF0009>>> BDC 
-26.987 -1.524 Td
( )Tj
EMC 
0.592 0 Td
[(P)18.2 (artial response ra)-9.8 (te \(%\))-12 (\035)]TJ
16.621 0 Td
(95 \(27\))Tj
9.774 0 Td
(66 \(18\))Tj
-0.017 Tc 0.017 Tw 5.32 0 0 5.6 36 524.0014 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 41 521.3374 Tm
(Assessed by BICR.)Tj
0.017 Tw 5.32 0 0 5.6 36 515.5014 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 41 512.8374 Tm
[(F)18.2 (inal PFS analysis.)]TJ
0.017 Tw 5.32 0 0 5.6 36 507.0014 Tm
(c)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 41 504.3374 Tm
[(Ka)-9.8 (plan-Meier estima)-9.8 (te.)]TJ
0.017 Tw 5.32 0 0 5.6 36 498.5014 Tm
(d)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 41 495.8374 Tm
[(Based on stra)-9.7 (tified Cox proportional hazard model.)]TJ
0.017 Tw 5.32 0 0 5.6 36 490.0014 Tm
(e)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 41 487.3374 Tm
[(Based on stra)-9.7 (tified log-rank test.)]TJ
0.017 Tw 5.32 0 0 5.6 36 481.5014 Tm
(f)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.011 Tc 0.08 Tw 7.6 0 0 8 41 478.8374 Tm
[(At the time of the final OS analysis,)36.8 ( which was event-driven and occurred after the final)-11 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
(PFS analysis.)Tj
0.017 Tw 5.32 0 0 5.6 36 464.5014 Tm
(g)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 41 461.8374 Tm
[(Not Significant a)-9.8 (t alpha level 0.04302.)]TJ
0.017 Tw 5.32 0 0 5.6 36 456.0014 Tm
(h)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 41 453.3374 Tm
[(Not formally tested based on the testing hierarchy)55.2 (.)]TJ
-0.658 -1.062 Td
(NR = Not reached.)Tj
/T1_0 1 Tf
-0.012 Tc 0.06 Tw 8 0 0 8 36 414.4874 Tm
(Figure 1:)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Progression-free Sur)-17.8 (viv)16.2 (al - RELA)55.2 (TIVITY)74.2 (-047)]TJ
ET
/PlacedGraphic /MC0 BDC 
EMC 
0.5 w 
/GS0 gs
q 1 0 0 1 73.869 220.2478 cm
0 0 m
16.686 -0.01 l
S
Q
BT
/T1_2 1 Tf
-0.01 Tc 0.01 Tw 8 0 0 8 96.7794 217.1228 Tm
(OPDUALAG)Tj
ET
1 j 2 J [4.5 1.5]0 d 
q 1 0 0 1 73.7067 210.9718 cm
0 0 m
16.686 -0.01 l
S
Q
BT
8 0 0 8 96.8189 208.2073 Tm
(Nivolumab)Tj
ET
q 1 0 0 1 84.1496 210.8558 cm
0 0 m
-1.995 0.056 l
-0.544 -1.312 l
-0.749 -1.516 l
-2.116 -0.065 l
-2.06 -2.06 l
-2.345 -2.06 l
-2.289 -0.065 l
-3.657 -1.516 l
-3.861 -1.312 l
-2.41 0.056 l
-4.405 0 l
-4.405 0.285 l
-2.41 0.219 l
-3.861 1.59 l
-3.657 1.792 l
-2.289 0.341 l
-2.345 2.336 l
-2.06 2.336 l
-2.116 0.341 l
-0.749 1.792 l
-0.544 1.59 l
-1.995 0.219 l
0 0.276 l
h
f
Q
q
36 130.399 252 279.859 re
W n
0.375 w 0 j 0 J []0 d 
q 1 0 0 1 84.1532 220.3158 cm
0 0 m
0 -1.211 -0.982 -2.193 -2.193 -2.193 c
-3.404 -2.193 -4.386 -1.211 -4.386 0 c
-4.386 1.212 -3.404 2.194 -2.193 2.194 c
-0.982 2.194 0 1.212 0 0 c
h
S
Q
[4.5 1.5]0 d 
q 1 0 0 1 70.7534 404.9009 cm
0 0 m
2.78 0 l
2.78 -0.881 l
3.248 -0.881 l
3.248 -1.431 l
3.826 -1.431 l
3.826 -3.193 l
4.431 -3.193 l
4.431 -4.927 l
5.835 -4.927 l
5.835 -6.771 l
6.413 -6.771 l
6.413 -7.706 l
6.881 -7.706 l
6.881 -8.56 l
7.761 -8.56 l
7.761 -10.679 l
8.147 -10.679 l
8.147 -11.229 l
9.358 -11.229 l
9.358 -12.303 l
10.128 -12.303 l
10.128 -13.706 l
10.844 -13.706 l
10.844 -15.358 l
11.394 -15.358 l
11.394 -16.651 l
11.972 -16.651 l
11.972 -19.073 l
12.716 -19.073 l
12.716 -20.119 l
13.321 -20.119 l
13.321 -25.046 l
13.954 -25.046 l
13.954 -26.532 l
15.193 -26.532 l
15.193 -27.798 l
15.605 -27.798 l
15.605 -28.927 l
15.908 -29.229 l
15.908 -30.275 l
16.294 -30.275 l
16.294 -31.183 l
16.734 -31.183 l
16.734 -32.229 l
17.285 -32.229 l
17.285 -33.248 l
18.11 -33.248 l
18.11 -33.881 l
18.11 -37.238 l
18.302 -37.238 l
18.302 -38.642 l
18.853 -38.642 l
18.853 -49.706 l
19.211 -49.706 l
19.211 -58.789 l
19.541 -58.789 l
19.541 -79.376 l
19.981 -79.376 l
19.981 -82.211 l
20.312 -82.211 l
20.312 -87.193 l
20.89 -87.193 l
20.89 -88.211 l
21.413 -88.211 l
21.413 -88.899 l
22.184 -88.899 l
22.184 -89.67 l
23.312 -89.67 l
23.312 -90.523 l
24 -90.523 l
24 -91.789 l
24.88 -91.789 l
24.88 -92.505 l
25.981 -92.505 l
25.981 -93 l
27.055 -93 l
27.055 -93.798 l
28.101 -93.798 l
28.101 -94.376 l
29.312 -94.376 l
29.312 -95.119 l
30.551 -95.119 l
30.551 -95.67 l
30.908 -95.67 l
30.908 -97.596 l
31.238 -97.596 l
31.238 -99 l
31.568 -99 l
31.568 -104.835 l
31.954 -104.835 l
31.954 -107.037 l
32.45 -107.037 l
32.45 -108.11 l
33.22 -108.11 l
33.22 -109.266 l
33.66 -109.266 l
33.66 -110.202 l
34.734 -110.202 l
34.734 -111 l
36.963 -111 l
36.963 -111.881 l
38.119 -111.881 l
38.119 -112.349 l
39.22 -112.349 l
39.22 -112.982 l
40.871 -112.871 40.871 -112.982 v
40.871 -113.752 l
43.128 -113.752 l
43.128 -114.963 l
44.009 -114.963 l
44.009 -116.092 l
44.725 -116.092 l
44.725 -116.752 l
45.137 -116.752 l
45.137 -117.468 l
51.247 -117.468 l
51.247 -117.908 l
52.321 -117.908 l
52.321 -118.404 l
53.697 -118.404 l
53.697 -119.064 l
54.963 -119.064 l
54.963 -119.725 l
55.679 -119.725 l
55.679 -120.44 l
56.229 -120.44 l
56.229 -121.569 l
57 -121.569 l
57 -122.422 l
57.66 -122.422 l
57.66 -123.082 l
61.734 -123.082 l
61.734 -123.881 l
67.816 -123.881 l
67.816 -124.761 l
68.367 -124.761 l
68.367 -125.972 l
69.275 -125.972 l
69.275 -126.881 l
70.046 -126.881 l
70.046 -127.459 l
73.046 -127.459 l
73.046 -128.202 l
79.321 -128.202 l
79.321 -128.807 l
81.385 -128.807 l
81.385 -129.66 l
82.486 -129.66 l
82.486 -130.156 l
92.311 -130.156 l
92.311 -131.477 l
97.431 -131.477 l
97.431 -132.468 l
98.559 -132.468 l
98.559 -133.486 l
100.734 -133.486 l
100.734 -134.807 l
115.541 -134.725 115.541 -134.807 v
115.541 -135.936 l
116.999 -135.936 l
116.999 -138 l
121.238 -138 l
121.238 -139.211 l
125.092 -139.211 l
125.092 -139.624 l
125.587 -139.624 l
125.587 -140.394 l
130.678 -140.229 130.678 -140.394 v
130.678 -141.55 l
134.311 -141.55 l
134.311 -142.679 l
152.257 -142.679 l
152.257 -143.339 l
153.88 -143.339 l
153.88 -143.89 l
189.385 -143.89 l
S
Q
q 1 0 0 1 211.8664 262.0898 cm
0 0 m
-1.452 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.047 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.303 l
-0.396 1.156 l
-1.452 0.16 l
0 0.2 l
h
f
Q
q 1 0 0 1 262.0574 260.9618 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.048 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.544 1.302 l
-0.396 1.156 l
-1.451 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 261.6784 260.9618 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.048 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.544 1.302 l
-0.396 1.156 l
-1.451 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 262.4219 260.9618 cm
0 0 m
-1.452 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.048 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.302 l
-0.396 1.156 l
-1.452 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 258.4659 260.9618 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.048 l
-1.498 -1.499 l
-1.705 -1.499 l
-1.665 -0.048 l
-2.659 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.659 1.302 l
-1.665 0.247 l
-1.705 1.699 l
-1.498 1.699 l
-1.539 0.247 l
-0.544 1.302 l
-0.396 1.156 l
-1.451 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 247.0014 260.9618 cm
0 0 m
-1.452 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.048 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.544 1.302 l
-0.396 1.156 l
-1.452 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 244.5239 260.9618 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.048 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.544 1.302 l
-0.396 1.156 l
-1.451 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 244.0699 260.9618 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.048 l
-1.499 -1.499 l
-1.705 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.705 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.544 1.302 l
-0.396 1.156 l
-1.451 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 243.6159 260.9618 cm
0 0 m
-1.452 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.048 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.302 l
-0.396 1.156 l
-1.452 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 243.1619 260.9618 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.048 l
-1.498 -1.499 l
-1.705 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.705 1.699 l
-1.498 1.699 l
-1.539 0.247 l
-0.544 1.302 l
-0.396 1.156 l
-1.451 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 242.7074 260.9618 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.048 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.752 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.752 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.302 l
-0.396 1.156 l
-1.451 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 238.5379 260.9618 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.048 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.544 1.302 l
-0.396 1.156 l
-1.451 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 228.7484 260.9618 cm
0 0 m
-1.452 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.048 l
-1.498 -1.499 l
-1.705 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.705 1.699 l
-1.498 1.699 l
-1.539 0.247 l
-0.545 1.302 l
-0.396 1.156 l
-1.452 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 226.6839 260.9618 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.048 l
-1.498 -1.499 l
-1.705 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.752 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.752 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.705 1.699 l
-1.498 1.699 l
-1.539 0.247 l
-0.544 1.302 l
-0.396 1.156 l
-1.451 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 225.7809 260.9618 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.048 l
-1.498 -1.499 l
-1.705 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.705 1.699 l
-1.498 1.699 l
-1.539 0.247 l
-0.544 1.302 l
-0.396 1.156 l
-1.451 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 224.8779 260.9618 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.048 l
-1.498 -1.499 l
-1.705 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.705 1.699 l
-1.498 1.699 l
-1.539 0.247 l
-0.544 1.302 l
-0.396 1.156 l
-1.451 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 224.8779 262.0778 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.048 l
-1.498 -1.499 l
-1.705 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.705 1.698 l
-1.498 1.698 l
-1.539 0.247 l
-0.544 1.302 l
-0.396 1.156 l
-1.451 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 224.0199 262.0778 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.048 l
-1.498 -1.499 l
-1.705 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.705 1.698 l
-1.498 1.698 l
-1.539 0.247 l
-0.544 1.302 l
-0.396 1.156 l
-1.451 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 223.2724 262.0778 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.048 l
-1.498 -1.499 l
-1.705 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.705 1.698 l
-1.498 1.698 l
-1.539 0.247 l
-0.544 1.302 l
-0.396 1.156 l
-1.451 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 208.2269 262.0778 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.048 l
-1.498 -1.499 l
-1.706 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.706 1.698 l
-1.498 1.698 l
-1.539 0.247 l
-0.544 1.302 l
-0.396 1.156 l
-1.451 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 196.3984 265.6748 cm
0 0 m
-1.451 0.041 l
-0.396 -0.954 l
-0.545 -1.102 l
-1.539 -0.047 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.047 l
-2.66 -1.102 l
-2.808 -0.954 l
-1.753 0.041 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.303 l
-0.396 1.156 l
-1.451 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 156.9189 274.5028 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.047 l
-1.498 -1.498 l
-1.705 -1.498 l
-1.665 -0.047 l
-2.659 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.659 1.303 l
-1.665 0.247 l
-1.705 1.699 l
-1.498 1.699 l
-1.539 0.247 l
-0.544 1.303 l
-0.396 1.156 l
-1.451 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 155.4674 274.5028 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.047 l
-1.498 -1.498 l
-1.705 -1.498 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.752 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.752 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.705 1.699 l
-1.498 1.699 l
-1.539 0.247 l
-0.544 1.303 l
-0.396 1.156 l
-1.451 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 155.0474 274.5028 cm
0 0 m
-1.452 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.047 l
-1.498 -1.498 l
-1.706 -1.498 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.498 1.699 l
-1.539 0.247 l
-0.544 1.303 l
-0.396 1.156 l
-1.452 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 152.7904 276.0443 cm
0 0 m
-1.452 0.041 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.048 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.041 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.706 1.698 l
-1.499 1.698 l
-1.539 0.247 l
-0.545 1.302 l
-0.396 1.156 l
-1.452 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 151.4364 276.5618 cm
0 0 m
-1.451 0.041 l
-0.396 -0.954 l
-0.544 -1.102 l
-1.539 -0.047 l
-1.499 -1.498 l
-1.706 -1.498 l
-1.665 -0.047 l
-2.66 -1.102 l
-2.808 -0.954 l
-1.753 0.041 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.157 l
-2.66 1.303 l
-1.665 0.248 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.248 l
-0.544 1.303 l
-0.396 1.157 l
-1.451 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 150.7209 276.5618 cm
0 0 m
-1.451 0.041 l
-0.396 -0.954 l
-0.544 -1.102 l
-1.539 -0.047 l
-1.498 -1.498 l
-1.705 -1.498 l
-1.665 -0.047 l
-2.659 -1.102 l
-2.808 -0.954 l
-1.752 0.041 l
-3.204 0 l
-3.204 0.207 l
-1.752 0.16 l
-2.808 1.157 l
-2.659 1.303 l
-1.665 0.248 l
-1.705 1.699 l
-1.498 1.699 l
-1.539 0.248 l
-0.544 1.303 l
-0.396 1.157 l
-1.451 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 142.8799 277.3988 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.047 l
-1.499 -1.498 l
-1.706 -1.498 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.302 l
-0.396 1.156 l
-1.451 0.16 l
0 0.2 l
h
f
Q
q 1 0 0 1 141.4084 278.4458 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.102 l
-1.539 -0.047 l
-1.498 -1.498 l
-1.705 -1.498 l
-1.665 -0.047 l
-2.659 -1.102 l
-2.808 -0.954 l
-1.752 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.752 0.16 l
-2.808 1.157 l
-2.659 1.302 l
-1.665 0.247 l
-1.705 1.699 l
-1.498 1.699 l
-1.539 0.247 l
-0.544 1.302 l
-0.396 1.157 l
-1.451 0.16 l
0 0.2 l
h
f
Q
q 1 0 0 1 140.5189 278.7658 cm
0 0 m
-1.452 0.04 l
-0.396 -0.954 l
-0.545 -1.102 l
-1.539 -0.047 l
-1.499 -1.498 l
-1.706 -1.498 l
-1.665 -0.047 l
-2.66 -1.102 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.302 l
-0.396 1.156 l
-1.452 0.16 l
0 0.2 l
h
f
Q
q 1 0 0 1 140.5189 280.1523 cm
0 0 m
-1.452 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.047 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.157 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.303 l
-0.396 1.157 l
-1.452 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 129.2719 282.8003 cm
0 0 m
-1.451 0.041 l
-0.396 -0.954 l
-0.545 -1.102 l
-1.539 -0.047 l
-1.499 -1.498 l
-1.705 -1.498 l
-1.665 -0.047 l
-2.659 -1.102 l
-2.808 -0.954 l
-1.753 0.041 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.659 1.303 l
-1.665 0.248 l
-1.705 1.699 l
-1.499 1.699 l
-1.539 0.248 l
-0.545 1.303 l
-0.396 1.156 l
-1.451 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 128.2884 283.7843 cm
0 0 m
-1.452 0.041 l
-0.396 -0.954 l
-0.545 -1.102 l
-1.539 -0.047 l
-1.499 -1.498 l
-1.706 -1.498 l
-1.665 -0.047 l
-2.66 -1.102 l
-2.808 -0.954 l
-1.753 0.041 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.303 l
-0.396 1.156 l
-1.452 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 128.2884 285.0578 cm
0 0 m
-1.452 0.041 l
-0.396 -0.954 l
-0.545 -1.102 l
-1.539 -0.047 l
-1.499 -1.498 l
-1.706 -1.498 l
-1.665 -0.047 l
-2.66 -1.102 l
-2.808 -0.954 l
-1.753 0.041 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.303 l
-0.396 1.156 l
-1.452 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 126.8959 286.0258 cm
0 0 m
-1.452 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.048 l
-1.499 -1.499 l
-1.705 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.705 1.698 l
-1.499 1.698 l
-1.539 0.247 l
-0.545 1.302 l
-0.396 1.156 l
-1.452 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 125.4959 286.6233 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.047 l
-1.498 -1.499 l
-1.705 -1.499 l
-1.665 -0.047 l
-2.659 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.659 1.303 l
-1.665 0.247 l
-1.705 1.698 l
-1.498 1.698 l
-1.539 0.247 l
-0.544 1.303 l
-0.396 1.156 l
-1.451 0.16 l
0 0.2 l
h
f
Q
q 1 0 0 1 116.2479 289.1448 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.047 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.248 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.248 l
-0.545 1.303 l
-0.396 1.156 l
-1.451 0.16 l
0 0.2 l
h
f
Q
q 1 0 0 1 115.7384 290.6163 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.047 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.157 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.303 l
-0.396 1.157 l
-1.451 0.16 l
0 0.2 l
h
f
Q
q 1 0 0 1 115.4554 291.2673 cm
0 0 m
-1.451 0.04 l
-0.396 -0.955 l
-0.545 -1.103 l
-1.539 -0.048 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.955 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.206 l
-1.753 0.159 l
-2.808 1.156 l
-2.66 1.302 l
-1.665 0.247 l
-1.706 1.698 l
-1.499 1.698 l
-1.539 0.247 l
-0.545 1.302 l
-0.396 1.156 l
-1.451 0.159 l
0 0.2 l
h
f
Q
q 1 0 0 1 110.2159 293.3863 cm
0 0 m
-1.451 0.041 l
-0.396 -0.954 l
-0.544 -1.102 l
-1.539 -0.047 l
-1.499 -1.498 l
-1.705 -1.498 l
-1.665 -0.047 l
-2.659 -1.102 l
-2.808 -0.954 l
-1.753 0.041 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.157 l
-2.659 1.303 l
-1.665 0.248 l
-1.705 1.699 l
-1.499 1.699 l
-1.539 0.248 l
-0.544 1.303 l
-0.396 1.157 l
-1.451 0.16 l
0 0.2 l
h
f
Q
q 1 0 0 1 105.5519 295.7943 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.047 l
-1.498 -1.499 l
-1.705 -1.499 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.705 1.699 l
-1.498 1.699 l
-1.539 0.247 l
-0.544 1.303 l
-0.396 1.156 l
-1.451 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 104.4484 299.8408 cm
0 0 m
-1.452 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.047 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.303 l
-0.396 1.156 l
-1.452 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 103.9389 300.5483 cm
0 0 m
-1.452 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.047 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.303 l
-0.396 1.156 l
-1.452 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 103.7974 304.7078 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.047 l
-1.498 -1.499 l
-1.705 -1.499 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.705 1.699 l
-1.498 1.699 l
-1.539 0.247 l
-0.544 1.303 l
-0.396 1.156 l
-1.451 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 103.1749 309.1788 cm
0 0 m
-1.452 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.047 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.157 l
-2.66 1.303 l
-1.665 0.248 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.248 l
-0.545 1.303 l
-0.396 1.157 l
-1.452 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 102.2409 310.0558 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.047 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.303 l
-0.396 1.156 l
-1.451 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 93.7804 316.6208 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.047 l
-1.498 -1.499 l
-1.706 -1.499 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.498 1.699 l
-1.539 0.247 l
-0.544 1.303 l
-0.396 1.156 l
-1.451 0.16 l
0 0.2 l
h
f
Q
q 1 0 0 1 92.9879 318.2053 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.047 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.544 1.303 l
-0.396 1.156 l
-1.451 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 92.0594 325.1413 cm
0 0 m
-1.452 0.041 l
-0.396 -0.954 l
-0.544 -1.102 l
-1.539 -0.047 l
-1.499 -1.498 l
-1.706 -1.498 l
-1.665 -0.047 l
-2.66 -1.102 l
-2.808 -0.954 l
-1.753 0.041 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.157 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.544 1.303 l
-0.396 1.157 l
-1.452 0.16 l
0 0.2 l
h
f
Q
q 1 0 0 1 91.8564 330.4013 cm
0 0 m
-1.451 0.041 l
-0.396 -0.954 l
-0.544 -1.102 l
-1.539 -0.047 l
-1.499 -1.498 l
-1.706 -1.498 l
-1.665 -0.047 l
-2.66 -1.102 l
-2.808 -0.954 l
-1.753 0.041 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.698 l
-1.499 1.698 l
-1.539 0.247 l
-0.544 1.303 l
-0.396 1.156 l
-1.451 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 91.7994 345.9363 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.048 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.048 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.157 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.303 l
-0.396 1.157 l
-1.451 0.16 l
0 0.2 l
h
f
Q
q 1 0 0 1 91.3184 355.1608 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.047 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.303 l
-0.396 1.156 l
-1.451 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 91.3754 359.1223 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.047 l
-1.499 -1.499 l
-1.705 -1.499 l
-1.665 -0.047 l
-2.659 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.157 l
-2.659 1.303 l
-1.665 0.247 l
-1.705 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.544 1.303 l
-0.396 1.157 l
-1.451 0.16 l
0 0.201 l
h
f
Q
q 1 0 0 1 91.1204 360.5939 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.047 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.544 1.303 l
-0.396 1.156 l
-1.451 0.16 l
0 0.2 l
h
f
Q
q 1 0 0 1 79.2925 396.474 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.544 -1.103 l
-1.539 -0.047 l
-1.498 -1.499 l
-1.705 -1.499 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.705 1.699 l
-1.498 1.699 l
-1.539 0.247 l
-0.544 1.303 l
-0.396 1.156 l
-1.451 0.16 l
0 0.2 l
h
f
Q
q 1 0 0 1 73.6898 404.7932 cm
0 0 m
-1.451 0.04 l
-0.396 -0.954 l
-0.545 -1.103 l
-1.539 -0.047 l
-1.499 -1.499 l
-1.706 -1.499 l
-1.665 -0.047 l
-2.66 -1.103 l
-2.808 -0.954 l
-1.753 0.04 l
-3.204 0 l
-3.204 0.207 l
-1.753 0.16 l
-2.808 1.156 l
-2.66 1.303 l
-1.665 0.247 l
-1.706 1.699 l
-1.499 1.699 l
-1.539 0.247 l
-0.545 1.303 l
-0.396 1.156 l
-1.451 0.16 l
0 0.2 l
h
f
Q
Q
q
37.732 130.399 248.536 279.036 re
W n
0.375 w 0 j 0 J []0 d 
q 1 0 0 1 70.5607 404.8734 cm
0 0 m
2.89 0 l
2.89 -0.55 l
3.33 -0.55 l
3.33 -1.266 l
4.486 -1.266 l
4.486 -1.899 l
5.45 -1.899 l
5.45 -3.11 l
5.835 -3.11 l
5.835 -4.321 l
6.33 -4.321 l
6.33 -4.761 l
6.716 -4.761 l
6.716 -5.257 l
7.376 -5.257 l
7.376 -6.661 l
8.917 -6.661 l
8.917 -7.239 l
9.33 -7.239 l
9.33 -7.982 l
9.523 -7.982 l
9.523 -10.239 l
10.624 -10.239 l
10.624 -11.56 l
10.872 -11.56 l
10.872 -12.853 l
11.67 -12.853 l
11.67 -13.294 l
11.917 -13.294 l
11.917 -14.174 l
12.633 -14.174 l
12.633 -15.11 l
13.211 -15.11 l
13.211 -15.881 l
13.624 -15.881 l
13.624 -18.633 l
14.202 -18.633 l
14.202 -19.596 l
14.697 -19.596 l
14.697 -20.202 l
14.697 -20.615 l
15.027 -20.615 l
15.027 -21.22 l
15.22 -21.22 l
15.22 -22.349 l
15.523 -22.349 l
15.523 -22.872 l
15.771 -22.872 l
15.771 -23.202 l
16.404 -23.202 l
16.404 -25.183 l
16.816 -25.183 l
16.816 -26.257 l
17.092 -26.257 l
17.092 -27.275 l
17.725 -27.275 l
17.725 -27.881 l
18.303 -27.881 l
18.303 -29.89 l
18.468 -29.89 l
18.468 -33.771 l
18.798 -33.771 l
18.798 -37.238 l
19.073 -37.238 l
19.073 -46.899 l
19.431 -46.899 l
19.431 -50.725 l
19.706 -50.725 l
19.706 -63.936 l
20.229 -63.936 l
20.229 -65.835 l
20.532 -65.835 l
20.532 -66.661 l
20.973 -66.661 l
20.973 -69.165 l
21.468 -69.165 l
21.468 -69.908 l
21.963 -69.908 l
21.963 -70.651 l
22.459 -70.651 l
22.459 -71.202 l
23.147 -71.202 l
23.147 -71.972 l
25.706 -71.972 l
25.706 -72.716 l
27.908 -72.716 l
27.908 -73.404 l
29.422 -73.404 l
29.422 -73.899 l
31.211 -73.899 l
31.211 -75.358 l
31.569 -75.358 l
31.569 -77.037 l
31.872 -77.037 l
31.872 -79.321 l
32.312 -79.321 l
32.312 -80.725 l
33.248 -80.725 l
33.248 -82.294 l
33.826 -82.294 l
33.826 -83.009 l
35.394 -83.009 l
35.394 -83.835 l
36.028 -83.835 l
36.028 -84.33 l
36.523 -84.33 l
36.523 -85.018 l
37.624 -85.018 l
37.624 -85.734 l
39.936 -85.734 l
39.936 -86.477 l
41.394 -86.477 l
41.394 -87.413 l
41.642 -87.413 l
41.642 -87.881 l
42.908 -87.881 l
42.908 -89.339 l
43.541 -89.339 l
43.541 -92.009 l
44.009 -92.009 l
44.009 -93.881 l
44.477 -93.881 l
44.477 -94.486 l
45.468 -94.486 l
45.468 -95.092 l
46.211 -95.092 l
46.211 -95.725 l
56.257 -95.725 l
56.257 -96.661 l
56.78 -96.661 l
56.78 -97.294 l
67.018 -97.294 l
67.018 -98.119 l
67.651 -98.119 l
67.651 -98.835 l
67.954 -98.835 l
67.954 -102.083 l
68.697 -102.083 l
68.697 -102.991 l
69.275 -102.991 l
69.275 -103.982 l
70.046 -103.982 l
70.046 -104.642 l
79.706 -104.642 l
79.706 -105.275 l
81.275 -105.275 l
81.275 -105.633 l
84.688 -105.633 l
84.688 -106.706 l
91.789 -106.706 l
91.789 -107.917 l
92.312 -107.917 l
92.312 -109.018 l
94.101 -109.018 l
94.101 -109.982 l
98.807 -109.982 l
98.807 -112.321 l
105.523 -112.321 l
105.523 -113.312 l
113.229 -113.312 l
113.229 -114.358 l
118.624 -114.358 l
118.624 -115.321 l
119.477 -115.321 l
119.477 -115.927 l
120.66 -115.927 l
120.66 -116.642 l
130.376 -116.642 l
130.376 -117.991 l
136.459 -117.991 l
136.459 -120.275 l
153.633 -120.275 l
153.633 -121.018 l
154.569 -121.018 l
154.569 -122.56 l
155.284 -122.56 l
155.284 -123.716 l
158.064 -123.716 l
158.064 -125.917 l
158.642 -125.917 l
158.642 -128.147 l
169.734 -128.147 l
169.734 -129.385 l
170.339 -129.385 l
170.339 -131.092 l
171.605 -131.092 l
171.605 -134.422 l
192 -134.422 l
188.394 -134.174 m
188.394 -134.949 187.766 -135.578 186.991 -135.578 c
186.215 -135.578 185.587 -134.949 185.587 -134.174 c
185.587 -133.399 186.215 -132.771 186.991 -132.771 c
187.766 -132.771 188.394 -133.399 188.394 -134.174 c
h
173.036 -130.789 m
173.036 -131.564 172.408 -132.193 171.633 -132.193 c
170.858 -132.193 170.229 -131.564 170.229 -130.789 c
170.229 -130.014 170.858 -129.385 171.633 -129.385 c
172.408 -129.385 173.036 -130.014 173.036 -130.789 c
h
171.633 -127.982 m
171.633 -128.757 171.004 -129.385 170.229 -129.385 c
169.454 -129.385 168.825 -128.757 168.825 -127.982 c
168.825 -127.206 169.454 -126.578 170.229 -126.578 c
171.004 -126.578 171.633 -127.206 171.633 -127.982 c
h
170.436 -127.982 m
170.436 -128.757 169.807 -129.385 169.032 -129.385 c
168.257 -129.385 167.628 -128.757 167.628 -127.982 c
167.628 -127.206 168.257 -126.578 169.032 -126.578 c
169.807 -126.578 170.436 -127.206 170.436 -127.982 c
h
165.812 -127.982 m
165.812 -128.757 165.183 -129.385 164.408 -129.385 c
163.633 -129.385 163.004 -128.757 163.004 -127.982 c
163.004 -127.206 163.633 -126.578 164.408 -126.578 c
165.183 -126.578 165.812 -127.206 165.812 -127.982 c
h
161.147 -127.982 m
161.147 -128.757 160.518 -129.385 159.743 -129.385 c
158.968 -129.385 158.339 -128.757 158.339 -127.982 c
158.339 -127.206 158.968 -126.578 159.743 -126.578 c
160.518 -126.578 161.147 -127.206 161.147 -127.982 c
h
159.619 -125.876 m
159.619 -126.651 158.991 -127.28 158.215 -127.28 c
157.44 -127.28 156.812 -126.651 156.812 -125.876 c
156.812 -125.101 157.44 -124.472 158.215 -124.472 c
158.991 -124.472 159.619 -125.101 159.619 -125.876 c
h
159.433 -123.42 m
159.433 -124.195 158.805 -124.823 158.03 -124.823 c
157.254 -124.823 156.626 -124.195 156.626 -123.42 c
156.626 -122.644 157.254 -122.016 158.03 -122.016 c
158.805 -122.016 159.433 -122.644 159.433 -123.42 c
h
155.759 -121.81 m
155.759 -122.585 155.13 -123.213 154.355 -123.213 c
153.58 -123.213 152.952 -122.585 152.952 -121.81 c
152.952 -121.034 153.58 -120.406 154.355 -120.406 c
155.13 -120.406 155.759 -121.034 155.759 -121.81 c
h
155.222 -121.81 m
155.222 -122.585 154.594 -123.213 153.819 -123.213 c
153.043 -123.213 152.415 -122.585 152.415 -121.81 c
152.415 -121.034 153.043 -120.406 153.819 -120.406 c
154.594 -120.406 155.222 -121.034 155.222 -121.81 c
h
155.222 -120.117 m
155.222 -120.892 154.594 -121.521 153.819 -121.521 c
153.043 -121.521 152.415 -120.892 152.415 -120.117 c
152.415 -119.342 153.043 -118.713 153.819 -118.713 c
154.594 -118.713 155.222 -119.342 155.222 -120.117 c
h
154.933 -120.117 m
154.933 -120.892 154.305 -121.521 153.53 -121.521 c
152.754 -121.521 152.126 -120.892 152.126 -120.117 c
152.126 -119.342 152.754 -118.713 153.53 -118.713 c
154.305 -118.713 154.933 -119.342 154.933 -120.117 c
h
154.644 -120.117 m
154.644 -120.892 154.016 -121.521 153.241 -121.521 c
152.465 -121.521 151.837 -120.892 151.837 -120.117 c
151.837 -119.342 152.465 -118.713 153.241 -118.713 c
154.016 -118.713 154.644 -119.342 154.644 -120.117 c
h
154.355 -120.117 m
154.355 -120.892 153.727 -121.521 152.952 -121.521 c
152.176 -121.521 151.548 -120.892 151.548 -120.117 c
151.548 -119.342 152.176 -118.713 152.952 -118.713 c
153.727 -118.713 154.355 -119.342 154.355 -120.117 c
h
154.066 -120.117 m
154.066 -120.892 153.438 -121.521 152.663 -121.521 c
151.887 -121.521 151.259 -120.892 151.259 -120.117 c
151.259 -119.342 151.887 -118.713 152.663 -118.713 c
153.438 -118.713 154.066 -119.342 154.066 -120.117 c
h
153.777 -120.117 m
153.777 -120.892 153.149 -121.521 152.374 -121.521 c
151.598 -121.521 150.97 -120.892 150.97 -120.117 c
150.97 -119.342 151.598 -118.713 152.374 -118.713 c
153.149 -118.713 153.777 -119.342 153.777 -120.117 c
h
150.433 -120.117 m
150.433 -120.892 149.805 -121.521 149.03 -121.521 c
148.254 -121.521 147.626 -120.892 147.626 -120.117 c
147.626 -119.342 148.254 -118.713 149.03 -118.713 c
149.805 -118.713 150.433 -119.342 150.433 -120.117 c
h
145.314 -120.117 m
145.314 -120.892 144.686 -121.521 143.91 -121.521 c
143.135 -121.521 142.507 -120.892 142.507 -120.117 c
142.507 -119.342 143.135 -118.713 143.91 -118.713 c
144.686 -118.713 145.314 -119.342 145.314 -120.117 c
h
137.82 -117.787 m
137.82 -118.562 137.191 -119.191 136.416 -119.191 c
135.641 -119.191 135.012 -118.562 135.012 -117.787 c
135.012 -117.012 135.641 -116.383 136.416 -116.383 c
137.191 -116.383 137.82 -117.012 137.82 -117.787 c
h
136.908 -117.787 m
136.908 -118.562 136.28 -119.191 135.504 -119.191 c
134.729 -119.191 134.101 -118.562 134.101 -117.787 c
134.101 -117.012 134.729 -116.383 135.504 -116.383 c
136.28 -116.383 136.908 -117.012 136.908 -117.787 c
h
136.521 -117.787 m
136.521 -118.562 135.893 -119.191 135.118 -119.191 c
134.343 -119.191 133.714 -118.562 133.714 -117.787 c
133.714 -117.012 134.343 -116.383 135.118 -116.383 c
135.893 -116.383 136.521 -117.012 136.521 -117.787 c
h
136.135 -117.787 m
136.135 -118.562 135.506 -119.191 134.731 -119.191 c
133.956 -119.191 133.327 -118.562 133.327 -117.787 c
133.327 -117.012 133.956 -116.383 134.731 -116.383 c
135.506 -116.383 136.135 -117.012 136.135 -117.787 c
h
135.748 -117.787 m
135.748 -118.562 135.12 -119.191 134.345 -119.191 c
133.569 -119.191 132.941 -118.562 132.941 -117.787 c
132.941 -117.012 133.569 -116.383 134.345 -116.383 c
135.12 -116.383 135.748 -117.012 135.748 -117.787 c
h
135.362 -117.787 m
135.362 -118.562 134.733 -119.191 133.958 -119.191 c
133.183 -119.191 132.554 -118.562 132.554 -117.787 c
132.554 -117.012 133.183 -116.383 133.958 -116.383 c
134.733 -116.383 135.362 -117.012 135.362 -117.787 c
h
121.442 -115.66 m
121.442 -116.436 120.813 -117.064 120.038 -117.064 c
119.263 -117.064 118.634 -116.436 118.634 -115.66 c
118.634 -114.885 119.263 -114.257 120.038 -114.257 c
120.813 -114.257 121.442 -114.885 121.442 -115.66 c
h
119.729 -115.66 m
119.729 -116.436 119.101 -117.064 118.326 -117.064 c
117.551 -117.064 116.922 -116.436 116.922 -115.66 c
116.922 -114.885 117.551 -114.257 118.326 -114.257 c
119.101 -114.257 119.729 -114.885 119.729 -115.66 c
h
100.673 -112.236 m
100.673 -113.011 100.044 -113.639 99.269 -113.639 c
98.494 -113.639 97.865 -113.011 97.865 -112.236 c
97.865 -111.461 98.494 -110.832 99.269 -110.832 c
100.044 -110.832 100.673 -111.461 100.673 -112.236 c
h
90.178 -106.519 m
90.178 -107.294 89.549 -107.922 88.774 -107.922 c
87.999 -107.922 87.37 -107.294 87.37 -106.519 c
87.37 -105.744 87.999 -105.115 88.774 -105.115 c
89.549 -105.115 90.178 -105.744 90.178 -106.519 c
h
84.185 -105.58 m
84.185 -106.355 83.556 -106.983 82.781 -106.983 c
82.006 -106.983 81.377 -106.355 81.377 -105.58 c
81.377 -104.805 82.006 -104.176 82.781 -104.176 c
83.556 -104.176 84.185 -104.805 84.185 -105.58 c
h
83.853 -105.58 m
83.853 -106.355 83.225 -106.983 82.449 -106.983 c
81.674 -106.983 81.046 -106.355 81.046 -105.58 c
81.046 -104.805 81.674 -104.176 82.449 -104.176 c
83.225 -104.176 83.853 -104.805 83.853 -105.58 c
h
83.522 -105.58 m
83.522 -106.355 82.893 -106.983 82.118 -106.983 c
81.343 -106.983 80.714 -106.355 80.714 -105.58 c
80.714 -104.805 81.343 -104.176 82.118 -104.176 c
82.893 -104.176 83.522 -104.805 83.522 -105.58 c
h
83.19 -105.58 m
83.19 -106.355 82.562 -106.983 81.787 -106.983 c
81.011 -106.983 80.383 -106.355 80.383 -105.58 c
80.383 -104.805 81.011 -104.176 81.787 -104.176 c
82.562 -104.176 83.19 -104.805 83.19 -105.58 c
h
82.058 -105.58 m
82.058 -106.355 81.429 -106.983 80.654 -106.983 c
79.879 -106.983 79.251 -106.355 79.251 -105.58 c
79.251 -104.805 79.879 -104.176 80.654 -104.176 c
81.429 -104.176 82.058 -104.805 82.058 -105.58 c
h
81.616 -105.58 m
81.616 -106.355 80.988 -106.983 80.212 -106.983 c
79.437 -106.983 78.809 -106.355 78.809 -105.58 c
78.809 -104.805 79.437 -104.176 80.212 -104.176 c
80.988 -104.176 81.616 -104.805 81.616 -105.58 c
h
81.174 -105.58 m
81.174 -106.355 80.546 -106.983 79.77 -106.983 c
78.995 -106.983 78.367 -106.355 78.367 -105.58 c
78.367 -104.805 78.995 -104.176 79.77 -104.176 c
80.546 -104.176 81.174 -104.805 81.174 -105.58 c
h
80.732 -105.58 m
80.732 -106.355 80.104 -106.983 79.329 -106.983 c
78.553 -106.983 77.925 -106.355 77.925 -105.58 c
77.925 -104.805 78.553 -104.176 79.329 -104.176 c
80.104 -104.176 80.732 -104.805 80.732 -105.58 c
h
80.484 -104.475 m
80.484 -105.25 79.855 -105.879 79.08 -105.879 c
78.305 -105.879 77.676 -105.25 77.676 -104.475 c
77.676 -103.7 78.305 -103.071 79.08 -103.071 c
79.855 -103.071 80.484 -103.7 80.484 -104.475 c
h
73.938 -104.475 m
73.938 -105.25 73.31 -105.879 72.534 -105.879 c
71.759 -105.879 71.131 -105.25 71.131 -104.475 c
71.131 -103.7 71.759 -103.071 72.534 -103.071 c
73.31 -103.071 73.938 -103.7 73.938 -104.475 c
h
71.287 -104.033 m
71.287 -104.808 70.658 -105.437 69.883 -105.437 c
69.108 -105.437 68.479 -104.808 68.479 -104.033 c
68.479 -103.258 69.108 -102.629 69.883 -102.629 c
70.658 -102.629 71.287 -103.258 71.287 -104.033 c
h
70.955 -103.785 m
70.955 -104.56 70.327 -105.188 69.552 -105.188 c
68.776 -105.188 68.148 -104.56 68.148 -103.785 c
68.148 -103.009 68.776 -102.381 69.552 -102.381 c
70.327 -102.381 70.955 -103.009 70.955 -103.785 c
h
70.624 -103.536 m
70.624 -104.311 69.995 -104.94 69.22 -104.94 c
68.445 -104.94 67.817 -104.311 67.817 -103.536 c
67.817 -102.761 68.445 -102.132 69.22 -102.132 c
69.995 -102.132 70.624 -102.761 70.624 -103.536 c
h
70.292 -103.287 m
70.292 -104.063 69.664 -104.691 68.889 -104.691 c
68.114 -104.691 67.485 -104.063 67.485 -103.287 c
67.485 -102.512 68.114 -101.884 68.889 -101.884 c
69.664 -101.884 70.292 -102.512 70.292 -103.287 c
h
69.961 -103.039 m
69.961 -103.814 69.333 -104.443 68.557 -104.443 c
67.782 -104.443 67.154 -103.814 67.154 -103.039 c
67.154 -102.264 67.782 -101.635 68.557 -101.635 c
69.333 -101.635 69.961 -102.264 69.961 -103.039 c
h
69.961 -102.597 m
69.961 -103.372 69.333 -104.001 68.557 -104.001 c
67.782 -104.001 67.154 -103.372 67.154 -102.597 c
67.154 -101.822 67.782 -101.193 68.557 -101.193 c
69.333 -101.193 69.961 -101.822 69.961 -102.597 c
h
69.616 -102.252 m
69.616 -103.027 68.987 -103.655 68.212 -103.655 c
67.437 -103.655 66.808 -103.027 66.808 -102.252 c
66.808 -101.477 67.437 -100.848 68.212 -100.848 c
68.987 -100.848 69.616 -101.477 69.616 -102.252 c
h
69.63 -101.824 m
69.63 -102.599 69.001 -103.227 68.226 -103.227 c
67.451 -103.227 66.822 -102.599 66.822 -101.824 c
66.822 -101.048 67.451 -100.42 68.226 -100.42 c
69.001 -100.42 69.63 -101.048 69.63 -101.824 c
h
69.63 -101.409 m
69.63 -102.185 69.001 -102.813 68.226 -102.813 c
67.451 -102.813 66.822 -102.185 66.822 -101.409 c
66.822 -100.634 67.451 -100.006 68.226 -100.006 c
69.001 -100.006 69.63 -100.634 69.63 -101.409 c
h
68.829 -97.902 m
68.829 -98.677 68.2 -99.305 67.425 -99.305 c
66.65 -99.305 66.021 -98.677 66.021 -97.902 c
66.021 -97.127 66.65 -96.498 67.425 -96.498 c
68.2 -96.498 68.829 -97.127 68.829 -97.902 c
h
68.055 -97.129 m
68.055 -97.904 67.427 -98.532 66.652 -98.532 c
65.877 -98.532 65.248 -97.904 65.248 -97.129 c
65.248 -96.353 65.877 -95.725 66.652 -95.725 c
67.427 -95.725 68.055 -96.353 68.055 -97.129 c
h
58.997 -97.239 m
58.997 -98.014 58.368 -98.643 57.593 -98.643 c
56.818 -98.643 56.189 -98.014 56.189 -97.239 c
56.189 -96.464 56.818 -95.835 57.593 -95.835 c
58.368 -95.835 58.997 -96.464 58.997 -97.239 c
h
58.665 -97.239 m
58.665 -98.014 58.037 -98.643 57.261 -98.643 c
56.486 -98.643 55.858 -98.014 55.858 -97.239 c
55.858 -96.464 56.486 -95.835 57.261 -95.835 c
58.037 -95.835 58.665 -96.464 58.665 -97.239 c
h
58.334 -97.239 m
58.334 -98.014 57.705 -98.643 56.93 -98.643 c
56.155 -98.643 55.526 -98.014 55.526 -97.239 c
55.526 -96.464 56.155 -95.835 56.93 -95.835 c
57.705 -95.835 58.334 -96.464 58.334 -97.239 c
h
58.002 -97.239 m
58.002 -98.014 57.374 -98.643 56.599 -98.643 c
55.823 -98.643 55.195 -98.014 55.195 -97.239 c
55.195 -96.464 55.823 -95.835 56.599 -95.835 c
57.374 -95.835 58.002 -96.464 58.002 -97.239 c
h
57.671 -97.239 m
57.671 -98.014 57.042 -98.643 56.267 -98.643 c
55.492 -98.643 54.864 -98.014 54.864 -97.239 c
54.864 -96.464 55.492 -95.835 56.267 -95.835 c
57.042 -95.835 57.671 -96.464 57.671 -97.239 c
h
57.339 -97.239 m
57.339 -98.014 56.711 -98.643 55.936 -98.643 c
55.161 -98.643 54.532 -98.014 54.532 -97.239 c
54.532 -96.464 55.161 -95.835 55.936 -95.835 c
56.711 -95.835 57.339 -96.464 57.339 -97.239 c
h
56.98 -95.499 m
56.98 -96.274 56.352 -96.903 55.577 -96.903 c
54.802 -96.903 54.173 -96.274 54.173 -95.499 c
54.173 -94.724 54.802 -94.095 55.577 -94.095 c
56.352 -94.095 56.98 -94.724 56.98 -95.499 c
h
56.511 -95.499 m
56.511 -96.274 55.882 -96.903 55.107 -96.903 c
54.332 -96.903 53.704 -96.274 53.704 -95.499 c
53.704 -94.724 54.332 -94.095 55.107 -94.095 c
55.882 -94.095 56.511 -94.724 56.511 -95.499 c
h
56.262 -95.499 m
56.262 -96.274 55.634 -96.903 54.859 -96.903 c
54.083 -96.903 53.455 -96.274 53.455 -95.499 c
53.455 -94.724 54.083 -94.095 54.859 -94.095 c
55.634 -94.095 56.262 -94.724 56.262 -95.499 c
h
51.926 -95.499 m
51.926 -96.274 51.298 -96.903 50.523 -96.903 c
49.747 -96.903 49.119 -96.274 49.119 -95.499 c
49.119 -94.724 49.747 -94.095 50.523 -94.095 c
51.298 -94.095 51.926 -94.724 51.926 -95.499 c
h
45.905 -94.45 m
45.905 -95.225 45.277 -95.853 44.502 -95.853 c
43.727 -95.853 43.098 -95.225 43.098 -94.45 c
43.098 -93.674 43.727 -93.046 44.502 -93.046 c
45.277 -93.046 45.905 -93.674 45.905 -94.45 c
h
45.546 -93.151 m
45.546 -93.927 44.918 -94.555 44.143 -94.555 c
43.367 -94.555 42.739 -93.927 42.739 -93.151 c
42.739 -92.376 43.367 -91.748 44.143 -91.748 c
44.918 -91.748 45.546 -92.376 45.546 -93.151 c
h
45.546 -92.792 m
45.546 -93.568 44.918 -94.196 44.143 -94.196 c
43.367 -94.196 42.739 -93.568 42.739 -92.792 c
42.739 -92.017 43.367 -91.389 44.143 -91.389 c
44.918 -91.389 45.546 -92.017 45.546 -92.792 c
h
45.546 -92.433 m
45.546 -93.209 44.918 -93.837 44.143 -93.837 c
43.367 -93.837 42.739 -93.209 42.739 -92.433 c
42.739 -91.658 43.367 -91.03 44.143 -91.03 c
44.918 -91.03 45.546 -91.658 45.546 -92.433 c
h
45.187 -92.019 m
45.187 -92.794 44.559 -93.423 43.784 -93.423 c
43.008 -93.423 42.38 -92.794 42.38 -92.019 c
42.38 -91.244 43.008 -90.615 43.784 -90.615 c
44.559 -90.615 45.187 -91.244 45.187 -92.019 c
h
44.607 -89.285 m
44.607 -90.06 43.979 -90.689 43.204 -90.689 c
42.428 -90.689 41.8 -90.06 41.8 -89.285 c
41.8 -88.51 42.428 -87.881 43.204 -87.881 c
43.979 -87.881 44.607 -88.51 44.607 -89.285 c
h
38.02 -84.907 m
38.02 -85.683 37.392 -86.311 36.617 -86.311 c
35.841 -86.311 35.213 -85.683 35.213 -84.907 c
35.213 -84.132 35.841 -83.504 36.617 -83.504 c
37.392 -83.504 38.02 -84.132 38.02 -84.907 c
h
33.878 -80.212 m
33.878 -80.987 33.249 -81.616 32.474 -81.616 c
31.699 -81.616 31.07 -80.987 31.07 -80.212 c
31.07 -79.437 31.699 -78.809 32.474 -78.809 c
33.249 -78.809 33.878 -79.437 33.878 -80.212 c
h
33.629 -79.964 m
33.629 -80.739 33.001 -81.367 32.225 -81.367 c
31.45 -81.367 30.822 -80.739 30.822 -79.964 c
30.822 -79.188 31.45 -78.56 32.225 -78.56 c
33.001 -78.56 33.629 -79.188 33.629 -79.964 c
h
33.38 -79.715 m
33.38 -80.49 32.752 -81.119 31.977 -81.119 c
31.202 -81.119 30.573 -80.49 30.573 -79.715 c
30.573 -78.94 31.202 -78.311 31.977 -78.311 c
32.752 -78.311 33.38 -78.94 33.38 -79.715 c
h
33.325 -79.246 m
33.325 -80.021 32.697 -80.649 31.922 -80.649 c
31.146 -80.649 30.518 -80.021 30.518 -79.246 c
30.518 -78.47 31.146 -77.842 31.922 -77.842 c
32.697 -77.842 33.325 -78.47 33.325 -79.246 c
h
33.325 -76.346 m
33.325 -77.121 32.697 -77.749 31.922 -77.749 c
31.146 -77.749 30.518 -77.121 30.518 -76.346 c
30.518 -75.57 31.146 -74.942 31.922 -74.942 c
32.697 -74.942 33.325 -75.57 33.325 -76.346 c
h
32.704 -75.724 m
32.704 -76.499 32.075 -77.128 31.3 -77.128 c
30.525 -77.128 29.896 -76.499 29.896 -75.724 c
29.896 -74.949 30.525 -74.321 31.3 -74.321 c
32.075 -74.321 32.704 -74.949 32.704 -75.724 c
h
32.704 -75.089 m
32.704 -75.864 32.075 -76.493 31.3 -76.493 c
30.525 -76.493 29.896 -75.864 29.896 -75.089 c
29.896 -74.314 30.525 -73.685 31.3 -73.685 c
32.075 -73.685 32.704 -74.314 32.704 -75.089 c
h
26.987 -71.885 m
26.987 -72.66 26.358 -73.289 25.583 -73.289 c
24.808 -73.289 24.179 -72.66 24.179 -71.885 c
24.179 -71.11 24.808 -70.482 25.583 -70.482 c
26.358 -70.482 26.987 -71.11 26.987 -71.885 c
h
23.673 -70.615 m
23.673 -71.39 23.044 -72.018 22.269 -72.018 c
21.494 -72.018 20.865 -71.39 20.865 -70.615 c
20.865 -69.84 21.494 -69.211 22.269 -69.211 c
23.044 -69.211 23.673 -69.84 23.673 -70.615 c
h
22.278 -66.624 m
22.278 -67.399 21.649 -68.028 20.874 -68.028 c
20.099 -68.028 19.471 -67.399 19.471 -66.624 c
19.471 -65.849 20.099 -65.22 20.874 -65.22 c
21.649 -65.22 22.278 -65.849 22.278 -66.624 c
h
21.366 -63.973 m
21.366 -64.748 20.738 -65.376 19.963 -65.376 c
19.188 -65.376 18.559 -64.748 18.559 -63.973 c
18.559 -63.197 19.188 -62.569 19.963 -62.569 c
20.738 -62.569 21.366 -63.197 21.366 -63.973 c
h
21.007 -57.344 m
21.007 -58.119 20.379 -58.748 19.604 -58.748 c
18.829 -58.748 18.2 -58.119 18.2 -57.344 c
18.2 -56.569 18.829 -55.94 19.604 -55.94 c
20.379 -55.94 21.007 -56.569 21.007 -57.344 c
h
158.36 -123.42 m
158.36 -124.195 157.731 -124.823 156.956 -124.823 c
156.181 -124.823 155.553 -124.195 155.553 -123.42 c
155.553 -122.644 156.181 -122.016 156.956 -122.016 c
157.731 -122.016 158.36 -122.644 158.36 -123.42 c
h
157.658 -123.42 m
157.658 -124.195 157.03 -124.823 156.254 -124.823 c
155.479 -124.823 154.851 -124.195 154.851 -123.42 c
154.851 -122.644 155.479 -122.016 156.254 -122.016 c
157.03 -122.016 157.658 -122.644 157.658 -123.42 c
h
157.369 -123.42 m
157.369 -124.195 156.741 -124.823 155.965 -124.823 c
155.19 -124.823 154.562 -124.195 154.562 -123.42 c
154.562 -122.644 155.19 -122.016 155.965 -122.016 c
156.741 -122.016 157.369 -122.644 157.369 -123.42 c
h
157.08 -123.42 m
157.08 -124.195 156.452 -124.823 155.676 -124.823 c
154.901 -124.823 154.273 -124.195 154.273 -123.42 c
154.273 -122.644 154.901 -122.016 155.676 -122.016 c
156.452 -122.016 157.08 -122.644 157.08 -123.42 c
h
156.791 -123.42 m
156.791 -124.195 156.163 -124.823 155.387 -124.823 c
154.612 -124.823 153.984 -124.195 153.984 -123.42 c
153.984 -122.644 154.612 -122.016 155.387 -122.016 c
156.163 -122.016 156.791 -122.644 156.791 -123.42 c
h
156.502 -123.42 m
156.502 -124.195 155.874 -124.823 155.098 -124.823 c
154.323 -124.823 153.695 -124.195 153.695 -123.42 c
153.695 -122.644 154.323 -122.016 155.098 -122.016 c
155.874 -122.016 156.502 -122.644 156.502 -123.42 c
h
156.213 -123.42 m
156.213 -124.195 155.585 -124.823 154.809 -124.823 c
154.034 -124.823 153.406 -124.195 153.406 -123.42 c
153.406 -122.644 154.034 -122.016 154.809 -122.016 c
155.585 -122.016 156.213 -122.644 156.213 -123.42 c
h
155.924 -123.42 m
155.924 -124.195 155.296 -124.823 154.52 -124.823 c
153.745 -124.823 153.117 -124.195 153.117 -123.42 c
153.117 -122.644 153.745 -122.016 154.52 -122.016 c
155.296 -122.016 155.924 -122.644 155.924 -123.42 c
h
172.582 -130.789 m
172.582 -131.564 171.954 -132.193 171.179 -132.193 c
170.403 -132.193 169.775 -131.564 169.775 -130.789 c
169.775 -130.014 170.403 -129.385 171.179 -129.385 c
171.954 -129.385 172.582 -130.014 172.582 -130.789 c
h
172.128 -130.789 m
172.128 -131.564 171.5 -132.193 170.724 -132.193 c
169.949 -132.193 169.321 -131.564 169.321 -130.789 c
169.321 -130.014 169.949 -129.385 170.724 -129.385 c
171.5 -129.385 172.128 -130.014 172.128 -130.789 c
h
171.674 -130.789 m
171.674 -131.564 171.046 -132.193 170.27 -132.193 c
169.495 -132.193 168.867 -131.564 168.867 -130.789 c
168.867 -130.014 169.495 -129.385 170.27 -129.385 c
171.046 -129.385 171.674 -130.014 171.674 -130.789 c
h
180.633 -134.174 m
180.633 -134.949 180.004 -135.578 179.229 -135.578 c
178.454 -135.578 177.825 -134.949 177.825 -134.174 c
177.825 -133.399 178.454 -132.771 179.229 -132.771 c
180.004 -132.771 180.633 -133.399 180.633 -134.174 c
h
178.238 -134.174 m
178.238 -134.949 177.61 -135.578 176.835 -135.578 c
176.059 -135.578 175.431 -134.949 175.431 -134.174 c
175.431 -133.399 176.059 -132.771 176.835 -132.771 c
177.61 -132.771 178.238 -133.399 178.238 -134.174 c
h
177.949 -134.174 m
177.949 -134.949 177.321 -135.578 176.546 -135.578 c
175.77 -135.578 175.142 -134.949 175.142 -134.174 c
175.142 -133.399 175.77 -132.771 176.546 -132.771 c
177.321 -132.771 177.949 -133.399 177.949 -134.174 c
h
177.66 -134.174 m
177.66 -134.949 177.032 -135.578 176.257 -135.578 c
175.481 -135.578 174.853 -134.949 174.853 -134.174 c
174.853 -133.399 175.481 -132.771 176.257 -132.771 c
177.032 -132.771 177.66 -133.399 177.66 -134.174 c
h
177.371 -134.174 m
177.371 -134.949 176.743 -135.578 175.968 -135.578 c
175.192 -135.578 174.564 -134.949 174.564 -134.174 c
174.564 -133.399 175.192 -132.771 175.968 -132.771 c
176.743 -132.771 177.371 -133.399 177.371 -134.174 c
h
177.082 -134.174 m
177.082 -134.949 176.454 -135.578 175.679 -135.578 c
174.903 -135.578 174.275 -134.949 174.275 -134.174 c
174.275 -133.399 174.903 -132.771 175.679 -132.771 c
176.454 -132.771 177.082 -133.399 177.082 -134.174 c
h
176.793 -134.174 m
176.793 -134.949 176.165 -135.578 175.39 -135.578 c
174.614 -135.578 173.986 -134.949 173.986 -134.174 c
173.986 -133.399 174.614 -132.771 175.39 -132.771 c
176.165 -132.771 176.793 -133.399 176.793 -134.174 c
h
176.504 -134.174 m
176.504 -134.949 175.876 -135.578 175.101 -135.578 c
174.325 -135.578 173.697 -134.949 173.697 -134.174 c
173.697 -133.399 174.325 -132.771 175.101 -132.771 c
175.876 -132.771 176.504 -133.399 176.504 -134.174 c
h
176.215 -134.174 m
176.215 -134.949 175.587 -135.578 174.812 -135.578 c
174.036 -135.578 173.408 -134.949 173.408 -134.174 c
173.408 -133.399 174.036 -132.771 174.812 -132.771 c
175.587 -132.771 176.215 -133.399 176.215 -134.174 c
h
175.926 -134.174 m
175.926 -134.949 175.298 -135.578 174.523 -135.578 c
173.747 -135.578 173.119 -134.949 173.119 -134.174 c
173.119 -133.399 173.747 -132.771 174.523 -132.771 c
175.298 -132.771 175.926 -133.399 175.926 -134.174 c
h
175.637 -134.174 m
175.637 -134.949 175.009 -135.578 174.234 -135.578 c
173.458 -135.578 172.83 -134.949 172.83 -134.174 c
172.83 -133.399 173.458 -132.771 174.234 -132.771 c
175.009 -132.771 175.637 -133.399 175.637 -134.174 c
h
175.348 -134.174 m
175.348 -134.949 174.72 -135.578 173.945 -135.578 c
173.169 -135.578 172.541 -134.949 172.541 -134.174 c
172.541 -133.399 173.169 -132.771 173.945 -132.771 c
174.72 -132.771 175.348 -133.399 175.348 -134.174 c
h
175.059 -134.174 m
175.059 -134.949 174.431 -135.578 173.656 -135.578 c
172.88 -135.578 172.252 -134.949 172.252 -134.174 c
172.252 -133.399 172.88 -132.771 173.656 -132.771 c
174.431 -132.771 175.059 -133.399 175.059 -134.174 c
h
174.77 -134.174 m
174.77 -134.949 174.142 -135.578 173.367 -135.578 c
172.591 -135.578 171.963 -134.949 171.963 -134.174 c
171.963 -133.399 172.591 -132.771 173.367 -132.771 c
174.142 -132.771 174.77 -133.399 174.77 -134.174 c
h
174.481 -134.174 m
174.481 -134.949 173.853 -135.578 173.078 -135.578 c
172.302 -135.578 171.674 -134.949 171.674 -134.174 c
171.674 -133.399 172.302 -132.771 173.078 -132.771 c
173.853 -132.771 174.481 -133.399 174.481 -134.174 c
h
174.192 -134.174 m
174.192 -134.949 173.564 -135.578 172.789 -135.578 c
172.013 -135.578 171.385 -134.949 171.385 -134.174 c
171.385 -133.399 172.013 -132.771 172.789 -132.771 c
173.564 -132.771 174.192 -133.399 174.192 -134.174 c
h
173.903 -134.174 m
173.903 -134.949 173.275 -135.578 172.5 -135.578 c
171.724 -135.578 171.096 -134.949 171.096 -134.174 c
171.096 -133.399 171.724 -132.771 172.5 -132.771 c
173.275 -132.771 173.903 -133.399 173.903 -134.174 c
h
173.614 -134.174 m
173.614 -134.949 172.986 -135.578 172.211 -135.578 c
171.436 -135.578 170.807 -134.949 170.807 -134.174 c
170.807 -133.399 171.436 -132.771 172.211 -132.771 c
172.986 -132.771 173.614 -133.399 173.614 -134.174 c
h
173.325 -134.174 m
173.325 -134.949 172.697 -135.578 171.922 -135.578 c
171.147 -135.578 170.518 -134.949 170.518 -134.174 c
170.518 -133.399 171.147 -132.771 171.922 -132.771 c
172.697 -132.771 173.325 -133.399 173.325 -134.174 c
h
173.035 -134.107 m
173.072 -134.882 172.474 -135.539 171.7 -135.576 c
170.925 -135.613 170.268 -135.016 170.231 -134.241 c
170.194 -133.467 170.791 -132.809 171.566 -132.772 c
172.34 -132.735 172.998 -133.333 173.035 -134.107 c
h
193.101 -134.174 m
193.101 -134.949 192.472 -135.578 191.697 -135.578 c
190.922 -135.578 190.293 -134.949 190.293 -134.174 c
190.293 -133.399 190.922 -132.771 191.697 -132.771 c
192.472 -132.771 193.101 -133.399 193.101 -134.174 c
h
192.688 -134.174 m
192.688 -134.949 192.059 -135.578 191.284 -135.578 c
190.509 -135.578 189.88 -134.949 189.88 -134.174 c
189.88 -133.399 190.509 -132.771 191.284 -132.771 c
192.059 -132.771 192.688 -133.399 192.688 -134.174 c
h
192.275 -134.174 m
192.275 -134.949 191.646 -135.578 190.871 -135.578 c
190.096 -135.578 189.468 -134.949 189.468 -134.174 c
189.468 -133.399 190.096 -132.771 190.871 -132.771 c
191.646 -132.771 192.275 -133.399 192.275 -134.174 c
h
191.862 -134.174 m
191.862 -134.949 191.234 -135.578 190.458 -135.578 c
189.683 -135.578 189.055 -134.949 189.055 -134.174 c
189.055 -133.399 189.683 -132.771 190.458 -132.771 c
191.234 -132.771 191.862 -133.399 191.862 -134.174 c
h
191.449 -134.174 m
191.449 -134.949 190.821 -135.578 190.046 -135.578 c
189.27 -135.578 188.642 -134.949 188.642 -134.174 c
188.642 -133.399 189.27 -132.771 190.046 -132.771 c
190.821 -132.771 191.449 -133.399 191.449 -134.174 c
h
191.036 -134.174 m
191.036 -134.949 190.408 -135.578 189.633 -135.578 c
188.857 -135.578 188.229 -134.949 188.229 -134.174 c
188.229 -133.399 188.857 -132.771 189.633 -132.771 c
190.408 -132.771 191.036 -133.399 191.036 -134.174 c
h
20.825 -50.504 m
20.825 -51.28 20.197 -51.908 19.422 -51.908 c
18.646 -51.908 18.018 -51.28 18.018 -50.504 c
18.018 -49.729 18.646 -49.101 19.422 -49.101 c
20.197 -49.101 20.825 -49.729 20.825 -50.504 c
h
20.494 -44.649 m
20.494 -45.424 19.865 -46.053 19.09 -46.053 c
18.315 -46.053 17.687 -45.424 17.687 -44.649 c
17.687 -43.874 18.315 -43.246 19.09 -43.246 c
19.865 -43.246 20.494 -43.874 20.494 -44.649 c
h
20.632 -41.004 m
20.632 -41.779 20.004 -42.407 19.228 -42.407 c
18.453 -42.407 17.825 -41.779 17.825 -41.004 c
17.825 -40.228 18.453 -39.6 19.228 -39.6 c
20.004 -39.6 20.632 -40.228 20.632 -41.004 c
h
20.135 -34.651 m
20.135 -35.427 19.506 -36.055 18.731 -36.055 c
17.956 -36.055 17.328 -35.427 17.328 -34.651 c
17.328 -33.876 17.956 -33.248 18.731 -33.248 c
19.506 -33.248 20.135 -33.876 20.135 -34.651 c
h
19.886 -33.022 m
19.886 -33.797 19.258 -34.426 18.483 -34.426 c
17.707 -34.426 17.079 -33.797 17.079 -33.022 c
17.079 -32.247 17.707 -31.618 18.483 -31.618 c
19.258 -31.618 19.886 -32.247 19.886 -33.022 c
h
19.748 -29.211 m
19.748 -29.986 19.12 -30.614 18.345 -30.614 c
17.569 -30.614 16.941 -29.986 16.941 -29.211 c
16.941 -28.435 17.569 -27.807 18.345 -27.807 c
19.12 -27.807 19.748 -28.435 19.748 -29.211 c
h
19.444 -28.161 m
19.444 -28.936 18.816 -29.565 18.041 -29.565 c
17.266 -29.565 16.637 -28.936 16.637 -28.161 c
16.637 -27.386 17.266 -26.757 18.041 -26.757 c
18.816 -26.757 19.444 -27.386 19.444 -28.161 c
h
17.373 -23.079 m
17.373 -23.854 16.745 -24.483 15.969 -24.483 c
15.194 -24.483 14.566 -23.854 14.566 -23.079 c
14.566 -22.304 15.194 -21.676 15.969 -21.676 c
16.745 -21.676 17.373 -22.304 17.373 -23.079 c
h
15.799 -19.461 m
15.799 -20.236 15.17 -20.865 14.395 -20.865 c
13.62 -20.865 12.991 -20.236 12.991 -19.461 c
12.991 -18.686 13.62 -18.058 14.395 -18.058 c
15.17 -18.058 15.799 -18.686 15.799 -19.461 c
h
14.97 -18.191 m
14.97 -18.966 14.342 -19.594 13.567 -19.594 c
12.791 -19.594 12.163 -18.966 12.163 -18.191 c
12.163 -17.416 12.791 -16.787 13.567 -16.787 c
14.342 -16.787 14.97 -17.416 14.97 -18.191 c
h
2.929 0.093 m
2.929 -0.683 2.3 -1.311 1.525 -1.311 c
0.75 -1.311 0.121 -0.683 0.121 0.093 c
0.121 0.868 0.75 1.496 1.525 1.496 c
2.3 1.496 2.929 0.868 2.929 0.093 c
h
S
Q
0 0 0 0.5 K
0.5 w 
q 1 0 0 1 64.1995 409.1642 cm
0 0 m
0.375 0 l
S
Q
[0.749 0.749]0 d 
q 1 0 0 1 65.3239 409.1642 cm
0 0 m
219.945 0 l
S
Q
[]0 d 
q 1 0 0 1 285.6429 409.1642 cm
0 0 m
0.375 0 l
0.375 -0.375 l
S
Q
[0.748 0.748]0 d 
q 1 0 0 1 286.0179 408.0414 cm
0 0 m
0 -209.001 l
S
Q
[]0 d 
q 1 0 0 1 286.0179 198.6668 cm
0 0 m
0 -0.375 l
S
Q
0 0 0 1 K
q 1 0 0 1 78.2935 196.3798 cm
0 0 m
0 1.959 l
6.611 0 m
6.611 1.959 l
20.251 0 m
20.251 1.959 l
26.023 0 m
26.023 1.959 l
39.664 0 m
39.664 1.959 l
46.274 0 m
46.274 1.959 l
59.496 0 m
59.496 1.959 l
66.106 0 m
66.106 1.959 l
79.328 0 m
79.328 1.959 l
85.938 0 m
85.938 1.959 l
99.159 0 m
99.159 1.959 l
105.77 0 m
105.77 1.959 l
118.991 0 m
118.991 1.959 l
125.602 0 m
125.602 1.959 l
138.823 0 m
138.823 1.959 l
145.434 0 m
145.434 1.959 l
158.655 0 m
158.655 1.959 l
165.266 0 m
165.266 1.959 l
178.487 0 m
178.487 1.959 l
185.098 0 m
185.098 1.959 l
207.936 1.912 m
-14.094 1.912 l
-14.094 213.055 l
-14.096 6.704 m
-17.316 6.704 l
-14.141 26.86 m
-17.361 26.86 l
-14.141 47.068 m
-17.361 47.068 l
-14.136 67.265 m
-17.356 67.265 l
-14.132 87.375 m
-17.352 87.375 l
-14.119 107.62 m
-17.339 107.62 l
-14.11 127.8 m
-17.33 127.8 l
-14.115 147.992 m
-17.335 147.992 l
-14.119 168.183 m
-17.339 168.183 l
-14.106 188.361 m
-17.325 188.361 l
-14.19 208.534 m
-17.409 208.534 l
52.794 1.959 m
52.794 -2.463 l
33.056 1.959 m
33.056 -2.463 l
13.133 1.959 m
13.133 -2.463 l
-6.608 1.959 m
-6.608 -2.463 l
72.649 -2.463 m
72.649 1.959 l
92.553 -2.463 m
92.553 1.959 l
112.514 -2.463 m
112.514 1.959 l
132.217 -2.463 m
132.217 1.959 l
152.05 -2.463 m
152.05 1.959 l
171.883 -2.463 m
171.883 1.959 l
191.715 -2.463 m
191.715 1.959 l
S
Q
Q
BT
8 0 0 8 38.1152 157.0828 Tm
(OPDUALAG )Tj
0 Tw -0 1.245 Td
(Number of Subjects at Risk)Tj
0.01 Tw 0 -3.36 Td
(Nivolumab)Tj
0 Tw 10.833 4.386 Td
(Progression F)Tj
4.883 0 Td
(ree Sur)Tj
2.631 0 Td
(vival \(Months\))Tj
-0.02 Tc 0.02 Tw 7.2 0 0 8 66.2844 148.6368 Tm
(35)Tj
1.325 Tc -1.325 Tw 0.96 0 Td
(52)Tj
-0.02 Tc 0.02 Tw 2.285 0 Td
(01)Tj
-0.06 Tc 0.06 Tw 2.315 -0 Td
(16)Tj
0 Tc 0 Tw 0.92 0 Td
(3)Tj
-0.08 Tc 0.08 Tw 1.855 -0 Td
(13)Tj
1.595 Tc -1.595 Tw 0.88 0 Td
(29)Tj
1.815 Tc -1.815 Tw 2.555 0 Td
(98)Tj
2.735 -0 Td
(17)Tj
1.805 Tc -1.805 Tw 2.775 -0 Td
(56)Tj
1.803 Tc -1.803 Tw 2.745 -0 Td
(73)Tj
2.036 Tc -2.036 Tw 2.763 -0 Td
(06)Tj
ET
q
36 130.399 252 279.859 re
W n
BT
0 Tc 0 Tw 7.2 0 0 8 66.3564 131.7503 Tm
(35)Tj
1.405 Tc -1.405 Tw 0.94 0 Td
(91)Tj
-0.08 Tc 0.08 Tw 2.285 0 Td
(74)Tj
2.355 -0 Td
(12)Tj
0 Tc 0 Tw 0.86 0 Td
(4)Tj
0.02 Tc -0.02 Tw 2.075 -0 Td
(94)Tj
-0.04 Tc 0.04 Tw 2.735 0 Td
(72)Tj
2.815 -0 Td
(61)Tj
0 Tc 0 Tw 2.725 0 Td
(57)Tj
2.755 -0 Td
(49)Tj
2.753 0 Td
(27)Tj
2.996 -0 Td
(6)Tj
-0.005 Tc 0 8 -8 0 44.3721 247.1298 Tm
(Probability of Progression F)Tj
9.924 0 Td
(ree Sur)Tj
0.005 Tw 2.666 0 Td
(vival)Tj
ET
Q
BT
0 Tc 0 Tw 7.2 0 0 8 50.6252 200.5953 Tm
(0.0)Tj
-0.006 2.523 Td
(0.1)Tj
-0 2.523 Td
(0.2)Tj
0.001 2.523 Td
(0.3)Tj
0.001 2.523 Td
(0.4)Tj
0.002 2.523 Td
(0.5)Tj
0.001 2.523 Td
(0.6)Tj
-0.001 2.523 Td
(0.7)Tj
-0.001 2.523 Td
(0.8)Tj
0.003 2.523 Td
(0.9)Tj
-0.012 2.523 Td
(1.0)Tj
10.961 -27.142 Td
(9)Tj
-2.755 0 Td
(6)Tj
-2.754 0 Td
(3)Tj
10.348 Tc -10.348 Tw -2.754 -0 Td
(01)Tj
0 Tc 0 Tw 11.208 -0 Td
(2)Tj
-0.1 Tc 0.1 Tw 2.374 -0 Td
(15)Tj
2.754 -0 Td
(18)Tj
-0.04 Tc 0.04 Tw 2.724 0 Td
(21)Tj
2.754 0 Td
(24)Tj
2.754 -0 Td
(27)Tj
-0.02 Tc 0.02 Tw 2.744 0.007 Td
(30)Tj
/GS2 gs
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 8 0 0 8 36 103.2393 Tm
(16)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(HOW SUPPLIED/STORAGE AND HANDLING)Tj
/T1_1 1 Tf
-0.014 Tc 0.2 Tw -3.375 -1.674 Td
[(OPDUALAG \(nivolumab and rela)-10.4 (tlimab-rmbw\) injection is a sterile,)36.6 ( preser)-18.4 (va)-10.4 (tive-free,)23.1 ( )]TJ
-0.019 Tc 0.117 Tw 0 -1.044 Td
[(c)20.2 (lear )0.5 (to )0.5 (opalescent,)37.2 ( )0.5 (colorless )0.5 (to )0.5 (slightly )0.5 (yello)-9.8 (w )0.5 (solution )0.5 (for )0.6 (intra)-9.8 (venous )0.5 (use )0.5 (supplied )0.5 (in)-19 ( )]TJ
0.084 Tw 0 -1.044 Td
[(a single-dose vial containing 240 mg of nivolumab and 80 mg of rela)-9.8 (tlimab per 20 mL)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
(\(12 mg and 4 mg per mL\) per carton \(NDC 0003-7125-11\).)Tj
-0.022 Tc 0.024 Tw 0 -1.674 Td
[(S)0.5 (t)0.6 (o)0.5 (r)0.5 (e)0.6 ( )0.5 (O)0.6 (P)0.5 (D)0.5 (U)0.6 (A)0.5 (L)0.5 (A)0.5 (G)0.6 ( )0.5 (r)0.6 (e)0.5 (f)0.5 (r)0.6 (i)0.5 (g)0.5 (e)0.6 (r)0.5 (a)-9.4 (t)0.5 (e)0.5 (d)0.6 ( )0.5 (a)-9.4 (t)0.5 ( )0.5 (2)0.6 (\260)0.5 (C)0.5 ( )0.6 (t)0.5 (o)0.6 ( )0.5 (8)0.5 (\260)0.6 (C)0.5 ( )0.5 (\()0.6 (3)0.5 (6)0.5 (\260)0.6 (F)0.5 ( )0.5 (t)0.6 (o)0.5 ( )0.6 (4)0.5 (6)0.5 (\260)0.6 (F)0.5 (\))0.5 ( )0.6 (i)0.5 (n)0.5 ( )0.6 (t)0.5 (h)0.5 (e)0.6 ( )0.5 (o)0.6 (r)0.5 (i)0.5 (g)0.6 (i)0.5 (n)0.5 (a)0.6 (l)0.5 ( )0.5 (c)0.6 (a)0.5 (r)0.5 (t)0.6 (o)0.5 (n)0.6 ( )0.5 (t)0.5 (o)0.6 ( )0.5 (p)0.5 (r)0.6 (o)0.5 (t)0.6 (e)0.5 (c)0.5 (t)-22 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(from light until time of use.)37.2 ( Do not freeze or shake.)]TJ
ET
0 j 0 J []0 d 
q 1 0 0 1 324 698.5981 cm
0 0 m
127.519 0 l
S
Q
q 1 0 0 1 324 467.3942 cm
0 0 m
76.11 0 l
S
Q
q 1 0 0 1 324 434.9822 cm
0 0 m
96.196 0 l
S
Q
q 1 0 0 1 324 402.5702 cm
0 0 m
60.639 0 l
S
Q
q 1 0 0 1 324 333.5662 cm
0 0 m
26.074 0 l
S
Q
BT
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 8 0 0 8 324 727.2481 Tm
(17)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(P)54.2 (A)55.2 (TIENT COUNSELING INFORMA)55.2 (TION)]TJ
/T1_1 1 Tf
-0.019 Tc 0.06 Tw -3.375 -1.674 Td
[(Advise the pa)-9.8 (tient to read the FDA-a)-9.8 (pproved pa)-9.8 (tient labeling \(Medica)-9.8 (tion Guide\).)]TJ
-0.017 Tc 0.048 Tw 0 -1.782 Td
[(Immune-Media)-9.8 (ted )37.2 (Adverse Reactions \(IMAR\))]TJ
-0.013 Tc 0.208 Tw 0 -1.494 Td
[(Inform pa)-9.7 (tients of the risk of IMARs tha)-9.7 (t may require corticosteroid trea)-9.7 (tment and)-13 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(withholding or discontinua)-9.8 (tion of OPDUALAG,)37.2 ( inc)20.2 (luding:)]TJ
-0.017 Tc 0.017 Tw 1.125 -1.54 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.094 Tw 1.125 0 Td
[(Pneumonitis:)37.2 ( )36.6 (Advise pa)-9.8 (tients to contact their healthcare provider immedia)-9.8 (tely for)-17 ( )]TJ
-0.015 Tc 0.12 Tw 0 -1.062 Td
[(an)-9.9 (y new or worsening cough,)37 ( chest pain,)37.1 ( or shortness of brea)-9.9 (th )]TJ
/T1_3 1 Tf
0.083 Tw [([see W)18.1 (arnings)-15 ( )]TJ
-0.017 Tc 0.06 Tw 0 -1.062 Td
(and Precautions \(5.1\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.017 Tw -1.125 -1.387 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.02 Tc 0.024 Tw 1.125 0 Td
[(C)0.5 (o)0.6 (l)0.5 (i)0.5 (t)0.6 (i)0.5 (s)0.5 (:)37.6 ( )37.5 (A)0.5 (d)0.6 (v)0.5 (i)0.5 (s)0.6 (e)0.5 ( )0.5 (p)0.6 (a)-9.5 (t)0.5 (i)0.6 (e)0.5 (n)0.6 (t)0.5 (s)0.5 ( )0.6 (t)0.5 (o)0.6 ( )0.5 (c)0.5 (o)0.6 (n)0.5 (t)0.5 (a)0.6 (c)0.5 (t)0.6 ( )0.5 (t)0.5 (h)0.6 (e)0.5 (i)0.5 (r)0.6 ( )0.5 (h)0.6 (e)0.5 (a)0.5 (l)0.6 (t)0.5 (h)0.5 (c)0.6 (a)0.5 (r)0.5 (e)0.6 ( )0.5 (p)0.6 (r)0.5 (o)0.5 (v)0.6 (i)0.5 (d)0.5 (e)0.6 (r)0.5 ( )0.6 (i)0.5 (m)0.5 (m)0.6 (e)0.5 (d)0.6 (i)0.5 (a)-9.5 (t)0.6 (e)0.5 (l)0.6 (y)0.5 ( )0.5 (f)0.6 (o)0.5 (r)0.5 ( )0.6 (d)0.5 (i)0.6 (a)0.5 (r)0.5 (r)0.6 (h)0.5 (e)0.5 (a)-20 ( )]TJ
-0.017 Tc 0.06 Tw 0 -1.062 Td
(or severe abdominal pain )Tj
/T1_3 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.1\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.017 Tw -1.125 -1.386 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.012 Tc 0.192 Tw 1.125 0 Td
[(Hepa)-10 (titis:)36.9 ( )36.9 (Advise pa)-10 (tients to contact their healthcare provider immedia)-10 (tely for)-12 ( )]TJ
-0.017 Tc 0.073 Tw 0 -1.062 Td
[(jaundice,)37.2 ( severe nausea or vomiting,)37.2 ( pain on the right side of abdomen,)37.2 ( letharg)-9.8 (y)55.2 (,)20 ( )]TJ
0.06 Tw 0 -1.062 Td
(or easy bruising or bleeding )Tj
/T1_3 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.1\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.017 Tw -1.125 -1.387 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.038 Tw 1.125 0 Td
[(Endocrinopa)-9.8 (thies:)37.1 ( )37.5 (Advise )0.5 (pa)-9.8 (tients )0.5 (to )0.5 (contact )0.5 (their healthcare )0.5 (provider )0.5 (immedia)-9.8 (tely)-17 ( )]TJ
-0.003 Tc 0.405 Tw 0 -1.062 Td
[(for signs or symptoms of hypophysitis,)37.4 ( adre)0.5 (nal insuf\037cienc)20.3 (y)55.4 (,)37.4 ( thyroiditis,)34 ( )]TJ
-0.006 Tc 0.328 Tw 0 -1.062 Td
[(h)0.5 (yp)0.5 (ot)0.5 (hy)0.5 (ro)0.5 (i)0.5 (di)0.5 (sm)0.5 (,)37.4 ( h)0.5 (yp)0.5 (er)0.5 (t)0.5 (hy)0.5 (ro)0.5 (id)0.5 (is)0.5 (m)0.5 (,)37.4 ( an)0.5 (d d)0.5 (ia)0.5 (be)0.5 (t)0.5 (es)0.5 ( me)0.5 (l)0.5 (li)0.5 (tu)0.5 (s )]TJ
/T1_3 1 Tf
0.291 Tw [([)0.5 (se)0.5 (e)0.5 ( W)18.5 (ar)0.5 (n)0.5 (in)0.5 (gs )-37.4 (a)0.5 (n)0.5 (d)-6 ( )]TJ
-0.017 Tc 0.06 Tw 0 -1.062 Td
(Precautions \(5.1\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.017 Tw -1.125 -1.387 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.01 Tc 0.229 Tw 1.125 0 Td
[(Nep)0.5 (hrit)0.5 (is with)0.5 ( R)0.5 (enal)0.5 ( Dy)0.5 (sfunc)0.5 (tio)0.5 (n:)37.4 ( )36.6 (A)0.5 (dvis)0.5 (e p)0.5 (a)-9.6 (ti)0.5 (ents)0.5 ( t)0.5 (o cont)0.5 (act th)0.5 (eir he)0.5 (alth)0.5 (care)-9.9 ( )]TJ
-0.02 Tc 0.024 Tw 0 -1.062 Td
[(provider immedia)-10.4 (tely for signs or symptoms of nephritis,)36.6 ( inc)19.6 (luding decreased urine)-19.9 ( )]TJ
-0.019 Tc 0 -1.062 Td
[(output,)37.3 ( blood in urine,)37.3 ( s)-9.7 (welling in ankles,)37.4 ( loss of a)-9.6 (ppetite,)37.3 ( and an)-9.7 (y other symptoms)-19 ( )]TJ
-0.017 Tc 0.06 Tw 0 -1.062 Td
[(of renal d)-9.8 (ysfunction )]TJ
/T1_3 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.1\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.017 Tw -1.125 -1.386 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.01 Tc 0.24 Tw 1.125 0 Td
[(Skin )37 (Adverse Reactions:)37 ( )37 (Advise pa)-10 (tients to contact their healthcare provider)-9.9 ( )]TJ
-0.017 Tc 0.06 Tw 0 -1.062 Td
[(immedia)-9.8 (tely for rash )]TJ
/T1_3 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.1\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.017 Tw -1.125 -1.387 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.016 Tc 0.12 Tw 1.125 0 Td
[(Myocarditis:)37.3 ( )37.3 (Advise pa)-9.6 (tients to contact their healthcare provider immedia)-9.7 (tely for)-16 ( )]TJ
-0.013 Tc 0.157 Tw 0 -1.062 Td
[(signs )0.5 (or )0.5 (symptoms of )0.5 (new or worsening chest )0.5 (pain,)37.3 ( palpita)-9.6 (tions,)37.3 ( )0.5 (shortness of)-13 ( )]TJ
-0.017 Tc 0.06 Tw 0 -1.062 Td
[(brea)-9.7 (th,)37.2 ( fa)-9.8 (tigue,)37.2 ( or s)-9.8 (welling in ankles )]TJ
/T1_3 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.1\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw -2.25 -1.629 Td
[(Infusion-Rela)-9.8 (ted Reactions)]TJ
0.017 Tw 1.125 -1.359 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.014 Tc 0.133 Tw 1.125 0 Td
[(Advise pa)-9.7 (tients of the potential risk of infusion-rela)-9.8 (ted reactions )]TJ
/T1_3 1 Tf
0.096 Tw [([see W)18.2 (arnings)-14.1 ( )]TJ
-0.017 Tc 0.06 Tw 0 -1.062 Td
(and Precautions \(5.2\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw -2.25 -1.629 Td
[(Complica)-9.8 (tions of )37.2 (Allogeneic HSCT)]TJ
0.017 Tw 1.125 -1.359 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.014 Tc 0.132 Tw 1.125 0 Td
[(Advise pa)-9.7 (tients of potential risk of post-transplant complica)-9.7 (tions )]TJ
/T1_3 1 Tf
0.095 Tw [([see W)18.3 (arnings)-14 ( )]TJ
-0.017 Tc 0.06 Tw 0 -1.062 Td
(and Precautions \(5.3\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.011 Tw -2.25 -1.629 Td
[(Embr)-17.7 (yo-F)24.2 (etal T)74.2 (oxicity)]TJ
0.017 Tw 1.125 -1.359 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.014 Tc 0.148 Tw 1.125 0 Td
[(Advise females )0.5 (of reproductive potential )0.5 (of the )0.5 (potential )0.5 (risk to )0.5 (a fetus and to)-14 ( )]TJ
-0.02 Tc 0.024 Tw 0 -1.062 Td
[(inform their healthcare provider of a kno)-10.3 (wn or suspected pregnanc)19.7 (y )]TJ
/T1_3 1 Tf
-0.013 Tw [([see W)17.7 (arnings)-20 ( )]TJ
-0.017 Tc 0.06 Tw 0 -1.062 Td
[(and Precautions \(5.4\),)37.2 ( Use in Speci\037c P)18.2 (opula)-9.7 (tions \(8.1\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.017 Tw -1.125 -1.387 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.012 Tc 0.183 Tw 1.125 0 Td
[(Advise )0.5 (females )0.5 (of )0.6 (reproductive )0.6 (potential )0.5 (to )0.5 (use )0.5 (effective )0.5 (contraception )0.5 (during)-12 ( )]TJ
0.192 Tw 0 -1.062 Td
[(trea)-10 (tment with OPDUALAG and for a)-10 (t least 5 months follo)-10.1 (wing the last dose)-12 ( )]TJ
/T1_3 1 Tf
0 Tc 0 Tw 0 -1.062 Td
([)Tj
-0.017 Tc 0.06 Tw 0.242 0 Td
(see Use)Tj
[( in Speci\037c P)18.2 (opula)-9.8 (tions \(8.3\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.017 Tw -2.492 -1.629 Td
[(Lacta)-9.8 (tion)]TJ
1.125 -1.359 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.009 Tc 0.256 Tw 1.125 0 Td
[(Advise women not to breastfeed during trea)-9.6 (tment with OPDUALAG and for)-9 ( )]TJ
-0.017 Tc 0.06 Tw 0 -1.062 Td
(5 months after the last dose )Tj
/T1_3 1 Tf
[([see Use in Speci\037c P)18.2 (opula)-9.8 (tions \(8.2\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.012 Tc 0.048 Tw -2.25 -3.537 Td
(Manufactured by:)Tj
0 Tc 0 Tw 6.305 0 Td
( )Tj
-0.012 Tc 0.048 Tw -6.305 -1.125 Td
[(Bristol-Myers Squibb Compan)-9.8 (y)]TJ
0 Tc 0 Tw 11.215 0 Td
( )Tj
-0.012 Tc 0.048 Tw -11.215 -1.125 Td
[(Princeton,)37.3 ( NJ 08543 USA)]TJ
0 Tc 0 Tw 9.179 0 Td
( )Tj
-0.012 Tc 0.048 Tw -9.179 -1.125 Td
[(U.S.)37.2 ( License No.)37.2 ( 1713)]TJ
ET
endstreamendobj28 0 obj<</BBox[0.0 792.0 612.0 0.0]/Length 565/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/Resources<</ExtGState<</GS0 16 0 R>>/Font<</T1_0 60 0 R>>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 36 748.9131 cm
0 0 m
252 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.008 Tc 0.008 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 36 750.2881 Tm
(OPDUALAG)Tj
0 Tc 0 Tw 5.6 0 0 5.6 80.3379 751.9521 Tm
(\231)Tj
-0.008 Tc -0.014 Tw 8 0 0 8 85.8912 750.2881 Tm
[( \(nivolumab and r)18.4 (elatlimab-rmbw\))]TJ
ET
q 1 0 0 1 324 748.9131 cm
0 0 m
252 0 l
S
Q
BT
0.008 Tw 8 0 0 8 400.5846 750.2881 Tm
(OPDUALAG)Tj
0 Tc 0 Tw 5.6 0 0 5.6 444.9225 751.9521 Tm
(\231)Tj
-0.008 Tc -0.014 Tw 8 0 0 8 450.4758 750.2881 Tm
[( \(nivolumab and r)18.4 (elatlimab-rmbw\))]TJ
ET
endstreamendobj60 0 obj<</BaseFont/IHGZJR+HelveticaNeueLTStd-Bd/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 61 0 R/LastChar 153/Subtype/Type1/ToUnicode 62 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 296 296 0 0 0 407 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 685 0 0 741 0 0 759 0 0 0 0 593 0 0 778 667 0 0 0 0 741 0 0 0 0 0 0 0 0 0 0 0 574 611 0 611 574 0 0 0 258 0 0 258 906 593 611 0 0 389 0 352 593 520 814 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1000]>>endobj61 0 obj<</Ascent 975/CapHeight 714/CharSet(/space/parenleft/parenright/hyphen/A/D/G/L/O/P/U/a/b/d/e/i/l/m/n/o/r/t/u/v/w/trademark)/Descent -218/Flags 32/FontBBox[-166 -218 1078 975]/FontFamily(HelveticaNeueLT Std)/FontFile3 63 0 R/FontName/IHGZJR+HelveticaNeueLTStd-Bd/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 144/Type/FontDescriptor/XHeight 517>>endobj62 0 obj<</Filter/FlateDecode/Length 360>>stream
H‰\’ÏŠƒ0Æï>EÛCQCMZa±-xØ?¬»`“±+¬1D{ğíw&Sº°Í/dæ›/™¤uslÜ°ˆô=L¦…Eôƒ³æéˆ\—äRØÁ,÷Uü›±óIŠÉí:/06®Ÿ’²énÎKXÅÓ³.°IÒ·`!î*¾êv#ÒöæıŒà‘‰ªzzéük7‚HcÚ¶±¸?,ësş">WBÆuÎfÌdaöĞ¹+$e†£åG•€³ÿö¥â´Ko¾»”’‚³'ä=óøÀ| >2‘wydœwÌ;bÍ¬‰kæšøÌŒfÊ‚kT«(˜dÅšŠ4•d–Ä¬¯H_q¼ŠñìM‘7ÅµÕRìS‘Oub>³E4ëkÒ×¬¯I_³¾&}­˜1ŸKÓ¹TWæRÆ‹½ß ]1¾ñèŸ¹…€­‹Ï%öŒº58x¼(?yYô%¿   ÿÿ   ÿÿ pÍªDendstreamendobj63 0 obj<</Filter/FlateDecode/Length 1909/Subtype/Type1C>>stream
H‰lTPWíf¦ß0Èv"C³„1=ÍˆFÂ|ø*aK‰¨øAE¨ÒdhdftAP´t³
«¨1&‚e*º¬ŸCi”(DX‹M´B-Ñ5şPI²¬Ftñ·‡;U»¯Ñh¥j««ß}÷¾{Ï;ï¼Ëh–e_1}Ú¢ÌùÑÓå’rÙë,pÌ‘WÊ³d{'L)TLŠ‘UBµÊ¨`'¢kèüP§/)#Ï
ÜÂ¨0f6.İ½¼Òã\Rì•¬)ÉÉ1´M±·öÉf±Ø¤É…î|YÊ®,óÊ¥eÒWÛ³ÜíqxåÂXirI‰4\\&yä2ÙS®ŸS’œe’Còz…r©Ã³LrI³œ.··r¹,¥S”XZ´ÄIq=r¡ätIŞbYÊ‰Í•æRt—Wr¸
¥Ï«³ŠŠœòp°ÔQ)QN¿®.=^µn
ã‘–®ô8Ë
^§ÛUö¸ËQ*ÿnä¤+(¡ğ®2Y~1<­4zl\FöÕ‰—
å"†aéÇèY†g3ÃŒa˜q3a,,“È0SXf*Ëd2Ìl“Í09¦aŒTif3ÙÌt0İl(›Ãf/Ä,8¢­©Ô\ĞšµSµµ§µCÜï¸\+÷_MÜäKœ±¹U¹×ÊÒ6ªU³Y«ÔøæúklÅÓà=î”°M ÕñïĞùIŞpÒúD9#¨=T=Şÿï0¡|hL{Ì˜åsv4¼Y8>-­h»£D"“!Ê	6°E@Üg`½‘â‹Ê‡j¥3…Ÿ ä$dÁø°,[
¼*b¹„c>EÚ"0®­“Qy< ÅÀ³mĞ®iƒbÚÇvÂoÛ[vĞ+™ì;¾,Í;a`'gÁÎÁG¤©I"ø‘/ÃrßêH/îæp6á¿ŞáJ.„³]`…`Õt…Á7\°Mˆ³MHCV@KÀÒ‡Qh‹Ï¶˜P"üÕ*ŸPû@Ni«Â€ÙĞbX£ÜëWÂ°õ`#†–qæ.cÄÈ\†0²šÈKÏOıĞ¯H¬B±Çq†a
c>P+º.¸ğ7oWi^«PYR†J„ãåZ	Î¯¬¢Pg§ÃM0(üRM¿0H|(Fj)ö3t¬aÏ(@dãH‘KMä3z"_MõÜ	<,¥Z«ÒÔCŒ*•Sdt˜f˜ğ{U^ üóÛÕKæê)&ä©¶*µ¾
¶“–¦Ì|I¾<­ş¹$rÉ"Ô¢¡âÊUQ™«Ft˜ÚXX Ù@~†‘—ªïNì¸ò	˜!
Ú¬Ã[BÉ&;jç×·9¶ûäNñä{­[÷âœ'ÂÙíŸík7¶~±aÎ¼‰[ã×šìëìnÔGD^]tÿ|çSÍ¢aÕ–ªmUÛWBY»wã©S°O/ãË‰Â@Q€¯üQä§VÆŞ[ƒ0³"¤Î¼şéV¶‡‘nagnşáóŞËÆG ¹	óajnFÍœY–[lª…z4å%ÿ[BBQjRRÑµ~üüÚ­[Ÿ§ÆÿU]ÏÆgd…õå¡ëkÉWË²öÏ1bL
h2Zpôe¤w¡³£ñì±ÔB®èN™`/êéîùäúÛOJRU„ßöBÀ {ˆŞ#å8x°¿ŸãğM#Z%Â8Œ€ZH}Ïà™p$Y¶aqñ|cêÛÇ{7™zµÇêö×kì:,§×›ø½åJCE?èÙ
×f¥®Š2^(P–z0šâË«x>®²'<¬¤…I÷Çƒ6„@æÓ?t”¡EÍ6òàìİ”‘%â	ê×}»»óz÷»ó3Dü’úÿÑADêW“ŸW*sÏkÌ4NÏ)É-2ÕC÷w¡ãíÏ'Pwe±zÚUèFòäÈ‰+u$ŠØLı:•{0:k¶{Ş±†®\D£Nİ *?½"fØF™7Á&?A!é	0)f`0	ÍÈ`Šæ°›‡nöİ;”œœâJ~=Úuó}yš)‰Ñ„A¾qøxê‡ITÃ¡ışñ½µ5õ¢¡Âu†C[7¬«[oÌ˜š—¹B]Æ7}*¼ñ'ĞB×]ö¶úì­õÅ«²Æ%Äü€$êrÅoÙÖ(‚FW³¦úÏkŒ¿_·ë´	v>¾;š*PÚñ÷•¤Š
(G• ‘˜—ş!m†ç‹š©A‡¡M‰ıõ¹ƒGÅ­Ä°*ÔÉ†·—İ®ìĞ(»ÔÒH‚,pµÔÀ ‡ã	Lõ7pôµâá•§¹ïúNh|-jîXƒhªq(’|LxÌ!}½’Õ²×ÈOĞÏÕ‘ÛØÏÁXŠqÑÇ_gaÚCHëƒ¦>ÍP¼zı$
£ ‘ÃQ~K4×‘læºÈ 4suØÜGü‹€ÿšzìy= '|Õ_Ş\Ú ol&°gçÃş+ºgÁ]°GÿÿÏ»ôƒA`1ø~p0˜wÿfK0„úŞş  ÿÿ   ÿÿ R-¶endstreamendobj34 0 obj<</Metadata 64 0 R>>endobj64 0 obj<</Length 8736/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="ï»¿" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c002 79.dba3da3, 2023/12/13-05:06:49        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:xmpTPg="http://ns.adobe.com/xap/1.0/t/pg/"
            xmlns:stDim="http://ns.adobe.com/xap/1.0/sType/Dimensions#"
            xmlns:stFnt="http://ns.adobe.com/xap/1.0/sType/Font#"
            xmlns:xmpG="http://ns.adobe.com/xap/1.0/g/"
            xmlns:illustrator="http://ns.adobe.com/illustrator/1.0/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:ExtensisFontSense="http://www.extensis.com/meta/FontSense/">
         <dc:format>application/postscript</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">OPDUALAG_PFS RELATIVITY-047</rdf:li>
            </rdf:Alt>
         </dc:title>
         <dc:creator>
            <rdf:Seq>
               <rdf:li>SAS Version 9.4</rdf:li>
            </rdf:Seq>
         </dc:creator>
         <xmp:CreatorTool>Adobe Illustrator 24.3 (Macintosh)</xmp:CreatorTool>
         <xmp:CreateDate>2021-07-30T15:21:50-04:00</xmp:CreateDate>
         <xmp:ModifyDate>2021-07-30T15:21:50-04:00</xmp:ModifyDate>
         <xmp:MetadataDate>2021-07-30T15:21:50-04:00</xmp:MetadataDate>
         <xmpMM:DocumentID>xmp.did:aee0a162-360a-41b9-b276-e22c5ce0c527</xmpMM:DocumentID>
         <xmpMM:InstanceID>xmp.iid:7c74cb77-7e7a-44f8-af16-66ad48db817e</xmpMM:InstanceID>
         <xmpMM:OriginalDocumentID>uuid:62A9D3A3-2981-43BA-8681-E7AF2F5921C6</xmpMM:OriginalDocumentID>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>uuid:2193a395-70c6-ae40-8295-1c6643a28255</stRef:instanceID>
            <stRef:documentID>xmp.did:2d73a4ff-4d04-403c-b5f0-03fb05e01131</stRef:documentID>
            <stRef:originalDocumentID>uuid:62A9D3A3-2981-43BA-8681-E7AF2F5921C6</stRef:originalDocumentID>
            <stRef:renditionClass>proof:pdf</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:cd81ade6-7d54-4e19-b836-c9cb49ab5b02</stEvt:instanceID>
                  <stEvt:when>2021-07-30T12:55:21-04:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 25.3 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:370e7028-63ed-4b27-918b-2568fd1177bb</stEvt:instanceID>
                  <stEvt:when>2021-07-30T14:53:03-04:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.3 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>converted</stEvt:action>
                  <stEvt:parameters>from application/postscript to application/vnd.adobe.illustrator</stEvt:parameters>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:2d73a4ff-4d04-403c-b5f0-03fb05e01131</stEvt:instanceID>
                  <stEvt:when>2021-07-30T15:05:11-04:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.3 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:aee0a162-360a-41b9-b276-e22c5ce0c527</stEvt:instanceID>
                  <stEvt:when>2021-07-30T15:21:50-04:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.3 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>converted</stEvt:action>
                  <stEvt:parameters>from application/postscript to application/vnd.adobe.illustrator</stEvt:parameters>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <xmpTPg:NPages>1</xmpTPg:NPages>
         <xmpTPg:HasVisibleTransparency>False</xmpTPg:HasVisibleTransparency>
         <xmpTPg:HasVisibleOverprint>False</xmpTPg:HasVisibleOverprint>
         <xmpTPg:MaxPageSize rdf:parseType="Resource">
            <stDim:w>7.000000</stDim:w>
            <stDim:h>7.862388</stDim:h>
            <stDim:unit>Inches</stDim:unit>
         </xmpTPg:MaxPageSize>
         <xmpTPg:Fonts>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <stFnt:fontName>HelveticaNeueLTStd-Cn</stFnt:fontName>
                  <stFnt:fontFamily>Helvetica Neue LT Std</stFnt:fontFamily>
                  <stFnt:fontFace>57 Condensed</stFnt:fontFace>
                  <stFnt:fontType>Open Type</stFnt:fontType>
                  <stFnt:versionString>OTF 1.029;PS 001.000;Core 1.0.33;makeotf.lib1.4.1585</stFnt:versionString>
                  <stFnt:composite>False</stFnt:composite>
                  <stFnt:fontFileName>HelveticaNeueLTStd-Cn.otf</stFnt:fontFileName>
               </rdf:li>
            </rdf:Bag>
         </xmpTPg:Fonts>
         <xmpTPg:PlateNames>
            <rdf:Seq>
               <rdf:li>Black</rdf:li>
            </rdf:Seq>
         </xmpTPg:PlateNames>
         <xmpTPg:SwatchGroups>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <xmpG:groupName>Default Swatch Group</xmpG:groupName>
                  <xmpG:groupType>0</xmpG:groupType>
                  <xmpG:Colorants>
                     <rdf:Seq>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>Black</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>100.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>C=0 M=0 Y=0 K=50</xmpG:swatchName>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>50.000000</xmpG:black>
                        </rdf:li>
                     </rdf:Seq>
                  </xmpG:Colorants>
               </rdf:li>
            </rdf:Seq>
         </xmpTPg:SwatchGroups>
         <illustrator:CreatorSubTool>AIRobin</illustrator:CreatorSubTool>
         <pdf:Producer>Adobe PDF library 15.00</pdf:Producer>
         <ExtensisFontSense:slug>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2061318306</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2061318306</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Cn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
            </rdf:Bag>
         </ExtensisFontSense:slug>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj18 0 obj<</BaseFont/HZWTVT+HelveticaNeueLTStd-BdCn/Encoding 65 0 R/FirstChar 29/FontDescriptor 66 0 R/LastChar 153/Subtype/Type1/ToUnicode 67 0 R/Type/Font/Widths[240 487 537 240 0 0 0 0 778 0 0 296 296 390 0 240 370 240 332 480 480 480 480 480 480 480 480 480 480 240 0 0 600 0 0 0 556 556 537 574 481 463 556 556 258 463 0 463 740 574 556 519 0 556 519 480 538 519 760 537 520 0 0 0 0 0 0 0 481 500 463 500 463 296 500 500 240 240 500 240 758 500 480 500 500 333 444 296 500 444 704 462 444 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 990]>>endobj19 0 obj<</BaseFont/HZWTVT+HelveticaNeueLTStd-Cn/Encoding 68 0 R/FirstChar 27/FontDescriptor 69 0 R/LastChar 233/Subtype/Type1/ToUnicode 70 0 R/Type/Font/Widths[463 463 240 497 463 240 0 0 0 0 759 0 0 241 241 352 0 240 352 240 278 480 480 480 480 480 480 480 480 480 480 240 240 600 600 0 0 0 500 519 519 556 463 444 537 537 204 426 500 444 704 556 556 481 0 519 500 463 519 462 722 0 462 0 259 0 259 0 0 0 444 463 426 463 444 259 463 463 204 204 444 204 722 463 444 463 463 296 407 259 463 406 648 406 406 389 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 500 0 0 990 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 400 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 444]>>endobj33 0 obj<</BaseFont/HZWTVT+HelveticaNeueLTStd-Cn/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 71 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[240 0 0 0 0 0 0 0 241 241 0 0 0 0 240 0 480 480 480 480 480 480 480 480 480 480 0 0 0 0 0 0 0 500 0 0 556 0 444 537 0 0 0 0 444 704 556 556 481 0 519 500 0 519 0 0 0 0 0 0 0 0 0 0 0 444 463 426 0 444 259 463 463 204 204 444 204 722 463 444 0 0 296 407 259 463 406 0 0 406]>>endobj24 0 obj<</BaseFont/HZWTVT+HelveticaNeueLTStd-CnO/Encoding 72 0 R/FirstChar 31/FontDescriptor 73 0 R/LastChar 121/Subtype/Type1/ToUnicode 74 0 R/Type/Font/Widths[463 240 0 0 0 0 0 0 0 241 241 0 0 240 0 240 278 0 480 480 480 480 480 480 0 480 0 240 0 0 0 0 0 0 500 0 519 556 463 0 537 537 204 0 500 0 704 556 556 481 0 519 500 463 519 462 722 0 0 0 259 0 259 0 0 0 444 463 426 463 444 259 463 463 204 0 444 204 722 463 444 463 0 296 407 259 463 406 648 0 406]>>endobj72 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[31/f_i]/Type/Encoding>>endobj73 0 obj<</Ascent 932/CapHeight 714/CharSet(/f_i/space/parenleft/parenright/comma/period/slash/one/two/three/four/five/six/eight/colon/A/C/D/E/G/H/I/K/M/N/O/P/R/S/T/U/V/W/bracketleft/bracketright/a/b/c/d/e/f/g/h/i/k/l/m/n/o/p/r/s/t/u/v/w/y)/Descent -272/Flags 96/FontBBox[-171 -272 1068 932]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 75 0 R/FontName/HZWTVT+HelveticaNeueLTStd-CnO/FontStretch/Condensed/FontWeight 400/ItalicAngle -12/StemV 84/Type/FontDescriptor/XHeight 536>>endobj74 0 obj<</Filter/FlateDecode/Length 503>>stream
H‰\“İn£0Fïy
_¶<ãVBHiÒJ¹Ømv€€“"5€r‘·_ş¢®´‘ˆÏœ<ùf·İÃbòŸaêö~1Çaìƒ¿L×Ğysğ§aÌV¥é‡n¹ß¥ÿîÜÎY7ïo—ÅŸwãqÊêÚä¿âÃËnæaİOÿ˜å?BïÃ0ÌÃŸÍşÑäûë<ú³S˜¦1½?Æ@ßÚù{{ö&OÛv}|>,·§¸çß¿o³7eº_Q¦›z™ÛÎ‡v<ù¬.â¯1õ{ü5™ûÿ‹ã¶Ã±ûhCV¯ŞãËE¡¯—&«Ë"İÇ%ò3ùüBNïlÈğùÌXqÉêj•8.‘Kr	®ÈØ’-XÈV²‚éPÁ¡Z“×‘-ã[Ä·ŒiÓ2¦ELË˜1­#;0cZÄ´¬Ë¢.ûJ~oÉ[0k´¨Ñ²F‹…½ôJX£ F¡ÀGè#ğú|„5
jº	Ü„¡ƒÀAY¯¢^e.E.e.E.e.E.e.E.Õû73—"—²Š>(ûÎ€ÒAá üÖŠo­ôÑäÃ(z¢÷3„8öÄ¡'nqÁ¾Ÿ\í8æknºkqdÒ˜¦YÁ”£ÿšäyšMÜ…+û  ÿÿ   ÿÿ Ş“óÍendstreamendobj75 0 obj<</Filter/FlateDecode/Length 3993/Subtype/Type1C>>stream
H‰lTkTGîf¦‹‘Ç`è4¶¦;ÆE4ˆèWE$QP¢FP8Â cÑaÂÛõ7gEqÕ(g£	nAã#ëjT"ê:At#¨Ç“Ås/lÍ¸&ÙsüQ§ëV×÷ÕW÷~uYFíÂ°,ûJtÒÒø%ñ¯G2­‹1U?ß°ŞgI›•µÀ±c´2’UüÔÅ.Ê(#ğÀ“¯„qŠ·—²à¥K#½ë½¥bÔ¬ëŸbŒ2­Í5WeXäIááÁòäààÉrdši¥AËÍ¶ÖdË1Y©&óZ“Yo1¤É‘™™²-›Ù³Õ±ø‹Ù˜-ëe‹YŸfX£7¿'›ÒåXc–É’»Ö GQ– 
Ze¤¼fCšlÌ’-yqP\¼²gYd}VšÿzAzº1Õà\\£Ï•©¦ÿG§Ì=ıš(Y^½ŞlÌN3¦ZŒ¦¬ìçäYú5†¨0™e#½A&¥ÏÊ6~ı=gÍÊè ‰³ãâAˆœfHgh¶X†Æ2ãÅ2ŞãÇ0"ÃŒf˜1.L€È0A*FÇ1ÓfÃÌÒ0±Ç1I»•a¦:ÒÃÄ2Û˜sL3Ä
ì,¶ÆEtIp9®š¦²©u°ºD}Q\&·Ÿû’û‰Ì"¤İu„ëf×^—f®&WsYóŸaâ°¿»t3¹İpu_ïşÔc†ÇJZÏ=Gy¦xÓJZ½ök/­×"¯B¯kÃùá™ –RîŸb!ÀGÙ6¸phíx^ÀPÉA/A¿ÀU¸‘dçf ‰rFpÌĞiñ#-À)Ö'>9ìm»
ú“ôBŸP1¢n5N®ÅĞ+(h¾$)ğZ	Œ9¡‡ab¼.à§ùñíªjŒÀ|ş!‡Aw&çBhšeä¾¶Çd`èjœ‹o ‹ìGeÙcà¯jói"%ÙS‹ry~\Ş½oïÕš›~{îrÉ³MmàJ7İ#û;—Š+¬ƒy9l‘²\UT(´eÄ`C´«÷Z•† ¡j¢á€
¢•^'È5pwŒLàóØ)&•h´«ËìÊY«¤ô¨”evÏ‘úŸ~~ü0¸ßõí½zîÜ>`4—ªÿ<†‰øû™Á8Â$u’Ï*¬x³:f~‘”?}ùŠè¤9I¾æM2¡¯F‘©ŠÂV8ÒºÅ
ûZ½¿íİú.¾ş?ü÷Í¤³aiX®„æèuKÅ©ù7.ï’t¤t#—¹9§Â"FŞéáÄŸ¬z:¢FSîj¯;Ù²ûº†oo¯-À †ë¨š39øC¯xµzÉÜBéÍ‚”Å3Åg Â¦rØV%I¥ŒS®åd6~Ça4™Y!äMã Š¬Âš’O!‚ûÔØ¸?Š›òLüıV²³m]ğA—
^†;ÂÍ­\íöSg.Š];Ã§çIQ©¨+NØÑÛXIÅ/*ŞŠL! Tà{H‚q[|çUqYBnÆ*©´ÜzÊI­ÃkÏøŞ‹Z½;ºaSOJ¯(Ÿ)ŸüÀáŠİ0
ÃEÔ/B†fH86s¾	"øvÀ¨‰WÀ¯aEz‰Ó/Y—#•’ÿäøÆÊ&xÜÄû“IØ€7^i«iìîû>˜™/Eæ¯˜¤ù]Iw[ä”ĞÜ
­Ş¶®»  “hÀK… ÷÷ t"è®¦w´·ßôõ´C·¾8^sSÃ÷ÙßŠjÕa1H²¥üˆ¿¾{9KÃ›–.´:vœVâ„oö$EJ1…©‰óÄ¹y§ZwIWv=y™†¡…Âíºã-bG},µAXî»±ábxNËí:Éét8á0ûrè”1ÂÿüÌĞöçsm-n‚<*ËñŞ¤Tó·6ÑgÑ	¼Oª0»GR“9t#|ïZ÷:|Àa<Ñî(´)ı6öQ\ï£~‡R!Äš>VQ[# ü‰&:ÓŠ=;gO-î¬è@#1£…)"·Ãp%í±2›r…¾¡ª~4úP•²ğ•,	_6%b0ŠÉ˜(–H¸oAôQ	¿Ø!h1hËìPe‹=¯Ô©Îû(/9}rœüª8¨suäX88â†8¢İ_h{ç<l±ÁQ›·ã>ıüIåG¥Zh¬ø¢PÿÁñ+KpÌíWO]üX*'|u<×JÚW×‘‚(^%üÉ@k*ú£ö©¸»{îÌbI»Ÿæü¾šs¨È©İi‡Ô‘·±™ÃRr	š9ÁÀ§É\'ùîsPJfá}hñÒ^ë`2Áfz³N´2:g	?+<tĞİqş9[û…= è¯„Àa8Í#Ø†¹RÒ0ˆ+ƒ ä­ƒênïŸÙ±˜Ÿ™y~íµß š+'ªéÁ´ ıES1€ğX;ÔBéÖ+-˜ÖÜÆ;zŸWºøµN…^ÊŠ|<tƒÏçz)ê¥@d•^	E>óÒO]p«K¥¼5˜)üÖ#›¨GEHlƒ8gµ£VB&ŠùÔÚbáôe‡g$ÓÙ‹r®}fû¬öR[YûéùÎÒ–KÀóQøÑö¢oB]ÙÛ"Î%¶(á!¹{06¥Àœy)óÄÑÔéİÚ¼•Q}•?òWá:î¤ùÌ–q…Rª¶dl]²³Àï1É­ŞX_İ^Zßª‹Ù§çWĞvÛYßÔQk×Ğfó_Ê«5¨ªë
s½#ZJ®Z·íñ9!­TB4QD5F„‡	¸HĞ Rä"…‹@xB"VãØ„”
%(í5¦w@ÉåM¨ƒD×f6©]ûÀgÒí3sö>û¬³ßú¾u„º=J¿§ñ}/6‡yie÷³ùÁÄ9“‡ãĞ;®¦]´^ûú/ØRÂ|˜½OºÀÊáß°ğ µÜ”æ»Ï‹0É0<P!sÄD´<ÈC°ÿ„Çß	ö„Y]†–·Î¶·öóÙàÍi²5BÈ¦_Ëh„š:OÙH°]iƒ 1ÕS o‘‘l8Ö°½§–§¨†ÇÔßÂgÛó°Œ€ÃØçÍÇ4é0'¬JZCÜÛ¾¯™İµŞ›ÿĞC¬{bÄ›í`¾CX~^şºé),ÿq:Å	çƒS%Ó>XŠ.ÊK Ô„À3vEM,$+(J@=¡}D,}ú.Z©¥wG‘%)‹r\ LÏüŒSz£ª…Šê>Cx‹£°R÷)½ğß3ï§Eâ1æsŠ·˜îƒ˜ûz<÷ø¦õ¶t£7|“óŒ¶WÇaËWš6x.’
NU…•Ã÷Hg]Ü>|<ôdªï1fõË“§m¶tJiÚ=I>ëjüô¢ÂÛ²ZóÏ‘êÚÂSErY·ğî‰œ\9zººæ´ÜíBgiõæNØâAÌú¨Q,^Ò´fú…’=ºæ«¥rÉ'•ÕU\®íÓ77YZsÖ¢ëM°“æTºQt+ ª¥ïj.='ıØâx-E¬õ$¿-œ„yµ²FË–²ji I
sP †ÿ¾9¼‹€Í°§s2Ì¯«ÄAn	Úw ÕğÏÍ5ÜõíÛdPU¦1Ğ©éºPº^–8ox™¹°%HĞ~\ÁÀ#,ª’İEÿŒ˜M[ÈÊFpø²\†½—>¯o'+~9X'?íüíÈ¬Cß·£ï°¸¡y°ŸŒŸp\–Ä}ZëL<sq[¦6tä.îeÙXè?mÜO˜SÎœóß’™çëuL éêlm­R’µPJ‡ŒàfTáWtf5ìƒÛRá{Â9}XŒ’ŞÂ­»3äœ8¡×GÒŸ`Áûå°Œg?‰iåuøÕ_K1¦ğì8w²¼l¹Äê‘{£ šTğ•zÀÎ,NÒhML¯‹XÖ#\,®6\ -b¹IØ%n<øÚÆ·å?Á“C«èg„E&úL—¿É¶Å6
ÚzMÜ¢	Òlæ%F®s%î% ©’g“£ùöwI¢¦Oë©ø8÷p«?aK½Ù¯ÙŠXœÚbØ>p%él¸Ò€™Ğz	š;‘ï¤¯g$,ªª­c`KÒAÊo"`1Ünç9)Ğ^]3®îÀ îPQè?ûÅ‡WÈ­Ìí‡²åç§EœîîR¡§¬ö1ûÙïû#B¸4Ñ¦”M¨ºA§îF Ò&|R1(™Åê	~f›r^MQuĞT5ŒÂˆ‡ ”ëRËÇH¾¦xN‘>³Ø>#æû¬lNøæls!qçÔÁçÉ£«‡á…qÍ•YßÍ7êZÈÍ§|ÿï»s9’À€Ã!Qòµ“1u;IğÎ7_Áè4·±„¢õÜgÖŒk.şùqüÑÂÍDºÕ¨úÇäŒª‡éÌ)¦„Ùƒç³İçt.ì™aÎÛ™=>—a‹•ÖaëZ¾/ãÕ29DÆO®b–	2^«~G¬™K2<g¢ë¹sà\™£š»
	€uıùÑû
,Jàsx²ÀéGßÕÈìEÍâg…pàLKÜ§dşÎY×Ëø“õLCüÂÃqÿÿ‰HFÿÙÌAä—^æœÛ M#Ï‚	î	cU·š?&gŞÍ+–5e•ƒ‚¦±0[WJv:¸÷náZÅ /–ãL®@2È+ôROiX0Wâ¼vÿª$9‘©{u'u'õhµ[¸ºeÄ“'>ÿ{6PÏø’É¡ÔP¹æÑ®Úİ5»jv”–õXö½®o ×J"½Óy?æ˜èj£jâ^¡MÒl£ñòxi¯?ÖüA.¿)äeeå¾MÂŞ©¸|FæcÖ}Ş²Îb¸rgzJH±íÇzÓ*4ä®ØğLó>J6•Ş¸T,s¸‹§m¿ŒDp$í×?hS†Âxìpä‡üGÏqÄÛ‚µCt±›¡»BÑÀ€é—|IÑ@’ÿà…dêû ğ‰E–ÎâD>±ğBíb÷€kàê‹å:5í‹ä9hEÑÀ­¸ÎñÙj‘ù)=.PØVãÔ’U>Õ«a£N:"Ä¥%%Fä´S™2¦%Ï`Èm"/{qZúŞä;¯´3^)Ô68±Ãd;@ßÔÜş?Éäéhi4÷Ÿb‚tÃT¨`¹A„zıˆ~º£xAjÅTh‹.µÄIıô7¥‹Ì?ë.**úÀÊª»®°Ğêç4|1-‘ş  ÿÿ   ÿÿ ?âÖhendstreamendobj71 0 obj<</Ascent 932/CapHeight 700/CharSet(/space/parenleft/parenright/period/zero/one/two/three/four/five/six/seven/eight/nine/A/D/F/G/L/M/N/O/P/R/S/U/a/b/c/e/f/g/h/i/j/k/l/m/n/o/r/s/t/u/v/y)/Descent -212/Flags 32/FontBBox[-164 -212 1000 932]/FontFile3 76 0 R/FontName/HZWTVT+HelveticaNeueLTStd-Cn/FontStretch/Condensed/FontWeight 400/ItalicAngle 0/StemV 84/Type/FontDescriptor/XHeight 500>>endobj76 0 obj<</Filter/FlateDecode/Length 3326/Subtype/Type1C>>stream
H‰lTkTSÙ¾—$‡‡î\”(¹WQQ'
dŒâƒA|KPÀqp"¹BM"Ê(.;¯aeZ­ZµckUêàbëkD­J}Ô¨5‚ÆÕ«-vfYì¾qgÖê‰]m×êêŸ³Ï¾÷ì³÷÷íı–QG0,Ë&æÎ),˜]ğ^®TY%¹m¥–iÒRiJÙm’mHRz±J‚ZéË+‰±ñ8Ëß¬|3BİáË½µ“ã½ŠyÆüÊv,®vÚÊÊİâ0“)Õ ¦¥¦¦‰YVÇ|I4W»ÜÒ"—˜g/u8;œ·d*fUVŠùá —˜/¹$gUøãŠm.Ñ"º«´Èâ\(:Ğ6«T9_r–INq¼siéÂEWi¹Í.ÙÅ¬‰QZ^Z¹Ôe«’*«ÅJ[©dwIVÑ]ît,-+§Øìwõb‰næ;-Îjqâ¢ù¹Ñb·Š‹,Õ"­Ò)•ÙhNd³‹¥’Óm¡¶b©Óæ²ÚJİ6‡İ54%Ç\¾$]´Jş?q”–a¢Y¦Ã¼Íôe˜ş“Ì2CÔŒ‘e2æƒ&'†1«™9“¦o*3ƒÙÀœe®³;‘ıE„6Â±!â*ƒê·êxõtµG}Hó®f°ÆªÙ¥ù+éG>'ßGö‰<¥ŠÊÚu!:3Úí‰¾ŠéS³'æy—¤.kºœèÒ›[²ª¶IéhbéÚ¯IU«V6g„6ø›y?×@;AÏòvB›#C¤äíÆ õ‰r†ï0ìiqŸƒïW½‰_ÆmSÁÌ`	oÀø"LG£ÓÎ`Æsäõß‘,H*ƒ~¡ƒ”:~ôÿÒ¦:ƒSøÒÁ¨ƒ´BÈ¼şCÒ‚Ißb?ÌĞaŠ‡ÄpÜ¾Ú×lK@ÕxB´5^å±—=,ÃrYŸÕğ`ŞV¬†|4£y5Z13·a>˜$ğ†‡ÔMĞ`6a_úkĞZLB™µƒôÚ=UJİÅé0>ìmÜkJï…êÚ×,šÉİXŸlZ¶.J[ëWÎùØc2,”UÊ$?ÈÖ“~×Xÿıãw¯¿ Œîòà¨Dú›SQ§—É‘/@ìíıyÓF/ø8~æMæÄ¬aØS§ˆapÈ»¶
~ík”ÇÈ¿‡ø_É¹2×ºráœÈG
G`ì´%…wrõÈ…­Wã§¤r„|è}õ)ğ/‹NÚ©÷DrÇ˜–İß^¹©»këÄØ#v¥ÙÏlyÔ~}ïìIzî63¾bÖ8=½z¡pa¬O‘hiû”k¼ïa.»™Ï„-8¶ÆŞóR¤÷#Ãvxa¨Ÿ="ƒ[V5C{½fWã™KOêL£³W :yHM{ƒŞHò÷¡ ™0°TĞe·õùpnu¹]¿Ñs ,ğøñÆ[À÷}ïûF»œ-sŠ’¥|Ã××@"šĞòtc&ïÀ™P¤ç:¡çõNH„„©Ï°Ûèg/©6'›a<Äè9åb}É6º•oÙıô9=ş|÷°¬,×0£À)F×Ó!ÜÖŸ=¬TVB<Ü!9Ãò“-IóúÚ1b•õ’l‡şĞı8°Ç^ŸÔx:êVhà[ÈÇ½°Ò× çÉ0.Ü«(ä‡Ã(0‚ñDµ¿(ıcÆ=×q³îë·u@r¼¨FuN’±_tÓ®ç^e8Jgt\ÌSÌüŸêæäæÙ‹'Or4y¯8uUà^adhÿ°şÊƒõSFŒ¨˜b2U\y¨'Ï÷Áı0AÙaŠ¸ÓÊWìÀD0e+¸!ÔĞ)óƒ='öÅDL¸œ
İüGÏîÛ!xÌ¤ì3œ€”Ÿé'š*‹V~\uÚz|Hõ“ÖÖ½Odë÷¦´«è ùàåµËâÖ(Û¹;kâä,i`99Eš Á‚`‰c×~~ ï!Ïğ¥ˆöh­O¹æc¯É°# ‚”`< ¾…Nßı„êË ¤c6s	‡	tœ‹NÍD›CÓ>öƒÛÏ6Ó‰Š—á1ìöãnŠí?¤!Ú½5¾™Í°Ö‡}qß`k ÏËRj”í|Ãçë -½°¸‚Ê<êq"L£âğ_hºôKÁC¸O{•H\’}"¹“†Oq jQ»t”=ÓNj´zîÔã“ÆıTĞæÔúƒİ—ı«EëÇ£ÁîF¢óª ú){QV²êb¼T{¤ı¨ÖÈÔÕÏj9X‚	&…®h6R£\ÑP—’1ƒ«”VèMél–a—ÌÍ¥èW©´z"¡:Ôª®Á#áv…Ú7Fâj¥]ƒ„ÆÕø”>–"­£dVòÿ†—[f(†âz0Ss+ÀŒÅB¶´;QGåbZAÍÿÀ´)»ç|°ÇG‘+ğ–àsÀèú—H k§
8‰ÈÙüßÈã†¢Ñ†Yó&}‰v¼éƒŸùÂÅ/páØ›Ğ…pÊñ?¬´YØ„*OùæÙ_®LxMª¶¯újıİµ í¹şRùé©›£è+Ôùğ«ıü:ĞŒ§zĞãŠp’Nòàä¼	¨7Ô
éD»ê-Ú¸ƒrf ªåì wG™¥ìã¡ÇÆ©×±w/Ìs`<»…_ÂSˆÆİØYÅôÜä×=º'	N‡Q?@×“`Òs·`>ÅXøHwûØ‘=w§m!ìM5¾`¿el“ëeU”ó˜ìÍ¤O½øç'ğO:«6(ª*³®{.šm—+×î•ñƒŒJlıb4Am1\S„ò…ü‚“İuÛXagXÙ•ÌµÃˆ0£ÅÍkÌl”HÌ5V35‡š²÷îœm¦s—üáfîŸsÏyßyŞç}Îó8É8+`¤bv­™™¸µó/yI©—Òİp¿ÆáÍ¾E"$‹ô%—Æ3P§L?ß»z¶ Kg*[YÂaÕVİ±´x{æ¢¨ØÏÓF.w5ÑÈé/µ\4cNËñ*ŞMU{ÏPÎî19œ<tQWM°Gd®Ájjğn†îÈX›“±º¤å«›£±k9İoıÈªÎ’Å/ÍñÂ}x·|t'é«ƒùÓşøî@ı\ÕúYI¯”À>° ;˜ADw
f*÷dGna_B$ÄÂØR2¯§­YW°¡„7ÀR'kyPJAqÎ«E¥ÄIã˜k…@‘;2w'ZJíN ÁQm@İæ4(}ÿÂäéFÂ¬»r¦ë[ÇªLN¦	6((.ø`-¾p“©§ÎUCˆ¯ÿTJW@ù´Ìy
¨0…ŒÁ§O?ÏMç–kæO5AØ™ëVâÑÛ@^Å ¨œ(JÛî	ñtÁnû„kõ®DóŞÙ4OMÒPê,œ*Àx¯ôROº—Øãb‘TAß‚=R!s×=) 9Šaˆ¨àéÖÃÌGô­eª­<çb:‹'m!v9-¥gAÂ•ËívŞ¼å[æà27æê<Æk²cr±Òß‰¼:‹@,”û¡ ıX!*»	J„zÏ¶ÿøş›¹ ¥0ÊcúsÙ«vl,âFéÆ×H˜KÿÇC…[$6"J.+>náTov±Ùw‹t;L•\Œ&Ğ²L¹™åæã]’LÑíÆÚZC-ûË…Ï|¼ß:V+Í“¤…õ2%ÔÁ0Ğ©f ¼
›T)IóN-êa¶«"ñëôÿáğëÈ“k’yôˆ°Hş"&Ñ`aboCkß“ÂõÔr´ÎèŒì¼œ½\oY~Ã
6óÍ]ë‹x¢òÌ§F¹’ó©¢Ûÿ—«è`GânÊqDWRŠ höA¾OÙLäc[p$ÄC\kPÎ±yI”·GâXøàfvÙ„B¨}äöİºŠCKc^åÕx'A/Ô7É×‡î% àºó]K[cu¥ñG×Qt¯åÈas›¶ı­u{eèÍƒä¥„ş¡øºóÄ‘“JzñBN`ã’²c°òFÉõ"¾s½H8µpÅ¡İsK¿¹N$aÆ,,ù¾Tµ§—;‰iÚOÔnkc¯=™,õ£^éE!¨sÒn"é BKoì´˜Or}”ñİ
C)»±¼î¿ı*ÄAA5j…ú'„J/¥‚PÒÊº…•7>å$¤	„Q©¦Éİuµ©Ó)[QIê ¥lzüš¬•ğji"½â'>D0Mr©âÉ³6&°˜Œ®i1Y©'ãÁ¥WsJXPÎìÏQT”íÛÂï?n>Ìk)£Ífp±¿;…şzâ¥>43˜ z4ÁA›_gÃ6˜jCpÆ:ltŸ Êêüº:¼­&”ü±î×ŒÆ‹Ï¸«ªªš&Lp7X,•öEHÕÌ¿   ÿÿ   ÿÿ !“gendstreamendobj68 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[27/uni03BC/fl/uni00A0/greaterequal/fi]/Type/Encoding>>endobj69 0 obj<</Ascent 932/CapHeight 714/CharSet(/uni03BC/fl/uni00A0/greaterequal/fi/space/percent/parenleft/parenright/asterisk/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon/less/equal/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/R/S/T/U/V/W/Y/bracketleft/bracketright/a\/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z/bullet/endash/trademark/degree/eacute)/Descent -212/Flags 32/FontBBox[-164 -212 1000 932]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 77 0 R/FontName/HZWTVT+HelveticaNeueLTStd-Cn/FontStretch/Condensed/FontWeight 400/ItalicAngle 0/StemV 84/Type/FontDescriptor/XHeight 536>>endobj70 0 obj<</Filter/FlateDecode/Length 615>>stream
H‰\ÔßŠâ0ğû>E.g.†¶ÉÉÉ"¨ã€û‡uö´na­¥Öß~óå“XAûÅ&=?å”ëíÛ¶ï&Sş/Í.NæØõí¯—ÛØDsˆ§®/jkÚ®™«üÛœ÷CQ¦Ã»ûuŠçm¼ó¹)¥›×i¼›§e{9Äç¢ü1¶qìú“yú½Ş=›rw†¿ñûÉTf±0m<¦}Ûß÷çhÊ|ìeÛ¦ûİtIg¾v|Ü‡hl^×Ä4—6^‡}Ç}ŠÅ¼JŸ…™¿§Ï¢ˆ}ûßıWá±Ã±ù³‹y½J›+·Z/R^#Wªé›×oy½¬7)[«ùıkß,­m•×û¬gÆ>ûÊüŠ<cÎû—ÌKdÖ´¨gY/]RŞ0oY/]Š¹c-‡Z®f®‘-³EvÌY˜™6›SfEÌ™f³£ÙÁìhv0»ó
™~¿£ßÁ/´	lB›À&´	lB›À&´	lB›À&´	lB›À&´	lB›À&´	lB›À&´I¶±·‚Ş
{+è­go=zëiö0{š=Ìf³§ÙÃìiö0{š=ÌN§§ÍÃæéñğ({¥è•²®¢®²®¢®²®¢®²n~Uï"2ë*ê*{¥è•ÒßUe¯½Rz}¼ûè•Ò¦ÙÆ^)z¥÷½
ìU@¯ış@€?Ğàôøış@€?Ğàôøış@€†çØÊ¢ÖLs®Qk†ı¶Îÿ¯è\Á¹ásÒƒá10"Ò$3Ÿó§¹c=yÜå™ƒiÓõñs"—Á¤Søÿ   ÿÿ   ÿÿ óö4½endstreamendobj77 0 obj<</Filter/FlateDecode/Length 4801/Subtype/Type1C>>stream
H‰lTPwß%ì&ü
’ír5»±ü¬E°ˆšP@kÕ˜,„D“ ¢Ò¢ÖŠÃÀŒ¿uzŞP=•™b‹È¤Ç¢§%è™¥•2¸jĞÁÓ::oñgn7w¹ş±ïûŞ~ß{ß÷>ïy{a8ÏL[Ÿ“•õ^WTÊÙM}&WÂedéìÆÈ³GT¸0Í[`üi”€
Şì~“@Àx 0/èÆŒ`ƒ#D7˜Ä¦ãPb6©5KS<‡:YoåôvÎÊm/Ñ¥X¶•[Mùv6&1QÁÆªÕ±l²Ñ²…cuå6;WlcÓÍ‹u›Å*Ú£Øä¢"Vë1°±ZÎÆYK=?ÿ&k²±zÖnÕ¹b½u+kÉïLF®hgÍç¬ì2k‰ak±Şf(0™93›¼"‚åvŠJl¦R®¨œ-28³3²ö«¥$¿€Í0™-öòmœÈl±ê­åìŠâ-i¬Şld‹õå¬¥•Ë7Ù<ÙY“™5pV»^<K¬&›Ñd°›,f[Ttª.Ëã$5ry˜a$†ùxaAØ¬@LC`1l†-Æ°¥Ó°b/Ìa§0ì+»…á¼°<h®ÂÖ`C8¯Â?ÅOã—ğ.|Ğk—ÎëÏ’’4ÉIoï%ŞD‘NX‰D+ñ+™I^ IeÒ¹ÒCÒ6©CúV![*Û-kö‘ø,ò9ãëã;Ç7ÇwŸoŸ/øQ~j¿+şAşÙşıß„Ôô¼GÊ7É­ò½?<è?åä”¾ YPLPYPCĞ3­ÈVQœW\£‚¨4ªzN½|‡i®nÆÚq‘În—T{UãkÜU$Ô¢-†#Œ’ˆE]4x÷a©›Ü8ÁÃb$Ê¤ĞI{8ä‘äÈ"‡®Š«PõQ\q‚¯B<”ê„å‚œÖUuÕvww×ê«t:æ¨{ınçËIjxä­úÿu¨Nw84ÒàwÂõüùg.ä‡ü>‹;~5,„£Ç¿'Gf´ ôMpşİ°Öo¤#Pp.ŠC%ŠíDñO­úL†|˜ñJˆ®‡ù÷ašêv@K:Qı‚; 4JˆÍøH U“ı(ä[4Å+Q´Í_ˆD;Vh.­hz]¡‚‹f›KÖaJŠlÏsşêœÓŞ˜ôˆ‹%=ìüVKEÀª_ãı.Ip‹4ì-+Ø©Ú 9sèÖ]åƒh©œ…ƒƒøU¨’\…ƒ4T¢*ò7&®×Ñ¢˜~¸t|g¾:${*h	»Çwé¤¼®Â!<pà—xØÁKàó
tÇÁó`i%h‘é*‘©Ñ¢ãH:‘ğ†õ!˜`‡Ğ,ñ*|?
AÂöC„«äuu¥BıõÕ°LæaêvŸPOÃ{îúa’jÏ]-¥nK¬ŒıB&¯«şæÄ[xØÊK„•ƒ4ú<Öv¡¹©áùƒ©?İjı0åí@‰«hN”*¼\àwÏ§g~·Y»^µv=±hEršªØ‰Tà¢c)œq(šøÅü_ ø+>§*!FèV’¿œ“€ü3·ç0T[åÂ­½Œf/Yt--Ìè}ô³Ü÷¿TÕH©¬ÿô·7ï(2½BsÑ´	(@|¾óèÈè­³Ù+UÔ]lYáGKT¢ëM¤'cHr
œXĞ&±…>ºıŒÒÈ¤Ãô"8Š’†!égçû·@:ã˜¢ñË<ØyIÓwlêüûÃúÄRv!ï°ÈŠÑF•†ÔC,‚¹= ©2üîÇÊÌªƒ5@O@Í º=™ó}'hŠox0ó)<õŠ„dáº¡f¢D¤ßƒì(…Bk!WE½‚©·^ÁL˜¶ê1
ü`söö
æ`7Ùx–¯Š®7l\Ãˆ ûO?z"ª?9“œl‹Ñ0” ±=êg&ÊëÄ/	s%—7÷ÈÔm˜>dÓ,3òú”•=#OÂœ&˜Ò
xËëî‘¦Ù?İs'ónuÀn‡¢‘Oç!S$ÔËFÈ¡£Z4 iÙèSÃµø*jìNı×Wî*Lu oäšÈ¤¯?¹cVQ/ã-†5Jj6	:úÇúõiéæu®´´;ú.üµ—¡^"©{ıKÃÍ¡¡†Œ„„ÂŒÄÄÂ›¿¨&^×:á¾¥N"Jc ¦O¡™úc`‡x­[Şšºbš‰¦İPCààw]çN15:2ÿs´‰ ­.¼ÒÃˆ32@/)Õ#Ëœ}È3Ô6v	31|Ğ69ÂlÚ3îZïÉAüÍÕïN3´M*Â»'Kñ6¡VÒ6Z¨E»‡Ô½rñó°?¢ø:@åøâ€¨èp×’èŒ÷$#o{3×	Ï^T—)ö	'©{û‚]dä°ƒì@¹„‹DYã	äKR£İ¡tù=#P)¿^í„:T:=<X]©.±uBa”~EŞ»É…§nÍˆb?©I¡!›„ğ¡k0‡7öiêqx„Ş?5õö*‰i‰R!É§Ğÿ"G7'#¯{ó˜PÑy…SxêT|ï‚c®ù.ê5*„‰«+®jw;ÉwR,Jâ—â!g¨Ï¥.¬a\$°2‡Pèt´®P\Li(í<ÒÁ&†uLéGùXµSèsâ}<œrI z<˜ÍâŠ3¬Bïì—U=ôr[a¹¸ÖY Y¤#åÕƒÿ¦»j ¢¸®°ëî¾!¦n(ÃBeíŒT"F4+"jEÅ¥ "òkˆ”ëoäGÑ`<ş,›•ˆÁ …¤A"k©fEÔC¡ÔMlVŒ+Ğ1¬!Z£ŞÙó–szgP£=§çpÎÌğö¾ùî}ßw¿;ğŞv(ZP˜>â/ô,| •Z‰ô8îp«‰¦ëÙóóoœĞóüºc«=¡vÚ¡şqzÛÈ6‰[ÅríÉâ]EW<Å¿ÔB£aö"Ç—çÛófÂn²‰]şÛò. šç«Á±M=Gcæ”ğéw€5€èFô­0j¥F°†f:¡Œ´ß‰„Û_•ëÊÌ{Œ×•F4«¶Ú]ãòÕÌÅ@•ˆ\™øNJÄâ·Z¸‹úÅÌ´s³àE¬ë–“Hôó°›tÜƒ$Ú¯ t›8VÃõDBMôGµ~ÄíM—çãŸ‹=ãòÄÿ‚wQõ*ZbˆSÙŠPTfSUj'^\*µyP…ğèBÇºÛÕF¼ˆíj|ÄC…A¹â5$Æl+œl!ìjñš™÷55Œ”c+Ü·-o«)Á8™e
<†Z$Ã1×jíSæX9ifDdÀÂUHÓø(h>¢~Ø3Ã·àå*Ïkª±âÍ(
»Tñ}r-šAA`äÍ+h˜)§1Ctï9™’´üwüoíøŞ—¥”/şû¼HXÑúÅÎ‰¥ü>ª4ç”&*õä–o;²ûÆNĞüjw[Î…¸R”Ôƒ©évøz¶Dn‘^ò€t7.ŸO¹S
?•>¤©cÎ™}PàŒêc¯²×Å$ñS-øã¾¦£uÔ°–úxö*=½ğÍô›”6ŸcoQí®ï:ù0BCš¦AÄ=Ùá{Ò^úXæ÷íç{]¨IÁÖ†‡èéP@<G]ZXèp'FBô §S–µÄ«óÈ§ò<ähi m&Ncşy~Í‰Åaîb&pmÒËSßlz =2š½¦{·¼Œb6»æø€ŠÀBlH¡8.Ğ1n—Äƒ1¢K-5ÄLàCOˆ°ß•Ì¦BÏ#ÂæÜ¯©Íd ‰ğˆ@ †#Ê©Âİ…áb—ÚŸÈ÷TÈÅ½C„–³ˆ‹–Zœ`a A\€/¢ş´‡†uŠ'ƒÆÚ\¥6…Ã¡tà€Ñ¶ Wé=~fí¾C	6Ü,0 .nµ%´Â÷¹0ÜæUëœ#@”À/q„ö}æ°é»¾KŸ­IË4m^”ÏQõ›j¶qAî[)sü‚ÏÆß=±ö\‡Í wAIƒ©NWU]òŞ>¾•Ù³{—±H·ŞTUÍÃEæ’i€ê©wJÕpğ!]§e—&g,]’_ÿEãÁªš
®şãÒcÔÄév˜çÕ,À2'Û„l®ÒşTù°×q$œzSM^Xä+wa8ÇÎ¤UÚNÂ6ÙÌLÖÆ¬x^ _UNïã“R×,Ëç°C/õüJ›¢Î	K¥È‰/hÿ¾lZáëi(*(¶y2ûæ&§'	[fG# õ¯Ÿ^üGÕâîYp8¾,ÜK¼t;z+ıÇRMaØ¤È¼nğæ ^\¢ÕÓFr6?µ6]GƒğcBE#ÏQ5°-¤Zhèd¤âÃë6˜jSœtB2±7\×aêÊ`˜³ãğ¼xnã4h3ÀÂX/ŸÃpF}‰x³ŠôãLàÙs~=«l@ìŠNAÙé#ˆ«úl¡íädåÁÜ)û"2#gÅ>6ÒàÀQ=Ö†Ÿ1bPK‚sš+`mØ°^Ü •^0m²~(zäyöˆoÑFöF´‘9]”Ñ ££ßÀÑcü¼2š†¾v¾ÆZÉ›ç“ì’étÎ›ËWnÚÍë	õ;Z“EÃ:Z`ª$KqƒTGrœ lFŒ„8Ú>³~»wáëœ›¢'ÓnzD¹ôÅ«—oâ†ÎP²Ñ’÷Ÿ;ŠV;² Zô¤[%Ü‘—h¬==×µW½ZÖ
ãD‹Vïn&i¦¬”íEæ÷¶sl~ÃZ‹ËËåºŸüÜÉ»JUú`A6IÜ^“Ğ(¡z´ ‡LÉ$S“Ú(Fê30+L¤•è#OMj‡+S/É]ÊI*c» s¤?ïÑlS»œ˜ĞöÉ©+O#ÌsCyú/M_™±‘kÛœıIœ.%qík›x#a»Ú#Í“måJ±Öÿ[*9ŒÃ°ëR’JœgSÔ:!Û©¬E–Òàzê¡0é”,‘à•à‹4šôõ¥Á:Êjí´ÍwÁ<*ïŞì­¤Ô£ p
‡¡¹ğª]œşJ²K–$h9oKšA¹¼pÔäÃŸ¸™8Î
°İL–¶®9§şÌ„¥ƒš²	YYERZı6Ä÷ì¶Cbê‚nÜvlÿ+’„8Œ»}(;Æ.i[ŒseD0l—ÁÈ4QM§jFNĞ àÏYkÏJS‰†ê±dÙÂÖ¼£RaÛ°bĞGn}]º¦lOñ~-ïfØ¶’ï˜7ëâßú}êF	Sm'~í¤È5óú“ğ[fóÙ“ÔâKÚöâ0ŒNÖMŠL¤Ê¯ò/oâÙ[—7Ù
£üfÇm[^ğ·Ë(Á¥fªƒ˜»W›AıĞğqL5š¡Úğa»ßµÖÒš¶ÊìhIš;íâ›¬K$(JĞMÈüª?ôü¹ºÄ|€»Â¿»İX [^Tq†‡şÛ¶I0qÉ}gCŞ
ˆ!2·	‰\ôÇÌÙ{¾ú'½Û“‰5ÿ‹—6UKı8?[K²éá«¹½ÊD4¬PŸ;Æ‹Ù¯İsÑcÅ¹²[%˜fåŠ1hUe.´*Ï ZU¯ƒVõ½;Go`1R²ªéøh$Spi™,ßOÃ{4ªdYIŠ}"§„—¡•Öaà}ÈyDs¤á}<ÔÁ(Ã7N¤‰A(½:ù¿¬–OhAÅ]ÖÍú'æ`€F<¸ˆ¶—œâÍˆS""ÔC‰‹Bz…æĞúŒšRe¥P¬H/^,’ƒÈ.©‡…È@d	ÖÖ‹M¼YfÎÆ€D<ÌÌğÁ÷¾ß{<C½7$Q¢Œãs¤8©\¹9sm:v½XŸMŒ©÷uıŞ³Ø·Ç´µœÀkŠGGûµÿ¬ı¤HÑm	+å56MPñ»~Rƒkó[*î°¸ò–¿ëORn|>mïuÚ‚û+qÛ/>c†¾(3Àê›ú!Ğm^4ñÊ¶ô€•d”·³’í—DÂ)0É“mxDsÒİ®ãt»iGÓÒi-a«^Ò’0Nq‰¢EeŒcPôµøFûCŞŞ#”
Tñ&¢©hş(EGDÕï(kâ@G40r†«ãl]2‚]6Øk’jd]·Ñpİl#•ÊfSñzÔ¬ÕL³6511¬šÿeM’ÿÇ^¢G¬¶!) ; Àïê~ÿGuoM¶Uá¶1şsúri%Ö—yà ¯™ó«‘ç‰%Ùd-’S±É3ŠÈÖ›ü„’SÙ0.+†:Ï¿Ã?|^”îåu~NÇ!=„§ÕUı¡:³äå—xaq‡¸ùZõ?-î¤»Ú»­J¥²[OÂ{ØÅ}ìù  ÿÿ   ÿÿ ı8-endstreamendobj65 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[29/uni00A0/greaterequal/f_i]/Type/Encoding>>endobj66 0 obj<</Ascent 961/CapHeight 714/CharSet(/uni00A0/greaterequal/f_i/space/percent/parenleft/parenright/asterisk/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/equal/A/B/C/D/E/F/G/H/I/J/L/M/N/O/P/R/S/T/U/V/W/X/Y/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/t\rademark)/Descent -224/Flags 32/FontBBox[-164 -224 1066 961]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 78 0 R/FontName/HZWTVT+HelveticaNeueLTStd-BdCn/FontStretch/Condensed/FontWeight 700/ItalicAngle 0/StemV 140/Type/FontDescriptor/XHeight 538>>endobj67 0 obj<</Filter/FlateDecode/Length 567>>stream
H‰\ÔÍ¢@à=OQËîE¨ºu«Mˆ‰mÛ‰‹ùÉ8ó ¥C2A\øöS‡cz’1QRx¿œPäÛıû¾ïf“Ÿ†ægsêúvŠ×á65Ñã¹ë³Òš¶kæÇÑòÙ\ê1ËÓÅ‡ûu—}²ª2ùtò:Owó´i‡c|ÎòoS§®?›§_ÛÃ³É·qü/±ŸMaÖkÓÆSú£/õøµ¾D“/—½ìÛt¾›ï/éš+~ŞÇhìr\Óm¼u§º?Ç¬*ÒkmªôZg±oÿ;/;šßõ”Uå{Z\›bò.ekÕ#,¿«¦÷*Ûb9¶Xg=3ÖÙWæWäó²~Ã¼AŞ2o‘9/}¥¼cŞ!s^úÊ*ÇY³\É\"[f‹ì˜²02m6§ÌŠ˜2ÍfG³ƒÙÑì`vt:8…Ah„Ah„Ah„Ah„Ah„½	zzdñ°7AoÂŞ½yöæÑ›§ÓÃééôpz:=œN§§ÓÃééôpz:=œN§²E'ÊYŠYÊYŠYÊYŠYÊYË½¥ú¸·9K1K9K1K9k¹÷”(:Ñ7æ7dö£èGÙ¢e?Š~ôq£ŸÀ~ú	ôøış@€?Ğàôøış@€?ĞàôøWÈ¶´vÙ‡­™ æsß7·iJ[~yÌ,{»¼ëãç“hF“®Â;û  ÿÿ   ÿÿ äñ\endstreamendobj78 0 obj<</Filter/FlateDecode/Length 4557/Subtype/Type1C>>stream
H‰tT{TçŸawgqXv‚«ÎŠåÈºë–X‹¤¨  ˆ¼”B»,®Â.ì.P1(mÌ%€Õ†£!øàxŒ1U|E!šÔb´*†`NOãIÁàÑªëriO¿Å¼úúc¾×Üûû~÷÷İ{iJéCÑ4­O\½*ke–!Q*®Ü6«e¹T.¥deºŒ‹
ÛÇMd–ƒ•²>€Ç(tsö›l•('İ˜Â7k)¢|©`ê9z6=¿Ün3›ãÌENÉâ–œRY¹¥¸ğ—¶ÅÒõN[Ñ·øÓùóÍ³ÅH³9RŒ+päKbæz—[*q‰Iv«ÃYêp·“W\,;¸D§ä’œŞÃïIŠ6—hİNKTbq®…bŠÍîp¯/•ÄÅÅDœŠl./Ñfİk$1Û”iWt»[´ØÄ¬ï½Ó
mViü°Ä²^$œşİÛ*9İ2;ŒS\[î´¹
lV·Íaw}n·”Hÿƒ…Ã)ÚHÅŞî’¤~/-ÉO4ÍIÈÌònæŠR!ED¤)Š¡(?j"K	5İ2*©çÕÔ¢Pª…¢k}¨d¯Ô©Ôrê.=•Î¦·ÒïÑçé~ú‘ÏBŸ|ŸS
³Â®¸¥\¦¬V1ª
U³ê09Ì{ÌšW/P¿­¾¬ş«o¨ïó¾e¾m¾÷üfú½á?Á¶¿äßä{BĞ„_Lø(@(èÈOÌ˜x›Õ²‘ìZv/{204pe`kà?59šßùÅm:ôTkÖ–iÏi»µ÷¹¤=õ]òHMÆ°.E½R®]1VÇ@#~ÄãBØ¡‚!EìæÁ»Û®còÆ×°É‘ÏñŞzw,=ÕıPÕoñ»*µí/= !w²†ë¯‘{ ‰¿ŞÔÑÑÑd]]kµZk;„iµ<òûSAšı½À_Ö‹Ô”¥"/¿±húÿ¦ÿäŞ¯Ù>v†¿ËÈ£uªH†Å$üyÅ7!•t„* c4Ÿ…fQÔ¡x÷Ñ,x˜(0ôÄş0?8C<Gó”_ á ò£Ã˜bä£Ğ@üîƒù8AÔhã,0ì\ùT%,'n¦;
0‘û0Xl‡3XkìŒ¾—n=¾5£ïtìc gŸ!kUA°š­3İC®é3æsÔ…UEk^âÕOßØwË£ƒ5+BøÓ'á°â$<äÑƒÿ:B(˜Õ,ÎÜ^1ZUI×ÁWŠºj”½
•ÛX=,¦wC˜!Lóä ’w¿ÔûV>&Õ˜üJfJê†c `ØA›Îš Šš!	^„¦œ!ŒÅ¢LÆm|§B®†„šìÅÍ™¦©N/2NŞh„i$“ØÆzPÊ[½
AŒäÕ ä±•ÙŞ¾÷èñ#Ÿß¼qàâßtÀÆ_ÇéhHˆÃç„RÔ·^ß~éÏ“Oí³¯XT³.%CŸ­š‘3µ:9q<
Ø4¼¾ê†µ­ `0‰{:™µÆ´‚•¯Sãä«Q0Uà>€œ£pïîšËæ}ƒš;Ñ·óØù¿è (ö£..õ„2}Í§{;ÛJ“n ½<;MÈ52Üg§™–ô”Ôß®ŠO©>ug‹Ş1„“€²+éP‚èÍ¨·áME†Ä×¦j`pÛXÛ0œ0
¿
Ê¥r6ÎbpÓXšŠ°~ .Pæ> 
”Z¯"&Â÷Œ3šÌ©n°lŒWÏpg:¶µí;6ùÊîµè7§ìåôÔW?íÔ£ğk&ú yöDH>õæ€²œ"pƒË-
Kõ[˜ğ3´<S§İ¦amyf#Ñ…#÷<ád9[ŞÇÃÔ-¦3'ãÆZÌÄ\ŒÛ‡‘°ZÏ=Èë_Á<àr‡Q›šë*té·f¿Ùß/pòé]ë²õøü„ÿºíÈ{r¾M2,x5-^ÏÉ‰5n—Fîİ&'*ÚH@¨³jÔãŠ4,*ÇX_00{ ÷*8Àæû‚zœ&IŸœqšäé¢ç³'áµ@.ÿÂœD’îÅ0iğ®õÚ‚·ò~#ı­û¯œÕ>ú<©E>:õ9û“û+…-jîÑ‚ÖøH7BrûyÏ¡ÎÎ=k—%9ÖZ,C¸G›ğ*uWÏ•+»²—&Ve%'W}Ø'Œ1y ı1ë5ræó8¥aèWŸ› ^†8'D¢W.Œ\bÆyÈuAÛÛ¹÷ı½ú3cSl¬À¼Tõn71©^şó¯õ5¯xáuÁP.ed–ùZğ–,Hß•mˆ·d1”IùíŠ…À; &ZvÊŠNèæåFĞŒ52xOùíŠ ‰h ¸	šúJm½ÜÍİ®WBs*È`!™"LÍSaÃ}‰¾ùoªHª²õX÷ Ò<Ú®g}€P'w…@-C!úÃPŞË¹İì-ùzë?¾­ƒ©óN¢¿€¯16?Ç\?ä\šXT­ÏgÂ•½ÄíR§+**×™ ÏdØ‹Õ¹İ£=LĞ—tÈ9Ä=”kåşñ+`À|,.E–`I;š Xà† ıL“Ã4I¥«RKB1äíºqCà^y'o†©÷È[=ôšB:É…¨d ³‡tçßAaLÅ\=ÖŒ³û„Ÿ?D‘×YY™®_Æ°MõD«,òE“JbVt‘¶ü<Ùş¸›üØLæÍäçoG­&Ú^ú±m¹ñÒmÆf«=K*à]üÆ£=AA˜åá:I97È[y˜¹l#1%qó¿ø®Ö¨(,,]Yw¡ÂÎ˜	q}D$Šh4&‰z‡ˆ£‰¼dÏ€Àˆ«	aA ”(òˆ  `@P4øˆ Á×dÍ
„gwo³5œ³·zP“Ùs¦«»nÕ½_}ß½·èê
KD¡¹³åX{µÖH„´eIEõ“}x¡ùÍM[¼Ó1)¼~å=İ¢ĞrùØÒÕZù»±ğ•±Úå†[ùÒi7¸¬£n´Œ.„2MIŠu#ëR<
ˆtaG×a0zËÈø»BäÖDö¥Ç:¾8ssXXæ©^±„ºnå©}í4˜î7¯ÂQ:ˆVˆ—Ô/o«B]0òR¿mA8,İÍî"¸J¬0^DKF‚µ“c¥F:9£µ\Ñ‡-ÄÍšËÈ+R.Gc‰rÈæ$–bØ„¶¶c@ûl#¾Öl¼ÑÈÕª7ê#é9†2Éi-úR#ª1ÎÀÖ˜>ã .^£[Çø„Ds`Ó·÷ï›ŞÆì¢÷ñòÒß‚QÙ€XÖY Î"C9ç	”u·	LúG'L}ş˜ºké>™?¤§üƒ%>Ñ[‚yØ1˜‡!Ê¦oäóKÈg	VKTÂ£.òuMì²7£ãü´„ºYİU8ÉLé6¹||K°Q»—¾˜›—hJùxì'‰¦Oês¾3ÀôŒ¶?æ€òzÔw¤îú Àw®2y}N”6ñ”àFjÙW–¿§	ı%¬Šç©ëõÅ0OnÇÃ.˜şc‚™Ãâ 8Çù—í8qVİpäÌ×¢pÛ\½TâQ/¾fÆB7ÉË“ñ¾Zß…ƒ±'“—«6$¼¿8µ±S,æåüİŒ—ivˆu-Ï‡µÜğ­“Å“ÎŒ1ñ#ROƒA)İç`¹(e!Y¼oÚê¥KÓ.~ƒcAÏÎ<O*Pä¡x®ã`%aGÍamœl=Îewé8§„S{ÀŸÎgÓŒdØ¸À\rW*ÄÊz×ZÈá \˜™H„Ú…hh óĞ‡óäÁBÛ@ÙaÛr¿T¢À\1ª¢~t”Oò/Èú7ÍâÀ‹P?…`áèlâAÓgA:G_'ÊF›!b„²³+­K8Z1Wó°RÂgò*­À­fB§Ü«ÔI¢îş€s9¸RÅŠ­ˆ&è`‘ä¨*äJÊšŠ¶EmÖ§Gíé8¡yFRT”»úêù?ß¨7µ!b6Ğíİ¾W—Ÿæ€}ˆ¾*»´U§ø¡­]Ô{Š×ê$îÀ-Å&Uà{É›6eTŸ9Wr¢ıxdoişç&e©Ş2ë!<¶€WŠs¯W@20ì8ê¸Òq(€:RÇÌ€ ÿÌp©Hñ‹+v—Œ|xe®MÜ…{a÷(£[¯5€á¨ÇnÑaØ®WŒr•–Á
„e}T ‚ÇJšD·vaŞ÷¯îÀdK×]täÊL3fr§ƒ]
‚ÃÄß¸wò©{‹ÇÜë¸òÄ=ÿ Ù=¬Ì=L"ÕHc|Lq˜İòÆô.´ĞˆŞÀµÕ·V"pÌ?Xø=Løµ‹¹ª*æo†qt.õO jÌ’ê˜2"À¥£ß'R'²lwjL¤fMÚÕkÚFş{ûb¾õğ%ó¥‚Èùy¬ïG)ü4œâÜ‹Îö÷º€(Şx£™T™ÕççïÉÉG‰ı“úÛ’s·i<C>œ¦õ_2³›W–ÒÜš,ğãÃY¬ŠôLvSĞ-Õ¨„ê ßQ´QC§¥Ò©Ô™†›ß‚ñgËN—k¾$$eC°(œNKßŸ¿C+$ïÈßm*R#¶ÂéY7ÂPgs¯İ„—Eé /4Ğ
Z¥æ`Ëó‘µô´«Ví¼ñ-b1Äí!\AT4a0B:Ê*šÏéBE+1Má-kšç®ŠøKd’h€tvâhX“òæóht^ƒ¯oØ£õsì;õ–şûlB*0+qíîö?_åsÍ9¬§ê–Ÿ´Rùgv¥òÂ°&ÅfgËû"Ìæ[®O“8˜Á$yÛÚâ³–FréÌ!&È'Ş0Z`ƒTÍâcø²ğœm¿‰“„9ÊÇäjyåÙúÂmëDë6æ3–4üÖ_òX¤ÄœYµB³j}ÊÚl¡…>3uåmø=Yánÿ~Â—2‚áÉ«ãq-áö5fÍîXÊ»r´˜Š~—#Õi@ÓTX'‚gÛ/(Í€È_è‚l-õJWhY–¿ÿNW{Q²U½=$øİïÀx<F:K^xüÄ¦¡ÿ'më*NÓÉúŠİ…1ak…>›¶C7êÂã˜ŸC—ä(½üÉ§Ëßdş>ä3‘ââöò	 û‚|kÜÆâĞ1iÚty¡¦¸±Û%uC ½ÁU/g$¡–¡G„›ĞË÷´?g*ÌÉ1!®|îî]¹»5AÑ[Âöµ=Ì«X=çRp¢{gÛ¿ğ |U©¼[ã»È‡¿µ×÷áÙ9x4Şå\d¡¾¤L]Wy´æËÃ‰¡"8•¡Àvú<}9ØÇsq}Do"Ö¼¡îÄ_KÓcÔët"¶U5‹E<Šıãa&wYê‰½¨PÔ1½‚ŞP»£±0î‹ò¼¼Jñg>g×ÎœšviĞÂYÌØuˆ¼-¹IA)O‰’
ß±~ECGH@R|DÔöâ6Qâñh[&Ÿøárë±‹,{ÅÊš°Û'ù) fªäMIÅa3Zksh¤¹A
Ş¨F'9ƒöûŸø	kÀÉ§1’3VÇo¬ÎÌ&àÀ,ğ€>[/Ä?Òid©<XÁ¸Z†mßO¥¤KToƒ—¼ëKÔ„w¼JÜÈ]ğ½K}Ùu‡J¼˜™Øe¬Mş²ËMÔWÕN`bUøŸÓ‚‹”Ã_buÀŞä§cï}’š°F“™™kÌÔ*¥‚‘qv˜íñöÍÅÈ=¼ßX$OºˆxÓ<4õ†<.²zZ ÖHi-7L¡# µ*´»öôÁLì4•Ê‚]=vÒ„NE«4¨šÇÃÿtë·k'ûï›¿-YÍÙÈ|Og½ÁŞóGAôòegvP£ Ïg¿séBKöïRÀ{öıF)÷{Éß4Qh™Ï&|m;R±Xì_Ã(ökgşŒ›ù;hæw¥™lß—Nz4éÏ¡ÉìUs~ÆÍù5(ò~ÒŸ—Ó9¿r}—ã¾8}úÄ‰§¯æáy¤'N8‘‡·‡‡ï{‹ÈBQ    ÿÿ   ÿÿ Õ¢şendstreamendobj22 0 obj<</AIS false/BM/Normal/CA 1.0/OP true/OPM 1/SA false/SMask/None/Type/ExtGState/ca 1.0/op true>>endobj31 0 obj<</Length 23061>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 311.7281 cm
0 0 m
32.262 0 l
S
Q
q 1 0 0 1 36 277.1681 cm
0 0 m
31.295 0 l
S
Q
q 1 0 0 1 36 195.8181 cm
0 0 m
57.378 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.019 Tc 0.036 Tw 8 0 0 8 36 727.248 Tm
[(12 mg of nivolumab,)37.2 ( 4 mg of rela)-9.8 (tlimab,)37.2 ( and histidine \(1.1 mg\),)37.2 ( L-histidine hydrochloride)-19 ( )]TJ
-0.013 Tc 0.205 Tw 0 -1.044 Td
[(monohydra)-9.6 (te \(2.7 mg\),)37.4 ( pentetic a)0.5 (cid \(0.008 mg\),)37.4 ( polysorba)-9.7 (t)0.5 (e 80 \(0.5 mg\),)37.4 ( sucrose)-13 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(\(85.6 mg\),)37.2 ( and )37.2 (W)18.2 (a)-9.8 (ter for Injection,)37.3 ( USP)129.2 (.)37.2 ( )37.2 (The pH is 5.8.)]TJ
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 0 -2.003 Td
(12)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(CLINIC)18.3 (AL PHARMACOLOGY)]TJ
0.017 Tw -3.375 -1.94 Td
(12.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(Mechanism of Action)Tj
/T1_0 1 Tf
-0.014 Tc 0.192 Tw -3.375 -1.539 Td
[(Rela)-10 (tlimab is a human IgG4 monoc)19.9 (lonal antibod)-10 (y tha)-10.1 (t binds to the LAG-3 receptor)73.9 (,)23 ( )]TJ
-0.013 Tc 0.224 Tw 0 -1.044 Td
[(blocks interaction with its ligands,)36.7 ( inc)19.7 (luding MHC II,)36.6 ( and reduces LAG-3 pa)-10.3 (thway-)]TJ
-0.019 Tc 0.024 Tw 0 -1.044 Td
[(media)-9.6 (ted inhibit)0.5 (ion of the immune response.)37.4 ( )37.4 (Anta)-9.6 (gonism of this pa)-9.6 (thway promot)0.5 (es )37.4 (T cell)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(prolifera)-9.8 (tion and c)20.2 (ytokine secretion.)]TJ
0.12 Tw 0 -1.674 Td
[(Binding of the PD-1 ligands,)37.1 ( PD-L1 and PD-L2,)37.1 ( to the PD-1 receptor found on )37.2 (T cells,)18 ( )]TJ
0.078 Tw 0 -1.044 Td
[(inhibits )37 (T)55.2 (-cell prolifera)-9.7 (tion and c)20.2 (ytokine production.)37.2 ( Upregula)-9.8 (tion of PD-1 ligands occurs)-19 ( )]TJ
0.044 Tw 0 -1.044 Td
[(in some tumors,)37.2 ( and signaling through this pa)-9.8 (thway can contribute to inhibition of active)-19 ( )]TJ
0.078 Tw 0 -1.044 Td
[(T)55.2 (-cell immune sur)-17.8 (veillance of tumors.)37.1 ( Nivolumab is a human IgG4 monoc)20.2 (lonal antibod)-9.8 (y)-18.9 ( )]TJ
-0.016 Tc 0.137 Tw 0 -1.044 Td
[(tha)-9.9 (t binds to the )0.5 (PD-1 )0.5 (receptor)74.2 (,)37.1 ( blocks )0.5 (interaction with its )0.5 (ligands PD-L1 )0.5 (and PD-L2,)21 ( )]TJ
-0.019 Tc 0.12 Tw 0 -1.044 Td
[(and reduces PD-1 pa)-9.8 (thway-media)-9.8 (ted inhibition of the immune response,)37.1 ( inc)20.1 (luding the)-19 ( )]TJ
0.065 Tw 0 -1.044 Td
[(anti-tumor immune response.)37.2 ( In syngeneic mouse tumor models,)37.2 ( blocking PD-1 activity)-18.9 ( )]TJ
0.06 Tw 0 -1.044 Td
[(resulted in decreased tumor gro)-9.7 (wth.)]TJ
-0.022 Tc 0.024 Tw 0 -1.674 Td
[(The combina)-9.6 (tion of nivolumab \(anti-PD-1\) and rela)-9.6 (tlimab \(anti-LAG-3\) results in increased)-22 ( )]TJ
-0.019 Tc 0.113 Tw 0 -1.044 Td
[(T)55.2 (-cell activa)-9.8 (tion compared to the activity of either antibod)-9.8 (y alone.)37.2 ( In murine syngeneic)-19 ( )]TJ
-0.015 Tc 0.169 Tw 0 -1.044 Td
[(tumor models,)36.9 ( LAG-3 blockade potentia)-10.2 (tes the anti-tumor activity of PD-1 blocka)-10.2 (ge,)22 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(inhibiting tumor gro)-9.8 (wth and promoting tumor regression.)]TJ
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 0 -1.94 Td
(12.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Pharmacodynamics)Tj
/T1_0 1 Tf
-0.019 Tc 0.083 Tw -3.375 -1.539 Td
[(The )0.5 (exposure-response )0.5 (rela)-9.8 (tionship )0.5 (and time course of )0.5 (pharmacod)-9.8 (ynamic response for)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(the safety and effectiveness of OPDUALAG ha)-9.8 (ve not been fully characterized.)]TJ
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 0 -1.94 Td
(12.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Pharmacokinetics)Tj
/T1_0 1 Tf
-0.013 Tc 0.22 Tw -3.375 -1.539 Td
[(The pharmacokinetics \(PK\) of rela)-10.2 (tlimab follo)-10.1 (wing the administra)-10.2 (tion of OPDUALAG)-13 ( )]TJ
-0.019 Tc 0.061 Tw 0 -1.044 Td
[(were characterized in pa)-9.8 (tients with cancer who received rela)-9.8 (tlimab 20 to 800 mg ever)-17.8 (y)-19 ( )]TJ
-0.022 Tc 0.024 Tw 0 -1.044 Td
[(2 weeks \(0.25 to 10 times the a)-9.8 (pproved recommended dosa)-9.8 (ge\) or 160 to 1440 mg ever)-17.8 (y)-22 ( )]TJ
-0.016 Tc 0.132 Tw 0 -1.044 Td
[(4 weeks \(1 to 9 times the a)-9.7 (pproved recommended dosa)-9.7 (ge\) either as a monothera)-9.7 (py)-16 ( )]TJ
-0.019 Tc 0.092 Tw 0 -1.044 Td
[(or in combina)-9.7 (tion with nivolumab dosa)-9.8 (ges of 80 or 240 mg ever)-17.8 (y 2 weeks or 480 mg)-19.1 ( )]TJ
0.06 Tw 0 -1.044 Td
[(ever)-17.8 (y 4 weeks.)]TJ
-0.015 Tc 0.177 Tw 0 -1.674 Td
[(Stead)-10.5 (y-sta)-10.5 (te concentra)-10.4 (tions of rela)-10.4 (tlimab )0.5 (were )0.5 (reached by )0.5 (16 weeks )0.5 (with an )0.5 (ever)-18.4 (y)-15 ( )]TJ
-0.021 Tc 0.024 Tw 0 -1.044 Td
[(4-week regimen and the systemic accumula)-10.1 (tion was 1.9-fold.)36.8 ( )36.9 (The a)-10.1 (vera)-10.1 (ge concentra)-10.1 (tion)-20.9 ( )]TJ
-0.019 Tc 0.019 Tw 0 -1.044 Td
(\(C)Tj
5.6 0 0 5.6 41.7728 394.778 Tm
[(a)-9.8 (vg)]TJ
0.097 Tw 8 0 0 8 48.8588 395.518 Tm
[(\) )0.6 (of )0.5 (rela)-9.8 (tlimab )0.5 (after )0.6 (the )0.5 (\037rst )0.5 (dose )0.5 (increased )0.6 (dose )0.6 (proportionally )0.6 (a)-9.8 (t )0.6 (doses )0.6 (\036160 )0.6 (mg)-19 ( )]TJ
0.06 Tw -1.607 -1.044 Td
[(ever)-17.8 (y 4 weeks.)]TJ
0.042 Tw 0 -1.674 Td
[(F)20.2 (ollo)-9.7 (wing the recommended dosa)-9.7 (ge,)37.2 ( the geometric mean [coef\037cient of varia)-9.8 (tion \(CV%\)])-19 ( )]TJ
-0.014 Tc 0.198 Tw 0 -1.044 Td
[(maximum and a)-10.3 (vera)-10.3 (ge concentra)-10.3 (tions \(C)]TJ
0.014 Tw 5.6 0 0 5.6 159.742 364.688 Tm
(max)Tj
0.198 Tw 8 0 0 8 168.3147 365.428 Tm
( and C)Tj
0.014 Tw 5.6 0 0 5.6 189.7654 364.688 Tm
[(a)-10.3 (vg)]TJ
0.198 Tw 8 0 0 8 196.9438 365.428 Tm
[(\) of rela)-10.2 (tlimab a)-10.3 (t stead)-10.3 (y sta)-10.3 (te)-14 ( )]TJ
-0.019 Tc 0.109 Tw -20.118 -1.044 Td
[(were 62.2 \(30%\),)37.2 ( and 28.8 \(45%\) \033g/mL,)37.2 ( respectively; and the mean C)]TJ
0.019 Tw 5.6 0 0 5.6 244.5411 356.338 Tm
(max)Tj
0.109 Tw 8 0 0 8 253.0215 357.078 Tm
( and C)Tj
0.019 Tw 5.6 0 0 5.6 272.8022 356.338 Tm
[(a)-9.8 (vg)]TJ
0.109 Tw 8 0 0 8 279.8882 357.078 Tm
[( of)-19 ( )]TJ
0.06 Tw -30.486 -1.044 Td
[(nivolumab a)-9.8 (t stead)-9.8 (y sta)-9.8 (te were 187 \(33%\) and 94.4 \(43%\) \033g/mL,)37.2 ( respectively)55.2 (.)]TJ
-0.014 Tc 0.191 Tw 0 -1.674 Td
[(In RELA)55 (TIVITY)74 (-047,)36.9 ( the nivolumab geometric mean minimum concentra)-10 (tion \(C)]TJ
0.014 Tw 5.6 0 0 5.6 269.7151 334.5981 Tm
(min)Tj
0.191 Tw 8 0 0 8 277.2586 335.338 Tm
[(\) a)-10 (t)-14 ( )]TJ
-0.019 Tc 0.06 Tw -30.157 -1.044 Td
[(stead)-9.8 (y sta)-9.8 (te in the OPDUALAG arm was comparable to the nivolumab arm.)]TJ
-0.017 Tc 0.017 Tw 0 -1.782 Td
(Distribution)Tj
-0.019 Tc 0.091 Tw 0 -1.494 Td
[(The )0.5 (geometric )0.5 (mean )0.6 (\(CV%\) )0.5 (volume )0.5 (of )0.5 (distribution )0.5 (a)-9.8 (t )0.5 (stead)-9.8 (y )0.5 (sta)-9.7 (te )0.5 (of )0.6 (rela)-9.8 (tlimab )0.5 (is )0.5 (6.6 )0.5 (L)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
(\(20%\) and 6.6 L \(19%\) of nivolumab.)Tj
-0.017 Tc 0.017 Tw 0 -1.782 Td
[(Elimina)-9.8 (tion)]TJ
-0.019 Tc 0.117 Tw 0 -1.494 Td
[(The geometric mean \(CV%\) c)20.2 (learance of rela)-9.8 (tlimab is 5.5 mL/h \(41%\) a)-9.8 (t stead)-9.8 (y sta)-9.7 (te,)18 ( )]TJ
-0.016 Tc 0.126 Tw 0 -1.044 Td
[(1)0.5 (0)0.6 (%)0.5 ( l)0.6 (o)-9.5 (w)0.6 (e)0.5 (r)0.6 ( t)0.5 (h)0.6 (a)0.5 (n)0.6 ( a)0.5 (f)0.6 (t)0.5 (e)0.6 (r)0.5 ( t)0.6 (h)0.5 (e)0.6 ( \037)0.5 (r)0.6 (s)0.5 (t)0.6 ( d)0.5 (o)0.6 (s)0.5 (e)0.6 ( [)0.5 (6)0.6 ( m)0.5 (L)0.6 (/)0.5 (h)0.6 ( \()0.5 (3)0.6 (9)0.5 (%)0.6 (\))0.5 (])0.5 (.)37.6 ( F)20.5 (o)0.6 (l)0.5 (l)0.5 (o)-9.4 (w)0.5 (i)0.6 (n)0.5 (g)0.5 ( O)0.5 (P)0.6 (D)0.5 (U)0.5 (A)0.6 (L)0.5 (A)0.5 (G)0.6 ( \()0.6 (n)0.5 (i)0.5 (v)0.6 (o)0.5 (l)0.5 (u)0.6 (m)0.5 (a)0.6 (b)-16 ( )]TJ
-0.011 Tc 0.255 Tw 0 -1.044 Td
[(480 mg and rela)-9.6 (tlimab 160 mg administered ever)-17.6 (y 4 weeks\) administra)-9.6 (tion,)37.3 ( the)-11 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
(geometric mean \(CV%\) effective half-life \(t)Tj
0.019 Tw 5.6 0 0 5.6 157.1918 240.4281 Tm
(1/2)Tj
0.06 Tw 8 0 0 8 163.802 241.1681 Tm
[(\) of rela)-9.8 (tlimab is 26.2 days \(37%\).)]TJ
-0.012 Tc 0.248 Tw -15.975 -1.674 Td
[(The geometric mean \(CV%\) c)19.7 (learance of nivolumab is 7.6 mL/h \(40%\) a)-10.2 (t stead)-10.3 (y)-12 ( )]TJ
-0.015 Tc 0.167 Tw 0 -1.044 Td
[(sta)-10.1 (te,)36.9 ( 21% lo)-10 (wer than after the \037rst dose [9.6 mL/h \(40%\)] and the terminal t)]TJ
0.015 Tw 5.6 0 0 5.6 273.4127 218.688 Tm
(1/2)Tj
0.167 Tw 8 0 0 8 280.0948 219.428 Tm
[( is)-15 ( )]TJ
-0.019 Tc 0.06 Tw -30.512 -1.044 Td
(26.5 days \(36%\).)Tj
-0.017 Tc 0.048 Tw 0 -1.782 Td
[(Speci\037c P)18.2 (opula)-9.8 (tions)]TJ
-0.02 Tc 0.024 Tw 0 -1.494 Td
[(The follo)-9.8 (wing factors had no c)20.2 (linically important effect on the c)20.1 (learance of nivolumab and)-20.1 ( )]TJ
-0.023 Tc 0 -1.044 Td
[(rela)-10.4 (tlimab:)36.6 ( a)-10.4 (ge \(17 to 92 years\),)36.6 ( sex,)36.7 ( race \(White,)36.6 ( )36.6 (Asian,)36.6 ( and Black/African )36.6 (American\),)36.7 ( mild)-23 ( )]TJ
-0.02 Tc 0 -1.044 Td
[(or modera)-10.2 (te renal impairment \(eGFR 30 to 89 mL/min/1.73 m)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 211.2701 170.832 Tm
(2)Tj
-0.02 Tc 0.024 Tw 8 0 0 8 213.8475 168.168 Tm
[(\),)36.8 ( mild hepa)-10.3 (tic impairment)-20 ( )]TJ
-0.016 Tc 0.13 Tw -22.231 -1.044 Td
[(\(total bilirubin [TB] less than or equal to upper limit of normal [ULN]\ and )37 (AST grea)-9.6 (ter)-16 ( )]TJ
-0.015 Tc 0.154 Tw 0 -1.044 Td
[(th)0.5 (an ULN)0.5 ( or)0.5 ( )37.1 (TB)0.5 ( gr)0.5 (ea)-9.5 (ter)0.5 ( t)0.5 (han 1 t)0.5 (o 1.5)0.5 ( ti)0.5 (mes)0.5 ( U)0.5 (LN a)0.5 (nd)0.5 ( an)-9.5 (y )37.1 (AS)0.5 (T\) o)0.5 (r mo)0.5 (der)0.5 (a)-9.6 (t)0.5 (e h)0.5 (epa)-9.5 (tic)-14.9 ( )]TJ
-0.016 Tc 0.134 Tw 0 -1.044 Td
[(impairment \(TB grea)-9.8 (ter than 1.5 to 3 times ULN and an)-9.8 (y )37.1 (AST\).)37.2 ( )37.2 (The effects of severe)-16 ( )]TJ
-0.019 Tc 0.114 Tw 0 -1.044 Td
[(renal impairment,)37.2 ( or severe hepa)-9.8 (tic impairment on the pharmacokinetics of nivolumab)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(and rela)-9.8 (tlimab are unkno)-9.8 (wn.)]TJ
/T1_2 1 Tf
-0.017 Tc 0.048 Tw 0 -1.782 Td
[(P)18.2 (edia)-9.7 (tric pa)-9.8 (tients:)]TJ
/T1_0 1 Tf
-0.019 Tc 0.046 Tw 0 -1.494 Td
[(The exposures of nivolumab and rela)-9.7 (tlimab in pedia)-9.8 (tric pa)-9.8 (tients 12 years of a)-9.8 (ge or older)-19 ( )]TJ
0.055 Tw 0 -1.044 Td
[(who weigh a)-9.8 (t least 40 kg are expected to be in the range of exposures in adult pa)-9.8 (tients)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(a)-9.8 (t the recommended dosa)-9.8 (ge.)]TJ
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 36 80.468 Td
(12.6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Immunogenicity)Tj
/T1_0 1 Tf
-0.019 Tc 0.024 Tw -3.375 -1.539 Td
[(The obser)-17.7 (ved incidence of anti-drug antibodies is highly dependent on the sensiti\vity and)-19 ( )]TJ
-0.024 Tc 0.021 Tw 0 -1.044 Td
[(speci\037city of the assay)55.3 (.)37.4 ( Differences in assay methods prec)20.3 (lude meaningful comparisons of)-24 ( )]TJ
-0.02 Tc 0.024 Tw 0 -1.044 Td
[(t)0.5 (h)0.5 (e )0.5 (i)0.5 (n)0.5 (ci)0.5 (d)0.5 (e)0.5 (n)0.5 (ce)0.5 ( )0.5 (o)0.5 (f)0.5 ( a)0.5 (n)0.5 (t)0.5 (i)0.5 (-d)0.5 (r)0.5 (u)0.5 (g)0.5 ( a)0.5 (n)0.5 (t)0.5 (i)0.5 (bo)0.5 (d)0.5 (i)0.5 (es)0.5 ( )0.5 (i)0.5 (n)0.5 ( t)0.5 (h)0.5 (e)0.5 ( )0.5 (st)0.5 (u)0.5 (d)0.5 (ie)0.5 (s)0.5 ( )0.5 (d)0.5 (es)0.5 (c)0.5 (r)0.5 (ib)0.5 (e)0.5 (d)0.5 ( )0.5 (be)0.5 (l)0.5 (o)-9.5 (w)0.5 ( )0.5 (wi)0.5 (t)0.5 (h)0.5 ( )0.5 (th)0.5 (e)0.5 ( )0.5 (in)0.5 (c)0.5 (i)0.5 (d)0.5 (en)0.5 (c)0.5 (e)0.5 ( o)0.5 (f)-20 ( )]TJ
0 -1.044 Td
[(a)0.5 (n)0.5 (t)0.6 (i)0.5 (-)0.5 (d)0.5 (r)0.5 (u)0.6 (g)0.5 ( )0.5 (a)0.5 (n)0.5 (t)0.6 (i)0.5 (b)0.5 (o)0.5 (d)0.5 (i)0.5 (e)0.6 (s)0.5 ( )0.5 (i)0.5 (n)0.5 ( )0.5 (o)0.6 (t)0.5 (h)0.5 (e)0.5 (r)0.5 ( )0.6 (s)0.5 (t)0.5 (u)0.5 (d)0.5 (i)0.6 (e)0.5 (s)0.5 (,)37.5 ( )0.5 (i)0.5 (n)0.6 (c)20.5 (l)0.5 (u)0.5 (d)0.5 (i)0.5 (n)0.5 (g)0.6 ( )0.5 (s)0.5 (t)0.5 (u)0.5 (d)0.5 (i)0.5 (e)0.6 (s)0.5 ( )0.5 (o)0.5 (f)0.6 ( )0.5 (n)0.5 (i)0.5 (v)0.5 (o)0.6 (l)0.5 (u)0.5 (m)0.5 (a)0.5 (b)0.5 ( )0.6 (a)0.5 (n)0.5 (d)0.5 ( )0.5 (r)0.6 (e)0.5 (l)0.5 (a)-9.5 (t)0.6 (l)0.5 (i)0.5 (m)0.5 (a)0.6 (b)0.5 (-)0.5 (r)0.5 (m)0.5 (b)0.5 (w)-20 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(products,)37.2 ( or nivolumab products.)]TJ
0 -1.674 Td
[(During the initial 24-month trea)-9.8 (tment period in RELA)55.1 (TIVITY)74.2 (-047,)37.2 ( the incidence of:)]TJ
-0.017 Tc 0.017 Tw 1.125 -1.54 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.019 Tc 0.024 Tw 1.125 0 Td
[(anti-nivolumab antibodies and neutralizing antibodies in the OPDUALAG gr\oup was)-19 ( )]TJ
-0.017 Tc 0.034 Tw 0 -1.062 Td
[(3.8% \(11/288\) and 0.3% \(1/288\),)37.2 ( respectively)55.2 (,)37.2 ( which was similar to tha)-9.7 (t obser)-17.7 (ved)-17 ( )]TJ
0.06 Tw 0 -1.062 Td
[(in the nivolumab group:)37.2 ( 5.9% \(16/272\) and 0.4% \(1/272\),)37.2 ( respectively)55.1 (.)]TJ
0.017 Tw -1.125 -1.387 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.025 Tw 1.125 0 Td
[(anti-rela)-9.8 (tlimab antibodies and neutralizing antibodies in the OPDUALAG group was)-17 ( )]TJ
0.06 Tw 0 -1.062 Td
[(5.6% \(16/286\) and 0.3% \(1/286\),)37.2 ( respectively)55.2 (.)]TJ
-0.022 Tc 0.024 Tw -2.25 -1.521 Td
[(Because of the lo)-9.6 (w incidence of anti-drug antibodies,)37.3 ( the effect of these antibodies on the)-22 ( )]TJ
0 -1.044 Td
[(pharmacokinetics,)36.7 ( pharmacod)-10.3 (ynamics,)36.7 ( safety)54.7 (,)36.7 ( or effectiveness of OPDUALAG is unkno)-10.3 (wn.)]TJ
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 0 -2.003 Td
(13)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(NONCLINIC)18.2 (AL TOXICOLOGY)]TJ
0.017 Tw -3.375 -1.67 Td
(13.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(Carcinogenesis,)37.2 ( Mutagenesis,)37.2 ( Impairment of F)20.2 (ertility)]TJ
/T1_0 1 Tf
-0.019 Tc 0.06 Tw -3.375 -1.539 Td
[(OPDUALAG contains nivolumab and rela)-9.7 (tlimab.)]TJ
0.109 Tw 0 -1.674 Td
[(No studies ha)-9.8 (ve been performed to assess the potential of nivolumab or rela)-9.8 (tlimab for)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(carcinogenicity or genotoxicity)55.2 (.)37.2 ( F)24.3 (ertility studies ha)-9.8 (ve not been performed with nivolumab)-19 ( )]TJ
0 -1.044 Td
[(or rela)-9.8 (tlimab.)]TJ
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 0 -1.94 Td
(13.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(Animal T)74.2 (oxicolog)-9.8 (y and/or Pharmacolog)-9.8 (y)]TJ
/T1_0 1 Tf
-0.019 Tc 0.09 Tw -3.375 -1.539 Td
[(In animal models,)37.2 ( inhibition of PD-1 signaling increased the severity of some infections)-19 ( )]TJ
-0.011 Tc 0.257 Tw 0 -1.044 Td
[(and enhanced in\034amma)-9.7 (tor)-17.7 (y responses.)37.3 ( )]TJ
/T1_2 1 Tf
(Mycobacterium tuberculosis)Tj
/T1_0 1 Tf
[(\226infected PD-1)-11 ( )]TJ
-0.019 Tc 0.05 Tw 0 -1.044 Td
[(knockout mice exhibited markedly decreased sur)-17.8 (vival compared with wild-type controls,)18 ( )]TJ
-0.016 Tc 0.139 Tw 0 -1.044 Td
[(which correla)-10 (ted with increased bacterial prolifera)-9.9 (tion and in\034amma)-9.9 (tor)-17.9 (y responses in)-16 ( )]TJ
-0.017 Tc 0.123 Tw 0 -1.044 Td
[(these animals.)36.7 ( PD-1 blockade using a prima)-10.3 (te anti-PD-1 antibod)-10.3 (y was also sho)-10.3 (wn to)-17 ( )]TJ
-0.015 Tc 0.015 Tw 0 -1.044 Td
[(e)0.5 (x)0.5 (a)0.5 (c)0.5 (e)0.5 (r)0.5 (b)0.5 (a)-9.5 (t)0.5 (e)0.5 ( )]TJ
/T1_2 1 Tf
0.152 Tw 4.302 0 Td
[(M)0.5 (.)37.5 ( t)0.5 (u)0.5 (be)0.5 (r)0.5 (c)0.5 (u)0.5 (l)0.5 (o)0.5 (s)0.5 (i)0.5 (s)]TJ
/T1_0 1 Tf
5.548 0 Td
[( )-60.4 (i)0.5 (n)0.5 (f)0.5 (e)0.5 (c)0.5 (t)0.5 (io)0.6 (n i)0.5 (n)0.5 ( r)0.5 (h)0.5 (e)0.5 (s)0.5 (u)0.5 (s m)0.5 (a)0.6 (ca)0.5 (q)0.5 (u)0.5 (e)0.5 (s)0.5 (.)37.5 ( P)0.5 (D)0.5 (-1)0.6 ( a)0.5 (n)0.5 (d)0.5 ( P)0.5 (D)0.5 (-)0.5 (L)0.5 (1)0.5 ( k)0.5 (n)0.5 (o)0.5 (c)0.5 (k)0.5 (o)0.5 (ut)-14.9 ( )]TJ
-0.019 Tc 0.12 Tw -9.85 -1.044 Td
[(mice receiving PD-L1 blocking antibod)-10.1 (y ha)-10.1 (ve also sho)-10.1 (wn decreased sur)-18.1 (vival follo)-10.1 (wing)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(infection with lymphoc)20.2 (ytic choriomeningitis virus.)]TJ
-0.02 Tc 0.024 Tw 0 -1.674 Td
[(Inhibition of PD-1 and LAG-3 results in autoimmunity in prec)19.8 (linical models.)36.9 ( Mice de\037cient)-20 ( )]TJ
-0.019 Tc 0.042 Tw 0 -1.044 Td
[(in both PD-1 and LAG-3 develop lethal systemic autoimmunity tha)-9.8 (t inc)20.2 (ludes myocarditis.)]TJ
-0.023 Tc 0.024 Tw 0 -1.674 Td
[(In a 1-month stud)-10.1 (y in monkeys dosed with nivolumab and rela)-10.1 (tlimab,)36.9 ( in\034amma)-10.1 (tion within)-23.1 ( )]TJ
-0.019 Tc 0.071 Tw 0 -1.044 Td
[(the central ner)-17.8 (vous system \(choroid plexus,)37.2 ( vascula)-9.7 (ture,)37.2 ( meninges,)37.2 ( spinal cord\) and the)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(reproductive tract \(epidid)-9.8 (ymis,)37.2 ( seminal vesic)20.2 (les,)37.2 ( and testes\) was obser)-17.8 (ved.)]TJ
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 0 -2.003 Td
(14)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(CLINIC)18.2 (AL STUDIES)]TJ
/T1_0 1 Tf
-0.008 Tc 0.328 Tw -3.375 -1.674 Td
[(T)0.5 (he)0.5 ( e)0.5 (f)0.5 (\037c)0.5 (a)0.5 (c)20.4 (y)0.5 ( o)0.5 (f)0.5 ( OP)0.5 (D)0.5 (UA)0.5 (L)0.5 (AG)0.5 ( w)0.5 (a)0.5 (s in)0.5 (ve)0.5 (s)0.5 (ti)0.5 (g)0.5 (a)-9.6 (t)0.5 (e)0.5 (d)0.5 ( in)0.5 ( R)0.5 (E)0.5 (LA)55.5 (TI)0.5 (V)0.5 (IT)0.5 (Y)74.4 (-)0.5 (0)0.5 (4)0.5 (7 \()0.5 (N)0.5 (CT)0.5 (03)0.5 (4)0.5 (70)0.5 (9)0.5 (22)0.5 (\),)29 ( )]TJ
-0.011 Tc 0.251 Tw 0 -1.044 Td
[(a)0.6 ( r)0.5 (a)0.6 (n)0.5 (d)0.6 (o)0.5 (m)0.6 (i)0.5 (z)0.6 (e)0.5 (d)0.5 ( \()0.6 (1)0.5 (:)0.6 (1)0.5 (\))0.6 (,)37.5 ( d)0.6 (o)0.5 (u)0.6 (b)0.5 (l)0.6 (e)0.5 (-)0.6 (b)0.5 (l)0.5 (i)0.6 (n)0.5 (d)0.6 (e)0.5 (d)0.6 ( t)0.5 (r)0.6 (i)0.5 (a)0.6 (l)0.5 ( i)0.6 (n)0.5 ( 7)0.6 (1)0.5 (4)0.6 ( p)0.5 (a)-9.4 (t)0.5 (i)0.6 (e)0.5 (n)0.6 (t)0.5 (s)0.6 ( w)0.5 (i)0.5 (t)0.6 (h)0.5 ( p)0.6 (r)0.5 (e)0.6 (v)0.5 (i)0.6 (o)0.6 (u)0.5 (s)0.5 (l)0.6 (y)0.5 ( u)0.6 (n)0.5 (t)0.6 (r)0.5 (e)0.6 (a)-9.5 (t)0.6 (e)0.5 (d)-11 ( )]TJ
-0.015 Tc 0.174 Tw 0 -1.044 Td
[(metasta)-10.3 (tic or unresectable Sta)-10.3 (ge III or IV melanoma.)36.7 ( P)17.6 (a)-10.3 (tients were allo)-10.4 (wed to ha)-10.4 (ve)-15 ( )]TJ
-0.016 Tc 0.147 Tw 0 -1.044 Td
[(received prior adjuvant or neoadjuvant melanoma thera)-10.3 (py:)36.7 ( anti-PD-1,)36.7 ( anti-CTLA-4,)36.7 ( or)-16 ( )]TJ
-0.019 Tc 0.09 Tw 0 -1.044 Td
[(BRAF-MEK inhibitors were allo)-9.8 (wed if received a)-9.8 (t least 6 months between the last dose)-19 ( )]TJ
0.036 Tw 0 -1.044 Td
[(of thera)-9.8 (py and da)-9.8 (te of recurrence; interferon thera)-9.8 (py was allo)-9.7 (wed if the last dose was a)-9.7 (t)-19 ( )]TJ
0 -1.044 Td
[(least 6 weeks prior to randomiza)-9.8 (tion.)37.2 ( )36.7 (The trial exc)20.2 (luded pa)-9.7 (tients with active autoimmune)-19 ( )]TJ
-0.016 Tc 0.136 Tw 0 -1.044 Td
[(disease,)37.2 ( medical conditions requiring systemic trea)-9.8 (tment with modera)-9.9 (te or high dose)-16 ( )]TJ
-0.012 Tc 0.238 Tw 0 -1.044 Td
[(corticosteroids or immunosuppressive medica)-9.9 (tions,)37.1 ( uveal melanoma,)37.1 ( and active or)-12 ( )]TJ
-0.014 Tc 0.191 Tw 0 -1.044 Td
[(untrea)-10 (ted brain or leptomeningeal )0.5 (metastases.)36.9 ( )0.5 (P)17.9 (a)-10 (tients were randomized )0.5 (to )0.5 (receive)-14 ( )]TJ
-0.017 Tc 0.124 Tw 0 -1.044 Td
[(OPDUALAG \(nivolumab 480 mg and rela)-10.3 (tlimab 160 mg\) by intra)-10.3 (venous infusion ever)-18.4 (y)-16.9 ( )]TJ
-0.019 Tc 0.072 Tw 0 -1.044 Td
[(4 weeks \(n=355\) or nivolumab 480 mg by intra)-9.8 (venous infusion ever)-17.8 (y 4 weeks \(n=359\))-19 ( )]TJ
0.032 Tw 0 -1.044 Td
[(until disease progression or unacceptable toxicity)55.2 (.)37.2 ( Randomiza)-9.7 (tion was stra)-9.8 (ti\037ed by tumor)-19 ( )]TJ
-0.02 Tc 0.024 Tw 0 -1.044 Td
[(PD-L1 expression \(\0361% vs.)36.9 ( <1%\) using PD-L1 IHC 28-8 pharmDx test,)36.9 ( LAG-3 expression)-20 ( )]TJ
-0.019 Tc 0.112 Tw 0 -1.044 Td
[(\(\0361% vs.)37.2 ( <1%\) using a c)20.2 (linical trial assay)55.2 (,)37.2 ( BRAF )36.6 (V600 muta)-9.8 (tion sta)-9.8 (tus \(V600 muta)-9.8 (tion)-19 ( )]TJ
0.05 Tw 0 -1.044 Td
[(positive vs.)37.2 ( wild type\),)37.2 ( and M sta)-9.7 (ge per the )37.2 (American Joint Committee on Cancer \(AJCC\))-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(version 8 sta)-9.8 (ging system \(M0/M1an)-9.8 (y[0] vs.)37.2 ( M1an)-9.7 (y[1]\).)]TJ
-0.016 Tc 0.141 Tw 0 -1.674 Td
[(The major ef\037cac)20 (y outcome measure was progression-free sur)-18 (vival \(PFS\) determined)-16.1 ( )]TJ
-0.014 Tc 0.18 Tw 0 -1.044 Td
[(by Blinded Independent Centr)0.5 (al Review \(BIC)0.5 (R\) using Response Evalua)-9.6 (tion Criteria in)-14 ( )]TJ
-0.019 Tc 0.084 Tw 0 -1.044 Td
[(Solid )36.7 (T)74.2 (umors \(RECIST v1.1\).)37.2 ( )36.6 (Additional ef\037cac)20.2 (y outcome measures were overall sur)-17.8 (vival)-19 ( )]TJ
-0.015 Tc 0.165 Tw 0 -1.044 Td
[(\(OS\) )0.5 (and )0.5 (overall )0.5 (response )0.5 (ra)-10 (te )0.5 (\(ORR\) )0.6 (determined )0.6 (by )0.5 (BICR )0.5 (using )0.5 (RECIST )0.5 (v1.1.)37 ( )37.6 (T)74 (umor)-15 ( )]TJ
-0.011 Tc 0.262 Tw 0 -1.044 Td
[(assessments were conducted 12 weeks after randomiza)-9.9 (tion and continued ever)-17.9 (y)-11 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(8 weeks up to week 52 and then ever)-17.8 (y 12 weeks.)]TJ
-0.012 Tc 0.234 Tw 0 -1.674 Td
[(The trial popula)-9.8 (tion characteristics were:)37.3 ( median a)-9.7 (ge 63 years \(range:)37.2 ( 20 to 94\);)-11.9 ( )]TJ
-0.014 Tc 0.187 Tw 0 -1.044 Td
[(58% male; 97% )37.3 (White 0.7% )37.3 (African )37.3 (American,)37.1 ( and )37.3 (American Indian/Alaskan Na)-9.8 (tive)-14 ( )]TJ
-0.016 Tc 0.145 Tw 0 -1.044 Td
[(0.1%; Hispanic 7%; and ECOG performance score was 0 \(67%\) or 1 \(33%\)\.)36.8 ( Disease)-15.9 ( )]TJ
-0.019 Tc 0.043 Tw 0 -1.044 Td
[(characteristics )0.5 (were:)37.2 ( )0.5 (PD-L1 )0.6 (expression )0.5 (\0361% )0.6 (\(41%\),)37.2 ( )0.6 (LAG-3 )0.5 (expression )0.6 (\0361% )0.5 (\(75%\),)37.2 ( )37.5 (AJCC)-19 ( )]TJ
0.095 Tw 0 -1.044 Td
[(Sta)-9.8 (ge IV disease \(92%\),)37.2 ( M1c disease \(39%\); M1d disease \(2.4%\),)37.2 ( eleva)-9.7 (ted LDH \(36%\),)18 ( )]TJ
0.06 Tw 0 -1.044 Td
[(and BRAF )37.2 (V600 muta)-9.8 (tion-positive melanoma \(39%\).)]TJ
-0.01 Tc 0.276 Tw 0 -1.674 Td
[(T)0.6 (h)0.5 (e)0.6 ( t)0.5 (r)0.6 (i)0.6 (a)0.5 (l)0.6 ( d)0.5 (e)0.6 (m)0.6 (o)0.6 (n)0.5 (s)0.6 (t)0.5 (r)0.6 (a)-9.4 (t)0.6 (e)0.5 (d)0.6 ( a)0.5 ( s)0.6 (t)0.6 (a)-9.5 (t)0.6 (i)0.6 (s)0.5 (t)0.6 (i)0.6 (c)0.5 (a)0.6 (l)0.6 (l)0.5 (y)0.6 ( s)0.5 (i)0.6 (g)0.5 (n)0.6 (i)0.6 (\037)0.5 (c)0.6 (a)0.6 (n)0.5 (t)0.6 ( i)0.5 (m)0.6 (p)0.6 (r)0.5 (o)0.6 (v)0.6 (e)0.6 (m)0.5 (e)0.6 (n)0.6 (t)0.5 ( i)0.6 (n)0.5 ( P)0.6 (F)0.5 (S)0.6 ( f)0.6 (o)0.5 (r)0.6 ( p)0.5 (a)-9.4 (t)0.6 (i)0.5 (e)0.6 (n)0.6 (t)0.6 (s)-10 ( )]TJ
-0.019 Tc 0.049 Tw 0 -1.044 Td
[(randomized to the OPDUALAG arm compared with the nivolumab arm.)37.2 ( )36.6 (The \037nal analysis)-19 ( )]TJ
0.045 Tw 0 -1.044 Td
[(of OS was not sta)-9.8 (tistically signi\037cant.)37.2 ( Ef\037cac)20.2 (y results are sho)-9.8 (wn in )36.8 (T)74.2 (able 5 and F)18.2 (igure 1.)]TJ
ET
endstreamendobj30 0 obj<</Length 38276>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 144.055 cm
0 0 m
41.95 0 l
S
Q
0 0 0 0 k
/GS0 gs
36 732.96 252 -10.212 re
36 722.748 97.2 -46.112 re
133.2 722.748 77.4 -21.412 re
210.6 722.748 77.4 -21.412 re
133.2 701.336 38.7 -24.7 re
171.9 701.336 38.7 -24.7 re
210.6 701.336 38.7 -24.7 re
249.3 701.336 38.7 -24.7 re
36 676.636 252 -12.192 re
36 664.444 97.2 -12.192 re
133.2 664.444 38.7 -12.192 re
171.9 664.444 38.7 -12.192 re
210.6 664.444 38.7 -12.192 re
249.3 664.444 38.7 -12.192 re
36 652.252 252 -12.192 re
36 640.06 97.2 -12.192 re
133.2 640.06 38.7 -12.192 re
171.9 640.06 38.7 -12.192 re
210.6 640.06 38.7 -12.192 re
249.3 640.06 38.7 -12.192 re
36 627.868 252 -12.192 re
36 615.677 97.2 -12.192 re
133.2 615.677 38.7 -12.192 re
171.9 615.677 38.7 -12.192 re
210.6 615.677 38.7 -12.192 re
249.3 615.677 38.7 -12.192 re
36 603.485 97.2 -12.192 re
133.2 603.485 38.7 -12.192 re
171.9 603.485 38.7 -12.192 re
210.6 603.485 38.7 -12.192 re
249.3 603.485 38.7 -12.192 re
36 591.293 252 -12.192 re
36 579.101 97.2 -12.192 re
133.2 579.101 38.7 -12.192 re
171.9 579.101 38.7 -12.192 re
210.6 579.101 38.7 -12.192 re
249.3 579.101 38.7 -12.192 re
36 566.909 97.2 -12.192 re
133.2 566.909 38.7 -12.192 re
171.9 566.909 38.7 -12.192 re
210.6 566.909 38.7 -12.192 re
249.3 566.909 38.7 -12.192 re
36 554.717 252 -12.192 re
36 542.525 97.2 -12.192 re
133.2 542.525 38.7 -12.192 re
171.9 542.525 38.7 -12.192 re
210.6 542.525 38.7 -12.192 re
249.3 542.525 38.7 -12.192 re
36 530.333 252 -12.192 re
36 518.141 97.2 -15.48 re
133.2 518.141 38.7 -15.48 re
171.9 518.141 38.7 -15.48 re
210.6 518.141 38.7 -15.48 re
249.3 518.141 38.7 -15.48 re
36 502.661 252 -12.192 re
36 490.469 97.2 -15.48 re
133.2 490.469 38.7 -15.48 re
171.9 490.469 38.7 -15.48 re
210.6 490.469 38.7 -15.48 re
249.3 490.469 38.7 -15.48 re
36 474.989 252 -12.192 re
36 462.797 97.2 -15.48 re
133.2 462.797 38.7 -15.48 re
171.9 462.797 38.7 -15.48 re
210.6 462.797 38.7 -15.48 re
249.3 462.797 38.7 -15.48 re
36 447.317 252 -21.412 re
f
1 w 
/GS2 gs
q 1 0 0 1 36 447.3174 cm
0 0 m
97.2 0 l
S
Q
0.5 w 
q 1 0 0 1 36 425.9055 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 133.2 425.9055 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 425.9055 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 425.9055 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 425.9055 cm
0 0 m
38.7 0 l
S
Q
1 w 
q 1 0 0 1 210.6 722.748 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 722.748 cm
0 0 m
38.7 0 l
S
Q
0.5 w 
q 1 0 0 1 210.6 701.3361 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 701.3361 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 676.8861 cm
0 0 m
0 24.2 l
S
Q
1 w 
q 1 0 0 1 36 722.748 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 133.2 722.748 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 722.748 cm
0 0 m
38.7 0 l
S
Q
0.5 w 
q 1 0 0 1 133.2 701.5861 cm
0 0 m
0 20.662 l
S
Q
q 1 0 0 1 210.6 701.5861 cm
0 0 m
0 20.662 l
S
Q
q 1 0 0 1 132.95 701.3361 cm
0 0 m
38.95 0 l
S
Q
q 1 0 0 1 133.2 676.8861 cm
0 0 m
0 24.2 l
S
Q
q 1 0 0 1 171.9 701.3361 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 676.8861 cm
0 0 m
0 24.2 l
S
Q
q 1 0 0 1 210.6 676.8861 cm
0 0 m
0 24.2 l
S
Q
q 1 0 0 1 36 640.0604 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 36 676.6361 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 36 664.4442 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 36 652.2523 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 36 627.8685 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 36 615.6766 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 36 591.2927 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 36 579.1008 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 36 554.717 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 36 542.5251 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 36 530.3331 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 36 518.1412 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 36 502.6613 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 36 490.4693 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 36 474.9893 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 36 462.7974 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 133.2 676.6361 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 676.6361 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 676.6361 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 676.6361 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 664.4442 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 652.5023 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 171.9 664.4442 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 652.5023 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 210.6 664.4442 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 652.5023 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 249.3 664.4442 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 652.5023 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 133.2 652.2523 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 652.2523 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 652.2523 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 652.2523 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 640.0604 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 628.1185 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 171.9 640.0604 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 628.1185 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 210.6 640.0604 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 628.1185 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 249.3 640.0604 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 628.1185 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 133.2 627.8685 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 627.8685 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 627.8685 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 627.8685 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 615.6766 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 603.4846 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 171.9 615.6766 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 603.4846 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 210.6 615.6766 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 603.4846 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 249.3 615.6766 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 603.4846 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 133.2 591.5427 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 171.9 591.5427 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 210.6 591.5427 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 249.3 591.5427 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 133.2 591.2927 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 591.2927 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 591.2927 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 591.2927 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 579.1008 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 566.9089 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 171.9 579.1008 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 566.9089 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 210.6 579.1008 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 566.9089 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 249.3 579.1008 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 566.9089 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 133.2 554.967 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 171.9 554.967 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 210.6 554.967 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 249.3 554.967 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 133.2 554.717 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 554.717 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 554.717 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 554.717 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 542.5251 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 530.5831 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 171.9 542.5251 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 530.5831 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 210.6 542.5251 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 530.5831 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 249.3 542.5251 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 530.5831 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 133.2 530.3331 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 530.3331 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 530.3331 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 530.3331 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 518.1412 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 502.9113 cm
0 0 m
0 14.98 l
S
Q
q 1 0 0 1 171.9 518.1412 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 502.9113 cm
0 0 m
0 14.98 l
S
Q
q 1 0 0 1 210.6 518.1412 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 502.9113 cm
0 0 m
0 14.98 l
S
Q
q 1 0 0 1 249.3 518.1412 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 502.9113 cm
0 0 m
0 14.98 l
S
Q
q 1 0 0 1 133.2 502.6613 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 502.6613 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 502.6613 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 502.6613 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 490.4693 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 475.2393 cm
0 0 m
0 14.98 l
S
Q
q 1 0 0 1 171.9 490.4693 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 475.2393 cm
0 0 m
0 14.98 l
S
Q
q 1 0 0 1 210.6 490.4693 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 475.2393 cm
0 0 m
0 14.98 l
S
Q
q 1 0 0 1 249.3 490.4693 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 475.2393 cm
0 0 m
0 14.98 l
S
Q
q 1 0 0 1 133.2 474.9893 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 474.9893 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 474.9893 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 474.9893 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 462.7974 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 447.8174 cm
0 0 m
0 14.73 l
S
Q
q 1 0 0 1 171.9 462.7974 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 447.8174 cm
0 0 m
0 14.73 l
S
Q
q 1 0 0 1 210.6 462.7974 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 447.8174 cm
0 0 m
0 14.73 l
S
Q
q 1 0 0 1 249.3 462.7974 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 447.8174 cm
0 0 m
0 14.73 l
S
Q
1 w 
q 1 0 0 1 133.2 447.3174 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 447.3174 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 447.3174 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 447.3174 cm
0 0 m
38.7 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.012 Tc 0.06 Tw 8 0 0 8 36 727.248 Tm
[(T)74.2 (able 3:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Adverse Reactions in \03615% of P)24.2 (atients - RELA)55.2 (TIVITY)74.2 (-047)]TJ
7.6 0 0 8 58.6392 696.8362 Tm
(Adverse Reaction)Tj
0.012 Tw 12.786 2.075 Td
(OPDUALAG)Tj
0 Tc 0 Tw 7.6 0 0 8 187.9838 713.4362 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 160.2767 704.9362 Tm
(\(n=355\))Tj
9.67 1.062 Td
(Nivolumab)Tj
0 Tc 0 Tw 7.6 0 0 8 265.0785 713.4362 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 237.8017 704.9362 Tm
(\(n=359\))Tj
0.06 Tw -13.219 -2.025 Td
(All Grades)Tj
0 Tc 0 Tw 7.6 0 0 8 167.7619 688.7361 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 147.4368 680.2361 Tm
(\(%\))Tj
0.06 Tw 3.616 1.062 Td
(Grades 3-4)Tj
0 Tc 0 Tw 7.6 0 0 8 207.5791 688.7361 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 186.1368 680.2361 Tm
(\(%\))Tj
0.06 Tw 3.763 1.062 Td
(All Grades)Tj
0 Tc 0 Tw 7.6 0 0 8 245.1619 688.7361 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 224.8368 680.2361 Tm
(\(%\))Tj
0.06 Tw 3.633 1.062 Td
(Grades 3-4)Tj
0 Tc 0 Tw 7.6 0 0 8 285.1041 688.7361 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 263.6618 680.2361 Tm
(\(%\))Tj
0.06 Tw -29.955 -1.569 Td
[(Musculoskeletal and Connective T)18.2 (issue)]TJ
/T1_1 1 Tf
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.524 Td
( )Tj
EMC 
0.592 0 Td
(Musculoskeletal pain)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 98.323 658.1563 Tm
(a)Tj
7.6 0 0 8 100.685 655.4923 Tm
(\035)Tj
-0.012 Tc 0.012 Tw 6.35 0 Td
(45)Tj
4.978 0 Td
(4.2)Tj
5.206 0 Td
(31)Tj
4.995 0 Td
(1.7)Tj
/T1_0 1 Tf
-30.041 -1.524 Td
(General)Tj
/T1_1 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.524 Td
( )Tj
EMC 
[(F)20.2 (a)-9.8 (tigue)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 60.678 633.7725 Tm
(a)Tj
7.6 0 0 8 63.04 631.1085 Tm
(\035)Tj
-0.012 Tc 0.012 Tw 11.304 0 Td
(39)Tj
0 Tc 0 Tw 5.326 0 Td
(2)Tj
-0.012 Tc 0.012 Tw 4.858 0 Td
(29)Tj
4.995 0 Td
(0.6)Tj
/T1_0 1 Tf
0.06 Tw -30.041 -1.524 Td
[(Skin and Subcutaneous T)18.2 (issue)]TJ
/T1_1 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.524 Td
( )Tj
EMC 
(Rash)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 54.2837 609.3887 Tm
(a)Tj
7.6 0 0 8 56.6457 606.7247 Tm
(\035)Tj
-0.012 Tc 0.012 Tw 12.145 0 Td
(28)Tj
4.978 0 Td
(1.4)Tj
5.206 0 Td
(21)Tj
4.995 0 Td
(1.9)Tj
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
-30.041 -1.524 Td
( )Tj
EMC 
(Pruritus)Tj
0.012 Tw 14.862 0 Td
(25)Tj
0 Tc 0 Tw 5.326 0 Td
(0)Tj
-0.012 Tc 0.012 Tw 4.858 0 Td
(17)Tj
4.995 0 Td
(0.6)Tj
/T1_0 1 Tf
-30.041 -1.524 Td
(Gastrointestinal)Tj
/T1_1 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.524 Td
( )Tj
EMC 
(Diarrhea)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 63.8988 572.8129 Tm
(a)Tj
7.6 0 0 8 66.2608 570.1489 Tm
(\035)Tj
-0.012 Tc 0.012 Tw 10.88 0 Td
(24)Tj
0 Tc 0 Tw 5.326 0 Td
(2)Tj
-0.012 Tc 0.012 Tw 4.858 0 Td
(17)Tj
4.995 0 Td
(1.4)Tj
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
-30.041 -1.524 Td
( )Tj
EMC 
(Nausea)Tj
0.012 Tw 14.862 0 Td
(17)Tj
4.978 0 Td
(0.6)Tj
5.206 0 Td
(14)Tj
0 Tc 0 Tw 5.342 0 Td
(0)Tj
/T1_0 1 Tf
-0.012 Tc 0.06 Tw -30.388 -1.524 Td
[(Ner)-17.7 (vous System)]TJ
/T1_1 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.524 Td
( )Tj
EMC 
(Headache)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 67.8355 536.2372 Tm
(a)Tj
7.6 0 0 8 70.1975 533.5732 Tm
(\035)Tj
-0.012 Tc 0.012 Tw 10.362 0 Td
(18)Tj
4.978 0 Td
(0.3)Tj
5.206 0 Td
(12)Tj
4.995 0 Td
(0.3)Tj
/T1_0 1 Tf
-30.041 -1.524 Td
(Endocrine)Tj
/T1_1 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.935 Td
( )Tj
EMC 
(Hypothyroidism)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 82.8817 508.5652 Tm
(a)Tj
7.6 0 0 8 85.2437 505.9012 Tm
(\035)Tj
-0.012 Tc 0.012 Tw 8.382 0 Td
(17)Tj
0 Tc 0 Tw 5.326 0 Td
(0)Tj
-0.012 Tc 0.012 Tw 4.858 0 Td
(14)Tj
0 Tc 0 Tw 5.342 0 Td
(0)Tj
/T1_0 1 Tf
-0.012 Tc 0.06 Tw -30.388 -1.524 Td
(Metabolism and Nutrition Disorders)Tj
/T1_1 1 Tf
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.935 Td
( )Tj
EMC 
0.592 0 Td
[(Decreased a)-9.8 (ppetite)-12 (\035)]TJ
0.012 Tw 14.27 0 Td
(15)Tj
4.978 0 Td
(0.6)Tj
0 Tc 0 Tw 5.44 0 Td
(7)Tj
-0.012 Tc 0.012 Tw 4.761 0 Td
(0.3)Tj
/T1_0 1 Tf
0.06 Tw -30.041 -1.524 Td
[(Respirator)-17.7 (y)55.2 (,)37.2 ( Thoracic and Mediastinal Disorders)]TJ
/T1_1 1 Tf
0.364 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.935 Td
( )Tj
EMC 
(Cough)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 58.1353 453.2214 Tm
(a)Tj
7.6 0 0 8 60.4973 450.5574 Tm
(\035)Tj
-0.012 Tc 0.012 Tw 11.638 0 Td
(15)Tj
4.978 0 Td
(0.3)Tj
5.206 0 Td
(11)Tj
0 Tc 0 Tw 5.342 0 Td
(0)Tj
-0.017 Tc 0.048 Tw -30.388 -1.569 Td
[(T)74.2 (oxicity was graded per NCI CTCAE v5.)]TJ
0.017 Tw 5.32 0 0 5.6 36 432.1695 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 41 429.5055 Tm
[(Inc)20.2 (ludes multiple terms.)]TJ
-0.013 Tc 0.217 Tw 8 0 0 8 36 406.8476 Tm
[(Clinically )0.5 (relevant )0.6 (adverse )0.6 (reactions )0.5 (in )0.6 (<15% )0.6 (of )0.5 (pa)-10.1 (tients )0.6 (who )0.5 (received )0.5 (OPDUALAG)-13 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.046 Td
[(inc)20.2 (luded vitiligo,)37.1 ( adrenal insuf\037cienc)20.2 (y)55.2 (,)37.2 ( myocarditis,)37.2 ( and hepa)-9.8 (titis.)]TJ
ET
0 0 0 0 k
/GS0 gs
36 386.762 252 -18.712 re
36 368.05 97.2 -37.612 re
133.2 368.05 77.4 -12.912 re
210.6 368.05 77.4 -12.912 re
133.2 355.138 38.7 -24.7 re
171.9 355.138 38.7 -24.7 re
210.6 355.138 38.7 -24.7 re
249.3 355.138 38.7 -24.7 re
36 330.438 252 -12.192 re
36 318.246 97.2 -12.192 re
133.2 318.246 38.7 -12.192 re
171.9 318.246 38.7 -12.192 re
210.6 318.246 38.7 -12.192 re
249.3 318.246 38.7 -12.192 re
36 306.054 97.2 -12.192 re
133.2 306.054 38.7 -12.192 re
171.9 306.054 38.7 -12.192 re
210.6 306.054 38.7 -12.192 re
249.3 306.054 38.7 -12.192 re
36 293.862 97.2 -12.192 re
133.2 293.862 38.7 -12.192 re
171.9 293.862 38.7 -12.192 re
210.6 293.862 38.7 -12.192 re
249.3 293.862 38.7 -12.192 re
36 281.67 97.2 -12.192 re
133.2 281.67 38.7 -12.192 re
171.9 281.67 38.7 -12.192 re
210.6 281.67 38.7 -12.192 re
249.3 281.67 38.7 -12.192 re
36 269.478 97.2 -12.192 re
133.2 269.478 38.7 -12.192 re
171.9 269.478 38.7 -12.192 re
210.6 269.478 38.7 -12.192 re
249.3 269.478 38.7 -12.192 re
36 257.286 252 -12.192 re
36 245.095 97.2 -12.192 re
133.2 245.095 38.7 -12.192 re
171.9 245.095 38.7 -12.192 re
210.6 245.095 38.7 -12.192 re
249.3 245.095 38.7 -12.192 re
36 232.903 97.2 -12.192 re
133.2 232.903 38.7 -12.192 re
171.9 232.903 38.7 -12.192 re
210.6 232.903 38.7 -12.192 re
249.3 232.903 38.7 -12.192 re
36 220.711 252 -29.912 re
f
/GS2 gs
q 1 0 0 1 36 220.7107 cm
0 0 m
97.2 0 l
S
Q
0.5 w 
q 1 0 0 1 36 190.7988 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 133.2 190.7988 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 190.7988 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 190.7988 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 190.7988 cm
0 0 m
38.7 0 l
S
Q
1 w 
q 1 0 0 1 210.6 368.0498 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 368.0498 cm
0 0 m
38.7 0 l
S
Q
0.5 w 
q 1 0 0 1 210.6 355.1379 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 355.1379 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 330.6879 cm
0 0 m
0 24.2 l
S
Q
1 w 
q 1 0 0 1 36 368.0498 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 133.2 368.0498 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 368.0498 cm
0 0 m
38.7 0 l
S
Q
0.5 w 
q 1 0 0 1 133.2 355.3879 cm
0 0 m
0 12.162 l
S
Q
q 1 0 0 1 210.6 355.3879 cm
0 0 m
0 12.162 l
S
Q
q 1 0 0 1 132.95 355.1379 cm
0 0 m
38.95 0 l
S
Q
q 1 0 0 1 133.2 330.6879 cm
0 0 m
0 24.2 l
S
Q
q 1 0 0 1 171.9 355.1379 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 330.6879 cm
0 0 m
0 24.2 l
S
Q
q 1 0 0 1 210.6 330.6879 cm
0 0 m
0 24.2 l
S
Q
q 1 0 0 1 36 330.4379 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 133.2 330.4379 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 330.4379 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 330.4379 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 330.4379 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 36 257.2864 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 36 245.0945 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 133.2 257.5364 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 171.9 257.5364 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 210.6 257.5364 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 249.3 257.5364 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 133.2 257.2864 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 257.2864 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 257.2864 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 257.2864 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 245.0945 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 232.9026 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 171.9 245.0945 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 232.9026 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 210.6 245.0945 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 232.9026 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 249.3 245.0945 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 232.9026 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 133.2 221.2107 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 171.9 221.2107 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 210.6 221.2107 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 249.3 221.2107 cm
0 0 m
0 11.692 l
S
Q
1 w 
q 1 0 0 1 133.2 220.7107 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 220.7107 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 220.7107 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 220.7107 cm
0 0 m
38.7 0 l
S
Q
0.5 w 
q 1 0 0 1 36 318.246 cm
0 0 m
97.2 0 l
S
Q
q 1 0 0 1 133.2 318.246 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 133.2 306.0541 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 171.9 318.246 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 171.9 306.0541 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 210.6 318.246 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 210.6 306.0541 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 249.3 318.246 cm
0 0 m
38.7 0 l
S
Q
q 1 0 0 1 249.3 306.0541 cm
0 0 m
0 11.942 l
S
Q
q 1 0 0 1 133.2 293.8622 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 171.9 293.8622 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 210.6 293.8622 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 249.3 293.8622 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 133.2 281.6703 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 171.9 281.6703 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 210.6 281.6703 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 249.3 281.6703 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 133.2 269.4783 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 171.9 269.4783 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 210.6 269.4783 cm
0 0 m
0 12.192 l
S
Q
q 1 0 0 1 249.3 269.4783 cm
0 0 m
0 12.192 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.012 Tc 0.125 Tw 8 0 0 8 36 381.0499 Tm
[(T)74.2 (able )65.2 (4:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Laborator)-17.8 (y Abnormalities \(\03615%\) That W)18.2 (orsened from Baseline)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.6 0 0 5.6 276.7313 383.7139 Tm
(a)Tj
-0.012 Tc 0.012 Tw 8 0 0 8 279.3565 381.0499 Tm
[(\035)-124.6 (in)-12 ( )]TJ
0.06 Tw -25.42 -1.062 Td
[(P)24.2 (atients Who Received OPDUALAG in RELA)55.2 (TIVITY)74.2 (-047)]TJ
7.6 0 0 8 49.5887 346.3879 Tm
[(Laborator)-17.8 (y Abnormality)]TJ
0.012 Tw 13.8 1.544 Td
(OPDUALAG)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 186.77 361.4019 Tm
(a)Tj
7.6 0 0 8 189.3289 358.7379 Tm
(\035)Tj
-0.012 Tc 0.012 Tw 5.671 0 Td
(Nivolumab)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 263.8647 361.4019 Tm
(a)Tj
0.039 Tc -0.039 Tw 7.6 0 0 8 266.4235 358.7379 Tm
(\035)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
-0.012 Tc 0.06 Tw -17.132 -2.025 Td
(Grades 1-4)Tj
0 Tc 0 Tw 7.6 0 0 8 168.8791 342.538 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 147.4368 334.038 Tm
(\(%\))Tj
0.06 Tw 3.616 1.062 Td
(Grades 3-4)Tj
0 Tc 0 Tw 7.6 0 0 8 207.5791 342.538 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 186.1368 334.038 Tm
(\(%\))Tj
0.06 Tw 3.616 1.062 Td
(Grades 1-4)Tj
0 Tc 0 Tw 7.6 0 0 8 246.2791 342.538 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 224.8368 334.038 Tm
(\(%\))Tj
0.06 Tw 3.633 1.062 Td
(Grades 3-4)Tj
0 Tc 0 Tw 7.6 0 0 8 285.1041 342.538 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 263.6618 334.038 Tm
(\(%\))Tj
-29.955 -1.569 Td
[(Chemistr)-17.8 (y)]TJ
/T1_1 1 Tf
0.011 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.524 Td
( )Tj
EMC 
0.592 0 Td
[(Increased AST)-12 (\035)]TJ
0.012 Tw 14.27 0 Td
(30)Tj
4.978 0 Td
(2.3)Tj
5.206 0 Td
(22)Tj
4.995 0 Td
(1.4)Tj
0.011 Tw /Span<</ActualText<FEFF0009>>> BDC 
-30.041 -1.524 Td
( )Tj
EMC 
0.592 0 Td
[(Increased AL)94.3 (T)-12 (\035)]TJ
0.012 Tw 14.27 0 Td
(26)Tj
4.978 0 Td
(3.2)Tj
5.206 0 Td
(25)Tj
0 Tc 0 Tw 5.342 0 Td
(2)Tj
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-30.388 -1.524 Td
( )Tj
EMC 
0.592 0 Td
(Decreased sodium)Tj
0.012 Tw 14.27 0 Td
(24)Tj
4.978 0 Td
(1.2)Tj
5.206 0 Td
(21)Tj
4.995 0 Td
(0.6)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-30.041 -1.524 Td
( )Tj
EMC 
0.592 0 Td
[(Increased alkaline phospha)-9.8 (tase)]TJ
0.012 Tw 14.27 0 Td
(19)Tj
4.978 0 Td
(0.6)Tj
5.206 0 Td
(17)Tj
4.995 0 Td
(0.9)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-30.041 -1.524 Td
( )Tj
EMC 
0.592 0 Td
[(Increased crea)-9.8 (tinine)]TJ
0.012 Tw 14.27 0 Td
(19)Tj
0 Tc 0 Tw 5.326 0 Td
(0)Tj
-0.012 Tc 0.012 Tw 4.858 0 Td
(16)Tj
0 Tc 0 Tw 5.342 0 Td
(0)Tj
/T1_0 1 Tf
-0.012 Tc 0.012 Tw -30.388 -1.524 Td
[(Hematolog)-9.8 (y)]TJ
/T1_1 1 Tf
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
0 -1.524 Td
( )Tj
EMC 
0.592 0 Td
(Decreased hemoglobin)Tj
0.012 Tw 14.27 0 Td
(37)Tj
4.978 0 Td
(2.7)Tj
5.206 0 Td
(31)Tj
4.995 0 Td
(3.5)Tj
0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-30.041 -1.524 Td
( )Tj
EMC 
0.592 0 Td
[(Decreased lymphoc)20.2 (ytes)]TJ
0.012 Tw 14.27 0 Td
(32)Tj
4.978 0 Td
(2.5)Tj
5.206 0 Td
(24)Tj
4.995 0 Td
(2.9)Tj
-0.017 Tc 0.017 Tw 5.32 0 0 5.6 36 214.0628 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.006 Tc 0.104 Tw 7.6 0 0 8 41 211.3988 Tm
[(Each test incidence is based on the number of pa)-10.1 (tients who had both baseline and a)-10 (t)-6 ( )]TJ
-0.018 Tc 0.036 Tw 0 -1.062 Td
[(l)0.5 (e)0.6 (a)0.6 (s)0.5 (t)0.5 ( )0.6 (o)0.5 (n)0.6 (e)0.5 ( )0.6 (o)0.5 (n)0.6 (-)0.5 (s)0.6 (t)0.5 (u)0.6 (d)-9.5 (y)0.6 ( )0.5 (l)0.5 (a)0.6 (b)0.5 (o)0.6 (r)0.5 (a)-9.4 (t)0.5 (o)0.6 (r)-17.4 (y)0.5 ( )0.6 (m)0.5 (e)0.6 (a)0.5 (s)0.6 (u)0.5 (r)0.6 (e)0.5 (m)0.6 (e)0.5 (n)0.6 (t)0.5 ( )0.5 (a)-9.4 (v)0.6 (a)0.5 (i)0.5 (l)0.6 (a)0.5 (b)0.6 (l)0.5 (e)0.6 (:)37.5 ( )0.6 (O)0.5 (P)0.6 (D)0.5 (U)0.5 (A)0.6 (L)0.5 (A)0.6 (G)0.5 ( )0.6 (g)0.5 (r)0.5 (o)0.6 (u)0.5 (p)0.6 ( )0.5 (\()0.6 (r)0.5 (a)0.6 (n)0.5 (g)0.6 (e)0.5 (:)37.5 ( )0.6 (2)0.5 (8)0.6 (0)0.5 ( )0.6 (t)0.5 (o)0.6 ( )0.5 (3)0.6 (4)0.5 (2)-18 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(pa)-9.8 (tients\) and nivolumab group \(range:)37.2 ( 276 to 345 pa)-9.8 (tients\).)]TJ
/T1_0 1 Tf
0.017 Tw 8 0 0 8 36 172.5309 Tm
(8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(USE IN SPECIFIC POPULA)55.2 (TIONS)]TJ
0.017 Tw -3.375 -1.785 Td
(8.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
[(Pregnanc)10.2 (y)]TJ
/T1_1 1 Tf
0.048 Tw -3.375 -1.65 Td
[(Risk Summar)-17.8 (y)]TJ
-0.019 Tc 0.024 Tw 0 -1.496 Td
[(Based on \037ndings in animals and mechanism of action,)37.2 ( OPDUALAG can cause fetal harm)-18.9 ( )]TJ
-0.016 Tc 0.126 Tw 0 -1.046 Td
[(w)0.5 (h)0.6 (e)0.5 (n)0.6 ( a)0.5 (d)0.6 (m)0.5 (i)0.5 (n)0.6 (i)0.5 (s)0.6 (t)0.5 (e)0.6 (r)0.5 (e)0.6 (d)0.5 ( t)0.5 (o)0.6 ( a)0.6 ( p)0.5 (r)0.5 (e)0.6 (g)0.5 (n)0.6 (a)0.5 (n)0.5 (t)0.6 ( w)0.6 (o)0.5 (m)0.6 (a)0.5 (n)0.5 (.)37.6 ( )37.1 (A)0.5 (d)0.5 (m)0.6 (i)0.5 (n)0.6 (i)0.5 (s)0.5 (t)0.6 (r)0.5 (a)-9.4 (t)0.5 (i)0.6 (o)0.5 (n)0.6 ( o)0.5 (f)0.6 ( n)0.5 (i)0.6 (v)0.5 (o)0.5 (l)0.6 (u)0.5 (m)0.6 (a)0.5 (b)0.6 ( t)0.5 (o)0.6 ( c)20.5 (y)0.6 (n)0.5 (o)0.5 (m)0.6 (o)0.5 (l)0.6 (g)0.5 (u)0.6 (s)-16 ( )]TJ
-0.02 Tc 0.024 Tw 0 -1.046 Td
[(monkeys from the onset of organogenesis through deliver)-18 (y resulted in increased abortion)-20.1 ( )]TJ
-0.016 Tc 0.148 Tw 0 -1.046 Td
[(and prema)-10.3 (ture infant dea)-10.4 (th )]TJ
/T1_2 1 Tf
[(\(see Da)-10.3 (ta\))]TJ
/T1_1 1 Tf
[(.)36.7 ( Human IgG4 is kno)-10.3 (wn to cross the placenta;)-16 ( )]TJ
-0.019 Tc 0.033 Tw 0 -1.046 Td
[(therefore,)37.2 ( nivolumab and rela)-9.8 (tlimab ha)-9.7 (ve the potential to be transmitted from the mother)-19 ( )]TJ
-0.016 Tc 0.146 Tw 0 -1.046 Td
[(to the developing fetus.)36.8 ( )36.6 (The effects of OPDUALAG are likely to be grea)-10.2 (ter during the)-16 ( )]TJ
-0.019 Tc 0.086 Tw 0 -1.046 Td
[(second and third trimesters of pregnanc)20.2 (y)55.2 (.)37.2 ( )37.3 (There are no a)-9.8 (vailable da)-9.8 (ta on OPDUALAG in)-19 ( )]TJ
0.106 Tw 0 -1.046 Td
[(pregnant women to evalua)-9.8 (te a drug-associa)-9.8 (ted risk.)37.2 ( )36.8 (Advise the pa)-9.8 (tient of the potential)-19 ( )]TJ
0.06 Tw 0 -1.046 Td
(risk to a fetus.)Tj
-0.015 Tc 0.167 Tw 0 -1.676 Td
[(In the U.S.)36.9 ( general popula)-10 (tion,)36.9 ( the estima)-10.1 (ted background risk of major birth defects)-15 ( )]TJ
0.152 Tw 0 -1.046 Td
[(a)0.5 (n)0.5 (d)0.5 ( m)0.5 (i)0.5 (s)0.5 (c)0.5 (a)0.5 (r)0.5 (r)0.5 (i)0.6 (a)-9.5 (g)0.5 (e)0.5 ( i)0.5 (n)0.5 ( c)20.5 (l)0.5 (i)0.5 (n)0.5 (i)0.5 (c)0.5 (a)0.5 (l)0.5 (l)0.5 (y)0.5 ( r)0.5 (e)0.5 (c)0.5 (o)0.5 (g)0.5 (n)0.5 (i)0.5 (z)0.5 (e)0.5 (d)0.5 ( p)0.5 (r)0.5 (e)0.6 (gn)0.6 (a)0.5 (n)0.5 (c)0.5 (i)0.5 (e)0.5 (s)0.5 ( i)0.5 (s)0.5 ( 2)0.5 (%)0.5 ( t)0.5 (o)0.5 ( 4)0.5 (%)0.5 ( a)0.5 (n)0.5 (d)0.5 ( 1)0.5 (5)0.5 (%)0.5 ( t)0.5 (o)0.6 ( 2)0.6 (0)0.5 (%)0.5 (,)22 ( )]TJ
-0.019 Tc 0.019 Tw 0 -1.046 Td
[(respectively)55.2 (.)]TJ
ET
q 1 0 0 1 324 726.248 cm
0 0 m
13.291 0 l
S
Q
q 1 0 0 1 324 507.0595 cm
0 0 m
41.95 0 l
S
Q
q 1 0 0 1 324 411.8919 cm
0 0 m
51.766 0 l
S
Q
q 1 0 0 1 324 377.1194 cm
0 0 m
39.372 0 l
S
Q
BT
-0.017 Tc 0.017 Tw 8 0 0 8 324 727.248 Tm
[(Da)-9.8 (ta)]TJ
/T1_2 1 Tf
0.048 Tw 0 -1.611 Td
[(Animal Da)-9.8 (ta)]TJ
/T1_1 1 Tf
-0.01 Tc 0.301 Tw 0 -1.503 Td
[(OPDUALAG injection for intra)-10.4 (venous use contains nivolumab and rela)-10.4 (tlimab )]TJ
/T1_2 1 Tf
0.01 Tw [([see)-9.9 ( )]TJ
-0.019 Tc 0.019 Tw 0 -1.053 Td
(Descript)Tj
0.06 Tw (ion \(11\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.019 Tc 0.019 Tw 0 -1.683 Td
(Nivolumab:)Tj
-0.013 Tc 0.215 Tw 0 -1.368 Td
[(One function of the PD-1/PD-L1 pa)-10 (thway is to preser)-18 (ve pregnanc)20 (y by maintaining)-13 ( )]TJ
-0.014 Tc 0.195 Tw 0 -1.053 Td
[(immune )0.5 (tolerance to )0.5 (the fetus.)36.8 ( )37.5 (The effects of nivolumab )0.5 (on )0.5 (prena)-10.2 (tal )0.5 (and )0.5 (postna)-10.2 (tal)-14 ( )]TJ
-0.016 Tc 0.149 Tw 0 -1.053 Td
[(development were evalua)-10.4 (ted in monkeys tha)-10.3 (t received nivolumab twice weekly from)-16 ( )]TJ
-0.013 Tc 0.215 Tw 0 -1.053 Td
[(the onset of organogenesis through deliver)-17.9 (y)54.9 (,)37 ( a)-10 (t exposure levels of between 9 and)-13 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc 0.124 Tw -31.5 -1.053 Td
[(42 times higher than )0.5 (those obser)-18.3 (ved a)-10.3 (t the c)19.7 (linical )0.5 (dose of 3 mg/kg )0.5 (\(based )0.5 (on )37.4 (AUC\).)20 ( )]TJ
-0.01 Tc 0.277 Tw 0 -1.053 Td
[(N)0.5 (i)0.5 (v)0.5 (o)0.5 (l)0.5 (u)0.5 (m)0.5 (a)0.5 (b)0.5 ( a)0.5 (d)0.5 (m)0.5 (i)0.5 (n)0.5 (i)0.5 (s)0.5 (t)0.5 (r)0.5 (a)-9.5 (t)0.5 (i)0.5 (o)0.5 (n)0.5 ( r)0.5 (e)0.5 (s)0.5 (ul)0.6 (t)0.5 (e)0.5 (d i)0.5 (n)0.5 ( a)0.5 ( n)0.5 (o)0.5 (n)0.5 (-)0.5 (d)0.5 (o)0.5 (s)0.5 (e)0.5 (-)0.5 (r)0.5 (e)0.5 (l)0.5 (a)-9.5 (t)0.5 (e)0.5 (d)0.5 ( i)0.5 (n)0.5 (c)0.5 (r)0.5 (e)0.5 (a)0.5 (s)0.5 (e)0.5 ( i)0.5 (n)0.5 ( s)0.5 (p)0.5 (o)0.5 (n)0.5 (t)0.5 (a)0.5 (n)0.5 (e)0.5 (o)0.5 (u)0.5 (s)-10 ( )]TJ
-0.019 Tc 0.066 Tw 0 -1.053 Td
[(abortion and increased neona)-9.8 (tal dea)-9.8 (th.)37.3 ( In sur)-17.8 (viving infants \(18 of 32 compared to 11 of)-19 ( )]TJ
0.06 Tw 0 -1.053 Td
[(16 vehic)20.2 (le-exposed infants\) of c)20.2 (ynomolgus monkeys trea)-9.8 (ted with nivolumab,)37.2 ( there were)-19 ( )]TJ
0.051 Tw 0 -1.053 Td
[(no a)-9.7 (pparent malforma)-9.7 (tions and no effects on neurobeha)-9.8 (vioral,)37.2 ( immunological,)37.2 ( or c)20.2 (linical)-19 ( )]TJ
0.06 Tw 0 -1.053 Td
[(pa)-9.8 (tholog)-9.8 (y parameters throughout the 6-month postna)-9.8 (tal period.)]TJ
0.019 Tw 0 -1.683 Td
[(Rela)-9.7 (tlimab:)]TJ
-0.015 Tc 0.165 Tw 0 -1.368 Td
[(There are no a)-10 (vailable animal da)-10 (ta on rela)-10 (tlimab.)37 ( )37.2 (The effects of a murine surroga)-10 (te)-14.9 ( )]TJ
0.153 Tw 0 -1.053 Td
[(a)0.5 (nt)0.5 (i)0.5 (-)0.5 (LA)0.5 (G)0.5 (-)0.5 (3 a)0.5 (n)0.5 (t)0.5 (ib)0.5 (o)0.5 (d)-9.5 (y w)0.5 (a)0.5 (s e)0.5 (v)0.5 (a)0.5 (lu)0.5 (a)-9.5 (t)0.5 (ed)0.5 ( i)0.5 (n m)0.5 (i)0.5 (c)0.5 (e u)0.5 (s)0.5 (in)0.5 (g)0.5 ( sy)0.5 (n)0.5 (ge)0.5 (n)0.5 (e)0.5 (ic)0.5 ( a)0.5 (n)0.5 (d a)0.5 (l)0.5 (lo)0.5 (g)0.5 (e)0.5 (ne)0.5 (i)0.5 (c b)0.5 (r)0.5 (e)0.5 (e)0.5 (di)0.5 (n)0.5 (g)-15 ( )]TJ
-0.018 Tc 0.12 Tw 0 -1.053 Td
[(models.)36.8 ( )36.9 (When anti-LAG-3 antibodies were administered beginning on gesta)-10.2 (tion day\035)-120.1 (6,)19 ( )]TJ
-0.013 Tc 0.214 Tw 0 -1.053 Td
[(there were no ma)-10 (ternal or developmental effects in either syngeneic or allogeneic)-13 ( )]TJ
-0.019 Tc 0.019 Tw 0 -1.053 Td
(breedings.)Tj
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 0 -1.791 Td
(8.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Lactation)Tj
/T1_1 1 Tf
0.048 Tw -3.375 -1.656 Td
[(Risk Summar)-17.8 (y)]TJ
-0.015 Tc 0.164 Tw 0 -1.503 Td
[(There are no da)-10 (ta on the presence of nivolumab and rela)-9.9 (tlimab in human milk,)37.1 ( the)-14.9 ( )]TJ
-0.019 Tc 0.053 Tw 0 -1.053 Td
[(effects on the breastfed child,)37.2 ( or the effects on milk production.)37.2 ( Because nivolumab and)-19 ( )]TJ
-0.026 Tc 0.012 Tw 0 -1.053 Td
[(rela)-10.3 (tlimab may be excreted in human milk and because of the potential for se\rious adverse)-26 ( )]TJ
-0.017 Tc 0.123 Tw 0 -1.053 Td
[(reactions in a breastfed child,)36.7 ( advise pa)-10.3 (tients not to breastfeed during trea)-10.3 (tment with)-17 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.053 Td
[(OPDUALAG and for a)-9.8 (t least 5 months after the last dose )]TJ
/T1_2 1 Tf
([see Pharmacokinetic)Tj
(s \(12.3\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 0 -1.791 Td
(8.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(F)20.2 (emales and Males of Reproductive P)24.2 (otential)]TJ
/T1_1 1 Tf
-0.019 Tc 0.088 Tw -3.375 -1.548 Td
(OPDUALAG can cause fetal harm when administered to a pregnant woman )Tj
/T1_2 1 Tf
[([see Use in)-19 ( )]TJ
0.06 Tw 0 -1.053 Td
[(Speci\037c P)18.2 (opula)-9.8 (tio)]TJ
(ns \(8.1\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.011 Tw -0 -1.791 Td
[(Pregnanc)20.2 (y T)74.2 (esting)]TJ
-0.011 Tc 0.253 Tw 0 -1.503 Td
[(V)18.5 (er)0.5 (if)0.5 (y)0.5 ( th)0.5 (e p)0.5 (re)0.5 (g)0.5 (na)0.5 (nc)20.5 (y)0.5 ( s)0.5 (t)0.5 (a)-9.6 (t)0.5 (u)0.5 (s o)0.5 (f f)0.5 (e)0.5 (ma)0.5 (l)0.5 (es)0.5 ( of)0.5 ( r)0.5 (ep)0.5 (r)0.5 (od)0.5 (uc)0.5 (ti)0.5 (v)0.5 (e p)0.5 (o)0.5 (te)0.5 (nt)0.5 (i)0.5 (al)0.5 ( pr)0.5 (i)0.5 (or)0.5 ( to)0.5 ( i)0.5 (ni)0.5 (ti)0.5 (a)-9.5 (ti)0.5 (ng)-11 ( )]TJ
-0.019 Tc 0.019 Tw 0 -1.053 Td
(OPDUALAG )Tj
/T1_2 1 Tf
0.06 Tw 4.22 0 Td
[([see Use in Speci\037c P)18.2 (opula)-9.7 (tio)]TJ
(ns \(8.1\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.017 Tw -4.22 -1.791 Td
(Contraception)Tj
-0.006 Tc 0.382 Tw 0 -1.503 Td
[(Advise )0.6 (females )0.6 (of )0.6 (reproductive )0.6 (potential )0.6 (to )0.6 (use )0.5 (effective )0.6 (contraception )0.6 (during)-6 ( )]TJ
-0.019 Tc 0.105 Tw 0 -1.053 Td
[(trea)-9.7 (tment and for a)-9.7 (t least 5 months follo)-9.8 (wing the last dose of OPDUALAG )]TJ
/T1_2 1 Tf
[([see Clinical)-19 ( )]TJ
0.019 Tw 0 -1.053 Td
(Pharmacolog)Tj
0.06 Tw 4.63 0 Td
(y \(12.3\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
/T1_0 1 Tf
-0.017 Tc 0.017 Tw -4.63 -1.791 Td
(8.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(P)24.2 (ediatric Use)]TJ
/T1_1 1 Tf
-0.024 Tc 0.022 Tw -3.375 -1.548 Td
[(The safety and effectiveness of OPDUALAG for the trea)-9.7 (tment of unresectable or metasta)-9.8 (tic)-23.9 ( )]TJ
-0.016 Tc 0.151 Tw 0 -1.053 Td
[(melanoma ha)-10.4 (ve been established in pedia)-10.4 (tric pa)-10.4 (tients 12 years of a)-10.4 (ge or older who)-16 ( )]TJ
-0.019 Tc 0.034 Tw 0 -1.053 Td
[(weigh a)-9.8 (t least 40 kg.)37.3 ( Use of OPDUALAG for this indica)-9.8 (tion is supported by evidence from)-19 ( )]TJ
-0.022 Tc 0.024 Tw 0 -1.053 Td
[(an adequa)-10 (te and well-controlled stud)-10 (y in adults and additional da)-10 (ta analyses tha)-10 (t suggest)-22 ( )]TJ
-0.019 Tc 0 -1.053 Td
[(tha)-9.7 (t nivolumab and rela)-9.8 (tlimab exposures in pedia)-9.8 (tric pa)-9.7 (tients 12 years of a)-9.8 (ge who weigh)-19 ( )]TJ
-0.015 Tc 0.153 Tw 0 -1.053 Td
[(a)-9.5 (t le)0.5 (a)0.5 (st)0.5 ( 4)0.5 (0 k)0.5 (g)0.5 ( ar)0.5 (e)0.5 ( e)0.5 (xp)0.5 (e)0.5 (ct)0.5 (ed)0.5 ( t)0.5 (o)0.5 ( re)0.5 (s)0.5 (ul)0.5 (t in)0.5 ( s)0.5 (im)0.5 (il)0.5 (a)0.5 (r s)0.5 (a)0.5 (fe)0.5 (t)0.5 (y an)0.5 (d ef)0.5 (\037)0.5 (ca)0.5 (c)20.4 (y)0.5 ( t)0.5 (o th)0.5 (a)-9.5 (t o)0.5 (f)0.5 ( a)0.5 (du)0.5 (lt)0.5 (s)0.5 (.)22 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.013 Tc 0.222 Tw -31.5 -1.053 Td
[(The pharmacokinetics of monoc)19.7 (lonal antibodies and the course of unresectable or)-12.9 ( )]TJ
-0.016 Tc 0.128 Tw 0 -1.053 Td
[(m)0.5 (et)0.5 (as)0.5 (t)0.5 (a)-9.6 (t)0.5 (i)0.5 (c m)0.5 (e)0.5 (la)0.5 (no)0.5 (m)0.5 (a a)0.5 (r)0.5 (e su)0.5 (f\037)0.5 (ci)0.5 (en)0.5 (t)0.5 (ly)0.5 ( si)0.5 (m)0.5 (il)0.5 (ar)0.5 ( i)0.5 (n ad)0.5 (ul)0.5 (ts)0.5 ( a)0.5 (nd)0.5 ( p)0.5 (ed)0.5 (ia)-9.5 (t)0.5 (ri)0.5 (c p)0.5 (a)-9.5 (ti)0.5 (e)0.5 (nt)0.5 (s 1)0.5 (2)0.5 ( ye)0.5 (a)0.5 (rs)-16 ( )]TJ
0.126 Tw 0 -1.053 Td
[(o)0.5 (f)0.6 ( a)-9.4 (g)0.5 (e)0.5 ( o)0.6 (r)0.5 ( o)0.6 (l)0.5 (d)0.5 (e)0.6 (r)0.5 ( t)0.6 (o)0.5 ( a)0.6 (l)0.5 (l)0.5 (o)-9.4 (w)0.5 ( e)0.5 (x)0.6 (t)0.5 (r)0.5 (a)-9.4 (p)0.5 (o)0.6 (l)0.5 (a)-9.5 (t)0.6 (i)0.5 (o)0.5 (n)0.6 ( o)0.5 (f)0.6 ( d)0.5 (a)-9.4 (t)0.5 (a)0.5 ( f)0.6 (r)0.5 (o)0.6 (m)0.5 ( a)0.6 (d)0.5 (u)0.5 (l)0.5 (t)0.6 ( p)0.5 (a)-9.4 (t)0.5 (i)0.5 (e)0.6 (n)0.5 (t)0.5 (s)0.6 ( t)0.5 (o)0.6 ( p)0.5 (e)0.6 (d)0.5 (i)0.5 (a)-9.5 (t)0.6 (r)0.5 (i)0.6 (c)0.5 ( p)0.5 (a)-9.4 (t)0.5 (i)0.5 (e)0.6 (n)0.5 (t)0.5 (s)-16 ( )]TJ
-0.021 Tc 0.024 Tw 0 -1.053 Td
[(12 years of a)-9.9 (ge or older \(who weigh a)-9.9 (t least 40 kg\).)37.1 ( )37.1 (A recommended dosa)-9.8 (ge for pedia)-9.8 (tric)-21 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.019 Tc 0.091 Tw -31.5 -1.053 Td
[(pa)-9.8 (tients 12 years of a)-9.8 (ge or older who weigh less than 40 kg has not been established)-19 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
/T1_2 1 Tf
-0.019 Tc 0.06 Tw -31.5 -1.053 Td
[([see )37.2 (Adverse Reactions \(6.1\),)37.2 ( Clinical Pharmacolog)-9.8 (y \(12.3\),)37.2 ( and Clinical Stud)]TJ
(ies \(14\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.024 Tc 0.024 Tw 0 -1.683 Td
[(The safety and effectiveness of OPDUALAG ha)-10.2 (ve not been established in pedia)-10.2 (tric pa)-10.2 (tients)-24 ( )]TJ
-0.019 Tc 0.038 Tw 0 -1.053 Td
[(12 years of a)-9.8 (ge or older who weigh less than 40 kg,)37.2 ( and pedia)-9.8 (tric pa)-9.8 (tients younger than)-19.1 ( )]TJ
0.06 Tw 0 -1.053 Td
[(12 years of a)-9.7 (ge.)]TJ
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 0 -1.949 Td
(8.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(Geriatric Use)Tj
/T1_1 1 Tf
0.12 Tw -3.375 -1.548 Td
[(O)0.5 (f)0.6 ( )0.6 (t)0.5 (h)0.6 (e)0.5 ( )0.6 (3)0.5 (5)0.6 (5)0.5 ( )0.6 (p)0.5 (a)-9.4 (t)0.5 (i)0.6 (e)0.5 (n)0.6 (t)0.5 (s)0.6 ( )0.5 (t)0.6 (r)0.5 (e)0.6 (a)-9.4 (t)0.5 (e)0.6 (d)0.5 ( )0.6 (w)0.5 (i)0.6 (t)0.5 (h)0.6 ( )0.5 (O)0.6 (P)0.5 (D)0.6 (U)0.5 (A)0.5 (L)0.6 (A)0.6 (G)0.5 ( )0.6 (i)0.5 (n)0.6 ( )0.5 (R)0.5 (E)0.6 (L)0.5 (A)55.6 (T)0.5 (I)0.6 (V)0.5 (I)0.6 (T)0.5 (Y)74.6 (-)0.5 (0)0.6 (4)0.5 (7)0.6 (,)37.5 ( )0.6 (4)0.5 (7)0.6 (%)0.5 ( )0.6 (o)0.5 (f)0.6 ( )0.5 (p)0.6 (a)-9.5 (t)0.6 (i)0.5 (e)0.6 (n)0.5 (t)0.6 (s)0.6 ( )0.5 (w)0.5 (e)0.6 (r)0.6 (e)-17 ( )]TJ
-0.015 Tc 0.165 Tw 0 -1.053 Td
[(65 years or older)74 (,)37 ( 29% were 65 to 74 years,)37.1 ( 17% were 75 to 84 years,)37 ( and 1.7%)-15 ( )]TJ
-0.019 Tc 0.05 Tw 0 -1.053 Td
[(were 85 years and older)74.2 (.)37.2 ( No overall differences in safety or effectiveness were obser)-17.7 (ved)-19 ( )]TJ
0.06 Tw 0 -1.053 Td
[(between elderly pa)-9.8 (tients and younger pa)-9.8 (tients.)]TJ
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 0 -2.011 Td
(11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(DESCRIPTION)Tj
/T1_1 1 Tf
-0.01 Tc 0.289 Tw -3.375 -1.683 Td
[(Nivolumab and rela)-9.9 (tlimab-rmbw is a \037xed-dose combina)-9.9 (tion of two IgG4 ka)-9.9 (ppa)-10 ( )]TJ
-0.014 Tc 0.181 Tw 0 -1.053 Td
[(monoc)20.4 (lonal antibodies \(mAbs\).)37.3 ( Nivolumab is a programmed dea)-9.6 (th receptor)37.3 (-1 \(PD-1\))-14 ( )]TJ
-0.021 Tc 0.024 Tw 0 -1.053 Td
[(blocking antibod)-10.2 (y tha)-10.2 (t has a calcula)-10.2 (ted molecular mass of 146 kDa and is expressed in a)-20.9 ( )]TJ
0 -1.053 Td
[(recombinant Chinese Hamster Ovar)-17.7 (y \(CHO\) cell line.)37.3 ( Rela)-9.7 (tlimab is a lymphoc)20.3 (yte activa)-9.7 (tion)-21 ( )]TJ
-0.019 Tc 0.054 Tw 0 -1.053 Td
[(gene-3 \(LAG-3\) blocking antibod)-9.8 (y tha)-9.8 (t has a calcula)-9.8 (ted molecular mass of 148 kDa and)-19 ( )]TJ
0.06 Tw 0 -1.053 Td
(is expressed in a recombinant CHO cell line.)Tj
-0.014 Tc 0.2 Tw 0 -1.683 Td
[(OPDUALAG \(nivolumab and rela)-10.4 (tlimab-rmbw\) injection is a sterile,)36.6 ( preser)-18.4 (va)-10.4 (tive-free,)23.1 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.019 Tc 0.024 Tw -31.5 -1.053 Td
[(c)20.2 (lear to opalescent,)37.2 ( colorless to slightly yello)-9.7 (w solution tha)-9.8 (t may contain few translucent-)]TJ
-0.025 Tc 0.014 Tw 0 -1.053 Td
[(to-white partic)20.4 (les.)37.3 ( OPDUALAG is supplied as 240 mg of nivolumab and 80 mg of rela)-9.7 (tlimab)-25 ( )]TJ
-0.019 Tc 0.029 Tw 0 -1.053 Td
[(in a 20 mL single-dose vial for intra)-9.8 (venous use.)37.2 ( Each mL of OPDUALAG solution contains)-19 ( )]TJ
ET
endstreamendobj29 0 obj<</Length 20766>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 726.248 cm
0 0 m
146.749 0 l
S
Q
q 1 0 0 1 36 573.058 cm
0 0 m
87.221 0 l
S
Q
q 1 0 0 1 36 436.5681 cm
0 0 m
124.529 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.017 Tc 0.048 Tw 8 0 0 8 36 727.248 Tm
[(Immune-Media)-9.8 (ted Derma)-9.8 (tologic )37.2 (Adverse Reactions)]TJ
-0.019 Tc 0.072 Tw 0 -1.494 Td
[(OPDUALAG can cause immune-media)-9.8 (ted rash or derma)-9.8 (titis,)37.2 ( de\037ned as requiring use of)-19 ( )]TJ
0.044 Tw 0 -1.044 Td
[(steroids and no c)20.2 (lear alterna)-9.7 (te etiolog)-9.8 (y)55.2 (.)37.2 ( Exfolia)-9.7 (tive derma)-9.8 (titis,)37.2 ( inc)20.2 (luding Stevens-Johnson)-19 ( )]TJ
-0.016 Tc 0.142 Tw 0 -1.044 Td
[(Syndrome,)36.9 ( toxic epidermal necrolysis,)36.9 ( and Drug Rash with Eosinophilia and Systemic)-16 ( )]TJ
0.145 Tw 0 -1.044 Td
[(Symptoms has occurred with PD-1/L-1 blocking antibodies.)36.8 ( )37.3 (T)73.8 (opical emollients and/or)-16 ( )]TJ
-0.019 Tc 0.038 Tw 0 -1.044 Td
[(topical corticosteroids may be adequa)-9.8 (te to trea)-9.7 (t mild to modera)-9.7 (te non-exfolia)-9.8 (tive rashes.)18 ( )]TJ
0.042 Tw 0 -1.044 Td
[(Withhold or permanently discontinue OPDUALAG )0.5 (depending on severity )]TJ
/T1_1 1 Tf
[([see )0.5 (Dosa)-9.8 (ge )0.5 (and)-19 ( )]TJ
0.019 Tw 0 -1.044 Td
[(Administra)-9.8 (ti)]TJ
0.06 Tw (on \(2.2\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.012 Tc 0.242 Tw 0 -1.674 Td
[(Immune-media)-10.1 (ted rash occurred in 9% \(33/355\) of pa)-10 (tients receiving OPDUALAG,)25 ( )]TJ
-0.019 Tc 0.054 Tw 0 -1.044 Td
[(inc)20.2 (luding Grade 3 \(0.6%\) and Grade 2 \(3.4%\) adverse reactions.)37.2 ( Immune-media)-9.8 (ted rash)-19 ( )]TJ
0.091 Tw 0 -1.044 Td
[(did )0.5 (not )0.6 (lead )0.5 (to )0.5 (permanent )0.5 (discontinua)-9.8 (tion )0.5 (of )0.5 (OPDUALAG.)37.2 ( )0.5 (Immune-media)-9.8 (ted )0.5 (rash )0.5 (led )0.5 (to)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(withholding of OPDUALAG in 1.4% of pa)-9.8 (tients.)]TJ
-0.023 Tc 0.024 Tw 0 -1.674 Td
[(Systemic corticosteroids were required in 88% \(29/33\) of pa)-10 (tients with immune-media)-10 (ted)-23.1 ( )]TJ
-0.018 Tc 0.12 Tw 0 -1.044 Td
[(ra)0.5 (sh)0.5 (.)37.4 ( R)0.5 (as)0.5 (h )0.5 (re)0.5 (so)0.5 (lve)0.5 (d )0.5 (in)0.5 ( 70)0.5 (% )0.5 (of)0.5 ( t)0.5 (he )0.5 (33)0.5 ( p)0.5 (a)-9.6 (t)0.5 (ie)0.5 (nts)0.5 (.)37.4 ( )0.5 (Of )0.5 (th)0.5 (e )0.5 (5 )0.5 (pa)-9.6 (t)0.5 (ie)0.5 (nt)0.5 (s )0.5 (in )0.5 (wh)0.5 (om )0.5 (OP)0.5 (DU)0.5 (AL)0.5 (AG)-18 ( )]TJ
-0.011 Tc 0.273 Tw 0 -1.044 Td
[(was withheld for immune-media)-10.3 (ted rash,)36.7 ( 4 reinitia)-10.3 (ted OPDUALAG after symptom)-11 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(improvement; of these,)37.2 ( 25% had recurrence of immune-media)-9.8 (ted rash.)]TJ
-0.017 Tc 0.048 Tw 0 -1.782 Td
[(Immune-Media)-9.8 (ted Myocarditis)]TJ
-0.014 Tc 0.196 Tw 0 -1.494 Td
[(OPDUALAG can cause immune-media)-10.3 (ted myocarditis,)36.8 ( which is de\037ned as requiring)-14 ( )]TJ
-0.013 Tc 0.205 Tw 0 -1.044 Td
[(use of steroids and no c)20.4 (lear alterna)-9.6 (te etiolog)-9.6 (y)55.4 (.)37.4 ( )37 (The dia)-9.5 (gnosis of immune-media)-9.6 (ted)-13 ( )]TJ
-0.019 Tc 0.03 Tw 0 -1.044 Td
[(myocarditis requires a high index of suspicion.)37.2 ( P)18.2 (a)-9.8 (tients with cardiac or cardio-pulmonar)-17.8 (y)-19 ( )]TJ
-0.015 Tc 0.172 Tw 0 -1.044 Td
[(symptoms should be assessed for potential myocarditis.)36.7 ( If myocarditis is suspected,)22 ( )]TJ
-0.016 Tc 0.139 Tw 0 -1.044 Td
[(withhold dose,)37.1 ( promptly initia)-9.9 (te high dose steroids \(prednisone or methylprednisolone)-16 ( )]TJ
-0.019 Tc 0.048 Tw 0 -1.044 Td
[(1\035)-48.4 (to\035)-48.4 (2 mg/kg/day\) and promptly arrange cardiolog)-9.8 (y consulta)-9.8 (tion with dia)-9.8 (gnostic workup.)18 ( )]TJ
-0.016 Tc 0.15 Tw 0 -1.044 Td
[(If c)19.6 (linically con\037rmed,)36.6 ( permanently discontinue OPDUALAG for Grade 2-4 myocarditis)-16 ( )]TJ
/T1_1 1 Tf
0 Tc 0 Tw 0 -1.044 Td
([)Tj
-0.019 Tc 0.06 Tw 0.24 0 Td
[(see Dosa)-9.8 (ge)]TJ
0.023 Tw [( )-36.8 (and Administra)-9.7 (ti)]TJ
0.06 Tw (on \(2.2\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.01 Tc 0.294 Tw -0.24 -1.674 Td
[(Myocarditis occurred in 1.7% \(6/355\) of pa)-10.1 (tients receiving OPDUALAG,)36.9 ( inc)19.9 (luding)-10 ( )]TJ
-0.016 Tc 0.133 Tw 0 -1.044 Td
[(Grade 3 )0.5 (\(0.6%\),)37.3 ( and Grade )0.5 (2 )0.5 (\(1.1%\) )0.5 (adverse )0.5 (reactions.)37.2 ( )0.5 (Myocarditis led to )0.5 (permanent)-16 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(discontinua)-9.8 (tion of OPDUALAG in 1.7% of pa)-9.8 (tients.)]TJ
-0.013 Tc 0.216 Tw 0 -1.674 Td
[(Systemic corticosteroids were required in 100% \(6/6\) of pa)-10 (tients with myocarditis.)24 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(Myocarditis resolved in 100% of the 6 pa)-9.8 (tients.)]TJ
-0.017 Tc 0.048 Tw 0 -1.782 Td
[(Other Immune-Media)-9.8 (ted )37.2 (Adverse Reactions)]TJ
-0.013 Tc 0.211 Tw 0 -1.494 Td
[(The follo)-9.8 (wing c)20.2 (linically signi\037cant IMARs occurred a)-9.8 (t an incidence of <1% \(unless)-13 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.019 Tc 0.092 Tw -31.5 -1.044 Td
[(otherwise noted\) in pa)-9.8 (tients who received OPDUALAG or were reported with the use of)-19 ( )]TJ
-0.022 Tc 0.024 Tw 0 -1.044 Td
[(other PD-1/PD-L1 blocking antibodies.)36.8 ( Severe or fa)-10.2 (tal cases ha)-10.3 (ve been reported for some)-22 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
(of these adverse reactions.)Tj
/T1_1 1 Tf
0.019 Tw 0 -1.674 Td
[(Cardiac/V)18.2 (ascular:)]TJ
/T1_0 1 Tf
0.06 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
6.138 0 Td
[( P)18.2 (ericarditis,)37.2 ( vasculitis.)]TJ
/T1_1 1 Tf
-0.01 Tc 0.295 Tw -6.138 -1.674 Td
[(Ner)-18.2 (vous System:)]TJ
/T1_0 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
6.431 0 Td
[( Meningitis,)36.9 ( encephalitis,)36.8 ( myelitis and demyelina)-10.1 (tion,)36.8 ( my)-10.2 (asthenic)-9.9 ( )]TJ
-0.014 Tc 0.178 Tw -6.431 -1.044 Td
[(s)0.5 (yn)0.5 (d)0.5 (ro)0.5 (m)0.5 (e)0.5 (/m)0.5 (y)-9.5 (as)0.5 (th)0.5 (e)0.5 (ni)0.5 (a)0.5 ( g)0.5 (r)0.5 (a)-9.6 (v)0.5 (i)0.5 (s \(i)0.5 (n)0.5 (c)20.4 (l)0.5 (ud)0.5 (i)0.5 (ng)0.5 ( e)0.5 (x)0.5 (ac)0.5 (e)0.5 (r)0.5 (ba)-9.5 (t)0.5 (io)0.5 (n)0.5 (\),)37.5 ( G)0.5 (u)0.5 (il)0.5 (l)0.5 (ai)0.5 (n)0.5 (-B)0.5 (a)0.5 (rr)0.5 (\351)0.5 ( s)0.5 (yn)0.5 (d)0.5 (ro)0.5 (m)0.5 (e,)37.5 ( n)0.5 (e)0.5 (r)-17.5 (ve)-14 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(paresis,)37.2 ( autoimmune neuropa)-9.8 (thy)55.2 (.)]TJ
/T1_1 1 Tf
0.019 Tw 0 -1.674 Td
(Ocular:)Tj
/T1_0 1 Tf
0.038 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
2.517 0 Td
[( Uveitis,)37.2 ( iritis,)37.2 ( and other ocular in\034amma)-9.8 (tor)-17.8 (y toxicities can occur)74.2 (.)37.2 ( Some cases can)-19 ( )]TJ
-0.016 Tc 0.135 Tw -2.517 -1.044 Td
[(be associa)-9.9 (ted with retinal detachment.)37.2 ( )36.9 (V)18.1 (arious grades of visual impairment,)37.2 ( inc)20.2 (luding)-16 ( )]TJ
-0.014 Tc 0.198 Tw 0 -1.044 Td
[(blindness,)36.7 ( can occur)73.7 (.)36.7 ( If uveitis occurs in combina)-10.3 (tion with other IMARs,)36.7 ( consider a)-14 ( )]TJ
-0.012 Tc 0.237 Tw 0 -1.044 Td
[(V)18.1 (ogt-K)20.1 (o)-9.8 (y)-9.9 (ana)-9.9 (gi-Harada-like syndrome,)37.1 ( as this may require trea)-9.9 (tment with systemic)-12 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
(steroids to reduce the risk of permanent vision loss.)Tj
/T1_1 1 Tf
-0.015 Tc 0.015 Tw 0 -1.674 Td
(Gastrointestinal:)Tj
/T1_0 1 Tf
0.166 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.75 0 Td
[( P)17.9 (ancrea)-10 (titis inc)20 (luding increases in serum amylase and lipase levels,)22.1 ( )]TJ
-0.019 Tc 0.06 Tw -5.75 -1.044 Td
[(gastritis,)37.2 ( duodenitis.)]TJ
/T1_1 1 Tf
-0.011 Tc 0.251 Tw 0 -1.674 Td
[(M)0.5 (u)0.6 (s)0.6 (c)0.5 (u)0.5 (l)0.6 (o)0.6 (s)0.5 (k)0.6 (e)0.5 (l)0.6 (e)0.5 (t)0.6 (a)0.5 (l)0.6 ( a)0.5 (n)0.6 (d)0.5 ( C)0.6 (o)0.6 (n)0.5 (n)0.5 (e)0.6 (c)0.5 (t)0.6 (i)0.6 (v)0.5 (e)0.6 ( )37.2 (T)18.5 (i)0.6 (s)0.5 (s)0.5 (u)0.6 (e)0.6 (:)]TJ
/T1_0 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
15.011 0 Td
( )Tj
EMC 
0.03 0 Td
[( M)0.6 (y)0.5 (o)0.6 (s)0.5 (i)0.6 (t)0.5 (i)0.6 (s)0.5 (/)0.6 (p)0.5 (o)0.6 (l)0.5 (y)0.6 (m)0.5 (y)0.6 (o)0.5 (s)0.6 (i)0.5 (t)0.6 (i)0.5 (s)0.6 (,)37.5 ( r)0.6 (h)0.5 (a)0.6 (b)0.5 (d)0.6 (o)0.5 (m)0.6 (y)0.6 (o)0.5 (l)0.6 (y)0.5 (s)0.6 (i)0.5 (s)0.6 ( \()0.5 (a)0.6 (n)0.5 (d)-11 ( )]TJ
-0.019 Tc 0.06 Tw -15.041 -1.044 Td
[(associa)-9.8 (ted sequelae inc)20.3 (luding renal failure\),)37.3 ( arthritis,)37.2 ( polymy)-9.8 (algia rheuma)-9.8 (tica.)]TJ
/T1_1 1 Tf
0.019 Tw 0 -1.674 Td
(Endocrine:)Tj
/T1_0 1 Tf
-0.198 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.736 0 Td
[( )-257.8 (Hypopara)-9.8 (thyroidism.)]TJ
/T1_1 1 Tf
-0.01 Tc 0.29 Tw -3.736 -1.674 Td
[(Other \(Hema)-10 (tologic/Immune\):)]TJ
/T1_0 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
10.928 0 Td
[( )0.5 (Hemolytic anemia,)37.1 ( a)-9.9 (plastic anemia,)37.1 ( hemopha)-9.9 (goc)20 (ytic)-10 ( )]TJ
-0.016 Tc 0.141 Tw -10.928 -1.044 Td
[(lymphohistioc)19.9 (ytosis,)36.9 ( systemic in\034amma)-10 (tor)-18 (y response syndrome,)37 ( histioc)20 (ytic necrotizing)-16 ( )]TJ
-0.017 Tc 0.12 Tw 0 -1.044 Td
[(lymphadenitis \(Kikuchi lymphadenitis\),)36.9 ( sarcoidosis,)37 ( immune thromboc)19.9 (ytopenic purpura,)20 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(solid organ transplant rejection,)37.3 ( other transplant \(inc)20.2 (luding corneal graft\) rejection.)]TJ
/T1_2 1 Tf
-0.017 Tc 0.017 Tw 0 -1.94 Td
(5.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(Infusion-Related Reactions)Tj
/T1_0 1 Tf
-0.012 Tc 0.242 Tw -3.375 -1.539 Td
[(OPDUALAG )0.6 (can )0.5 (cause )0.6 (severe )0.6 (infusion-rela)-10.1 (ted )0.6 (reactions.)37 ( )0.5 (Discontinue )0.6 (OPDUALAG )0.6 (in)-12 ( )]TJ
-0.019 Tc 0.12 Tw 0 -1.044 Td
[(pa)-10.3 (tients with severe or life-threa)-10.3 (tening infusion-rela)-10.3 (ted reactions.)36.7 ( Interrupt or slo)-10.3 (w the)-19 ( )]TJ
0.055 Tw 0 -1.044 Td
[(ra)-9.8 (te of infusion in pa)-9.8 (tients with mild or modera)-9.8 (te infusion-rela)-9.8 (ted reactions )]TJ
/T1_1 1 Tf
[([see Dosa)-9.8 (ge)-18.9 ( )]TJ
0.023 Tw 0 -1.044 Td
[(and Administra)-9.8 (ti)]TJ
0.06 Tw (on \(2.2\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.022 Tc 0.024 Tw 0 -1.674 Td
[(I)0.5 (n )0.5 (p)0.5 (a)-9.5 (ti)0.5 (e)0.5 (n)0.5 (ts)0.5 ( )0.5 (w)0.5 (ho)0.5 ( )0.5 (r)0.5 (ec)0.5 (e)0.5 (i)0.5 (ve)0.5 (d)0.5 ( )0.5 (OP)0.5 (D)0.5 (UA)0.5 (L)0.5 (AG)0.5 ( )0.5 (a)0.5 (s)0.5 ( a)0.5 ( )0.5 (6)0.5 (0-)0.5 (m)0.5 (i)0.5 (nu)0.5 (t)0.5 (e)0.5 ( i)0.5 (n)0.5 (tr)0.5 (a)-9.5 (v)0.5 (e)0.5 (no)0.5 (u)0.5 (s)0.5 ( i)0.5 (n)0.5 (fu)0.5 (s)0.5 (io)0.5 (n)0.5 (,)37.5 ( i)0.5 (n)0.5 (f)0.5 (us)0.5 (i)0.5 (on)0.5 (-)0.5 (r)0.5 (el)0.5 (a)-9.5 (t)0.5 (e)0.5 (d)-22.1 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(reactions occurred in 7% \(23/355\) of pa)-9.8 (tients.)]TJ
/T1_2 1 Tf
-0.017 Tc 0.017 Tw 0 -1.94 Td
(5.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(Complications of Allogeneic Hematopoietic Stem Cell T)74.2 (ransplantation)]TJ
/T1_0 1 Tf
-0.014 Tc 0.197 Tw -3.375 -1.539 Td
[(F)19.7 (a)-10.2 (tal and other serious complica)-10.2 (tions can occur in pa)-10.3 (tients who receive allogeneic)-14 ( )]TJ
0.196 Tw 0 -1.044 Td
[(hema)-10.2 (topoietic stem cell transplanta)-10.3 (tion \(HSCT\) before or after being trea)-10.3 (ted with a)-13.9 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.007 Tc 0.364 Tw -31.5 -1.044 Td
[(PD-1/PD-L1 receptor blocking antibod)-9.9 (y)55 (.)37 ( )37 (T)74 (ransplant-rela)-9.9 (ted complica)-10 (tions inc)20 (lude)-7 ( )]TJ
-0.01 Tc 0.293 Tw 0 -1.044 Td
[(hyperacute graft-versus-host-disease \(GVHD\),)36.9 ( acute GVHD,)36.9 ( chronic GVHD,)36.9 ( hepa)-10.1 (tic)-10 ( )]TJ
-0.009 Tc 0.312 Tw 0 -1.044 Td
[(veno-occ)20.1 (lusive disease after reduced intensity conditioning,)37.1 ( and steroid-requiring)-9 ( )]TJ
-0.018 Tc 0.12 Tw 0 -1.044 Td
[(febrile syndrome \(without )0.5 (an i)0.5 (dent)0.5 (i\037)0.5 (ed in)0.5 (fectious cause\) )]TJ
/T1_1 1 Tf
0.083 Tw [([see Adverse )-36.6 (Reaction)]TJ
0.12 Tw (s \(6.1\)])Tj
/T1_0 1 Tf
-0.037 Tc 0.037 Tw (. )Tj
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.011 Tc 0.274 Tw -31.5 -1.044 Td
[(These complica)-10.3 (tions may occur despite inter)-18.3 (vening thera)-10.3 (py between PD-1/PD-L1)-11 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(blockade and allogeneic HSCT)92.2 (.)]TJ
-0.016 Tc 0.144 Tw 36 84.145 Td
[(F)19.8 (ollo)-10.1 (w pa)-10.1 (tients c)19.9 (losely for evidence of transplant-rela)-10.1 (ted complica)-10.1 (tions and inter)-18.1 (vene)-16 ( )]TJ
-0.015 Tc 0.156 Tw 0 -1.044 Td
[(promptly)55.4 (.)37.3 ( Consider the bene\037t versus risks of trea)-9.7 (tment with a PD-1/PD-L1 receptor)-15 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(blocking antibod)-9.8 (y prior to or after an allogeneic HSCT)92.2 (.)]TJ
/T1_2 1 Tf
-0.017 Tc 0.017 Tw 0 -1.94 Td
(5.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(Embr)-17.8 (yo-F)20.2 (etal T)74.2 (oxicity)]TJ
/T1_0 1 Tf
-0.019 Tc 0.075 Tw -3.375 -1.539 Td
[(Based on its mechanism of action and da)-9.8 (ta from animal studies,)37.2 ( OPDUALAG can cause)-19 ( )]TJ
-0.015 Tc 0.154 Tw 0 -1.044 Td
[(fe)0.5 (tal)0.5 ( ha)0.5 (rm whe)0.5 (n adm)0.5 (inis)0.5 (ter)0.5 (ed to a pre)0.5 (gna)0.5 (nt wom)0.5 (an.)37.4 ( In)0.5 ( an)0.5 (ima)0.5 (l r)0.5 (epr)0.5 (oduc)0.5 (tio)0.5 (n s)0.5 (tudi)0.5 (es,)22 ( )]TJ
-0.017 Tc 0.12 Tw 0 -1.044 Td
[(administra)-10.1 (tion of nivolumab to c)19.8 (ynomolgus monkeys from the onset of organogenesis)-17 ( )]TJ
-0.013 Tc 0.218 Tw 0 -1.044 Td
[(through deliver)-18.1 (y resulted in increased abortion and prema)-10.1 (ture infant dea)-10.1 (th.)36.9 ( )37.1 (Advise)-13 ( )]TJ
-0.019 Tc 0.051 Tw 0 -1.044 Td
[(pregnant women of the potential risk to a fetus.)37.2 ( )37.2 (Advise females of reproductive potential)-19 ( )]TJ
-0.017 Tc 0.123 Tw 0 -1.044 Td
[(to use effective contraception )0.5 (during trea)-10.2 (tment with )0.5 (OPDUALAG )0.5 (for a)-10.2 (t )0.5 (least )0.5 (5 months)-16.9 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
(after the last dose of OPDUALAG )Tj
/T1_1 1 Tf
[([see Use in Speci\037c P)18.2 (opula)-9.8 (tions \(8)]TJ
[(.1,)37.2 ( 8.3\)])]TJ
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_2 1 Tf
-0.017 Tc 0.017 Tw 0 -2.003 Td
(6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(ADVERSE REACTIONS)Tj
/T1_0 1 Tf
-0.016 Tc 0.131 Tw -3.375 -1.674 Td
[(The follo)-9.6 (wing c)20.3 (linically signi\037cant adverse reactions are discussed in grea)-9.6 (ter detail in)-16 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
(other sections of the labeling.)Tj
-0.017 Tc 0.017 Tw 1.125 -1.54 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.06 Tw 1.125 0 Td
[(Severe and F)20.2 (a)-9.7 (tal IMARs )]TJ
/T1_1 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.1\)])]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.387 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.06 Tw 1.125 0 Td
[(Infusion-Rela)-9.8 (ted Reactions )]TJ
/T1_1 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.2\)])]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.387 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.06 Tw 1.125 0 Td
[(Complica)-9.8 (tions of )37.2 (Allogeneic HSCT )]TJ
/T1_1 1 Tf
[([see )37.2 (W)18.3 (arnings and Precautions \(5.3\)])]TJ
/T1_2 1 Tf
0.017 Tw -2.25 -1.787 Td
(6.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(Clinical T)74.2 (rials Experience)]TJ
/T1_0 1 Tf
-0.019 Tc 0.114 Tw -3.375 -1.539 Td
[(Because c)20.2 (linical trials are conducted under widely var)-17.7 (ying conditions,)37.2 ( adverse reaction)-19 ( )]TJ
0.056 Tw 0 -1.044 Td
[(ra)-9.8 (tes obser)-17.7 (ved in the c)20.2 (linical trials of a drug cannot be directly compared to ra)-9.8 (tes in the)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(c)20.2 (linical trials of another drug and may not re\034ect the ra)-9.7 (tes obser)-17.7 (ved in practice.)]TJ
0.069 Tw 0 -1.674 Td
[(The safety of OPDUALAG was evalua)-9.7 (ted in RELA)55.2 (TIVITY)74.2 (-047,)37.3 ( a randomized \(1:1\),)37.2 ( double-)-19 ( )]TJ
-0.011 Tc 0.26 Tw 0 -1.044 Td
[(blinded trial in 714 pa)-9.8 (tients with previously untrea)-9.8 (ted metasta)-9.8 (tic or unresectable)-11 ( )]TJ
-0.007 Tc 0.007 Tw 0 -1.044 Td
(melanoma )Tj
/T1_1 1 Tf
0.361 Tw 4.424 0 Td
([see Clinical Studies \(14\)])Tj
/T1_0 1 Tf
[(.)37.1 ( P)18.2 (a)-9.9 (tients received intra)-9.9 (venous OPDUALAG)-7 ( )]TJ
-0.023 Tc 0.024 Tw -4.424 -1.044 Td
[(\(nivolumab 480 mg and rela)-10.2 (tlimab 160 mg\) ever)-18.1 (y 4 weeks \(n=355\) or nivolumab 480 mg)-23 ( )]TJ
-0.019 Tc 0.109 Tw 0 -1.044 Td
[(by intra)-9.8 (venous infusion ever)-17.8 (y 4 weeks \(n=359\).)37.2 ( P)18.2 (a)-9.8 (tients were trea)-9.8 (ted with OPDUALAG)-18.9 ( )]TJ
-0.015 Tc 0.153 Tw 0 -1.044 Td
[(o)0.5 (r n)0.5 (i)0.5 (vo)0.5 (l)0.5 (um)0.5 (a)0.5 (b un)0.5 (ti)0.5 (l)0.5 ( di)0.5 (se)0.5 (a)0.5 (se)0.5 ( p)0.5 (r)0.5 (og)0.5 (r)0.5 (es)0.5 (si)0.5 (o)0.5 (n)0.5 ( or)0.5 ( u)0.5 (na)0.5 (c)0.5 (ce)0.5 (p)0.5 (ta)0.5 (bl)0.5 (e)0.5 ( t)0.5 (ox)0.5 (i)0.5 (ci)0.5 (t)0.5 (y)55.4 (.)37.5 ( )36.9 (Th)0.5 (e)0.5 ( me)0.5 (d)0.5 (ia)0.5 (n)0.5 ( du)0.5 (r)0.5 (a)-9.6 (t)0.5 (i)0.5 (o)0.5 (n)-15 ( )]TJ
-0.019 Tc 0.104 Tw 0 -1.044 Td
[(of exposure was 6 months \(range:)37.2 ( 0 to 31 months\) in OPDUALAG-trea)-9.7 (ted pa)-9.7 (tients and)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(5 months \(range:)37.2 ( 0 to 32 months\) in nivolumab-trea)-9.8 (ted pa)-9.8 (tients.)]TJ
-0.02 Tc 0.024 Tw 0 -1.674 Td
[(Serious adverse reactions occurred in 36% of pa)-10.1 (tients trea)-10.1 (ted with OPDUALAG.)36.9 ( )36.8 (The most)-20 ( )]TJ
-0.019 Tc 0.087 Tw 0 -1.044 Td
[(frequent )0.5 (serious )0.6 (adverse )0.6 (reactions )0.6 (reported )0.5 (in )0.6 (\0361% )0.6 (of )0.6 (pa)-9.8 (tients )0.6 (trea)-9.7 (ted )0.6 (with )0.5 (OPDUALAG)-19 ( )]TJ
-0.022 Tc 0.024 Tw 0 -1.044 Td
[(were adrenal insuf\037cienc)20.2 (y \(1.4%\),)37.2 ( anemia \(1.4%\),)37.1 ( colitis \(1.4%\),)37.1 ( pneumonia \(1.4%\),)37.2 ( acute)-22 ( )]TJ
-0.019 Tc 0.063 Tw 0 -1.044 Td
[(myocardial infarction \(1.1%\),)37.2 ( back pain \(1.1%\),)37.2 ( diarrhea \(1.1%\),)37.2 ( myocarditis \(1.1%\),)37.2 ( and)-19 ( )]TJ
-0.014 Tc 0.179 Tw 0 -1.044 Td
[(pneumoni)0.5 (tis \(1.)0.5 (1%\).)37.4 ( F)20.4 (a)-9.5 (tal adverse react)0.5 (io)0.5 (n o)0.5 (ccurred in 3)0.5 ( \(0.8)0.5 (%\) pa)-9.6 (t)0.5 (ients who were)-14 ( )]TJ
-0.012 Tc 0.231 Tw 0 -1.044 Td
[(trea)-9.6 (ted )0.5 (with )0.5 (OPDUALAG; )0.6 (these )0.6 (inc)20.4 (luded )0.5 (hemopha)-9.6 (goc)20.4 (ytic )0.5 (lymphohistioc)20.3 (ytosis,)37.4 ( )0.5 (acute)-12 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(edema of the lung,)37.2 ( and pneumonitis.)]TJ
0.082 Tw 0 -1.674 Td
[(OPDUALAG was permanently discontinued due to adverse reactions in 18% of\ pa)-9.8 (tients.)18 ( )]TJ
0.065 Tw 0 -1.044 Td
[(Adverse reactions which resulted in permanent discontinua)-9.8 (tion of OPDUALAG in \0361% of)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(pa)-9.8 (tients inc)20.2 (luded myocarditis \(1.7%\) and pneumonitis \(1.4%\).)]TJ
-0.013 Tc 0.208 Tw 0 -1.674 Td
[(Dosa)-9.7 (ge interruptions due to an adverse reaction occurred in 43% of pa)-9.8 (tients who)-13 ( )]TJ
-0.014 Tc 0.192 Tw 0 -1.044 Td
[(received OPDUALAG.)36.9 ( )36.9 (Adverse reactions tha)-10 (t required dosa)-10.1 (ge interruption in \0362% of)-14 ( )]TJ
-0.019 Tc 0.072 Tw 0 -1.044 Td
[(pa)-9.8 (tients who received OPDUALAG were diarrhea \(3.9%\),)37.2 ( troponin increased \(3.9%\),)37.2 ( )37.2 (AST)-19 ( )]TJ
0.115 Tw 0 -1.044 Td
[(increased \(2.8%\),)37.2 ( troponin )37.4 (T increased \(2.8%\),)37.2 ( )37.4 (AL)94.2 (T )0.5 (increased \(2.3%\),)37.1 ( )0.5 (arthralgia )0.5 (\(2.3%\),)18 ( )]TJ
0.06 Tw 0 -1.044 Td
[(hypothyroidism \(2.3%\),)37.2 ( anemia \(2%\),)37.3 ( fa)-9.8 (tigue \(2%\),)37.2 ( pneumonitis \(2%\),)37.2 ( and rash \(2%\).)]TJ
-0.014 Tc 0.186 Tw 0 -1.674 Td
[(The most common \(\03620%\) adverse reactions tha)-9.8 (t occurred in pa)-9.8 (tients trea)-9.9 (ted with)-14.1 ( )]TJ
-0.019 Tc 0.059 Tw 0 -1.044 Td
[(OPDUALAG were musculoskeletal pain \(45%\),)37.2 ( fa)-9.8 (tigue \(39%\),)37.2 ( rash \(28%\),)37.2 ( pruritus \(25%\),)18 ( )]TJ
-0.018 Tc 0.12 Tw 0 -1.044 Td
[(and diarrhea \(24%\).)36.9 ( )36.9 (The most common \(\03620%\) labora)-10.1 (tor)-18.1 (y abnormalities tha)-10.1 (t occurred)-18 ( )]TJ
-0.012 Tc 0.237 Tw 0 -1.044 Td
[(in pa)-9.9 (tients trea)-9.8 (ted with OPDUALAG were decreased hemoglobin \(37%\),)37.1 ( decreased)-12 ( )]TJ
-0.008 Tc 0.335 Tw 0 -1.044 Td
[(lymphoc)20.2 (ytes \(32%\),)37.2 ( increased )37 (AST \(30%\),)37.2 ( increased )36.9 (AL)94.2 (T \(26%\),)37.1 ( and decreased)-8 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
(sodium \(24%\).)Tj
-0.015 Tc 0.172 Tw 0 -1.674 Td
[(T)73.7 (ables )0.6 (3 )0.5 (and )0.5 (4 )0.5 (summarize )0.5 (both )0.5 (the )0.6 (adverse )0.5 (reactions )0.5 (and )0.5 (labora)-10.2 (tor)-18.2 (y )0.5 (abnormalities,)22 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(respectively)55.2 (,)37.2 ( in RELA)55.2 (TIVITY)74.2 (-047.)]TJ
ET
1 w 4 M 
q 1 0 0 1 319.5 41.6519 cm
0 0 m
S
Q
endstreamendobj27 0 obj<</Length 21315>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 546.5681 cm
0 0 m
89.596 0 l
S
Q
q 1 0 0 1 36 426.778 cm
0 0 m
71.643 0 l
S
Q
q 1 0 0 1 36 290.2881 cm
0 0 m
79.288 0 l
S
Q
q 1 0 0 1 36 178.848 cm
0 0 m
103.356 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.019 Tc 0.11 Tw 8 0 0 8 36 727.248 Tm
[(IMARs,)37.2 ( which may be severe or fa)-9.8 (tal,)37.2 ( can occur in an)-9.8 (y organ system or tissue.)37.2 ( IMARs)-19 ( )]TJ
0.118 Tw 0 -1.044 Td
[(can occur a)-9.7 (t an)-9.8 (y time after starting trea)-9.8 (tment with a LAG-3 and PD-1/PD-L1 blocking)-19 ( )]TJ
-0.02 Tc 0.024 Tw 0 -1.044 Td
[(antibodies.)37.1 ( )37.2 (While IMARs usually manifest during trea)-9.9 (tment,)37.2 ( IMARs can also manifest after)-20 ( )]TJ
-0.019 Tc 0.019 Tw 0 -1.044 Td
[(discontinua)-9.8 (tion.)]TJ
-0.01 Tc 0.278 Tw 0 -1.674 Td
[(E)0.5 (a)0.5 (r)0.5 (l)0.5 (y)0.5 ( )0.5 (id)0.5 (e)0.5 (n)0.5 (t)0.5 (i)0.5 (\037)0.5 (c)0.5 (a)-9.5 (t)0.5 (i)0.5 (o)0.5 (n )0.5 (a)0.5 (n)0.5 (d)0.5 ( )0.5 (m)0.5 (a)0.5 (n)0.5 (a)-9.5 (g)0.5 (e)0.5 (m)0.5 (e)0.5 (n)0.5 (t)0.5 ( o)0.5 (f)0.5 ( )0.5 (I)0.5 (M)0.5 (A)0.5 (R)0.5 (s)0.5 ( )0.5 (a)0.5 (r)0.5 (e )0.5 (e)0.5 (s)0.5 (s)0.5 (e)0.5 (n)0.5 (t)0.5 (i)0.5 (a)0.5 (l)0.5 ( )0.5 (t)0.5 (o)0.5 ( e)0.5 (n)0.5 (s)0.5 (u)0.5 (r)0.5 (e)0.5 ( )0.5 (s)0.5 (a)0.5 (f)0.5 (e)0.5 ( u)0.5 (s)0.5 (e)0.5 (.)27 ( )]TJ
-0.019 Tc 0.102 Tw 0 -1.044 Td
[(Monitor pa)-9.8 (tients c)20.2 (losely for symptoms and signs tha)-9.8 (t may be c)20.2 (linical manifesta)-9.8 (tions of)-19 ( )]TJ
-0.021 Tc 0.024 Tw 0 -1.044 Td
[(underlying IMARs.)37.1 ( Evalua)-9.8 (te liver enzymes,)37.2 ( crea)-9.8 (tinine,)37.1 ( and thyroid function a)-9.9 (t baseline and)-21 ( )]TJ
-0.02 Tc 0 -1.044 Td
[(periodically during trea)-10.2 (tment.)36.8 ( In cases of suspected IMARs,)36.8 ( initia)-10.2 (te a)-10.2 (ppropria)-10.2 (te workup to)-20 ( )]TJ
-0.021 Tc 0 -1.044 Td
[(exc)20 (lude alterna)-9.9 (tive etiologies,)37.1 ( inc)20 (luding infection.)37 ( Institute medical mana)-9.9 (gement promptly)55.1 (,)16 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(inc)20.2 (luding specialty consulta)-9.8 (tion as a)-9.7 (ppropria)-9.7 (te.)]TJ
0.042 Tw 0 -1.674 Td
[(Withhold or permanently discontinue OPDUALAG )0.5 (depending on severity )]TJ
/T1_1 1 Tf
[([see )0.5 (Dosa)-9.8 (ge )0.5 (and)-19 ( )]TJ
-0.016 Tc 0.137 Tw 0 -1.044 Td
[(Administra)-9.8 (tion \(2.2\)])]TJ
/T1_0 1 Tf
[(.)37.1 ( In general,)37.2 ( if OPDUALAG requires interruption or discontinua)-9.9 (tion,)21 ( )]TJ
-0.019 Tc 0.102 Tw 0 -1.044 Td
[(administer systemic corticosteroid thera)-9.7 (py \(1 to 2 mg/kg/day prednisone or equivalent\))-19 ( )]TJ
-0.015 Tc 0.154 Tw 0 -1.044 Td
[(un)0.5 (ti)0.5 (l )0.5 (im)0.5 (pr)0.5 (ov)0.5 (em)0.5 (e)0.5 (nt)0.5 ( t)0.5 (o )0.5 (G)0.5 (ra)0.5 (de)0.5 ( 1)0.5 ( o)0.5 (r)0.5 ( l)0.5 (es)0.5 (s.)37.4 ( )0.5 (U)0.5 (po)0.5 (n )0.5 (im)0.5 (pr)0.5 (ov)0.5 (em)0.5 (en)0.5 (t )0.5 (t)0.5 (o )0.5 (Gr)0.5 (ad)0.5 (e )0.5 (1)0.5 ( o)0.5 (r )0.5 (le)0.5 (ss)0.5 (,)37.4 ( )0.5 (in)0.5 (it)0.5 (ia)-9.5 (te)-14.9 ( )]TJ
-0.019 Tc 0.05 Tw 0 -1.044 Td
[(corticosteroid ta)-9.8 (per and continue to ta)-9.8 (per over a)-9.8 (t least 1 month.)37.2 ( Consider administra)-9.8 (tion)-19 ( )]TJ
0.063 Tw 0 -1.044 Td
[(of other systemic immunosuppressants in pa)-9.7 (tients whose IMARs are not controlled with)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(corticosteroid thera)-9.8 (py)55.2 (.)]TJ
-0.016 Tc 0.148 Tw 0 -1.674 Td
[(T)73.7 (oxicity mana)-10.3 (gement guidelines for adverse reactions tha)-10.3 (t do not necessarily require)-16 ( )]TJ
-0.025 Tc 0.015 Tw 0 -1.044 Td
[(systemic steroids \(e.g.,)37.2 ( endocrinopa)-9.8 (thies and derma)-9.9 (tologic reactions\) are discussed belo)-9.8 (w)37.1 (.)]TJ
-0.017 Tc 0.048 Tw 0 -1.782 Td
[(Immune-Media)-9.8 (ted Pneumonitis)]TJ
-0.018 Tc 0.12 Tw 0 -1.494 Td
[(OPDUALAG can cause immune-media)-10.1 (ted pneumonitis,)36.9 ( which may be fa)-10 (tal.)36.9 ( In pa)-10.1 (tients)-18 ( )]TJ
-0.022 Tc 0.024 Tw 0 -1.044 Td
[(trea)-9.8 (ted with other PD-1/PD-L1 blocking antibodies,)37.3 ( the incidence of pneumonitis is higher)-22 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(in pa)-9.7 (tients who ha)-9.8 (ve received prior thoracic radia)-9.8 (tion.)]TJ
-0.008 Tc 0.344 Tw 0 -1.674 Td
[(Immune-media)-10.1 (ted pneumonitis occurred in 3.7% \(13/355\) of pa)-10.1 (tients receiving)-8 ( )]TJ
-0.022 Tc 0.024 Tw 0 -1.044 Td
[(OPDUALAG,)37.2 ( inc)20.2 (luding Grade 3 \(0.6%\),)37.2 ( and Grade 2 \(2.3%\) adverse reactions.)37.2 ( Pneumonitis)-22.1 ( )]TJ
-0.019 Tc 0.098 Tw 0 -1.044 Td
[(led to permanent discontinua)-9.7 (tion of OPDUALAG in 0.8% and withholding of OPDUALAG)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(in 1.4% of pa)-9.8 (tients.)]TJ
-0.017 Tc 0.127 Tw 0 -1.674 Td
[(Systemic corticosteroids were required in 100% \(13/13\) of pa)-10.5 (tients with pneumonitis.)20 ( )]TJ
-0.019 Tc 0.086 Tw 0 -1.044 Td
[(Pneumonitis resolved in 85% of the 13 pa)-9.8 (tients.)37.2 ( Of the 5 pa)-9.8 (tients in whom OPDUALAG)-19 ( )]TJ
0.107 Tw 0 -1.044 Td
[(was withheld for pneumonitis,)37.2 ( 5 reinitia)-9.8 (ted OPDUALAG after symptom improvement; of)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(these,)37.2 ( none had recurrence of pneumonitis.)]TJ
-0.017 Tc 0.048 Tw 0 -1.782 Td
[(Immune-Media)-9.8 (ted Colitis)]TJ
-0.025 Tc 0.014 Tw 0 -1.494 Td
[(OPDUALAG can cause immune-media)-9.7 (ted colitis,)37.3 ( de\037ned as requiring use of corticosteroids)-25 ( )]TJ
-0.019 Tc 0.103 Tw 0 -1.044 Td
[(and no c)20.2 (lear alterna)-9.8 (te etiolog)-9.8 (y)55.2 (.)37.3 ( )37 (A common symptom inc)20.2 (luded in the de\037nition of colitis)-19 ( )]TJ
0.104 Tw 0 -1.044 Td
[(was )0.6 (diarrhea.)37.2 ( )0.5 (Cytomegalovirus )0.6 (infection/reactiva)-9.8 (tion )0.6 (has )0.6 (been )0.6 (reported )0.5 (in )0.6 (pa)-9.8 (tients )0.6 (with)-19 ( )]TJ
-0.016 Tc 0.143 Tw 0 -1.044 Td
[(corticosteroid-refractor)-18.1 (y immune-media)-10.1 (ted colitis.)36.9 ( In cases of corticosteroid-refractor)-18.1 (y)-16 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(colitis,)37.2 ( consider repea)-9.7 (ting infectious workup to exc)20.1 (lude alterna)-9.8 (tive etiologies.)]TJ
-0.013 Tc 0.207 Tw 0 -1.674 Td
[(Immune-media)-9.7 (ted diarrhea or colitis occurred in 7% \(24/355\) of pa)-9.7 (tients receiving)-13 ( )]TJ
-0.019 Tc 0.096 Tw 0 -1.044 Td
[(OPDUALAG,)37.2 ( inc)20.2 (luding Grade 3 \(1.1%\) and Grade 2 \(4.5%\) adverse reactions.)37.2 ( Colitis led)-19.1 ( )]TJ
-0.022 Tc 0.024 Tw 0 -1.044 Td
[(to permanent discontinua)-10.3 (tion of OPDUALAG in 2% and withholding of OPDUALAG in 2.8%)-22 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(of pa)-9.8 (tients.)]TJ
-0.015 Tc 0.166 Tw 0 -1.674 Td
[(Systemic corticosteroids were required in 100% \(24/24\) of pa)-10 (tients with diarrhea or)-14.9 ( )]TJ
-0.019 Tc 0.038 Tw 0 -1.044 Td
[(colitis.)37.2 ( Colitis resolved in 83% of the 24 pa)-9.8 (tients.)37.2 ( Of the 10 pa)-9.7 (tients in whom OPDUALAG)-18.9 ( )]TJ
0.096 Tw 0 -1.044 Td
[(was withheld for colitis,)37.2 ( 9 reinitia)-9.8 (ted OPDUALAG after symptom improvement; of these,)18 ( )]TJ
0.06 Tw 0 -1.044 Td
(67% had recurrence of colitis.)Tj
-0.017 Tc 0.048 Tw 0 -1.782 Td
[(Immune-Media)-9.8 (ted Hepa)-9.8 (titis)]TJ
-0.013 Tc 0.22 Tw 0 -1.494 Td
[(OPDUALAG can cause immune-media)-10.2 (ted hepa)-10.2 (titis,)36.8 ( de\037ned as requiring the use of)-13 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(corticosteroids and no c)20.2 (lear alterna)-9.8 (te etiolog)-9.7 (y)55.2 (.)]TJ
-0.017 Tc 0.12 Tw 0 -1.674 Td
[(Immune-media)-10.2 (ted hepa)-10.1 (titis occurred in 6% \(20/355\) of pa)-10.1 (tients receiving OPDUALAG,)20 ( )]TJ
-0.013 Tc 0.224 Tw 0 -1.044 Td
[(inc)19.6 (luding Grade 4 \(0.6%\),)36.6 ( Grade 3 \(3.4%\),)36.6 ( and Grade 2 \(1.4%\) adverse reactions.)24 ( )]TJ
-0.015 Tc 0.151 Tw 0 -1.044 Td
[(H)0.6 (e)0.5 (p)0.5 (a)-9.4 (t)0.5 (i)0.6 (t)0.5 (i)0.6 (s)0.5 ( l)0.5 (e)0.6 (d)0.5 ( t)0.5 (o)0.5 ( p)0.5 (e)0.6 (r)0.6 (m)0.5 (a)0.6 (n)0.5 (e)0.5 (n)0.6 (t)0.5 ( d)0.5 (i)0.6 (s)0.5 (c)0.5 (o)0.6 (n)0.5 (t)0.6 (i)0.5 (n)0.6 (u)0.5 (a)-9.4 (t)0.5 (i)0.5 (o)0.6 (n)0.5 ( o)0.5 (f)0.6 ( O)0.6 (P)0.5 (D)0.6 (U)0.5 (A)0.6 (L)0.5 (A)0.5 (G)0.6 ( i)0.6 (n)0.5 ( 1)0.5 (.)0.6 (7)0.5 (%)0.5 ( a)0.6 (n)0.5 (d)0.5 ( w)0.5 (i)0.6 (t)0.5 (h)0.6 (h)0.5 (o)0.5 (l)0.6 (d)0.5 (i)0.6 (n)0.5 (g)0.6 ( o)0.6 (f)-15 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(OPDUALAG in 2.3% of pa)-9.8 (tients.)]TJ
-0.012 Tc 0.228 Tw 0 -1.674 Td
[(S)0.5 (y)0.5 (s)0.5 (t)0.5 (e)0.5 (m)0.5 (i)0.5 (c)0.5 ( )0.5 (c)0.5 (o)0.5 (r)0.5 (t)0.5 (i)0.5 (c)0.5 (o)0.5 (s)0.5 (t)0.5 (e)0.5 (r)0.5 (o)0.5 (i)0.5 (d)0.5 (s )0.6 (w)0.5 (e)0.5 (r)0.5 (e)0.5 ( )0.5 (r)0.5 (e)0.5 (q)0.5 (u)0.5 (i)0.5 (r)0.5 (e)0.5 (d)0.5 ( )0.5 (i)0.5 (n)0.5 ( )0.5 (1)0.5 (0)0.5 (0)0.5 (%)0.5 ( )0.5 (\()0.5 (2)0.5 (0)0.5 (/)0.5 (2)0.5 (0)0.5 (\))0.5 ( )0.5 (o)0.5 (f)0.5 ( )0.5 (p)0.5 (a)-9.5 (t)0.5 (i)0.5 (e)0.5 (n)0.5 (t)0.5 (s)0.5 ( )0.5 (w)0.5 (i)0.5 (t)0.5 (h)0.5 ( )0.5 (h)0.5 (e)0.5 (p)0.5 (a)-9.5 (t)0.5 (i)0.5 (t)0.5 (i)0.5 (s)0.5 (.)25 ( )]TJ
-0.019 Tc 0.055 Tw 0 -1.044 Td
[(Hepa)-9.7 (titis resolved in 70% of the 20 pa)-9.7 (tients.)37.2 ( Of the 8 pa)-9.7 (tients in whom OPDUALAG was)-19 ( )]TJ
-0.016 Tc 0.147 Tw 0 -1.044 Td
[(withheld for hepa)-10.3 (titis,)36.7 ( )0.5 (6 )0.5 (reinitia)-10.2 (ted )0.5 (OPDUALAG )0.5 (after symptom improvement; )0.5 (of )0.5 (these,)21 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(50% had recurrence of hepa)-9.8 (titis.)]TJ
-0.017 Tc 0.048 Tw 0 -1.782 Td
[(Immune-Media)-9.8 (ted Endocrinopa)-9.8 (thies)]TJ
/T1_1 1 Tf
0 -1.602 Td
[(Adrenal Insuf\037cienc)20.3 (y)]TJ
/T1_0 1 Tf
-0.019 Tc 0.064 Tw 0 -1.494 Td
[(OPDUALAG can cause primar)-17.8 (y or secondar)-17.8 (y adrenal insuf\037cienc)20.2 (y)55.2 (.)37.2 ( F)20.2 (or Grade 2 or higher)-19 ( )]TJ
-0.015 Tc 0.176 Tw 0 -1.044 Td
[(adrenal )0.6 (insuf\037cienc)19.6 (y)54.6 (,)36.6 ( )0.5 (initia)-10.4 (te )0.6 (symptoma)-10.4 (tic )0.6 (trea)-10.4 (tment,)36.6 ( )0.6 (inc)19.6 (luding )0.6 (hormone )0.5 (replacement)-15 ( )]TJ
-0.014 Tc 0.198 Tw 0 -1.044 Td
[(as )0.6 (c)19.6 (linically )0.5 (indica)-10.3 (ted.)36.7 ( )37.5 (Withhold )0.5 (OPDUALAG )0.5 (depending )0.6 (on )0.5 (severity )]TJ
/T1_1 1 Tf
25.126 0 Td
[([see )0.5 (Dosa)-10.3 (ge )0.5 (and)-14 ( )]TJ
-0.019 Tc 0.019 Tw -25.126 -1.044 Td
[(Administra)-9.8 (ti)]TJ
0.06 Tw (on \(2.2\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.011 Tc 0.268 Tw 0 -1.674 Td
[(Adrenal insuf\037cienc)19.8 (y occurred in 4.2% \(15/355\) of pa)-10.1 (tients receiving OPDUALAG,)26 ( )]TJ
-0.016 Tc 0.128 Tw 0 -1.044 Td
[(in)0.5 (c)20.4 (l)0.5 (ud)0.5 (ing)0.5 ( Gr)0.5 (a)0.5 (de)0.5 ( 3 \()0.5 (1.)0.5 (4%)0.5 (\) a)0.5 (nd)0.5 ( G)0.5 (rad)0.5 (e)0.5 ( 2 \()0.5 (2.)0.5 (5%)0.5 (\) a)0.5 (dv)0.5 (er)0.5 (se)0.5 ( r)0.5 (ea)0.5 (ct)0.5 (io)0.5 (ns.)37.5 ( )36.6 (Ad)0.5 (re)0.5 (na)0.5 (l i)0.5 (ns)0.5 (uf)0.5 (\037c)0.5 (ie)0.5 (nc)20.4 (y)-16 ( )]TJ
-0.019 Tc 0.098 Tw 0 -1.044 Td
[(led to permanent discontinua)-9.7 (tion of OPDUALAG in 1.1% and withholding of OPDUALAG)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(in 0.8% of pa)-9.8 (tients.)]TJ
-0.014 Tc 0.195 Tw 0 -1.674 Td
[(A)-10.2 (pproxima)-10.2 (tely 87% \(13/15\) of pa)-10.2 (tients with adrenal insuf\037cienc)19.7 (y received hormone)-13.9 ( )]TJ
-0.019 Tc 0.077 Tw 0 -1.044 Td
[(replacement thera)-9.8 (py)55.2 (.)37.2 ( Systemic corticosteroids were required in 87% \(13/15\) of pa)-9.8 (tients)-19 ( )]TJ
0.12 Tw 0 -1.044 Td
[(with adrenal insuf\037cienc)19.6 (y)54.7 (.)36.7 ( )36.6 (Adrenal insuf\037cienc)19.7 (y resolved in 33% of the 15 pa)-10.3 (tients.)36.6 ( Of)-19 ( )]TJ
-0.02 Tc 0.024 Tw 0 -1.044 Td
[(the 3 pa)-9.8 (tients in whom OPDUALAG was withheld for adrenal insuf\037cienc)20.2 (y)55.1 (,)37.2 ( all 3 reinitia)-9.9 (ted)-20.1 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
(OPDUALAG after symptom improvement.)Tj
ET
q 1 0 0 1 324 221.4481 cm
0 0 m
147.538 0 l
S
Q
BT
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 8 0 0 8 324 727.248 Tm
(Hypophysitis)Tj
/T1_0 1 Tf
-0.016 Tc 0.151 Tw 0 -1.494 Td
[(OPDUALAG can cause immune-media)-10.5 (ted hypophysitis.)36.6 ( Hypophysitis can present with)-16 ( )]TJ
-0.019 Tc 0.086 Tw 0 -1.044 Td
[(acute symptoms )0.5 (associa)-9.8 (ted )0.5 (with )0.5 (mass effect )0.5 (such )0.5 (as )0.5 (headache,)37.2 ( )0.5 (photophobia,)37.2 ( )0.5 (or )0.5 (visual)-19 ( )]TJ
-0.013 Tc 0.213 Tw 0 -1.044 Td
[(\037eld defects.)37.1 ( Hypophysitis can cause hypopituitarism.)37.1 ( Initia)-9.9 (te hormone replacement)-13 ( )]TJ
-0.016 Tc 0.151 Tw 0 -1.044 Td
[(as c)19.5 (linically indica)-10.4 (ted.)36.6 ( )36.5 (Withhold or permanently discontinue OPDUALAG depending on)-16 ( )]TJ
-0.019 Tc 0.019 Tw 0 -1.044 Td
(severity )Tj
/T1_1 1 Tf
0.06 Tw 2.993 0 Td
[([see Dosa)-9.8 (ge and )37.2 (Administra)-9.7 (ti)]TJ
(on \(2.2\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.011 Tc 0.261 Tw -2.993 -1.674 Td
[(Hypophysitis occurred in 2.5% \(9/355\) of pa)-9.9 (tients receiving OPDUALAG,)37.1 ( inc)20.2 (luding)-11 ( )]TJ
-0.017 Tc 0.12 Tw 0 -1.044 Td
[(Grade 3 \(0.3%\) and Grade 2 \(1.4%\) adverse reactions.)36.9 ( Hypophysitis led to permanent)-17 ( )]TJ
-0.02 Tc 0.024 Tw 0 -1.044 Td
[(discontinua)-10.2 (tion of OPDUALAG in 0.3% and withholding of OPDUALAG in 0.6% of pa)-10.3 (tients.)]TJ
-0.019 Tc 0.097 Tw 0 -1.674 Td
[(All \(9/9\) of pa)-9.8 (tients with hypophysitis received hormone replacement thera)-9.8 (py)55.2 (.)37.2 ( Systemic)-19 ( )]TJ
0.115 Tw 0 -1.044 Td
[(corticosteroids were required in 100% \(9/9\) of pa)-9.8 (tients with hypophysitis.)37.3 ( Hypophysitis)-19 ( )]TJ
0.09 Tw 0 -1.044 Td
[(resolved in 22% of the 9 pa)-9.8 (tients.)37.2 ( Of the 2 pa)-9.8 (tients in whom OPDUALAG was withheld)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(for hypophysitis,)37.2 ( none reinitia)-9.8 (ted OPDUALAG after symptom improvement.)]TJ
/T1_1 1 Tf
-0.017 Tc 0.048 Tw 0 -1.782 Td
(Thyroid Disorders)Tj
/T1_0 1 Tf
-0.019 Tc 0.093 Tw 0 -1.494 Td
[(OPDUALAG can cause immune-media)-9.8 (ted thyroid disorders.)37.2 ( )36.7 (Thyroiditis can present with)-19.1 ( )]TJ
0.09 Tw 0 -1.044 Td
[(or without endocrinopa)-9.7 (thy)55.2 (.)37.2 ( Hypothyroidism can follo)-9.8 (w hyperthyroidism.)37.2 ( Initia)-9.8 (te hormone)-19 ( )]TJ
-0.016 Tc 0.149 Tw 0 -1.044 Td
[(replacement or medical mana)-10.4 (gement as c)19.7 (linically indica)-10.4 (ted.)36.6 ( )36.6 (Withhold or permanently)-16 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
(discontinue OPDUALAG depending on severity )Tj
/T1_1 1 Tf
[([see Dosa)-9.8 (ge and )37.2 (Administra)-9.8 (ti)]TJ
(on \(2.2\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 0 -1.782 Td
(Thyroiditis)Tj
/T1_0 1 Tf
-0.01 Tc 0.292 Tw 0 -1.494 Td
[(Thyroiditis occurred in )0.5 (2.8% \(10/355\) of pa)-10 (tients receiving OPDUALAG,)37 ( inc)20 (luding)-10 ( )]TJ
-0.019 Tc 0.088 Tw 0 -1.044 Td
[(Grade )0.5 (2 )0.5 (\(1.1%\) )0.5 (adverse )0.5 (reactions.)37.2 ( )37.5 (Thyroiditis )0.5 (did )0.5 (not )0.5 (lead )0.5 (to )0.5 (permanent )0.5 (discontinua)-9.7 (tion)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(of OPDUALAG.)37.2 ( )37.2 (Thyroiditis led withholding of OPDUALAG in 0.3% of pa)-9.8 (tients.)]TJ
-0.011 Tc 0.266 Tw 0 -1.674 Td
[(Systemic corticosteroids were required in 20% \(2/10\) of pa)-10 (tients with thyroiditis.)26 ( )]TJ
-0.019 Tc 0.024 Tw 0 -1.044 Td
[(Thyroiditis resolved in 90% of the 10 pa)-9.6 (tients.)37.4 ( F)20.4 (or the 1 pa)-9.6 (tient in whom OPDUALAG was)-19 ( )]TJ
0.106 Tw 0 -1.044 Td
[(withheld for thyroiditis,)37.2 ( OPDUALAG was reinitia)-9.8 (ted after symptom improvement without)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
(recurrence of thyroiditis.)Tj
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 0 -1.782 Td
(Hyperthyroidism)Tj
/T1_0 1 Tf
-0.015 Tc 0.172 Tw 0 -1.494 Td
[(Hyperthyroidism occurred in 6% \(22/355\) of pa)-10.2 (tients receiving OPDUALAG,)36.7 ( inc)19.8 (luding)-15 ( )]TJ
-0.008 Tc 0.35 Tw 0 -1.044 Td
[(Grade 2 \(1.4%\) adverse reactions.)36.6 ( Hyperthyroidism did not lead to permanent)-8 ( )]TJ
-0.019 Tc 0.053 Tw 0 -1.044 Td
[(discontinua)-9.8 (tion )0.5 (of OPDUALAG.)37.3 ( Hyperthyroidism led to withholding of OPDUALAG in 0.3%)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(of pa)-9.8 (tients.)]TJ
-0.012 Tc 0.239 Tw 0 -1.674 Td
[(Systemic corticosteroids were required in 23% \(5/22\) of pa)-9.9 (tients.)37.1 ( Hyperthyroidism)-12 ( )]TJ
-0.019 Tc 0.064 Tw 0 -1.044 Td
[(resolved )0.5 (in 82% of the )0.5 (22 pa)-9.7 (tients.)37.2 ( )0.5 (F)20.2 (or )0.5 (the )0.5 (1 )0.5 (pa)-9.8 (tient in whom OPDUALAG )0.5 (was )0.5 (withheld)-19 ( )]TJ
-0.014 Tc 0.189 Tw 0 -1.044 Td
[(for hyperthyroidism,)37 ( OPDUALAG was reinitia)-10 (ted after symptom improvement without)-14 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
(recurrence of hyperthyroidism.)Tj
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 0 -1.782 Td
(Hypothyroidism)Tj
/T1_0 1 Tf
-0.015 Tc 0.156 Tw 0 -1.494 Td
[(Hypothyroidism occurred in 17% \(59/355\) of pa)-9.6 (tients receiving OPDUALAG,)37.3 ( inc)20.3 (luding)-15 ( )]TJ
-0.019 Tc 0.102 Tw 0 -1.044 Td
[(Grade 2 \(11%\) adverse reactions.)37.3 ( Hypothyroidism led to the permanent discontinua)-9.8 (tion)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(of OPDUALAG in 0.3% and withholding of OPDUALAG in 2.5% of pa)-9.8 (tients.)]TJ
-0.002 Tc 0.479 Tw 0 -1.674 Td
[(None)0.5 ( o)0.5 (f the pa)-9.5 (tien)0.5 (ts with hypo)0.5 (thyr)0.5 (oidism)0.5 ( requir)0.5 (ed syst)0.5 (emic co)0.5 (rtico)0.5 (stero)0.5 (ids.)35 ( )]TJ
-0.022 Tc 0.024 Tw 0 -1.044 Td
[(Hypothyroidism resolved in 12% of the 59 pa)-10.1 (tients.)37 ( Of the 9 pa)-10 (tients in whom OPDUALAG)-21.9 ( )]TJ
0 -1.044 Td
[(was withheld for hypothyroidism,)36.8 ( 6 reinitia)-10.1 (ted OPDUALAG after symptom improvement; of)-22 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(these,)37.2 ( 33% had recurrence of hypothyroidism.)]TJ
/T1_1 1 Tf
-0.017 Tc 0.048 Tw 0 -1.782 Td
[(T)55.2 (ype 1 Diabetes Mellitus,)37.2 ( which can present with Diabetic Ketoacidosis)]TJ
/T1_0 1 Tf
-0.015 Tc 0.152 Tw 0 -1.494 Td
[(M)0.5 (o)0.5 (n)0.5 (i)0.5 (t)0.5 (o)0.5 (r)0.5 ( p)0.5 (a)-9.5 (t)0.5 (i)0.5 (e)0.5 (n)0.5 (t)0.5 (s)0.5 ( f)0.5 (o)0.5 (r)0.5 ( h)0.5 (y)0.5 (p)0.5 (e)0.5 (r)0.5 (g)0.5 (l)0.5 (y)0.5 (c)0.5 (e)0.5 (m)0.5 (i)0.5 (a)0.5 ( o)0.5 (r)0.5 ( o)0.5 (t)0.5 (h)0.5 (e)0.5 (r)0.5 ( s)0.5 (i)0.5 (g)0.5 (n)0.5 (s a)0.5 (n)0.5 (d)0.5 ( s)0.5 (y)0.5 (m)0.5 (p)0.5 (t)0.5 (o)0.5 (m)0.5 (s)0.5 ( o)0.5 (f)0.5 ( d)0.5 (ia)0.5 (b)0.5 (e)0.5 (t)0.5 (e)0.6 (s.)37.5 ( I)0.5 (ni)0.5 (t)0.6 (ia)-9.4 (t)0.5 (e)-15 ( )]TJ
-0.011 Tc 0.257 Tw 0 -1.044 Td
[(trea)-9.7 (tment with insulin as c)20.4 (linically indica)-9.7 (ted.)37.3 ( )37.2 (Withhold or permanently discontinue)-11 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
(OPDUALAG depending on severity )Tj
/T1_1 1 Tf
[([see Dosa)-9.8 (ge and )37.2 (Administra)-9.8 (ti)]TJ
(on \(2.2\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.018 Tc 0.12 Tw 0 -1.674 Td
[(Diabetes occurred in 0.3% \(1/355\) of pa)-10 (tients receiving OPDUALAG,)37 ( a Grade 3 \(0.3%\))-18 ( )]TJ
-0.016 Tc 0.144 Tw 0 -1.044 Td
[(adverse reaction,)36.8 ( and no cases of diabetic ketoacidosis.)36.8 ( Diabetes did not lead to the)-16 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(permanent discontinua)-9.8 (tion or withholding of OPDUALAG in an)-9.8 (y pa)-9.8 (tient.)]TJ
-0.017 Tc 0.048 Tw 0 -1.782 Td
[(Immune-Media)-9.8 (ted Nephritis with Renal Dysfunction)]TJ
-0.019 Tc 0.076 Tw 0 -1.494 Td
[(OPDUALAG can cause immune-media)-9.8 (ted nephritis,)37.1 ( which is de\037ned as requiring use of)-19 ( )]TJ
0.058 Tw 0 -1.044 Td
[(steroids and no c)20.2 (lear alterna)-9.7 (te etiolog)-9.8 (y)55.2 (.)37.2 ( )37.4 (Withhold or permanently discontinue OPDUALAG)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
(depending on severity )Tj
/T1_1 1 Tf
[([see Dosa)-9.8 (ge and )37.2 (Administra)-9.8 (ti)]TJ
(on \(2.2\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.016 Tc 0.139 Tw 0 -1.674 Td
[(Immune-media)-9.9 (ted nephritis and renal d)-9.9 (ysfunction occurred in 2% \(7/355\) of pa)-9.9 (tients)-16 ( )]TJ
-0.019 Tc 0.12 Tw 0 -1.044 Td
[(receiving OPDUALAG,)36.7 ( inc)19.6 (luding Grade 3 \(1.1%\) and Grade 2 \(0.8%\) adverse reactions.)18 ( )]TJ
-0.017 Tc 0 -1.044 Td
[(Immune-media)-10 (ted nephritis and renal d)-10.1 (ysfunction led to permanent discontinua)-10.1 (tion of)-17 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.044 Td
[(OPDUALAG in 0.8% and withholding of OPDUALAG in 0.6% of pa)-9.8 (tients.)]TJ
-0.014 Tc 0.178 Tw 0 -1.674 Td
[(S)0.5 (ys)0.5 (t)0.5 (em)0.5 (i)0.5 (c c)0.5 (o)0.5 (rt)0.5 (i)0.5 (co)0.5 (s)0.5 (te)0.5 (r)0.5 (oi)0.5 (d)0.5 (s we)0.5 (r)0.5 (e r)0.5 (e)0.5 (q)0.5 (ui)0.5 (re)0.5 (d)0.5 ( i)0.5 (n 1)0.5 (0)0.5 (0%)0.5 ( \()0.5 (7/)0.5 (7\))0.5 ( o)0.5 (f)0.5 ( pa)-9.5 (t)0.5 (ie)0.5 (n)0.5 (ts)0.5 ( w)0.5 (it)0.5 (h)0.5 ( ne)0.5 (p)0.5 (hr)0.5 (i)0.5 (ti)0.5 (s)0.5 ( a)0.5 (nd)-14 ( )]TJ
-0.015 Tc 0.151 Tw 0 -1.044 Td
[(r)0.5 (e)0.6 (n)0.5 (a)0.6 (l)0.5 ( d)-9.5 (y)0.6 (s)0.5 (f)0.5 (u)0.6 (n)0.5 (c)0.5 (t)0.6 (i)0.5 (o)0.5 (n)0.6 (.)37.5 ( N)0.5 (e)0.6 (p)0.5 (h)0.5 (r)0.6 (i)0.5 (t)0.6 (i)0.5 (s)0.5 ( a)0.5 (n)0.6 (d)0.5 ( r)0.5 (e)0.6 (n)0.5 (a)0.6 (l)0.5 ( d)-9.5 (y)0.5 (s)0.6 (f)0.5 (u)0.5 (n)0.6 (c)0.5 (t)0.6 (i)0.5 (o)0.5 (n)0.6 ( r)0.6 (e)0.5 (s)0.6 (o)0.5 (l)0.5 (v)0.6 (e)0.5 (d)0.6 ( i)0.6 (n)0.5 ( 7)0.5 (1)0.5 (%)0.6 ( o)0.5 (f)0.6 ( t)0.6 (h)0.5 (e)0.6 ( 7)0.6 ( p)0.5 (a)-9.5 (t)0.6 (i)0.5 (e)0.6 (n)0.5 (t)0.5 (s)0.6 (.)22 ( )]TJ
-0.019 Tc 0.12 Tw 0 -1.044 Td
[(Of the 2 pa)-10.1 (tients in whom OPDUALAG was withheld for nephritis or renal d)-10.3 (ysfunction,)18 ( )]TJ
0.103 Tw 0 -1.044 Td
[(1 reinitia)-9.8 (ted OPDUALAG after symptom improvement without recurrence of nephritis o\r)-19 ( )]TJ
0.06 Tw 0 -1.044 Td
[(renal d)-9.8 (ysfunction.)]TJ
ET
endstreamendobj20 0 obj<</Length 26614>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.017 Tc 0.048 Tw 8 0 0 8 36 750.2881 Tm
[(FULL PRESCRIBING INFORMA)55.1 (TION)]TJ
0.017 Tw 0 -2.144 Td
(1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(INDIC)18.2 (A)55.2 (TIONS AND USAGE)]TJ
/T1_1 1 Tf
-0.02 Tc 0.02 Tw -3.375 -1.68 Td
(OPDUALAG)Tj
0 Tc 0 Tw 5.6 0 0 5.6 67.3781 721.3638 Tm
(\231)Tj
-0.02 Tc 0.024 Tw 8 0 0 8 72.8096 719.6998 Tm
[( \(nivolumab and rela)-9.9 (tlimab-rmbw\) is indica)-9.9 (ted for the trea)-9.9 (tment of adult and)-20 ( )]TJ
-0.019 Tc 0.06 Tw -4.601 -1.05 Td
[(pedia)-9.7 (tric pa)-9.8 (tients 12 years of a)-9.8 (ge or older with unresectable or metasta)-9.8 (tic melanoma.)]TJ
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 0 -1.896 Td
(2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(DOSAGE AND ADMINISTRA)55.2 (TION)]TJ
0.017 Tw -3.375 -1.789 Td
(2.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(Recommended Dosage)Tj
/T1_1 1 Tf
-0.025 Tc 0.02 Tw -3.375 -1.545 Td
[(The recommended dosa)-10.4 (ge of OPDUALAG for adult pa)-10.4 (tients and pedia)-10.4 (tric pa)-10.4 (tients 12 years)-25 ( )]TJ
-0.019 Tc 0.086 Tw 0 -1.05 Td
[(of a)-9.8 (ge or older who weigh a)-9.8 (t least 40 kg is 480 mg nivolumab and 160 mg rela)-9.8 (tlimab)-19 ( )]TJ
-0.015 Tc 0.169 Tw 0 -1.05 Td
[(administered intra)-10.2 (venously ever)-18.2 (y 4 weeks until disease progression or unacceptable)-15 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.05 Td
(toxicity occurs.)Tj
0.026 Tw 0 -1.68 Td
[(The recommended dosa)-9.8 (ge for pedia)-9.8 (tric pa)-9.8 (tients 12 years of a)-9.8 (ge or older who weigh less)-19.1 ( )]TJ
0.06 Tw 0 -1.05 Td
(than 40 kg has not been established )Tj
/T1_2 1 Tf
[([see Use in Speci\037c P)18.2 (opula)-9.8 (tio)]TJ
(ns \(8.4\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 0 -1.789 Td
(2.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(Dosage Modi\037cations)Tj
/T1_1 1 Tf
-0.019 Tc 0.096 Tw -3.375 -1.545 Td
[(No )0.6 (dose )0.5 (reduction )0.5 (for )0.5 (OPDUALAG )0.5 (is )0.6 (recommended.)37.2 ( )0.5 (In )0.5 (general,)37.2 ( )0.5 (withhold )0.5 (OPDUALAG )0.5 (for)-19 ( )]TJ
0.073 Tw 0 -1.05 Td
[(severe \(Grade 3\) immune-media)-9.8 (ted adverse reactions \(IMARs\).)37.2 ( P)18.2 (ermanently discontinue)-19 ( )]TJ
0.115 Tw 0 -1.05 Td
[(OPDUALAG )0.5 (for )0.5 (life-threa)-9.7 (tening )0.6 (\(Grade )0.6 (4\) )0.6 (IMARs,)37.2 ( )0.6 (recurrent )0.5 (severe )0.6 (\(Grade )0.6 (3\) )0.6 (IMARs )0.5 (tha)-9.8 (t)-19 ( )]TJ
0.12 Tw 0 -1.05 Td
[(require systemic immunosuppressive trea)-10.1 (tment,)36.8 ( or an inability to reduce corticosteroid)-19 ( )]TJ
-0.011 Tc 0.254 Tw 0 -1.05 Td
[(do)0.5 (se to 10 m)0.5 (g o)0.5 (r le)0.5 (ss of p)0.5 (re)0.5 (dnis)0.5 (one)0.5 ( or)0.5 ( eq)0.5 (uiv)0.5 (ale)0.5 (nt per)0.5 ( da)0.5 (y wi)0.5 (thi)0.5 (n 1)0.5 (2 we)0.5 (eks)0.5 ( of)-11 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.05 Td
[(initia)-9.7 (ting steroids.)]TJ
-0.022 Tc 0.024 Tw 0 -1.68 Td
[(Dosa)-9.6 (ge modi\037ca)-9.6 (tions for adverse reactions tha)-9.6 (t require mana)-9.6 (gement different from these)-22 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.05 Td
[(general guidelines are summarized in )37.2 (T)74.2 (able 1.)]TJ
ET
0 0 0 0 k
/GS0 gs
36.25 522.156 251.75 -10.212 re
36.25 511.944 63.47 -11.472 re
99.72 511.944 108 -11.472 re
207.72 511.944 80.28 -11.472 re
36.25 500.473 251.75 -11.472 re
36.25 489.001 63.47 -25.464 re
99.72 489.001 108 -12.732 re
207.72 489.001 80.28 -12.732 re
99.72 476.269 108 -12.732 re
207.72 476.269 80.28 -12.732 re
36.25 463.537 63.47 -25.464 re
99.72 463.537 108 -12.732 re
207.72 463.537 80.28 -12.732 re
99.72 450.805 108 -12.732 re
207.72 450.805 80.28 -12.732 re
36.25 438.073 63.47 -102.824 re
99.72 438.073 108 -51.412 re
207.72 438.073 80.28 -51.412 re
99.72 386.661 108 -51.412 re
207.72 386.661 80.28 -51.412 re
36.25 335.249 63.47 -38.232 re
99.72 335.249 108 -38.232 re
207.72 335.249 80.28 -38.232 re
36.25 297.017 63.47 -33.964 re
99.72 297.017 108 -21.232 re
207.72 297.017 80.28 -21.232 re
99.72 275.785 108 -12.732 re
207.72 275.785 80.28 -12.732 re
36.25 263.053 63.47 -29.732 re
99.72 263.053 108 -12.732 re
207.72 263.053 80.28 -12.732 re
99.72 250.322 108 -17 re
207.72 250.322 80.28 -17 re
36.25 233.322 63.47 -12.732 re
99.72 233.322 108 -12.732 re
207.72 233.322 80.28 -12.732 re
36.25 220.59 63.47 -25.464 re
99.72 220.59 108 -12.732 re
207.72 220.59 80.28 -12.732 re
99.72 207.858 108 -12.732 re
207.72 207.858 80.28 -12.732 re
36.25 195.126 251.75 -12.732 re
36.25 182.394 63.47 -37.932 re
99.72 182.394 108 -21.232 re
207.72 182.394 80.28 -21.232 re
99.72 161.162 108 -16.7 re
207.72 161.162 80.28 -16.7 re
36.25 144.462 251.75 -108.212 re
f
0 0 0 1 K
0.5 w 
/GS2 gs
q 1 0 0 1 36.25 489.0006 cm
0 0 m
63.47 0 l
S
Q
q 1 0 0 1 99.72 463.7868 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 207.72 463.7868 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 36.25 233.3215 cm
0 0 m
63.47 0 l
S
Q
q 1 0 0 1 36.25 220.5896 cm
0 0 m
63.47 0 l
S
Q
q 1 0 0 1 36.25 463.5368 cm
0 0 m
63.47 0 l
S
Q
q 1 0 0 1 99.72 438.323 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 207.72 438.323 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 36.25 438.073 cm
0 0 m
63.47 0 l
S
Q
q 1 0 0 1 99.72 335.4991 cm
0 0 m
0 50.912 l
S
Q
q 1 0 0 1 207.72 335.4991 cm
0 0 m
0 50.912 l
S
Q
q 1 0 0 1 99.72 489.0006 cm
0 0 m
108 0 l
S
Q
q 1 0 0 1 99.72 476.5187 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 207.72 489.0006 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 207.72 476.5187 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 99.47 476.2687 cm
0 0 m
108.25 0 l
S
Q
q 1 0 0 1 207.72 476.2687 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 99.72 233.3215 cm
0 0 m
108 0 l
S
Q
q 1 0 0 1 207.72 233.3215 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 99.72 463.5368 cm
0 0 m
108 0 l
S
Q
q 1 0 0 1 99.72 451.0549 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 207.72 463.5368 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 207.72 451.0549 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 99.47 450.8049 cm
0 0 m
108.25 0 l
S
Q
q 1 0 0 1 207.72 450.8049 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 36.25 335.2491 cm
0 0 m
63.47 0 l
S
Q
q 1 0 0 1 99.72 335.2491 cm
0 0 m
108 0 l
S
Q
q 1 0 0 1 99.72 297.2672 cm
0 0 m
0 37.732 l
S
Q
q 1 0 0 1 207.72 335.2491 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 207.72 297.2672 cm
0 0 m
0 37.732 l
S
Q
q 1 0 0 1 36.25 195.1257 cm
0 0 m
63.47 0 l
S
Q
q 1 0 0 1 36.25 36.25 cm
0 0 m
63.47 0 l
S
Q
q 1 0 0 1 99.72 36.25 cm
0 0 m
108 0 l
S
Q
q 1 0 0 1 207.72 36.25 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 99.72 250.5715 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 207.72 250.5715 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 99.47 250.3215 cm
0 0 m
108.25 0 l
S
Q
q 1 0 0 1 99.72 233.5715 cm
0 0 m
0 16.5 l
S
Q
q 1 0 0 1 207.72 250.3215 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 207.72 233.5715 cm
0 0 m
0 16.5 l
S
Q
q 1 0 0 1 99.72 220.8396 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 207.72 220.8396 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 99.72 195.3757 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 207.72 195.3757 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 99.72 195.1257 cm
0 0 m
108 0 l
S
Q
q 1 0 0 1 207.72 195.1257 cm
0 0 m
80.28 0 l
S
Q
1 w 
q 1 0 0 1 36 511.9445 cm
0 0 m
63.72 0 l
S
Q
q 1 0 0 1 99.72 511.9445 cm
0 0 m
108 0 l
S
Q
q 1 0 0 1 207.72 511.9445 cm
0 0 m
80.28 0 l
S
Q
0 0 0 0 K
0.5 w 
/GS3 gs
q 1 0 0 1 36.25 500.7225 cm
0 0 m
0 10.722 l
S
Q
0 0 0 1 K
/GS2 gs
q 1 0 0 1 99.72 500.7225 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 207.72 500.7225 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 36 500.4725 cm
0 0 m
63.72 0 l
S
Q
q 1 0 0 1 99.72 500.4725 cm
0 0 m
108 0 l
S
Q
q 1 0 0 1 207.72 500.4725 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 99.72 438.073 cm
0 0 m
108 0 l
S
Q
q 1 0 0 1 99.72 386.9111 cm
0 0 m
0 50.912 l
S
Q
q 1 0 0 1 207.72 438.073 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 207.72 386.9111 cm
0 0 m
0 50.912 l
S
Q
q 1 0 0 1 99.47 386.6611 cm
0 0 m
108.25 0 l
S
Q
q 1 0 0 1 207.72 386.6611 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 99.72 220.5896 cm
0 0 m
108 0 l
S
Q
q 1 0 0 1 99.72 208.1077 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 207.72 220.5896 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 207.72 208.1077 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 99.47 207.8577 cm
0 0 m
108.25 0 l
S
Q
q 1 0 0 1 207.72 207.8577 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 36.25 297.0172 cm
0 0 m
63.47 0 l
S
Q
q 1 0 0 1 99.72 297.0172 cm
0 0 m
108 0 l
S
Q
q 1 0 0 1 99.72 276.0353 cm
0 0 m
0 20.732 l
S
Q
q 1 0 0 1 207.72 297.0172 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 207.72 276.0353 cm
0 0 m
0 20.732 l
S
Q
q 1 0 0 1 99.47 275.7853 cm
0 0 m
108.25 0 l
S
Q
q 1 0 0 1 99.72 263.3034 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 207.72 275.7853 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 207.72 263.3034 cm
0 0 m
0 12.232 l
S
Q
q 1 0 0 1 36.25 263.0534 cm
0 0 m
63.47 0 l
S
Q
q 1 0 0 1 99.72 263.0534 cm
0 0 m
108 0 l
S
Q
q 1 0 0 1 207.72 263.0534 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 36.25 182.3938 cm
0 0 m
63.47 0 l
S
Q
q 1 0 0 1 99.72 182.3938 cm
0 0 m
108 0 l
S
Q
q 1 0 0 1 99.72 161.4119 cm
0 0 m
0 20.732 l
S
Q
q 1 0 0 1 207.72 182.3938 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 207.72 161.4119 cm
0 0 m
0 20.732 l
S
Q
q 1 0 0 1 99.47 161.1619 cm
0 0 m
108.25 0 l
S
Q
q 1 0 0 1 99.72 144.9619 cm
0 0 m
0 15.95 l
S
Q
q 1 0 0 1 207.72 161.1619 cm
0 0 m
80.28 0 l
S
Q
q 1 0 0 1 207.72 144.9619 cm
0 0 m
0 15.95 l
S
Q
1 w 
q 1 0 0 1 36.25 144.4619 cm
0 0 m
63.47 0 l
S
Q
q 1 0 0 1 99.72 144.4619 cm
0 0 m
108 0 l
S
Q
q 1 0 0 1 207.72 144.4619 cm
0 0 m
80.28 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.012 Tc 8 0 0 8 36.25 516.4445 Tm
[(T)74.2 (able 1:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
(Recommended Dosage Modifications for Adverse Reactions)Tj
7.6 0 0 8 42.1492 503.3525 Tm
(Adverse Reaction)Tj
0.012 Tw 12.933 0 Td
(Severity*)Tj
0.06 Tw 10.64 0 Td
(Dose Modification)Tj
-24.349 -1.434 Td
(Immune-Mediated Adverse Reactions )Tj
/T1_3 1 Tf
[([see W)18.2 (arnings and Precautions \(5.1\)])]TJ
/T1_1 1 Tf
0.012 Tw 0 -2.308 Td
(Pneumonitis)Tj
0.048 Tw 8.943 0.796 Td
(Grade 2)Tj
-0.198 Tw 17.169 0 Td
(Withhold)Tj
/Span<</ActualText<FEFF200A200A>>> BDC 
[( )0.6 ( )]TJ
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 258.9004 482.4427 Tm
(a)Tj
7.6 0 0 8 261.2624 479.7787 Tm
(\035)Tj
-0.012 Tc 0.048 Tw -20.663 -1.591 Td
(Grade 3 or 4)Tj
14.483 0 Td
[(P)18.2 (ermanently discontinue)]TJ
0.012 Tw -23.426 -2.387 Td
(Colitis)Tj
0.048 Tw 8.943 0.796 Td
(Grade 2 or 3)Tj
0.012 Tw 17.168 0 Td
(Withhold)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 258.6634 456.9789 Tm
(a)Tj
7.6 0 0 8 261.0254 454.3149 Tm
(\035)Tj
-0.012 Tc 0.048 Tw -20.632 -1.591 Td
(Grade 4)Tj
14.466 0 Td
[(P)18.2 (ermanently discontinue)]TJ
0.012 Tw -23.41 -7.222 Td
[(Hepa)-9.8 (titis)]TJ
0.048 Tw 8.943 5.631 Td
[(AST/AL)94.3 (T increases to more than 3)-12 ( )]TJ
0 -1.062 Td
(and up to 8 times ULN)Tj
0.012 Tw 0 -1.355 Td
(or)Tj
0.048 Tw 0 -1.355 Td
[(T)74.2 (otal bilirubin increases to more)-12 ( )]TJ
0 -1.062 Td
(than 1.5 and up to 3 times ULN.)Tj
0.012 Tw 17.168 2.417 Td
(Withhold)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 258.6634 412.1751 Tm
(a)Tj
7.6 0 0 8 261.0254 409.5111 Tm
(\035)Tj
-0.012 Tc 0.048 Tw -20.632 -4.009 Td
[(AST or )37.2 (AL)94.2 (T increases to more than)-12.1 ( )]TJ
0 -1.062 Td
(8 times ULN regardless of baseline.)Tj
0.012 Tw 0 -1.355 Td
(or)Tj
0.048 Tw 0 -1.355 Td
[(T)74.2 (otal bilirubin increases to more)-12 ( )]TJ
0 -1.062 Td
(than 3 times ULN.)Tj
14.466 2.418 Td
[(P)18.2 (ermanently discontinue)]TJ
0.012 Tw -23.41 -5.603 Td
[(Endocrinopa)-9.7 (thies)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 83.3254 315.9412 Tm
(b)Tj
7.6 0 0 8 85.7885 313.2772 Tm
(\035)Tj
-0.012 Tc 0.048 Tw 2.425 0 Td
(Grade 3 or 4)Tj
16.428 1.594 Td
[(Withhold until)-12 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 268.6515 326.0272 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 223.2739 317.5272 Tm
[(c)20.2 (linically stable or)-12 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 274.4494 317.5272 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 214.1639 309.0272 Tm
[(permanently discontinue)-11.9 ( )]TJ
0.446 -1.062 Td
(depending on severity)Tj
-23.856 -2.387 Td
[(Nephritis with)-12 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 76.2479 281.4294 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 36.25 272.9294 Tm
(Renal Dysfunction)Tj
8.943 1.858 Td
[(Grade 2 or 3 increased blood)-12 ( )]TJ
0.012 Tw 0 -1.062 Td
[(crea)-9.8 (tinine)]TJ
17.168 0.531 Td
(Withhold)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 258.6634 286.2093 Tm
(a)Tj
7.6 0 0 8 261.0254 283.5453 Tm
(\035)Tj
-0.012 Tc 0.048 Tw -20.632 -2.123 Td
[(Grade 4 increased blood crea)-9.8 (tinine)]TJ
14.466 0 Td
[(P)18.2 (ermanently discontinue)]TJ
0.012 Tw -23.41 -1.591 Td
[(Exfolia)-9.8 (tive)-12 ( )]TJ
0 -1.062 Td
[(Derma)-9.8 (tologic)-12 ( )]TJ
0 -1.062 Td
(Conditions)Tj
0.048 Tw 8.943 2.125 Td
[(Suspected SJS,)37.2 ( )37.2 (TEN,)37.2 ( or DRESS)]TJ
0.012 Tw 17.332 0 Td
(Withhold)Tj
0.048 Tw -17.332 -1.591 Td
[(Confirmed SJS,)37.2 ( )37.2 (TEN,)37.2 ( or DRESS)]TJ
14.466 0 Td
[(P)18.2 (ermanently discontinue)]TJ
0.012 Tw -23.41 -2.125 Td
(Myocarditis)Tj
0.048 Tw 8.943 0 Td
[(Grade 2,)37.2 ( 3,)37.2 ( or 4)]TJ
14.466 0 Td
[(P)18.2 (ermanently discontinue)]TJ
0.011 Tw -23.41 -2.387 Td
[(Neurological T)74.2 (oxicities)]TJ
0.048 Tw 8.943 0.796 Td
(Grade 2)Tj
0.012 Tw 17.168 0 Td
(Withhold)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 258.6634 214.0317 Tm
(a)Tj
7.6 0 0 8 261.0254 211.3677 Tm
(\035)Tj
-0.012 Tc 0.048 Tw -20.632 -1.591 Td
(Grade 3 or 4)Tj
14.466 0 Td
[(P)18.2 (ermanently discontinue)]TJ
/T1_0 1 Tf
0.06 Tw -23.41 -1.591 Td
(Other Adverse Reactions)Tj
/T1_1 1 Tf
0.012 Tw 0 -1.591 Td
[(Infusion-Rela)-9.8 (ted)-12 ( )]TJ
0 -1.062 Td
[(Reactions)-12 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 64.9469 164.6719 Tm
( )Tj
/T1_2 1 Tf
-0.017 Tc 0.011 Tw 8 0 0 8 36.25 156.3219 Tm
[([see W)18.3 (arnings )-36.8 (and)-17 ( )]TJ
0.048 Tw 0 -1.044 Td
(Precautions \(5.2\)])Tj
/T1_1 1 Tf
-0.012 Tc 7.6 0 0 8 104.22 168.9219 Tm
(Grade 1 or 2)Tj
14.367 0.531 Td
[(Interrupt or slo)-9.8 (w the ra)-9.8 (te)-12 ( )]TJ
2.645 -1.062 Td
(of infusion)Tj
-17.012 -1.839 Td
(Grade 3 or 4)Tj
14.466 0 Td
[(P)18.2 (ermanently discontinue)]TJ
-0.017 Tc 0.017 Tw 5.32 0 0 5.6 36.25 136.914 Tm
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tc 0.132 Tw 7.6 0 0 8 41.25 134.25 Tm
[(Based on Na)-9.7 (tional Cancer Institute Common )36.7 (T)74.3 (erminolog)-9.8 (y Criteria for )36.7 (Adverse Events,)37 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(V)18.2 (ersion 5.0.)]TJ
0.017 Tw 5.32 0 0 5.6 36.25 119.914 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.011 Tc 0.078 Tw 7.6 0 0 8 41.25 117.25 Tm
[(Resume in pa)-9.8 (tients with complete or partial resolution \(Grade 0 to 1\) after cortic\osteroid)-11 ( )]TJ
-0.005 Tc 0.112 Tw 0 -1.062 Td
[(ta)-10.4 (per)73.6 (.)36.5 ( P)17.6 (ermanently discontinue )0.5 (if no )0.5 (complete or partial resolution within 12 weeks of)-5 ( )]TJ
-0.014 Tc 0.066 Tw 0 -1.062 Td
[(last dose or inability to reduce prednisone to 10 mg per day \(or equiva\lent\) or less within)-14 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(12 weeks of initia)-9.8 (ting steroids.)]TJ
0.017 Tw 5.32 0 0 5.6 36.25 85.914 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.001 Tc 0.131 Tw 7.6 0 0 8 41.25 83.25 Tm
[(Depending on c)19.6 (linical severity)54.6 (,)36.6 ( consider withholding for Grade 2 endocrinopa)-10.3 (thy until)-1 ( )]TJ
-0.01 Tc 0.082 Tw 0 -1.062 Td
[(sym)0.5 (ptom)0.5 ( imp)0.5 (rove)0.5 (ment)0.5 ( wit)0.5 (h h)0.5 (ormo)0.5 (ne r)0.5 (eplac)0.5 (emen)0.5 (t.)37.4 ( )0.5 (Resume)0.5 ( on)0.5 (ce )0.5 (acute)0.5 ( sy)0.5 (mptom)0.5 (s h)0.5 (a)-9.6 (ve)-10 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.062 Td
(resolved.)Tj
-0.013 Tc 0.068 Tw 0.053 -1.062 Td
[(AL)94.2 (T = alanine aminotransferase,)37.2 ( )37.2 (AST = asparta)-9.7 (te aminotransferase,)37.2 ( DRESS = Drug Rash)-13 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 288 57.75 Tm
( )Tj
-0.018 Tc 0.036 Tw 7.6 0 0 8 41.65 49.25 Tm
[(with Eosinophilia and Systemic Symptoms,)37.3 ( SJS = Stevens Johnson Syndrome,)37.4 ( )37.4 (TEN = toxic)-18 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
[(epidermal necrolysis,)37.2 ( ULN = upper limit normal)]TJ
ET
0.5 w 
q 1 0 0 1 324 660.5031 cm
0 0 m
32.607 0 l
S
Q
q 1 0 0 1 324 337.5872 cm
0 0 m
82.195 0 l
S
Q
q 1 0 0 1 324 214.8333 cm
0 0 m
40.946 0 l
S
Q
BT
/T1_0 1 Tf
0.017 Tw 8 0 0 8 324 727.248 Tm
(2.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(Preparation and Administration)Tj
-0.019 Tc 0.06 Tw -3.375 -1.554 Td
(OPDUALAG is a \037xed-dose combination of nivolumab and relatlimab.)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF2004>>> BDC 
26.502 0 Td
( )Tj
EMC 
-0.01 Tc 0.298 Tw -26.502 -1.689 Td
[(Visually inspect the solution in the drug product vial for particula)-10.3 (te ma)-10.3 (tter and)-10 ( )]TJ
-0.015 Tc 0.157 Tw 0 -1.059 Td
[(discolora)-9.6 (tion prior to administra)-9.7 (tion.)37.3 ( OPDUALAG is a c)20.3 (lear to opalescent,)37.3 ( colorless to)-15 ( )]TJ
-0.019 Tc 0.103 Tw 0 -1.059 Td
[(slightly yello)-9.8 (w solution.)37.3 ( Discard the vial if the solution is c)20.2 (loud)-9.8 (y)55.2 (,)37.2 ( discolored,)37.2 ( or contains)-19 ( )]TJ
0.06 Tw 0 -1.059 Td
[(extraneous particula)-9.8 (te ma)-9.8 (tter other than a few translucent-to-white partic)20.2 (les.)]TJ
-0.017 Tc 0.017 Tw 0 -1.798 Td
[(Prepara)-9.8 (tion)]TJ
1.125 -1.555 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.021 Tc 0.024 Tw 1.125 0 Td
[(During prepara)-10.3 (tion of the infusion solution,)36.7 ( use aseptic technique to assure sterility)54.8 (,)16 ( )]TJ
-0.017 Tc 0.06 Tw 0 -1.078 Td
[(as the product does not contain a preser)-17.8 (va)-9.7 (tive.)]TJ
0.017 Tw -1.125 -1.402 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.107 Tw 1.125 0 Td
[(OPDUALAG )0.5 (can be )0.5 (administered diluted or )0.5 (undiluted and administered a)-9.7 (t a \037nal)-17 ( )]TJ
0.06 Tw 0 -1.078 Td
[(concentra)-9.8 (tion as speci\037ed in )37.2 (T)74.2 (able 2 belo)-9.8 (w)37.2 (.)]TJ
0.017 Tw -1.125 -1.402 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.013 Tc 0.172 Tw 1.125 0 Td
[(Withdra)-10.2 (w the required volume of OPDUALAG and transfer into an intra)-10.3 (venous)-13 ( )]TJ
-0.005 Tc 0.37 Tw 0 -1.078 Td
[(container)73.9 (.)36.8 ( OPDUALAG )0.5 (is compa)-10.1 (tible )0.5 (with )0.5 (di\(2-ethylhexyl\)phthala)-10.2 (te \(DEHP\)-)]TJ
-0.015 Tc 0.12 Tw 0 -1.078 Td
[(plasticized polyvin)-9.7 (yl chloride \(PVC\),)37.3 ( ethyl vin)-9.8 (yl aceta)-9.7 (te \(EV)37.3 (A\),)37.3 ( and polyole\037n \(PO\))-15 ( )]TJ
-0.017 Tc 0.06 Tw 0 -1.078 Td
[(intra)-9.7 (venous ba)-9.8 (gs.)]TJ
0.017 Tw -1.125 -1.402 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.06 Tw 1.125 0 Td
[(If diluting OPDUALAG prior to administra)-9.7 (tion:)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.483 -1.402 Td
( )Tj
EMC 
-0.483 0 Td
(\226)Tj
-0.008 Tc 0.278 Tw 1.125 0 Td
[(D)0.5 (i)0.5 (l)0.5 (ut)0.5 (e)0.5 ( )0.5 (O)0.5 (PD)0.5 (U)0.5 (A)0.5 (L)0.5 (A)0.5 (G)0.5 ( s)0.5 (o)0.5 (l)0.5 (u)0.5 (t)0.5 (io)0.5 (n)0.5 ( )0.5 (wi)0.5 (t)0.5 (h)0.5 ( )0.5 (0.)0.5 (9)0.5 (%)0.5 ( S)0.5 (o)0.5 (d)0.5 (i)0.5 (u)0.5 (m)0.5 ( C)0.5 (h)0.5 (l)0.5 (o)0.5 (r)0.5 (i)0.5 (de)0.5 ( )0.5 (I)0.5 (nj)0.5 (e)0.5 (c)0.5 (t)0.5 (i)0.5 (o)0.5 (n)0.5 (,)37.5 ( U)0.5 (S)0.5 (P)0.5 ( o)0.5 (r)-8 ( )]TJ
0 Tc 0 Tw 28.125 0 Td
( )Tj
-0.005 Tc 0.364 Tw -28.125 -1.078 Td
[(5% Dextrose Injection,)37.1 ( USP to prepare an infusion meeting the \037nal)-5 ( )]TJ
-0.009 Tc 0.259 Tw 0 -1.078 Td
[(concentra)-9.7 (tion and maximum infusion volume parameters as speci\037ed in)-9 ( )]TJ
-0.017 Tc 0.06 Tw 0 -1.078 Td
[(T)74.2 (able\035)-59.8 (2 belo)-9.8 (w)37.2 (.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-0.642 -1.402 Td
( )Tj
EMC 
-0.483 0 Td
(\226)Tj
-0.017 Tc 0.06 Tw 1.125 0 Td
[(Then mix the diluted solution by gentle inversion.)37.2 ( Do not shake.)]TJ
0.017 Tw -2.25 -1.402 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.06 Tw 1.125 0 Td
[(Discard partially used vials or empty vials follo)-9.8 (wing infusion prepara)-9.8 (tion.)]TJ
ET
0 0 0 0 k
/GS0 gs
324 500.579 252 -10.212 re
324 490.367 66.24 -21.412 re
390.24 490.367 84.6 -21.412 re
474.84 490.367 101.16 -21.412 re
324 468.955 66.24 -55.412 re
390.24 468.955 84.6 -55.412 re
474.84 468.955 101.16 -55.412 re
324 413.544 66.24 -23.932 re
390.24 413.544 84.6 -23.932 re
474.84 413.544 101.16 -23.932 re
324 389.612 252 -29.912 re
f
1 w 
/GS2 gs
q 1 0 0 1 324 490.3673 cm
0 0 m
66.24 0 l
S
Q
q 1 0 0 1 474.84 490.3673 cm
0 0 m
101.16 0 l
S
Q
0.5 w 
q 1 0 0 1 324 468.9554 cm
0 0 m
66.24 0 l
S
Q
q 1 0 0 1 390.24 413.7935 cm
0 0 m
0 54.912 l
S
Q
q 1 0 0 1 474.84 468.9554 cm
0 0 m
101.16 0 l
S
Q
q 1 0 0 1 474.84 413.7935 cm
0 0 m
0 54.912 l
S
Q
q 1 0 0 1 324 413.5435 cm
0 0 m
66.24 0 l
S
Q
q 1 0 0 1 390.24 413.5435 cm
0 0 m
84.6 0 l
S
Q
q 1 0 0 1 390.24 390.1116 cm
0 0 m
0 23.182 l
S
Q
q 1 0 0 1 474.84 413.5435 cm
0 0 m
101.16 0 l
S
Q
q 1 0 0 1 474.84 390.1116 cm
0 0 m
0 23.182 l
S
Q
1 w 
q 1 0 0 1 390.24 490.3673 cm
0 0 m
84.6 0 l
S
Q
0.5 w 
q 1 0 0 1 390.24 469.2054 cm
0 0 m
0 20.662 l
S
Q
q 1 0 0 1 474.84 469.2054 cm
0 0 m
0 20.662 l
S
Q
q 1 0 0 1 390.24 468.9554 cm
0 0 m
84.6 0 l
S
Q
1 w 
q 1 0 0 1 324 389.6116 cm
0 0 m
66.24 0 l
S
Q
q 1 0 0 1 390.24 389.6116 cm
0 0 m
84.6 0 l
S
Q
q 1 0 0 1 474.84 389.6116 cm
0 0 m
101.16 0 l
S
Q
0.5 w 
q 1 0 0 1 324 359.6997 cm
0 0 m
66.24 0 l
S
Q
q 1 0 0 1 390.24 359.6997 cm
0 0 m
84.6 0 l
S
Q
q 1 0 0 1 474.84 359.6997 cm
0 0 m
101.16 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.031 Tc -0.002 Tw 8 0 0 8 324 494.8673 Tm
[(T)55.2 (a)-18.8 (b)-18.8 (l)-18.8 (e)-18.8 ( )-80.8 (2)-18.8 (:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
3.012 0 Td
( )Tj
EMC 
1.988 0 Td
[(Maximum Infusion V)24.1 (olumes and Concentration Ranges by P)24.1 (atient Group)]TJ
-0.012 Tc 0.06 Tw 7.6 0 0 8 324 481.0554 Tm
[(P)24.2 (atient Group)-12 ( )]TJ
9.069 0 Td
[(Maximum Infusion V)24.2 (olume)-12 ( )]TJ
2.396 -1.062 Td
(\(mL or mL/kg\))Tj
10.963 1.062 Td
[(Concentration Range)-12 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 558.4818 481.0554 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 511.3313 472.5554 Tm
(\(mg/mL\)*)Tj
/T1_1 1 Tf
0.048 Tw -24.649 -1.614 Td
[(Adult pa)-9.8 (tients who)-12 ( )]TJ
0 -1.062 Td
[(weigh a)-9.8 (t least 40\035)-47.8 (kg)-12 ( )]TJ
0 -1.062 Td
[(and pedia)-9.8 (tric pa)-9.8 (tients)-12 ( )]TJ
0 -1.062 Td
[(12\035)-47.8 (years of a)-9.8 (ge or)-12 ( )]TJ
0 -1.062 Td
[(older who weigh a)-9.8 (t)-12 ( )]TJ
0 -1.062 Td
(least 40 kg)Tj
12.865 2.656 Td
(160 mL)Tj
7.574 0.689 Td
[(Nivolumab:)37.2 ( 3 mg/mL to 12 mg/mL)]TJ
0 -1.377 Td
[(Rela)-9.7 (tlimab:)37.2 ( 1 mg/mL to 4 mg/mL)]TJ
-20.439 -3.739 Td
[(Adult pa)-9.8 (tients who)-12 ( )]TJ
0 -1.062 Td
(weigh less than 40 kg)Tj
12.759 0.531 Td
(4 mL/kg)Tj
7.681 0.689 Td
[(Nivolumab:)37.2 ( 3 mg/mL to 12 mg/mL)]TJ
0 -1.377 Td
[(Rela)-9.7 (tlimab:)37.2 ( 1 mg/mL to 4 mg/mL)]TJ
-0.017 Tc 0.017 Tw 5.32 0 0 5.6 324 382.9637 Tm
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0 Tc 0.133 Tw 7.6 0 0 8 329 380.2997 Tm
[(The concentra)-9.9 (tion range in each group inc)20.1 (ludes 12 mg/mL nivolumab and 4 mg/mL )]TJ
-0.008 Tc 0.095 Tw 0 -1.062 Td
[(rela)-10.1 (tlimab as the upper limit,)36.8 ( which represents a scenario in which the drug product is)-8 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.062 Td
(infused without dilution.)Tj
8 0 0 8 324 338.5872 Tm
[(Stora)-9.7 (ge of Prepared Solution)]TJ
-0.019 Tc 0.06 Tw 0 -1.689 Td
(Store the prepared solution either:)Tj
-0.017 Tc 0.017 Tw 1.125 -1.375 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.113 Tw 1.125 0 Td
[(a)-9.8 (t room tempera)-9.8 (ture and room light for no more than 8 hours from the time of)-17 ( )]TJ
0.114 Tw 0 -1.078 Td
[(prepara)-9.8 (tion to the end of the infusion.)37.2 ( Discard the prepared solution if not used)-17 ( )]TJ
0.06 Tw 0 -1.078 Td
[(within 8 hours from the time of prepara)-9.8 (tion;)]TJ
0.017 Tw -1.125 -1.24 Td
[(-or)37.2 (-)]TJ
0.08 Tw 1.125 -1.24 Td
[(under refrigera)-9.7 (tion a)-9.8 (t 2\260C to 8\260C \(36\260F to 46\260F\) with protection from light for\ no)-16.9 ( )]TJ
0.027 Tw 0 -1.078 Td
[(more than 24 hours from the time of prepara)-9.7 (tion,)37.2 ( which inc)20.2 (ludes the time allo)-9.8 (wed)-17 ( )]TJ
0.091 Tw 0 -1.078 Td
[(for equilibra)-9.7 (tion of the infusion ba)-9.8 (g to room tempera)-9.8 (ture and the dura)-9.8 (tion of the)-17 ( )]TJ
0.08 Tw 0 -1.078 Td
[(infusion.)37.2 ( Discard the prepared solution if not used within 24 hours from the time\)-16.9 ( )]TJ
0.06 Tw 0 -1.078 Td
[(of prepara)-9.8 (tion.)]TJ
-0.019 Tc -2.25 -1.536 Td
(Do not freeze.)Tj
-0.017 Tc 0.017 Tw 0 -1.798 Td
[(Administra)-9.8 (tion)]TJ
1.125 -1.555 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.07 Tw 1.125 0 Td
[(Administer the infusion over 30 minutes through an intra)-9.8 (venous line containing a)-17 ( )]TJ
0.048 Tw 0 -1.078 Td
[(sterile,)37.2 ( non-pyrogenic,)37.2 ( lo)-9.8 (w protein binding in-line polyethersulfone \(PES\),)37.2 ( n)-9.8 (ylon,)37.2 ( or)-17 ( )]TJ
-0.022 Tc 0.023 Tw 0 -1.078 Td
[(polyvin)-9.8 (ylidene \034uoride \(PVDF\) \037lter \(pore size of 0.2 micrometer to 1.\2 micrometer\).)]TJ
-0.017 Tc 0.017 Tw -1.125 -1.402 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.06 Tw 1.125 0 Td
[(Flush the intra)-9.7 (venous line a)-9.8 (t the end of the infusion.)]TJ
0.017 Tw -1.125 -1.402 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.06 Tw 1.125 0 Td
[(Do not coadminister other drugs through the same intra)-9.8 (venous line.)]TJ
/T1_0 1 Tf
0.017 Tw -2.25 -1.865 Td
(3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
/T1_1 1 Tf
-0.019 Tc 0.038 Tw -3.375 -1.689 Td
[(Injection:)37.2 ( 240 mg nivolumab and 80 mg rela)-9.8 (tlimab per 20 mL \(12 mg and 4 mg per mL\))-19 ( )]TJ
0.06 Tw 0 -1.059 Td
[(as a c)20.2 (lear to opalescent,)37.2 ( colorless to slightly yello)-9.8 (w solution in a single-dose vial.)]TJ
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 0 -2.018 Td
(4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
[(CONTRAINDIC)18.2 (A)55.2 (TIONS)]TJ
/T1_1 1 Tf
-0.019 Tc 0.019 Tw -3.375 -1.689 Td
(None.)Tj
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 0 -2.018 Td
(5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(W)18.2 (ARNINGS AND PREC)18.2 (AUTIONS)]TJ
0.017 Tw -3.375 -1.955 Td
(5.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.375 0 Td
[(Severe and F)20.2 (atal Immune-Mediated Adverse Reactions)]TJ
/T1_1 1 Tf
-0.01 Tc 0.285 Tw -3.375 -1.554 Td
[(OPDUALAG potentially breaks )0.5 (peripheral )0.5 (tolerance )0.5 (and )0.5 (induces )0.5 (immune-media)-9.7 (ted)-10 ( )]TJ
-0.015 Tc 0.168 Tw 0 -1.059 Td
(adverse reactions \(IMARs\) )Tj
/T1_2 1 Tf
[([see Clinical Pharmacolog)-10.1 (y \(12.1\)])]TJ
/T1_1 1 Tf
[(.)36.9 ( Important IMARs listed)-15 ( )]TJ
-0.019 Tc 0.06 Tw 0 -1.059 Td
[(under )37.2 (W)18.3 (arnings and Precautions may not inc)20.2 (lude all possible severe and fa)-9.8 (tal IMARs.)]TJ
ET
endstreamendobj26 0 obj<</BBox[0.0 792.0 612.0 0.0]/Length 324/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/Resources<</ExtGState<</GS0 16 0 R>>/Font<</T1_0 79 0 R>>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 324 748.9131 cm
0 0 m
252 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.008 Tc 0.008 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 400.5846 750.2881 Tm
(OPDUALAG)Tj
0 Tc 0 Tw 5.6 0 0 5.6 444.9225 751.9521 Tm
(\231)Tj
-0.008 Tc -0.014 Tw 8 0 0 8 450.4758 750.2881 Tm
[( \(nivolumab and r)18.4 (elatlimab-rmbw\))]TJ
ET
endstreamendobj79 0 obj<</BaseFont/IHGZJR+HelveticaNeueLTStd-Bd/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 80 0 R/LastChar 153/Subtype/Type1/ToUnicode 81 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 296 296 0 0 0 407 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 685 0 0 741 0 0 759 0 0 0 0 593 0 0 778 667 0 0 0 0 741 0 0 0 0 0 0 0 0 0 0 0 574 611 0 611 574 0 0 0 258 0 0 258 906 593 611 0 0 389 0 352 593 520 814 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1000]>>endobj80 0 obj<</Ascent 975/CapHeight 714/CharSet(/space/parenleft/parenright/hyphen/A/D/G/L/O/P/U/a/b/d/e/i/l/m/n/o/r/t/u/v/w/trademark)/Descent -218/Flags 32/FontBBox[-166 -218 1078 975]/FontFamily(HelveticaNeueLT Std)/FontFile3 82 0 R/FontName/IHGZJR+HelveticaNeueLTStd-Bd/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 144/Type/FontDescriptor/XHeight 517>>endobj81 0 obj<</Filter/FlateDecode/Length 360>>stream
H‰\’ÏŠƒ0Æï>EÛCQCMZa±-xØ?¬»`“±+¬1D{ğíw&Sº°Í/dæ›/™¤uslÜ°ˆô=L¦…Eôƒ³æéˆ\—äRØÁ,÷Uü›±óIŠÉí:/06®Ÿ’²énÎKXÅÓ³.°IÒ·`!î*¾êv#ÒöæıŒà‘‰ªzzéük7‚HcÚ¶±¸?,ësş">WBÆuÎfÌdaöĞ¹+$e†£åG•€³ÿö¥â´Ko¾»”’‚³'ä=óøÀ| >2‘wydœwÌ;bÍ¬‰kæšøÌŒfÊ‚kT«(˜dÅšŠ4•d–Ä¬¯H_q¼ŠñìM‘7ÅµÕRìS‘Oub>³E4ëkÒ×¬¯I_³¾&}­˜1ŸKÓ¹TWæRÆ‹½ß ]1¾ñèŸ¹…€­‹Ï%öŒº58x¼(?yYô%¿   ÿÿ   ÿÿ pÍªDendstreamendobj82 0 obj<</Filter/FlateDecode/Length 1909/Subtype/Type1C>>stream
H‰lTPWíf¦ß0Èv"C³„1=ÍˆFÂ|ø*aK‰¨øAE¨ÒdhdftAP´t³
«¨1&‚e*º¬ŸCi”(DX‹M´B-Ñ5şPI²¬Ftñ·‡;U»¯Ñh¥j««ß}÷¾{Ï;ï¼Ëh–e_1}Ú¢ÌùÑÓå’rÙë,pÌ‘WÊ³d{'L)TLŠ‘UBµÊ¨`'¢kèüP§/)#Ï
ÜÂ¨0f6.İ½¼Òã\Rì•¬)ÉÉ1´M±·öÉf±Ø¤É…î|YÊ®,óÊ¥eÒWÛ³ÜíqxåÂXirI‰4\\&yä2ÙS®ŸS’œe’Còz…r©Ã³LrI³œ.··r¹,¥S”XZ´ÄIq=r¡ätIŞbYÊ‰Í•æRt—Wr¸
¥Ï«³ŠŠœòp°ÔQ)QN¿®.=^µn
ã‘–®ô8Ë
^§ÛUö¸ËQ*ÿnä¤+(¡ğ®2Y~1<­4zl\FöÕ‰—
å"†aéÇèY†g3ÃŒa˜q3a,,“È0SXf*Ëd2Ìl“Í09¦aŒTif3ÙÌt0İl(›Ãf/Ä,8¢­©Ô\ĞšµSµµ§µCÜï¸\+÷_MÜäKœ±¹U¹×ÊÒ6ªU³Y«ÔøæúklÅÓà=î”°M ÕñïĞùIŞpÒúD9#¨=T=Şÿï0¡|hL{Ì˜åsv4¼Y8>-­h»£D"“!Ê	6°E@Üg`½‘â‹Ê‡j¥3…Ÿ ä$dÁø°,[
¼*b¹„c>EÚ"0®­“Qy< ÅÀ³mĞ®iƒbÚÇvÂoÛ[vĞ+™ì;¾,Í;a`'gÁÎÁG¤©I"ø‘/ÃrßêH/îæp6á¿ŞáJ.„³]`…`Õt…Á7\°Mˆ³MHCV@KÀÒ‡Qh‹Ï¶˜P"üÕ*ŸPû@Ni«Â€ÙĞbX£ÜëWÂ°õ`#†–qæ.cÄÈ\†0²šÈKÏOıĞ¯H¬B±Çq†a
c>P+º.¸ğ7oWi^«PYR†J„ãåZ	Î¯¬¢Pg§ÃM0(üRM¿0H|(Fj)ö3t¬aÏ(@dãH‘KMä3z"_MõÜ	<,¥Z«ÒÔCŒ*•Sdt˜f˜ğ{U^ üóÛÕKæê)&ä©¶*µ¾
¶“–¦Ì|I¾<­ş¹$rÉ"Ô¢¡âÊUQ™«Ft˜ÚXX Ù@~†‘—ªïNì¸ò	˜!
Ú¬Ã[BÉ&;jç×·9¶ûäNñä{­[÷âœ'ÂÙíŸík7¶~±aÎ¼‰[ã×šìëìnÔGD^]tÿ|çSÍ¢aÕ–ªmUÛWBY»wã©S°O/ãË‰Â@Q€¯üQä§VÆŞ[ƒ0³"¤Î¼şéV¶‡‘nagnşáóŞËÆG ¹	óajnFÍœY–[lª…z4å%ÿ[BBQjRRÑµ~üüÚ­[Ÿ§ÆÿU]ÏÆgd…õå¡ëkÉWË²öÏ1bL
h2Zpôe¤w¡³£ñì±ÔB®èN™`/êéîùäúÛOJRU„ßöBÀ {ˆŞ#å8x°¿ŸãğM#Z%Â8Œ€ZH}Ïà™p$Y¶aqñ|cêÛÇ{7™zµÇêö×kì:,§×›ø½åJCE?èÙ
×f¥®Š2^(P–z0šâË«x>®²'<¬¤…I÷Çƒ6„@æÓ?t”¡EÍ6òàìİ”‘%â	ê×}»»óz÷»ó3Dü’úÿÑADêW“ŸW*sÏkÌ4NÏ)É-2ÕC÷w¡ãíÏ'Pwe±zÚUèFòäÈ‰+u$ŠØLı:•{0:k¶{Ş±†®\D£Nİ *?½"fØF™7Á&?A!é	0)f`0	ÍÈ`Šæ°›‡nöİ;”œœâJ~=Úuó}yš)‰Ñ„A¾qøxê‡ITÃ¡ışñ½µ5õ¢¡Âu†C[7¬«[oÌ˜š—¹B]Æ7}*¼ñ'ĞB×]ö¶úì­õÅ«²Æ%Äü€$êrÅoÙÖ(‚FW³¦úÏkŒ¿_·ë´	v>¾;š*PÚñ÷•¤Š
(G• ‘˜—ş!m†ç‹š©A‡¡M‰ıõ¹ƒGÅ­Ä°*ÔÉ†·—İ®ìĞ(»ÔÒH‚,pµÔÀ ‡ã	Lõ7pôµâá•§¹ïúNh|-jîXƒhªq(’|LxÌ!}½’Õ²×ÈOĞÏÕ‘ÛØÏÁXŠqÑÇ_gaÚCHëƒ¦>ÍP¼zı$
£ ‘ÃQ~K4×‘læºÈ 4suØÜGü‹€ÿšzìy= '|Õ_Ş\Ú ol&°gçÃş+ºgÁ]°GÿÿÏ»ôƒA`1ø~p0˜wÿfK0„úŞş  ÿÿ   ÿÿ R-¶endstreamendobj25 0 obj<</BaseFont/HZWTVT+HelveticaNeueLTStd-BdCnO/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 83 0 R/LastChar 117/Subtype/Type1/ToUnicode 84 0 R/Type/Font/Widths[240 0 0 0 0 0 0 0 296 296 0 0 0 0 240 0 0 480 0 0 0 480 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 519 0 0 0 0 0 0 760 0 0 0 315 0 315 0 0 0 481 0 463 500 463 0 500 0 240 0 0 0 0 500 480 0 0 333 444 296 500]>>endobj83 0 obj<</Ascent 961/CapHeight 714/CharSet(/space/parenleft/parenright/period/one/five/P/W/bracketleft/bracketright/a/c/d/e/g/i/n/o/r/s/t/u)/Descent -271/Flags 96/FontBBox[-171 -271 1116 961]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 85 0 R/FontName/HZWTVT+HelveticaNeueLTStd-BdCnO/FontStretch/Condensed/FontWeight 700/ItalicAngle -12/StemV 140/Type/FontDescriptor/XHeight 538>>endobj84 0 obj<</Filter/FlateDecode/Length 339>>stream
H‰\’Ínƒ0€ïy
×C¥%´BZÿ$ûÑØ€&¦C!
ôÀÛÏÆU'-ø‹26Ñ¡<–®!z½©p„¦u6àĞß‚A¸àµuj•€mÍxßÍoÓÕ^E”\MÃˆ]éš^å9Dt8Œa‚§gÛ_p¡¢·`1´î
O_‡jQuóş;t#ÄP`±!ÑKí_ë!šÓ–¥¥óvœ–”ówãsòÉ¼_I1¦·8øÚ`¨İUÓ* ?Ó*:ûï<I$íÒ˜ï:¨<áËqLx+¼eŞ	ï˜OÂ'âõjf
Ä©pJœŠ'eOš	gÌ{á=óQøH¬Å£Ù£×Âkæğ†YüšıZœšZjÓ\›–Ú4×¦ÏÂôáy–ÌLXüû3ñgìÏÄOuï·Œ&y˜[4Šyüó¸û­ÃÇâ{”Åú  ÿÿ   ÿÿ ~¤ ¯endstreamendobj85 0 obj<</Filter/FlateDecode/Length 2015/Subtype/Type1C>>stream
H‰lTPSg¾!ÜK 4j®7¢—å^Ô
­R[XßâY$Jğ¹ÀH€ 	˜ÄD…Rƒ(„â ‚‚ˆøŠuµâª¸0vµÕ:£îvº©LÙÙ)ÿtÜÿâ®Îì{çşßùÏ9óıçûÏ‘¾>„D"áãÖ¯I^<5NŸkÓ[ÚDıf}B²Æª‹X¨‹5©EŸ‰+Æúnô‚4µ¼ú×«U¤0j”0{Ì×Á²&á#&SJ&ÅæåšYÙVş£˜Õ‡ü4•j¿@——®ç5…«Şhá—™2òÌùyf­U¯‹ääæò#Ş¬·èÍ6Ñø–o°ğZŞjÖêôF­y#Ÿ—É'LyÖÂ|=‹³Dâ ,ÎkÖëxƒ‰·fëùU‘šH~În²òZ“O~­ÎÌ4dèGŒFm!9ı6:Co¶jñ?§1ó9›Í‹Îa5ä™,ÿKnÒõÿ‡E™7àäâô&‹^ÿëöRcz\dÔM²fğ:}&	áO£¡$>"¢‰ÙÄ\b!±ˆXL,!âˆxBM¬ 4D2±ŠXMŒÃ•%–aãn¢—x,ñ“˜%.‰O˜Úç™tºô3é/¾µ¾WI?2…l¤¦S%ÔMØ[Ñ-vK \)”{VxË)¨B74ğO
ñè"ğVûy©´‘5ÌESÂUF\!Éå<úØöJi—|c¤ğ£'Aãj>Š0"Ş„øq©dÃÔZ˜º˜S0¿7?˜*{«a´>ÄÁWĞÔ*Äd¡9ø]‰ä‡¦â`ªÑüqàw@D<¨dò
PI®CŒô9¨˜¤"!ˆê)ÿ¦É&”»ÂiÃà‰)áÏZ2”šc\–Á–PöB©Po9ö-×à+¹¡°Â¥Â€'ñ’"¼	u®îX«‹½}(ù[¸({VêJvyuÿ¥ƒ
¡ö³·|Š …ø{/!ª“ß– P0›˜Z”™Íí¥ºa&	NJ²&œã°DĞA˜´[	“©[p†ü†‚àŸïBx÷òHşK4…Eû)x7”é£î7f,ŞÊ-,J5$±Ä<ˆbl4»B<Õt>„(a&IB=ù	eôÖ“"êò¤‘˜}i¼­ä^ªMh1Z;‚:ß ùt”0äI’¸„h©%0PH5‘)xß“Hş,®Qá¯^9Ø+çh^)Å=[vCïÿ’ˆƒäß»g=†»¶§nÅ5ø¼ã—C}	*¦ª<_ÓÖv½XgNßÁ•em(¶…mZ—n›"‹-jˆyÁÒ—ïœwö^à>¡è­…¶ı[B°œe•Gu÷Á© úÒ`Ó–{(š¡E£7qå%$èP&³¢dµ%“ÍÜyÒUÃü¢íØÚÃŸ¶Ö4;eò¾b· ’Ü…`Xã¥B52@[ÿ¢YDOZ6¥p(7õz„°0åá#=Î¡ jFI—Ê.¯èñmŒ>ÚÒw½ºW³¦”“Gı /‡á÷vÅ×ÀÑP Íø·¶öõ±·ö©‘¿™ÃŸEÈª+ú°s#¼D‰[¬ùŸğ¹=·i‹È%Ñ(eGÿ¥hOFÉ^?ßÔíÂç™Ãì'0Ö-¹ÉÇ#J ’qtÓUšÉ¢Dš€&çrhBEB
Ê0¦ƒC£©e›7e§²k÷üõ+'Wó9Ùğ„ÙßDvlû²‡ı²25f+>	Jøût˜|qÿ5¬h‡àÀÁ‚ctmb….†>±M©öÿù°E¬CáH‘Ï¡uÚ³óÁ‡½pùè¹S˜éÖE$İ™\jÒjØ-[5¥m-­Ùí¬:,Ã…Œ*èYş,Ìü¶&ç€ôFôt–÷7_¾Åö8Ö£qùœÊnLXÉ®¬ºó·Ï89nİ.û3ÀİxAzE	!PB—X<ç£V¹½ƒØ1Iä.L‚÷èş‹¢çCğ}u'Ú/±®:ÛªRn¶×Äæ§Â$’>=Üœ~i&»2Ù²:÷$İ_÷‰Iâşwr·ä„àB‡HŸbA3º5fUÉ`ÚƒŸ á,wÔæŸĞ¬rš6?%è8±ë|Zšİc{«“Ñ“¨‚1YÃ.=ô|pòÅ˜\48íŠ‹Âdúô9º¿’÷ëo¶~Á:ë÷ísrôé6"+wî¨ÜÉ&¥ÖèFxÕßáåÂw b#ÜŠË¯‰]¥Äë×çJ	LRcéÎ>XÄàÉC»&on_
Q,È^ôÙÂ5|·ùÂÚetçÜ¶õÛ›GÇŸ9p²±‹=â,+qpôíêâ
û®|Œ¦ö7cåSzÑM\´pZW4¯=e ÿûì –íEeÙ2ÚµaûF›–M)ìÀ³®ê0)çwÁ¿İ’ñŒÄ§‹Y,Ò*İ"‘ÄZ—{¢­ªªƒk|AîÛQº¯”ÍØİp¾†»ÈÇT£›œ…çsäùÄV’ìŠ¬^><PŠ]ò_¡ç!©Ş¶Ñ”Â¦7]?Ä=üDóÇ^QÆP«+å{£§åÚ9±UŠ4'JrÂD'G«ŸW{{ømiğ¤5 œZ¶U{İµşÃòÎ@m­Ãá¨=8„ÿGà»•r(+„1ÿ  ÿÿ   ÿÿ Eendstreamendobj23 0 obj<</AIS false/BM/Normal/CA 1.0/OP false/OPM 1/SA false/SMask/None/Type/ExtGState/ca 1.0/op false>>endobj15 0 obj<</Length 14464>>stream
0 0 0 1 K
0.5 w 
/GS0 gs
q 1 0 0 1 45 476.2441 cm
0 0 m
107.921 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.017 Tc 0.012 Tw 8 0 0 8 36 750.2881 Tm
[(HIGHLIGHTS OF PRESCRIBING INFORMA)55.3 (TION)]TJ
-0.018 Tc 0 Tw 0 -1.242 Td
[(These highlights do not inc)19.7 (lude all the information needed to use OPDUALAG safely)-17.9 ( )]TJ
-0.017 Tc 0.12 Tw 0 -1.062 Td
[(and effectively)55.2 (.)37.2 ( See full prescribing information for OPDUALAG.)]TJ
0.017 Tw 0 -1.805 Td
(OPDUALAG)Tj
0 Tc 0 Tw 5.6 0 0 5.6 69.443 719.0721 Tm
(\231)Tj
-0.017 Tc 0.12 Tw 8 0 0 8 74.8907 717.4081 Tm
[( \(nivolumab and relatlimab-rmbw\) injection,)37.2 ( for intravenous use)]TJ
-4.861 -1.242 Td
[(Initial U.S.)37.2 ( Appro)-9.8 (v)16.2 (al: 2022)]TJ
0.017 Tw 0 -2.188 Td
(------------------------------)Tj
0.12 Tw 10.683 0 Td
(RECENT MAJOR CHANGES)Tj
0.017 Tw 10.132 0 Td
(------------------------------)Tj
/T1_1 1 Tf
0.06 Tw -20.815 -1.54 Td
[(W)18.2 (arnings and Precautions \(5.1\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
28.908 0 Td
(3/2024)Tj
/T1_0 1 Tf
0.017 Tw -28.908 -1.787 Td
(------------------------------)Tj
0.12 Tw 10.858 0 Td
[(INDIC)18.2 (A)55.2 (TIONS AND USAGE)]TJ
-0.05 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(------------------------------)Tj
/T1_1 1 Tf
-0.016 Tc 0.24 Tw -10.858 -1.54 Td
[(OPDUALAG is a combina)-9.8 (tion of nivolumab,)37.2 ( a programmed dea)-9.8 (th receptor)37.1 (-1 \(PD-1\))-16 ( )]TJ
0 -1.062 Td
[(blocking antibod)-10.3 (y)54.8 (,)36.8 ( and rela)-10.2 (tlimab,)36.7 ( a lymphoc)19.8 (yte activa)-10.2 (tion gene-3 \(LAG-3\) blocking)-16 ( )]TJ
-0.017 Tc 0.097 Tw 0 -1.062 Td
[(antibod)-9.8 (y)55.2 (,)37.2 ( indica)-9.8 (ted for the trea)-9.7 (tment of )0.5 (adult and )0.5 (pedia)-9.8 (tric )0.5 (pa)-9.8 (tients 12 )0.5 (years of a)-9.8 (ge or)-17 ( )]TJ
0.06 Tw 0 -1.062 Td
[(older with unresectable or metasta)-9.8 (tic melanoma.)37.2 ( \(1\))]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.787 Td
(---------------------------)Tj
0.12 Tw 9.69 0 Td
[(DOSAGE AND ADMINISTRA)55.2 (TION)]TJ
-0.16 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(---------------------------)Tj
/T1_1 1 Tf
0.017 Tw -9.69 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.154 Tw 1.125 0 Td
[(Adult pa)-9.8 (tients and pedia)-9.8 (tric pa)-9.8 (tients 12 years of a)-9.8 (ge or older who weigh a)-9.8 (t least)-17 ( )]TJ
0.109 Tw 0 -1.062 Td
[(40 kg:)37.2 ( 480 mg nivolumab and 160 mg rela)-9.8 (tlimab intra)-9.8 (venously ever)-17.7 (y 4 weeks.)37.2 ( \(2\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.12 Tw 1.125 0 Td
[(Administer OPDUALAG as an intra)-9.8 (venous infusion over 30 minutes.)37.2 ( \(2\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.093 Tw 1.125 0 Td
[(See )0.5 (full )0.5 (Prescribing )0.5 (Informa)-9.8 (tion )0.5 (for )0.5 (dosa)-9.8 (ge )0.5 (modi\037ca)-9.7 (tions )0.5 (for )0.5 (adverse )0.5 (reactions \(2.2\))-17 ( )]TJ
0.12 Tw 0 -1.062 Td
[(and prepara)-9.8 (tion and administra)-9.8 (tion instructions for the injection \(2.3\).)]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.715 Td
(--------------------------)Tj
0.12 Tw 9.183 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
0.039 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(-------------------------)Tj
/T1_1 1 Tf
0.017 Tw -9.183 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.173 Tw 1.125 0 Td
[(Injection:)37.2 ( 240 mg of nivolumab and 80 mg of rela)-9.7 (tlimab per 20 mL \(12 mg and)-17 ( )]TJ
0.12 Tw 0 -1.062 Td
[(4 mg per mL\) in a single-dose vial.)37.2 ( \(3\))]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.715 Td
(---------------------------------)Tj
11.731 0 Td
[(CONTRAINDIC)18.2 (A)55.2 (TIONS)]TJ
8.025 0 Td
(---------------------------------)Tj
/T1_1 1 Tf
-19.757 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.12 Tw 1.125 0 Td
[(None.)37.1 ( \(4\))]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.715 Td
(---------------------------)Tj
0.12 Tw 9.799 0 Td
[(W)18.2 (ARNINGS AND PREC)18.2 (AUTIONS)]TJ
-0.051 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(---------------------------)Tj
/T1_1 1 Tf
0.017 Tw -9.799 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.083 Tw 1.125 0 Td
[(Immune-Media)-9.8 (ted Adverse )-36.8 (Reactions)]TJ
-0.198 Tw (:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
13.737 0 Td
[( )-317.8 (\(5.1\))]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-13.153 -1.314 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.585 0 Td
<017C>Tj
/T1_1 1 Tf
-0.018 Tc 0.085 Tw 1.125 0 Td
[(Immune-media)-9.7 (ted adverse reactions,)37.2 ( which may be severe or fa)-9.8 (tal,)37.2 ( can occur in)-18 ( )]TJ
-0.021 Tc 0 Tw 0 -1.062 Td
[(a)0.5 (n)-9.4 (y)0.5 ( )0.5 (o)0.6 (r)0.5 (g)0.5 (a)0.6 (n)0.5 ( )0.5 (s)0.5 (y)0.6 (s)0.5 (t)0.5 (e)0.5 (m)0.6 ( )0.5 (o)0.6 (r)0.5 ( )0.5 (t)0.5 (i)0.6 (s)0.5 (s)0.5 (u)0.5 (e)0.6 (,)37.5 ( )0.5 (i)0.6 (n)0.5 (c)20.5 (l)0.5 (u)0.5 (d)0.6 (i)0.5 (n)0.5 (g)0.5 ( )0.6 (t)0.5 (h)0.5 (e)0.6 ( )0.5 (f)0.5 (o)0.6 (l)0.5 (l)0.5 (o)-9.4 (w)0.5 (i)0.5 (n)0.5 (g)0.6 (:)37.5 ( )0.5 (i)0.5 (m)0.6 (m)0.5 (u)0.5 (n)0.6 (e)0.5 (-)0.5 (m)0.6 (e)0.5 (d)0.5 (i)0.5 (a)-9.4 (t)0.5 (e)0.5 (d)0.6 ( )0.5 (p)0.5 (n)0.6 (e)0.5 (u)0.5 (m)0.5 (o)0.6 (n)0.5 (i)0.5 (t)0.6 (i)0.5 (s)0.5 (,)16 ( )]TJ
ET
q 1 0 0 1 333 690.5881 cm
0 0 m
75.478 0 l
S
Q
q 1 0 0 1 333 663.6481 cm
0 0 m
95.029 0 l
S
Q
q 1 0 0 1 333 636.7081 cm
0 0 m
58.581 0 l
S
Q
BT
-0.008 Tc 0.653 Tw 8 0 0 8 342 750.2881 Tm
[(immune-media)-10.5 (ted colitis,)36.5 ( immune-media)-10.4 (ted hepa)-10.4 (titis,)36.5 ( immune-media)-10.5 (ted)-8 ( )]TJ
-0.017 Tc 0.24 Tw 0 -1.062 Td
[(endocrinopa)-10.3 (thies,)36.7 ( immune-media)-10.3 (ted derma)-10.3 (tologic adverse reactions,)36.8 ( immune-)]TJ
-0.018 Tc 0.12 Tw 0 -1.062 Td
[(media)-9.8 (ted nephritis with renal d)-9.8 (ysfunction,)37.2 ( and immune-media)-9.7 (ted myocarditis.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-0.539 -1.387 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/T1_1 1 Tf
-0.021 Tc 1.125 0 Td
[(Monitor for early identi\037ca)-9.7 (tion and mana)-9.6 (gement.)37.3 ( Evalua)-9.7 (te liver enzymes,)37.3 ( crea)-9.7 (tinine,)16 ( )]TJ
-0.017 Tc 0.12 Tw 0 -1.062 Td
[(and thyroid function a)-9.8 (t baseline and periodically during trea)-9.8 (tment.)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-0.539 -1.387 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/T1_1 1 Tf
-0.017 Tc 0.061 Tw 1.125 0 Td
[(Withhold or permanently discontinue based on severity and type of reacti\on.)37.2 ( \(2.2\))]TJ
0.017 Tw -2.25 -1.314 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.013 Tc 0.325 Tw 1.125 0 Td
[(Infusion-rela)-9.9 (ted reactions)]TJ
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
9.69 0 Td
[( Interrupt,)37.1 ( slo)-9.9 (w the ra)-9.9 (te of infusion,)37.1 ( or permanently)-13 ( )]TJ
0.317 Tw -9.69 -1.062 Td
[(discontinue OPDUALAG \(nivolumab and rela)-9.7 (tlimab-rmbw\) based on severity of)-13 ( )]TJ
-0.017 Tc 0.12 Tw 0 -1.062 Td
[(reaction.)37.2 ( \(2.2,)37.2 ( 5.2\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.036 Tw 1.125 0 Td
[(Complica)-9.8 (tions of allogeneic HSCT)]TJ
11.879 0 Td
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.247 0 Td
[( F)20.2 (a)-9.7 (tal and other serious complica)-9.8 (tions can occur in)-17 ( )]TJ
0.038 Tw -12.126 -1.062 Td
[(pa)-9.8 (tient who receive allogeneic HSCT before or after being trea)-9.8 (ted with a PD-1/PD-L1)-17 ( )]TJ
0.12 Tw 0 -1.062 Td
[(blocking antibod)-9.7 (y)55.2 (.)37.2 ( \(5.3\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.062 Tw 1.125 0 Td
[(Embr)-17.7 (yo-fetal toxicity)]TJ
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
7.57 0 Td
[( Can cause fetal harm.)37.2 ( )37.2 (Advise females of reproductive potential)-17 ( )]TJ
0.12 Tw -7.57 -1.062 Td
[(of potential risk to a fetus and to use effective contraception.)37.2 ( \(5.4,)37.3 ( 8.1,)37.2 ( 8.3\))]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.715 Td
(--------------------------------)Tj
0.12 Tw 11.615 0 Td
(ADVERSE REACTIONS)Tj
0.001 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(--------------------------------)Tj
/T1_1 1 Tf
0.156 Tw -11.615 -1.54 Td
[(The most common adverse reactions \(\03620%\) are musculoskeletal pain,)37.2 ( fa)-9.8 (tigue,)37.2 ( rash,)20 ( )]TJ
0.06 Tw 0 -1.062 Td
[(pruritus,)37.3 ( and diarrhea.)37.2 ( \(6.1\))]TJ
-0.022 Tc -0.004 Tw 0 -1.387 Td
[(The )0.6 (most )0.6 (common )0.6 (labora)-9.7 (tor)-17.6 (y )0.5 (abnormalities )0.5 (\(\03620%\) )0.6 (are )0.6 (decreased )0.6 (hemoglobin,)37.3 ( )0.5 (decreased)-22 ( )]TJ
-0.017 Tc 0.06 Tw 0 -1.062 Td
[(lymphoc)20.1 (ytes,)37.2 ( increased )37.2 (AST)92.2 (,)37.2 ( increased )37.2 (AL)94.2 (T)92.2 (,)37.2 ( and decreased sodium.)37.2 ( \(6.1\))]TJ
/T1_0 1 Tf
-0.014 Tc 0.289 Tw 0 -1.387 Td
[(T)74.1 (o report SUSPECTED ADVERSE REACTIONS,)37.1 ( contact Bristol-Myers Squibb at)-14 ( )]TJ
-0.017 Tc 0.06 Tw 0 -1.062 Td
[(1-800-721-5072 or FD)34.2 (A at 1-800-FD)34.2 (A-1088 or www)37.2 (.fda.go)-9.7 (v/medwatch.)]TJ
0.017 Tw 0 -1.787 Td
(---------------------------)Tj
0.12 Tw 9.72 0 Td
[(USE IN SPECIFIC POPULA)55.2 (TIONS)]TJ
-0.13 Tw /Span<</ActualText<FEFF002D>>> BDC 
12.06 0 Td
( )Tj
EMC 
(---------------------------)Tj
/T1_1 1 Tf
0.017 Tw -21.78 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.12 Tw 1.125 0 Td
[(Lacta)-9.8 (tion:)37.2 ( )37.2 (Advise not to breastfeed.)37.2 ( \(8.2\))]TJ
/T1_0 1 Tf
-1.125 -3.403 Td
[(See 17 for P)54.2 (A)55.2 (TIENT COUNSELING INFORMA)55.2 (TION and Medication Guide.)]TJ
25.299 -1.625 Td
(Revised: 3/2024)Tj
ET
1 w 4 M 
q 1 0 0 1 35.28 438.72 cm
0 0 m
540 0 l
S
Q
q 1 0 0 1 35.28 181.188 cm
0 0 m
540 0 l
S
Q
BT
0.012 Tw 8 0 0 8 36 413.3281 Tm
[(FULL PRESCRIBING INFORMA)55.2 (TION: CONTENTS*)]TJ
0.017 Tw 0 -1.917 Td
(1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(INDIC)18.2 (A)55.2 (TIONS AND USAGE)]TJ
0.017 Tw -3.125 -1.647 Td
(2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(DOSAGE AND ADMINISTRA)55.2 (TION)]TJ
/T1_1 1 Tf
0.017 Tw 0.003 -1.536 Td
(2.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.06 0 Td
[(Recommended Dosa)-9.8 (ge)]TJ
0.017 Tw -3.06 -1.469 Td
(2.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.06 0 Td
[(Dosa)-9.7 (ge Modi\037ca)-9.8 (tions)]TJ
0.017 Tw -3.06 -1.469 Td
(2.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.011 Tw 3.06 0 Td
[(Prepara)-9.8 (tion )-36.7 (and Administra)-9.8 (tion)]TJ
/T1_0 1 Tf
0.017 Tw -6.187 -1.58 Td
(3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
0.017 Tw -3.125 -1.647 Td
(4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(CONTRAINDIC)18.2 (A)55.2 (TIONS)]TJ
-3.125 -1.647 Td
(5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(W)18.2 (ARNINGS AND PREC)18.2 (AUTIONS)]TJ
/T1_1 1 Tf
0.017 Tw 0.003 -1.536 Td
(5.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.06 0 Td
[(Severe and F)20.2 (a)-9.7 (tal Immune-Media)-9.8 (ted )37.2 (Adverse Reactions)]TJ
0.017 Tw -3.06 -1.469 Td
(5.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.06 0 Td
[(Infusion-Rela)-9.8 (ted Reactions)]TJ
0.017 Tw -3.06 -1.469 Td
(5.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.06 0 Td
[(Complica)-9.8 (tions of )37.2 (Allogeneic Hema)-9.8 (topoietic Stem Cell )37.2 (T)74.2 (ransplanta)-9.8 (tion)]TJ
0.017 Tw -3.06 -1.469 Td
(5.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.011 Tw 3.06 0 Td
[(Embr)-17.7 (yo-F)24.2 (etal T)74.2 (oxicity)]TJ
/T1_0 1 Tf
0.017 Tw -6.187 -1.58 Td
(6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
(ADVERSE REACTIONS)Tj
/T1_1 1 Tf
0.017 Tw 0.003 -1.536 Td
(6.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.011 Tw 3.06 0 Td
[(Clinical T)74.1 (rials )-36.8 (Experience)]TJ
/T1_0 1 Tf
0.017 Tw -6.187 -1.58 Td
(8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(USE IN SPECIFIC POPULA)55.2 (TIONS)]TJ
/T1_1 1 Tf
0.017 Tw 0.003 -1.536 Td
(8.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.06 0 Td
[(Pregnanc)20.2 (y)]TJ
-3.06 -1.469 Td
(8.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.06 0 Td
[(Lacta)-9.8 (tion)]TJ
32.94 24.757 Td
(8.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.06 0 Td
[(F)24.2 (emales and Males of Reproductive P)18.2 (otential)]TJ
0.017 Tw -3.06 -1.469 Td
(8.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.06 0 Td
[(P)18.2 (edia)-9.7 (tric Use)]TJ
0.017 Tw -3.06 -1.469 Td
(8.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.06 0 Td
[(Geria)-9.7 (tric Use)]TJ
/T1_0 1 Tf
0.017 Tw -6.187 -1.58 Td
(11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
(DESCRIPTION)Tj
-3.125 -1.647 Td
(12)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(CLINIC)18.2 (AL PHARMACOLOGY)]TJ
/T1_1 1 Tf
0.017 Tw 0.003 -1.536 Td
(12.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.011 Tw 3.06 0 Td
[(Mechanism )-36.8 (of Action)]TJ
0.017 Tw -3.06 -1.469 Td
(12.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.06 0 Td
[(Pharmacod)-9.8 (ynamics)]TJ
-3.06 -1.469 Td
(12.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.06 0 Td
(Pharmacokinetics)Tj
-3.06 -1.469 Td
(12.6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.06 0 Td
(Immunogenicity)Tj
/T1_0 1 Tf
-6.187 -1.58 Td
(13)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(NONCLINIC)18.2 (AL TOXICOLOGY)]TJ
/T1_1 1 Tf
0.017 Tw 0.003 -1.536 Td
(13.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.06 0 Td
[(Carcinogenesis,)37.2 ( Muta)-9.8 (genesis,)37.2 ( Impairment of F)24.2 (ertility)]TJ
0.017 Tw -3.06 -1.469 Td
(13.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.06 0 Td
[(Animal )37.3 (T)74.1 (oxicolog)-9.8 (y and/or Pharmacolog)-9.8 (y)]TJ
/T1_0 1 Tf
0.017 Tw -6.187 -1.58 Td
(14)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(CLINIC)18.2 (AL STUDIES)]TJ
0.017 Tw -3.125 -1.647 Td
(16)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
(HOW SUPPLIED/STORAGE AND HANDLING)Tj
0.017 Tw -3.125 -1.647 Td
(17)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 3.125 0 Td
[(P)54.2 (A)55.2 (TIENT COUNSELING INFORMA)55.2 (TION)]TJ
/T1_1 1 Tf
-0.012 Tc -3.125 -1.917 Td
[(*Sections or subsections omitted from the full prescribing informa)-9.8 (tion are not listed.)]TJ
ET
endstreamendobj86 0 obj<</CreationDate(D:20240304144829-05'00')/Creator(Adobe InDesign 19.2 \(Macintosh\))/ModDate(D:20240304144830-05'00')/Producer(Adobe PDF Library 17.0)/Trapped/False>>endobjxref
0 87
0000000000 65535 f
0000000016 00000 n
0000000124 00000 n
0000008590 00000 n
0000000000 00000 f
0000008701 00000 n
0000009641 00000 n
0000010778 00000 n
0000011939 00000 n
0000013112 00000 n
0000014296 00000 n
0000015470 00000 n
0000016693 00000 n
0000017806 00000 n
0000018920 00000 n
0000427542 00000 n
0000056860 00000 n
0000062852 00000 n
0000266408 00000 n
0000266978 00000 n
0000393668 00000 n
0000142672 00000 n
0000289930 00000 n
0000427428 00000 n
0000268168 00000 n
0000424129 00000 n
0000420334 00000 n
0000372301 00000 n
0000253522 00000 n
0000351483 00000 n
0000313155 00000 n
0000290042 00000 n
0000172794 00000 n
0000267732 00000 n
0000257558 00000 n
0000156984 00000 n
0000062981 00000 n
0000063507 00000 n
0000034443 00000 n
0000142785 00000 n
0000020060 00000 n
0000056971 00000 n
0000035049 00000 n
0000035521 00000 n
0000035774 00000 n
0000036203 00000 n
0000057008 00000 n
0000125441 00000 n
0000125466 00000 n
0000097686 00000 n
0000097939 00000 n
0000064214 00000 n
0000064461 00000 n
0000065065 00000 n
0000098486 00000 n
0000125876 00000 n
0000126150 00000 n
0000126219 00000 n
0000126479 00000 n
0000126589 00000 n
0000254287 00000 n
0000254765 00000 n
0000255135 00000 n
0000255564 00000 n
0000257595 00000 n
0000283990 00000 n
0000284095 00000 n
0000284652 00000 n
0000277671 00000 n
0000277786 00000 n
0000278420 00000 n
0000273858 00000 n
0000268637 00000 n
0000268721 00000 n
0000269208 00000 n
0000269780 00000 n
0000274260 00000 n
0000279104 00000 n
0000285288 00000 n
0000420858 00000 n
0000421336 00000 n
0000421706 00000 n
0000422135 00000 n
0000424529 00000 n
0000424920 00000 n
0000425328 00000 n
0000442058 00000 n
trailer<</Size 87/Root 1 0 R/Info 86 0 R/ID[<421683537DC14B9D9694D3AE122F37EC><3EB20A09C8FF4AAA9200C976233D8F70>]>>startxref442240%%EOF1 0 obj<</Lang(en-US)/Metadata 2 0 R/Pages 3 0 R/Type/Catalog/ViewerPreferences<</Direction/L2R/DisplayDocTitle true>>>>endobj2 0 obj<</Length 10758/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="ï»¿" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c001 79.675d0f7, 2023/06/11-19:21:16        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:ExtensisFontSense="http://www.extensis.com/meta/FontSense/">
         <xmp:CreateDate>2024-03-04T14:48:29-05:00</xmp:CreateDate>
         <xmp:MetadataDate>2024-03-04T15:53:07-05:00</xmp:MetadataDate>
         <xmp:ModifyDate>2024-03-04T15:53:07-05:00</xmp:ModifyDate>
         <xmp:CreatorTool>Adobe InDesign 19.2 (Macintosh)</xmp:CreatorTool>
         <xmpMM:InstanceID>uuid:67d1d2e2-4fd5-cf4e-88c7-a1e12ca8d153</xmpMM:InstanceID>
         <xmpMM:OriginalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.id:d26d4221-1e82-4d9d-8fbe-c3e9fc8b34a8</xmpMM:DocumentID>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>xmp.iid:1002752c-92f7-43cb-95e0-6dee3e9d6f86</stRef:instanceID>
            <stRef:documentID>xmp.did:f8bd02c7-78aa-471e-ba45-4e74ffb9c164</stRef:documentID>
            <stRef:originalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</stRef:originalDocumentID>
            <stRef:renditionClass>default</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>converted</stEvt:action>
                  <stEvt:parameters>from application/x-indesign to application/pdf</stEvt:parameters>
                  <stEvt:softwareAgent>Adobe InDesign 19.2 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
                  <stEvt:when>2024-03-04T14:48:29-05:00</stEvt:when>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">OPDUALAG U.S. Prescribing Information</rdf:li>
            </rdf:Alt>
         </dc:title>
         <dc:creator>
            <rdf:Bag>
               <rdf:li>Bristol Myers Squibb</rdf:li>
            </rdf:Bag>
         </dc:creator>
         <pdf:Producer>Adobe PDF Library 17.0</pdf:Producer>
         <pdf:Trapped>False</pdf:Trapped>
         <ExtensisFontSense:slug>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>2061318306</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>2061318306</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Cn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1252007918</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1252007918</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>ArialMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3939600684</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3939600684</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Arial-BoldMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3357634683</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3357634683</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>4073973744</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>4073973744</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3030352917</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3030352917</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-CnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3691150952</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3691150952</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Bd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
            </rdf:Bag>
         </ExtensisFontSense:slug>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                           
<?xpacket end="w"?>endstreamendobj87 0 obj<</Author(Bristol Myers Squibb)/CreationDate(D:20240304144829-05'00')/Creator(Adobe InDesign 19.2 \(Macintosh\))/ModDate(D:20240304155307-05'00')/Producer(Adobe PDF Library 17.0)/Title(OPDUALAG U.S. Prescribing Information)/Trapped/False>>endobjxref
0 3
0000000000 65535 f
0000444132 00000 n
0000444261 00000 n
87 1
0000455096 00000 n
trailer<</Size 88/Root 1 0 R/Info 87 0 R/ID[<421683537DC14B9D9694D3AE122F37EC><6B27CF71D78145ADB649EE6CB2CA39AD>]/Prev 442240>>startxref455352%%EOF